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Abstract 
Mycobacterium tuberculosis, the causative agent of tuberculosis exists in a number of 
different environmental states. It must therefore have gene regulatory systems which are 
specific for virulence. One major signalling method is through reversible 
phosphorylation of proteins, mediated by protein kinases and phosphatases. This study 
focuses on the function of one serine-threonine protein kinase, PknF, and its substrate, 
the ABC transporter Rv1747 which is necessary for growth in a virulent infection. This 
kinase is known to interact with both of the fork-head associated (FHA) domains of 
Rv1747 in a phosphorylation dependent manner. The aims of this study were to analyse 
the function of Rv1747 particularly in relation to its requirement for a virulent infection 
and to investigate how PknF is controlling Rv1747 function. 
pknF was shown to be co-transcribed with Rv1747 and the stimulus sensed by the kinase 
was investigated. Phenotypic analysis linked the function of Rv1747 to properties of the 
cell wall. Transcriptional microarray analysis of pknF and Rv1747 mutants showed 
altered expression levels of genes involved in cell wall functions. Moreover, thin layer 
chromatography revealed changes in lipid profiles between wild type and mutant, but 
these differences could not be confirmed to be due to the mutation since they were not 
restored by complementation. Cell wall structure, however, appeared normal by 
transmission electron microscopy. 
Experiments to determine how PknF regulates the function of Rv1747 demonstrated that 
phosphorylation occurs on two specific threonine residues; mutation analysis indicated 
that these are likely to be the only residues phosphorylated. The involvement of the FHA 
domains in this regulation was demonstrated by isothermal titration calorimetry, using 
peptides containing both phosphothreonine residues. Furthermore, FHA-1 domain 
mutation resulted in attenuation in macrophages highlighting its critical role in Rv1747 
function. Infection experiments in macrophages and in mice have been performed using 
the threonine mutants to determine the in vivo consequences of phosphorylation and 
hence construct a model of how this regulation takes place. This study has revealed that 
PknF positively regulates the function of Rv1747 which is required for growth in both 
the lungs and spleens of mice. 
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CHAPTER 1. INTRODUCTION 
1.1 Tuberculosis 
Tuberculosis (TB) remains one of the earliest recorded human diseases; clay tablets 
dating back to the seventh century B.C. describe people coughing blood and those from 
the fifth century B.C portray patients wasting away with chest pain and coughing 
(Smith, 2003). The causative agent of TB has been known to be the actinobacterium 
Mycobacterium tuberculosis since the description of the classic infection experiment by 
Robert Koch to the Berlin Physiological Society in 1882 (Brown, 1932; Smith, 2003). 
Subsequently, a live attenuated vaccine was developed at the Institute of Pasteur in Paris 
in the 1920’s which has been given to more than three billion individuals worldwide 
(Andersen & Doherty, 2005; Behr & Small, 1999). Since the Second World War an 
effective drug therapy comprising multiple antibiotics has been in use and from the 
1990’s the World Health Organisation (WHO) has endorsed a global strategy called the 
DOTs (Directly Observed Treatment, Short-course) programme with the aim to properly 
monitor the treatment and outcome of each TB patient; consequently the programme has 
been identified as one of the most cost effective health strategies 
(http://www.tbalert.org/worldwide/DOTS).  
It is therefore all the more remarkable that despite these preventative and therapeutic 
measures, TB has continued to be the world’s most rampant infective agent, at the latest 
estimate killing 1.8 million people a year; furthermore, an estimated two billion people 
are latently infected with TB bacilli (WHO fact sheet 2009 (http://www.stoptb.org/)). 
Moreover there is apparently no animal host reservoir for M. tuberculosis. In 1993 the 
WHO declared TB to be a global health emergency to help raise awareness of the 
universal scale and magnitude of the problem with the aim to reduce the worldwide 
burden of the epidemic by 2015 (WHO fact sheet 2009). This disease burden now 
largely falls on developing countries; TB was effectively eradicated from Western 
Europe and North American countries in the 20th century, and re-occurrence in its 
incidence in the UK over the last 20 years are nearly all the result of immigration from 
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developing countries (Antoine et al., 2006). Globally, this disease burden has escalated 
due to its deadly synergy with human immunodeficiency virus (HIV). TB is a leading 
cause of death among those people living with HIV; of the 1.8 million TB deaths in 
2008, 0.5 million people were HIV positive (WHO fact sheet 2009). This HIV burden 
coupled with the emergence of multi-drug resistant (MDR) M. tuberculosis strains 
makes the search for novel vaccine candidates and drugs ever more important. In 2008 
the cases of MDR-TB were the highest rates ever recorded (WHO fact sheet 2009).  
Over the last 20 years TB has been a re-emerging problem in England and Wales; since 
1988 the incidences of TB cases have increased year on year (Antoine et al., 2006). In 
2003, 45 % of all TB cases in England and Wales occurred in London (out of a total of 
6780 cases) (Antoine et al., 2006). The largest proportion of infections occurred in those 
people born outside the UK but infections were also prevalent in less affluent sections of 
the community including the homeless, drug users and prisoners (Antoine et al., 2006). 
This highlights that TB is once again no longer only a problem of the developing world 
and it must be addressed to curb both the human suffering and enormous economic cost 
of this disease. 
1.1.1 Mycobacterium tuberculosis complex 
The Mycobacterium genus consists of rod shaped, high GC content, acid-fast Gram-
positive bacteria. Mycobacteria are categorised as acid-fast due to the property of 
retention of a pink carbol-fuchsin stain when treated with acid-alcohol (Russell, 2001). 
This acid-fast property is due to the extremely hydrophobic cell wall of mycobacteria 
which contains molecules known as mycolic acids. The prevalence of these long chain 
fatty acids in the cell wall results in the acid-fast property as the fuchsin dye reacts with 
the carboxylic acid group of the mycolic acids (Madigan et al., 2003).   
The actinomycetes are a diverse group of Gram-positive bacteria which include 
Mycobacterium, Corynebacterium, Nocardia and Streptomyces. The genus 
Mycobacterium is thought to have originated in soil, like other actinomycetes, and then 
some species are believed to have evolved to colonise mammals (Smith, 2003). 
Mycobacteria can be divided into two groups according to in vitro growth rate; 
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organisms including Mycobacterium smegmatis are so called ‘fast growers’ as they take 
3-4 days to form colonies whereas ‘slow growers’, which includes M. tuberculosis, take 
3-6 weeks (Jacobs et al., 1991).  
The M. tuberculosis complex is comprised of seven members; M. tuberculosis is the 
primary cause of the disease in humans, Mycobacterium bovis can infect many animal 
species and up until the practice of pasteurisation, infected milk was the common route 
of infection into humans from this species (Cole, 2002). Mycobacterium africanum 
causes tuberculosis disease in humans in sub-Saharan Africa and Mycobacterium 
cannetti is a rare occurrence but also causes human TB. Apart from M. bovis other 
members of the complex which cause disease in animals include Mycobacterium 
microti, which infects seals and voles (Cole, 2002) and the newly identified M. mungi, 
which is the causative agent of TB among banded mongooses in Botswana (Alexander et 
al., 2010). 
It was commonly believed, up until a few years ago, that M. bovis was the evolutionary 
predecessor of M. tuberculosis (Smith, 2003). However, this hypothesis has now been 
considered doubtful as through analysis of the sequence insertions and deletions in the 
genomes of the M. tuberculosis complex it has been demonstrated that M. bovis and M. 
tuberculosis probably evolved independently from a common ancestor of M. cannetti 
(Brosch et al., 2002). 
M. tuberculosis H37Rv, a virulent and well-defined strain, was originally sequenced in 
1998 (Cole et al., 1998) and the genome was re-annotated four years later (Camus et al., 
2002). This strain was originally isolated from a 19 year old male TB patient in 1905 
(Steenken & Gardner, 1946). The H37Rv genome is 4.4 megabases in size and contains 
approximately 4000 predicted protein encoding genes, about 40 percent of which encode 
proteins that have no known function (Sassetti et al., 2003). Remarkably, approximately 
18% of the annotated genes have predicted roles in cell wall and cell processes reflecting 
the incredible complexity of this structure in M. tuberculosis (Camus et al., 2002).  
M. tuberculosis has an unusual cell envelope, quite unlike that of typical gram-positive 
or gram-negative bacteria. Particularly characteristic is that it has a highly complex cell 
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wall rich in lipids, which make up to 60 percent of the dry weight of the bacteria 
(Kremer & Besra, 2005). The cell envelope consists of three main structures: the 
cytoplasmic membrane, the cell wall and the outer lipid layer (figure 1.1). The outer 
lipid layer functions as a second permeability barrier composed of mycolic acids and 
other lipid components (figure 1.1); in M. tuberculosis mycolic acids are critical for 
pathogenicity (Bhatt et al., 2007). The extreme hydrophobicity of the cell wall accounts 
for its acid-fastness when stained with carbol-fuchsin, low permeability and resistance to 
many drugs and chemotherapeutics. 
1.1.2 M. tuberculosis infection, treatment and vaccination   
1.1.2.1 Infection and disease symptoms 
Infection with M. tuberculosis, an obligate aerobe, occurs primarily via the respiratory 
route and is spread in the air through fine droplets containing the bacilli (Russell, 2001). 
In more then 90 percent of cases the infection is contained within organised collections 
of immune cells (macrophages and lymphocytes) which aggregate forming granulomas 
to halt disease progression (Russell, 2001). The ability to enter a latent-like state is one 
of the defining properties which makes M. tuberculosis a successful pathogen. 
Individuals with a latent infection have a 10 percent life time risk of re-activation 
whereas in individuals with a compromised immune system, such as those co-infected 
with HIV, the elderly, or those suffering from malnutrition, this risk increases to 10 
percent per year (Russell, 2001). Progression to active pulmonary disease occurs when 
the granuloma breaks down and releases viable bacilli back into the airways of the lungs 
leading to aerosol spread of the infectious bacilli (Russell, 2001; Russell, 2007). 
Symptoms of a productive infection include a persistent cough, weight loss, fever, chest 
pain and night sweats (Smith, 2003). Extra-pulmonary tuberculosis can also develop 
through dissemination of the disease and can infect the lymphatic system, the central 
nervous system, the abdomen and bones; miliary TB is a severe form of the disease 
resulting from widespread dissemination of the disease to many organs of the body 
including the brain and is typified by multiple small lesions (Madigan et al., 2003; 
Smith, 2003). 
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Figure 1.1 The M. tuberculosis cell wall. The complete structure is referred to as the 
mycolyl-arabinogalactan-peptidoglycan complex (Brennan & Nikaido, 1995). LAM = 
lipoarabinomannan, mAG = mycolyl arabinogalactan, PDIM = phthiocerol 
dimycoserosates, PG = peptidoglycan, SL = sulpholipid, DAT = diacyl trehalose, PAT = 
penta-acyl trehalose, PIM = phosphatidyl-myo-inositol mannoside (Kremer & Besra, 
2005).  
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1.1.2.1.1 M. tuberculosis infection cycle and immune response 
During the course of an M. tuberculosis infection the tubercle bacilli encounter changing 
environmental conditions. Upon inhalation, the bacilli enter the respiratory tract and are 
engulfed by alveolar macrophages lining the lungs (figure 1.2) (Russell et al., 2010). 
Inside the macrophage, the M. tuberculosis bacilli are phagocytosed within vacuoles 
known as phagosomes. Usually, as phagosomes mature they fuse with lysosomes 
forming phagolysosomes; the acid hydrolase enzymes and lysosomal proteases within 
the lysosomes result in the digestion of the invading pathogen. However, M. tuberculosis 
has the ability to evade the host’s defence mechanisms by inhibiting phagosome-
lysosome fusion allowing survival and replication within the macrophages; it was 
demonstrated more than 40 years ago that phagosomes infected with M. tuberculosis 
failed to fuse with lysosomes (Armstrong & Hart, 1971). 
Initial infection of alveolar macrophages leads to inflammation and as a result 
mononuclear cells (including lymphocytes, macrophages and monocytes) and 
neutrophils are recruited to the area from the blood vessels (figure 1.2) (Russell et al., 
2010); in addition, mycobacterial fragments can also be taken up by dendritic cells 
which migrate to the lymph nodes to activate T cells which in turn recruit and activate 
more macrophages (Stewart et al., 2003). The collection of recruited cells forms the 
starting material for the granuloma which functions to wall off and contain the infected 
cells (Russell, 2007). As the granuloma matures it consists of infected macrophages 
surrounded by other macrophages which differentiate into several different cell types 
(figure 1.2). Lymphocytes are also recruited to granulomas and in later stages a fibrous 
wall of collagen is formed around the infected cells to produce a mature granuloma 
(Russell, 2007; Russell et al., 2010). At this late stage the inside of the granuloma 
becomes hypoxic (Russell et al., 2010). The M. tuberculosis infection can persist 
asymptomatically for an unknown length of time at this stage (Stewart et al., 2003). 
Upon immune suppression (or anything which leads to the loss of CD4+ T cells) the 
granuloma breaks down releasing the caseated material facilitating a productive M. 
tuberculosis infection and the cycle can begin once more (Russell, 2007; Russell et al., 
2010).  
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The immune system plays a large role in protection against M. tuberculosis disease; a 
TH1 cell mediated response is required for the defence against infection (Stewart et al., 
2003). M. tuberculosis can be eliminated when the macrophage is activated by a TH1 cell 
(a subset of CD4+ T cells); TH1 cells are first activated following antigen presentation 
by MHC class two molecules, TH1 cells then secrete IFNγ which activates macrophages 
(Stewart et al., 2003). Upon activation, macrophages increase their production of TNF 
receptors and are stimulated to secrete TNFα. A combination of TNFα secretion and the 
secretion of IFNγ by TH1 cells induces the production of nitric oxide, superoxide ions, 
antimicrobial peptides and proteases which increases the antimicrobial action of the 
macrophage and helps to destroy the invading pathogen (Janeway et al., 2005; Stewart et 
al., 2003). IL-12 is produced by macrophages to induce CD4+ T-cell differentiation into 
TH1-like cells; IL-12 is secreted by macrophages when mycobacteria ligate to Toll-like 
receptor 2 (TLR-2) on the surface of the macrophage, this ligation also induces the 
macrophage to produce intracellular nitric oxide (Janeway et al., 2005). Activated 
macrophages are able to more effectively form phagolysosomes to destroy the invading 
pathogen (Janeway et al., 2005; Stewart et al., 2003).  
Therefore, to allow the bacilli to persist inside macrophages requires complex regulation 
of gene expression; sensing the external environment allows M. tuberculosis to switch 
on and off appropriate sets of genes which facilitate survival. The identification of these 
virulence determinants may aid in the discovery of new drug targets and vaccine 
candidates which are needed to stem the burden of this disease.  
1.1.2.2 Treatment  
The discovery of streptomycin in the 1940’s began the era of the antibiotic treatment of 
TB (Smith, 2003) and between 1952 and 1966 four new drugs were introduced: 
isoniazid (inhibitor of mycolic acid synthesis), pyrazinamide (unknown action), 
ethambutol (inhibitor of cell wall synthesis) and rifampicin (inhibitor of RNA synthesis) 
(Webb & Davies, 1999). Currently, treatment for active TB which is not drug resistant 
typically takes six months; initial treatment of a patient involves a four-drug 
combination of isoniazid, rifampicin, ethambutol and pyrazinamide for two months  
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Figure 1.2 M. tuberculosis infection cycle.  This figure depicts all stages of the M. 
tuberculosis infection cycle from infection of alveolar macrophages to the formation and 
then breakdown of the granuloma leading to a productive infection where the bacilli are 
expectorated. Figure adapted from Russell et al. (2010). 
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followed by treatment with only rifampicin and isoniazid for a further four months 
(Webb & Davies, 1999). Streptomycin is not currently part of the treatment regimen but 
is still widely considered a front line anti-TB drug, although when first used in the 
1940’s as a single antibiotic treatment it was found that within three months of treatment 
in 80% of cases resistant bacteria had evolved (Webb & Davies, 1999). Furthermore, 
those patients which test positive for TB by the skin test but do not display any clinical 
symptoms are required to undergo a six to nine month treatment with isoniazid alone 
(Russell, 2001). 
However, patients infected with drug resistant strains of TB require a much longer 
treatment period with a larger cocktail of chemotherapeutics (Russell, 2001). Multidrug-
resistant TB (MDR-TB) is diagnosed when the population of bacteria are resistant to 
both the front line drugs izoniazid and rifampicin. M. tuberculosis bacteria that are 
resistant to both front-line and second-line anti-TB drugs are becoming more 
widespread. This extensively drug-resistant TB (XDR-TB) is caused by bacteria that are 
resistant to izoniazid, rifampicin and also any fluoroquinolone treatments plus any of the 
intravenously administered anti-TB drugs including kanamycin, amikacin or 
capreomycin (WHO, 2010). As of March 2010 XDR-TB had been reported in 58 
countries and territories (WHO, 2010).  
Clearly the current treatment regimen is very long and coupled with the side effects of 
some of the drugs this leads to the problem of patient non-compliance. New drugs and 
treatment regimens are required to shorten treatment time and overcome the current 
problem of increasing drug resistance. New therapeutic compounds currently in the 
developmental pipeline include inhibitors of cell wall and protein synthesis, and more 
importantly inhibitors of ATP synthesis which will also hopefully target latent bacilli 
(figure 1.3). The fluoroquinolone compounds moxifloxacin and gatifloxacin (DNA 
gyrase inhibitors) are now in phase three development, compounds TMC207 and PA-
824 are in phase two development whilst SQ-109 is under phase one development 
(figure 1.3) (Lalloo & Ambaram, 2010). 
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Furthermore, with one-third of the world’s population latently infected with the TB 
bacillus the development of new treatments to stop the progression of latent infection 
into active disease would be an attractive and important goal (Stewart et al., 2003).  
1.1.2.3 Vaccination  
The attenuated M. bovis bacillus Calmette-Guérin (BCG) strain is the only vaccine 
against M. tuberculosis currently in use and has variable efficacy around the world 
(Andersen & Doherty, 2005). The vaccine was produced in the 1920’s by two French 
scientists who repeatedly passaged M. bovis for over 13 years to produce the attenuated 
BCG strain. It was first administered in 1921 in France and Belgium (Andersen & 
Doherty, 2005; Behr & Small, 1999), and after double-blind trials started in 1950 was 
subsequently introduced into the UK immunisation program in 1953 (Hart & Sutherland, 
1977; Teo & Shingadia, 2006). In the UK, BCG vaccination is effective against 
pulmonary tuberculosis in children and provides approximately 70 to 80 percent 
protection, but it confers no protection in some third world regions; it is thought that 
genetic differences in populations and prior exposure to environmental mycobacteria 
that share antigens with M. tuberculosis results in a weaker immune response to BCG 
vaccination (Andersen & Doherty, 2005; Colditz et al., 1994). Furthermore, BCG 
vaccination is largely ineffective at protecting against adult pulmonary disease in 
endemic TB areas (Colditz et al., 1994). Various local seed lots of the initial BCG strain 
are used around the world to vaccinate the population either at birth or in childhood 
(Behr & Small, 1999). Routine BCG vaccination of school children began in the UK in 
1953 but was stopped in 2005 as there was now only a low risk of TB infection in that 
population; however the vaccine is still given to those sections of the population 
considered to be at high risk from catching the disease (Teo & Shingadia, 2006). 
Due to the variable efficacy of BCG in different populations around the world there is 
now an urgent need to develop new vaccines (Brennan, 2005; Fletcher & McShane, 
2006; Fletcher et al., 2009; Young & Dye, 2006). There are currently nine new TB 
vaccine candidates in clinical development and the hope is that three new vaccines will 
be in phase III trials by 2016 (Fletcher et al., 2009). A new vaccine would ideally be 
effective in all ages, populations, races and be protective against all stages of the 
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Figure 1.3 New TB drugs under development. Figure taken from the National 
Institute of Allergy and Infectious Diseases (NIAID) accessed at 
www.niaid.nih.gov/topics/tuberculosis/Understanding/WhatIsTB/ScientificIllustrations/
pages/newtbdrugs.aspx. Compounds highlighted with asterisks are those which have 
been taken into development by NIAID. 
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infection including pulmonary, extra-pulmonary and latent stages of TB (Fletcher et al., 
2009). Besides such a prophylactic vaccine, a therapeutic vaccine is also required to deal 
with multidrug resistant TB. Vaccines under development fall under two main 
categories: live attenuated M. tuberculosis vaccines and subunit vaccines. Clinical trials 
of the first candidate subunit vaccine BCG-MVA85A (recombinant modified vaccinia 
virus Ankara (MVA) expressing antigen 85A) started in 2002 (McShane et al., 2004; 
McShane et al., 2005). It is hoped that boosting BCG vaccination with MVA85A could 
both enhance and prolong the antimycobacterial immunity (McShane et al., 2004; 
McShane et al., 2005). There are also several other versions of the Ag85A subunit 
vaccine in clinical trials some of which also include other mycobacterial antigens 
(Brennan et al., 2007; Fletcher & McShane, 2006). Although subjected to tight 
regulatory and ethical requirements there are also five live M. tuberculosis vaccines 
currently in advanced pre-clinical development including an M. tuberculosis phoP 
deletion strain (Walker et al., 2010).  
Research into the function of key proteins is required to learn more about how M. 
tuberculosis causes disease and how it continues to be such a successful pathogen in 
order to produce novel treatments and find new drug targets to help eradicate the burden 
of this disease.  
1.2 Protein Phosphorylation: A Universal Signal Transduction 
Pathway 
Protein phosphorylation in signal transduction pathways is the most widespread post-
translational mechanism (Ubersax & Ferrell, 2007). Phosphorylation has been 
implicated in nearly all basic cellular processes including metabolic regulation, 
transcription, cellular growth and movement, apoptosis, differentiation, cell cycle 
progression, intercellular communication, immunity, learning and memory (Manning et 
al., 2002a; Manning et al., 2002b; Ubersax & Ferrell, 2007). Phosphorylation is carried 
out by protein kinases. 
Protein kinases catalyse the transfer of the γ-phosphate of ATP to a hydroxyl group on 
the side chain of specific amino acids in proteins whilst protein phosphatases function to 
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de-phosphorylate the protein or peptide through removal of the phosphate group. 
Phosphorylation of target proteins leads to transduction of the signal by creating 
conformational changes within the target protein, by creating opportunities for further 
intramolecular or electrostatic interactions and by further protein-protein interactions to 
activate or inhibit protein function (Ubersax & Ferrell, 2007). 
Aberrant kinase activity is known to cause cancer as well as other diseases; therefore a 
large number of ATP competitive kinase inhibitors have been developed with the aim to 
treat these diseases (Lapenna & Giordano, 2009). Most small molecule kinase inhibitors 
are usually designed to compete with ATP for the ATP binding site thus functioning to 
inhibit autophosphorylation of the kinase, therefore keeping it in an inactive 
conformation. One hugely successful kinase inhibitor in the treatment of chronic 
myelogenous leukaemia (CML) and some other cancers is imanitib (Gleevec). Imanitib, 
developed by rational drug design, inhibits the activity of a tyrosine kinase called ABL 
and prevents its activity; in CML cells the tyrosine kinase enzyme is constitutively 
active (Lapenna & Giordano, 2009; Ren, 2005).   
1.2.1 The protein kinase domain 
The protein kinase domain (or catalytic domain) consists of a small N-terminal lobe (~ 
85 amino acids) and a larger C-terminal lobe (~ 170 amino acids) (figure 1.4). The two 
lobes form a cleft where ATP can dock (figure 1.4) (Kornev et al., 2006). Before kinases 
become active enzymes they have to convert from an inactive conformation into a 
catalytically competent form (Kornev et al., 2006). This process is known as 
autophosphorylation of the protein kinase; one common mechanism of activation is 
through phosphorylation of the kinase activation loop on serine, threonine or tyrosine 
residues (figure 1.4) (Lochhead, 2009; Wang & Wu, 2002). Phosphorylation of these 
residues results in a conformational change in the activation loop rendering the kinase in 
a stabilised active conformation (Lochhead, 2009; Nolen et al., 2004). There are three 
mechanisms by which the activation loop is phosphorylated: by an upstream kinase in a 
signalling cascade; by autophosphorylation in trans either where an active kinase trans-
phosphorylates an inactive kinase or where two inactive molecules dimerise and 
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exchange activation segments; or by autophosphorylation in cis, an intramolecular event 
whereby kinases phosphorylate their own activation loops; much is still not known about 
this third mechanism of activation (Lochhead, 2009). Activated kinase domains play 
three main roles: binding and orientation of the ATP phosphate donor as a complex with 
a divalent cation (Mg
2+
 or Mn
2+
); binding and orientation of the protein substrate; and 
transfer of the γ-phosphate from ATP to the acceptor residue of the protein substrate 
(serine, threonine or tyrosine) (Kornev et al., 2006).  
Archetypal protein kinases contain a conserved lysine-glutamic acid pair in their active 
site which forms critical contacts with the ATP (in figure 1.4 these residues are K72 and 
E91). The lysine residue binds to the α and ß phosphate groups of ATP and this residue 
is essential for enzyme activation (Young et al., 2003). Two other important conserved 
motifs within kinase domains include the DFG motif and the HRD motif (where each 
letter represents the conserved amino acid). The aspartate residue in the DFG motif 
forms polar contacts with all three phosphate groups of ATP and is important for 
catalysis (figure 1.4) (Kornev et al., 2006). The aspartate residue in the HRD motif helps 
to orientate the peptide substrate (Kornev et al., 2006). Kinases with this motif are 
known as RD kinases. The arginine residue interacts with the phosphorylated activation 
loop and controls its fold finally resulting in activation of kinase activity (Kornev et al., 
2006).  
1.2.2 M. tuberculosis signal transduction via protein phosphorylation 
Reversible protein phosphorylation is a key mechanism used to transduce extracellular 
signals into cellular responses. Bacterial signal transduction systems can control many 
diverse processes including gene expression, adaptation to environmental stimuli, 
growth, development, stress responses, pathogenicity and host-pathogen interactions 
(Av-Gay & Deretic, 2005).  
In M. tuberculosis signal transduction occurs via five main families of kinases and 
phosphatases (Chao et al., 2010). The first family comprise the classic bacterial two-
component systems involving histidine kinases and response regulators, the second 
family are the eukaryotic like serine/threonine protein kinases (STPKs), the third family  
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Figure 1.4 Diagram depicting the known interactions between the catalytic core of 
the protein kinase, ATP and a substrate protein. The amino acid numbering used in 
the diagram is for the eukaryotic cAMP-dependent protein kinase A. Image adapted 
from Kornev et al. (2006).  
 
 
 
 
 
 
 
 
 
 
Chapter 1. Introduction 
 34 
 
 
 
 
 
 
 
Figure 1.5 A comparison of signalling systems in bacteria. Figure adapted from 
Wehenkel et al. (2008). The genome sizes of different bacteria (in Mb) are shown by 
grey bars; the number of genes encoding histidine kinases are shown by blue dots and 
response regulators and shown by green dots; genes encoding STPKs are shown with red 
dots. The numbers of each of these systems were defined by homology searches.  
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comprises the single serine/threonine phosphatase, the fourth family comprises one 
protein tyrosine kinase, named PtkA, which has been recently identified and is a member 
of a newly identified class of tyrosine kinases (Bach et al., 2009), and the fifth family 
comprises two secreted tyrosine phosphatases named PtpA and PtpB (Chao et al., 2010; 
Koul et al., 2000).  
Signal transduction in M. tuberculosis has become a target for the development of novel 
therapeutics in the treatment of TB (Szekely et al., 2008). Protein kinases and 
phosphatases allow reversible protein phosphorylation providing cells with a tool to 
sense and respond to both internal and external stimuli and thus represent attractive drug 
targets for new therapeutics.   
1.2.2.1 Histidine kinases and response regulators: the classical bacterial two-
component system 
One major way prokaryotes sense their environment and regulate their gene expression 
profile is via the classical two-component signal transduction systems which were first 
described almost three decades ago (Av-Gay & Deretic, 2005; West & Stock, 2001). 
These systems are not present in humans (West & Stock, 2001). Two-component 
systems consist of a histidine sensor kinase protein and a response regulator protein. 
When the signal input domain of the sensor undergoes autophosphorylation a phosphate 
group from ATP is transferred from a conserved histidine residue on the sensor to a 
conserved aspartate or glutamate residue on the receiver domain to transduce the signal 
(West & Stock, 2001). Intriguingly, mycobacterial genomes contain relatively few 
histidine kinases and response regulators compared to other bacterial genomes of a 
similar size (figure 1.5) (Wehenkel et al., 2008); although thirty genes encoding putative 
two-component system proteins have been identified in the M. tuberculosis genome 
(Cole et al., 1998), only 11 systems paired in operons have been characterised. This is 
far fewer than in E. coli where over 30 pairs have been characterised (Mizuno, 1997). 
However, this can be explained by the fact that M. tuberculosis contains a relatively 
large number of STPKs; 11 eukaryotic-like STPKs and one tyrosine kinase are present 
in the genome meaning that phosphorylation can also occur on a serine, threonine or 
tyrosine residue. Therefore it is thought that in M. tuberculosis STPKs fulfil the roles of 
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the classical bacterial two-component systems (Av-Gay & Everett, 2000; Wehenkel et 
al., 2008). 
1.2.2.2 The ‘eukaryotic-like’ serine/threonine protein kinases of M. tuberculosis  
STPKs involve the transfer of the γ-phosphate from ATP directly to a substrate and 
although originally thought to be present only in eukaryotes, these signalling domains 
have now been described in a number of bacteria (Bakal & Davies, 2000; Greenstein et 
al., 2005). Eleven STPKs have been identified in the M. tuberculosis genome, named 
protein kinase A (PknA) to protein kinase L (PknL) (with the exception of PknC) (Cole 
et al., 1998), nine of which are predicted to have a transmembrane-spanning region 
(Grundner et al., 2005) (figure 1.6). Interestingly STPKs have been discovered in many 
species of pathogenic bacteria including Listeria monocytogenes, Pseudomonas 
aeruginosa and Streptococcus pneumoniae implicating STPKs in the regulation of 
virulence and pathogenesis of these organisms (Cozzone, 2005). For comparison, the 
human genome contains over 500 putative serine/threonine and tyrosine protein kinase 
genes (Manning et al., 2002b), the yeast genome contains over 100, whilst only one is 
found in E. coli (Young et al., 2003).  
1.2.2.2.1 Structure, homology and activation of M. tuberculosis STPKs 
Kinase domains of STPKs are approximately 250 amino acid residues in length and 
comprise 11 conserved subdomains which were initially described by Hanks et al. 
(Hanks et al., 1988; Hanks, 1991; Hanks & Hunter, 1995). Like eukaryotic STPKs,  M. 
tuberculosis kinase domains are activated through phosphorylation of specific residues 
in the activation loop; PknB, PknD, PknE and PknF show a conserved pattern of 
autophosphorylation in their activation loops (Boitel et al., 2003; Duran et al., 2005).  
The structures of the kinase domains of PknB, PknD, PknE and PknG have been solved; 
the PknB, PknD and PknE kinase domains have been shown to be dimeric, which in the 
cell would presumably occur upon extracellular ligand binding to the sensor domain, and 
this dimerisation seemingly results in trans or cis autophosphorylation of the activation 
loop causing a conformational change leading to activation of the kinase (Gay et al., 
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2006; Greenstein et al., 2007a; Mieczkowski et al., 2008; Ortiz-Lombardia et al., 2003; 
Scherr et al., 2007; Young et al., 2003). This mechanism of activation is suggested to be 
conserved among other mycobacterial STPKs (Young et al., 2003). However, PknG is 
unique among mycobacterial kinases as the critical arginine residue in the kinase domain 
is lacking (refer to section 1.2.1) (Av-Gay & Everett, 2000; Chao et al., 2010). 
Therefore PknG is a non-RD kinase which suggests the absence of autophosphorylation 
in the activation loop; this was shown by O’Hare and Scherr (O'Hare et al., 2008; Scherr 
et al., 2009). PknG is therefore presumed to be activated via a different mechanism 
which involves the thioredoxin domain which senses the redox status of the cell (figure 
1.6) (Av-Gay & Everett, 2000). 
In M. leprae, where massive gene decay has occurred, only four of the M. tuberculosis 
STPKs are present, namely PknA, PknB, PknG and PknL, highlighting the probable 
essential roles of these proteins for bacterial viability  (Cole et al., 2001).  Furthermore, 
all 11 M. tuberculosis STPKs are present in the M. bovis BCG vaccine strains (Behr et 
al., 1999). Upon multiple sequence comparison of the M. tuberculosis STPKs with other 
prokaryotic kinases and eukaryotic kinases it was found that all the M. tuberculosis 
kinases clustered with other prokaryotic kinases with the exception of PknG and PknK 
which were most similar to the eukaryotic STPKs (Av-Gay & Everett, 2000). PknG and 
PknK are the two kinases with no transmembrane-spanning region and are therefore 
predicted to be soluble.  
1.2.2.2.2 M. tuberculosis kinases as novel drug targets 
The inhibition of essential signalling pathways in M. tuberculosis is an attractive 
prospect to yield novel classes of drug targets (Hegymegi-Barakonyi et al., 2008). There 
has been much work focussed into designing inhibitors against the essential M. 
tuberculosis kinases PknA and PknB (Szekely et al., 2008; Wehenkel et al., 2006), 
although to date no kinase inhibitor has been discovered which has a high potency 
against M. tuberculosis despite appearing to be an effective inhibitor in in vitro assays 
(K. Lougheed, unpublished data) (Magnet et al., 2010). 
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a. Serine/Threonine protein kinases 
 
Figure 1.6 Structural analyses of M. tuberculosis serine/threonine protein kinases 
and protein phosphatase. The figure shows domain structures of the M. tuberculosis 
STPKs and the single serine/threonine phosphatase. Figure a adapted from Av-Gay and 
Everett 2000. The SMART domain database was used to construct the image in figure b 
(Letunic et al., 2006). PQQ = pyrroloquinoline quinine, TPR = tetratricopeptide, Trx = 
thioredoxin. 
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1.2.2.2.3 M. tuberculosis STPK function 
M. tuberculosis STPKs have been implicated to have diverse regulatory functions; PknA 
and B (the two essential STPKs) have been suggested to have roles in cell morphology 
and shape (Dasgupta et al., 2006; Kang et al., 2005). A recent study showed that InhA, 
involved in mycolic acid biosynthesis and the primary target of isoniazid, was 
phosphorylated in vitro by PknA, PknB, PknH and to a lesser extent by PknF 
demonstrating that at least in vitro there are overlapping phosphorylation motifs of the 
M. tuberculosis kinases (Khan et al., 2010). PknA has also been shown to phosphorylate 
mtFabH (beta-ketoacyl-acyl carrier protein (ACP) synthase III) which is also involved in 
mycolic acid synthesis (Veyron-Churlet et al., 2009) and FtsZ in vitro (Thakur & 
Chakraborti, 2006). PknA and PknB both phosphorylate the forkhead-associated 
domain-containing (FHA) protein Rv0019c (Gupta et al., 2009; Sureka et al., 2010) and 
EmbR in vitro, which is essential for the regulation of the embCAB operon encoding cell 
wall arabinosyltransferases (Sharma et al., 2006); EmbR is also phosphorylated in vitro 
by PknJ (Jang et al., 2010) and PknH (Molle et al., 2003)). PknJ also phosphorylates 
pyruvate kinase A, an enzyme that catalyses the last step of glycolysis (Arora et al., 
2010). Furthermore, PknB phosphorylates PBPA in vitro, a penicillin-binding protein 
required for cell division (Dasgupta et al., 2006) and both SigH and its cognate anti-
sigma factor RshA in vitro and in vivo (Park et al., 2008). SigH, which is negatively 
regulated by RshA, responds to oxidative, nitrosative and heat stress and is required for 
virulence in animal infection models (Park et al., 2008).  
PknD phosphorylates an FHA domain of Rv1747 in vitro (Grundner et al., 2005) and 
Rv0516c, a putative anti-anti-sigma factor of unknown function in vitro and in vivo 
(Greenstein et al., 2007b). A 2010 study by Vanzembergh and colleagues showed that 
PknD contributed to the survival of M. tuberculosis in phosphate poor conditions 
suggesting that PknD may play a role in detecting environmental phosphate 
(Vanzembergh et al.). In an earlier 2006 study MmpL7 was proposed to be a potential 
substrate for this kinase; PknD was shown to phosphorylate this protein which is 
required for the virulence of M. tuberculosis due to its role in PDIM translocation to the 
cell wall (Perez et al., 2006).  
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PknE was shown to be involved in the nitric oxide stress response and apoptosis of M. 
tuberculosis in a human macrophage model of infection (Jayakumar et al., 2008) whilst 
PknI has been implicated in controlling the slow growth of M. tuberculosis during 
infection and a mutant strain displayed a hypervirulence phenotype in SCID mice 
(Gopalaswamy et al., 2009).   
The phosphorylation of Rv1827 by PknB or PknG abrogates binding of Rv1827 to three 
proteins which are all involved in α-ketoglutarate metabolism (Nott et al., 2009). Using 
pull-down assays and mass spectrometry it was found that PknG phosphorylates Rv1827 
at threonine 21, adjacent to the residue phosphorylated by PknB (T22), and these two 
phosphorylation events are mutually exclusive (O'Hare et al., 2008). Loss of Rv1827 
phosphorylation leads to increased glutamate levels in the cell which is intriguing given 
the finding that a pknG deletion mutant led to a threefold higher accumulation of 
glutamine and glutamate in the cell compared with wild type (Cowley et al., 2004). In 
the related actinobacterium Corynebacterium glutamicum, the homologue of Rv1827, 
Odh1, has been shown to be a regulator of a key enzyme of the tricarboxylic acid cycle, 
originally thought to be 2-oxoglutarate dehydrogenase (ODH) but now known to be 2-
hydroxy-3-oxoadipate synthase (de Carvalho et al., 2010), and was shown to be 
phosphorylated by PknG (Niebisch et al., 2006). In addition, an earlier paper published 
in 2004 suggested PknG promotes mycobacterial survival within macrophages by 
preventing phagosome-lysosome fusion; PknG was shown to be secreted in macrophage 
phagosomes and the inactivation of PknG resulted in mycobacterial cell death 
(Walburger et al., 2004). It has also been shown that PknB, D, E and F can 
phosphorylate Rv1827 but with 5, 32 and 2 times lower that PknB activity again 
demonstrating that more than one STPK can phosphorylate the same substrate, at least in 
vitro (Villarino et al., 2005).  
PknL is predicted to have a role in transcriptional regulation and cell division 
(Lakshminarayan et al., 2008) and phosphorylates the regulatory protein Rv2175c 
(Canova et al., 2008). PknH has been suggested to play a role in regulating cell growth; 
a pknH deletion mutant actually resulted in a higher bacillary load in mouse organs 
compared to wild type (Papavinasasundaram et al., 2005). Furthermore, PknK has been 
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implicated in a similar role where it is thought to be involved in early infection events in 
macrophages; a ∆pknK mutant showed increased survival during a persistent mouse 
infection thus implying a role in slowing down the growth of mycobacteria. The mutant 
was also more resistant to low pH, oxidative and hypoxic stress (Malhotra et al., 2010). 
Clearly, the signalling network of the M. tuberculosis STPKs is highly complex and 
much more work is needed to be performed in order to fully elucidate the inter-
relationships and function of these important M. tuberculosis signalling proteins. 
1.3 The forkhead-associated domain  
Forkhead-associated (FHA) domain-containing proteins are phosphorylation-dependent 
proteins, conserved from bacteria to man, that specifically recognise phosphothreonine 
(pT) epitopes, distinguishing them from phosphoserine epitopes, and were initially 
identified within fork head transcription factors in 1995 (Hammet et al., 2003; Hofmann 
& Bucher, 1995; Mahajan et al., 2008). FHA domains are present in proteins with 
diverse functions including signal transduction, transcription factors, protein transport, 
cell cycle regulation and are particularly prevalent in DNA damage and repair genes 
(Mahajan et al., 2008); furthermore in eukaryotes at least, FHA domains have been 
shown to be essential in the transduction of the phospho-signal (Durocher & Jackson, 
2002). To date, FHA domains have been identified in more than 2000 prokaryotic and 
eukaryotic proteins (Mahajan et al., 2008).  
FHA domains form 11 stranded ß-sandwiches and are between 95 and 150 amino acid 
residues in size (Durocher, 2003; Hammet et al., 2003; Mahajan et al., 2008). The 
structure of the Rad53 FHA-1 domain from Saccharomyces cerevisiae was solved in 
complex with a phosphopeptide and is shown in figure 1.7 (Durocher & Jackson, 2002). 
Rad53 is a kinase which contains two FHA domains. Highly conserved residues within 
FHA domains are involved in direct contact with the phosphopeptide, either by 
contacting the peptide backbone or by forming a network of hydrogen bonds with the pT 
residue on the epitope (Durocher & Jackson, 2002). In the Rad53 FHA domain-
containing protein, there are six highly conserved residues in the FHA-1 domain, five of 
which are located around the peptide binding site. Residues arginine-70 and serine-85 
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bind directly to the pT residue itself (Durocher et al., 2000). Consequently, mutation of 
the conserved serine 85 residue within one of the peptide binding loops abolishes the 
binding activity of the FHA domain to the pT residue.  
1.3.1 FHA domain-containing proteins in M. tuberculosis  
Six FHA domain containing proteins have been identified in M. tuberculosis, four of 
which lie in putative operons with serine/threonine protein kinases; they include embR 
(Rv1267c) which forms a putative operon with pknH, fhaA (Rv0020c) and fhaB 
(Rv0019c) which both lie in the same putative operon with pknA (Rv0015c) and pknB 
(Rv0014c), and the focus of this project Rv1747 which is in a putative operon with pknF. 
A schematic of the six M. tuberculosis FHA domains are shown in figure 1.8. Using the 
CLUSTAL W protein alignment program (http://www.ebi.ac.uk/Tools/clustalw2/index 
.html) I found that Rv3360 and Rv1747 FHA-1 are very similar sharing 62 % sequence 
identity and 78 % sequence similarity (figure 1.9). Intriguingly Rv3360 contains an 
alanine residue at a critical position where all the other FHA domains contain a serine 
residue necessary for the interaction of the FHA domain with phosphopeptides 
suggesting that the function of the FHA domain in Rv3360 may be abrogated (figure 
1.9). FHA-1 and FHA-2 from Rv1747 share 26.2 % sequence identity. Of the M. 
tuberculosis FHA domain-containing proteins, only the EmbR structure has been solved 
in complex with a phosphopeptide; it contains the 11 stranded ß-sandwich seen in 
eukaryotic FHA domains (Alderwick et al., 2006). Kinase activation loop 
phosphorylation renders the protein kinase in an active conformation to receive 
substrates. In the case of FHA domain-containing proteins it is thought that the peptide 
binding pocket of the FHA domain recognises and binds to one of the phosphorylated 
activation loop threonine residues on the kinase and then this delivers another part of the 
protein to the active site to be phosphorylated (Villarino et al., 2005).  
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Figure 1.7 S. cerevisiae RAD53 FHA-1 domain in complex with a complex with a 
phosphothreonine-containing peptide. Figure adapted from Durocher and Jackson, 
(2002).  
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Figure 1.8 Structural analyses of the M. tuberculosis FHA domain-containing 
proteins. The SMART domain database was used to construct images in the figure 
(http://smart.embl-heidelberg.de/smart/set_mode.cgi?GENOMIC=1) (Letunic et al., 
2006). CHP = conserved hypothetical protein. Areas in pink denote regions of low 
complexity. 
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a. M. tuberculosis FHA domain-containing proteins alignment 
 
b. Cladogram of the evolutionary relationships between the FHA domains 
 
Figure 1.9 Alignment of the M. tuberculosis FHA domains Figure a is a sequence alignment 
and figure b is a cladogram of the evolutionary relationships between the FHA domains. 
Sequences were aligned using the Clustal W programme accessed at 
http://www.ebi.ac.uk/Tools/clustalw2/. Red residues = small amino acids, blue = acidic residues, 
magenta = basic residues and green = hydroxyl + amine + basic residues. * means that the 
residues or nucleotides in that column are identical in all sequences in the alignment. : means 
that conserved substitutions have been observed, according to the colour of the residues and "." 
means that semi-conserved substitutions are observed. The blue arrow highlights the serine 
residue critical for pT epitope binding which is not conserved in Rv3360. 
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1.4 PknF and Rv1747 
This project focuses on PknF and Rv1747, an adjacent gene in the same putative operon 
coding for an ABC transporter (figure 1.10). PknF is a transmembrane STPK that 
contains an intracellular kinase domain and an extracellular domain presumed to be 
responsible for signal recognition (figure 1.10). Rv1747 contains two FHA modules, a 
feature unique to the six FHA domain-containing proteins of M. tuberculosis (figure 
1.8).  
1.4.1 ATP-binding cassette transporters 
ATP-binding cassette (ABC) transporters form one of the largest families of 
transmembrane proteins thought to be present in all species from microbes to humans 
(Dassa, 2003).  
ABC transporters bind and hydrolyse ATP providing energy for uptake or export of 
substrates across cell membranes and can be divided into three main groups: importers, 
exporters and those ABC proteins which do not appear to have a transport function but 
are involved in DNA repair and mRNA translation (Davidson et al., 2008). Functions of 
ABC transporters include the uptake of nutrients into the cells and the export of 
virulence factors, toxins, proteins, lipids, and hydrophobic drugs (Davidson et al., 2008). 
More diverse functions include roles in cell division, signal transduction, sporulation, 
nodulation, bacterial pathogenesis and antigen presentation (Davidson et al., 2008; 
Higgins & Linton, 2003); cell survival is dependent on the transport of substrates across 
cell membranes.  
ABC transporters are integral membrane proteins and the archetypal transporter 
comprises two hydrophobic transmembrane domains (TMDs) and two cytoplasmic 
nucleotide binding domains (NBDs), also known as ATPase domains. The two 
transmembrane domains span the membrane multiple times; in a typical transporter there 
are six membrane spanning segments per domain, a total of 12 per transporter (Higgins 
& Linton, 2003). The core ABC protein domain is approximately 215 amino acids in 
size (Higgins et al., 1986); the NBD amino acid sequence contains three major 
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conserved motifs: the commonly found WalkerA and WalkerB motifs and a specific 
linker peptide signature motif located upstream of the WalkerB motif (Saurin et al., 
1999; Schneider & Hunke, 1998; Walker et al., 1982). 
In humans, many ABC transporters are associated with disease; for example, mutations 
in ABC transporters are associated with genetic diseases including Cystic Fibrosis, 
Tangier disease and Macular Dystrophy; ABC transporters are also behind the problem 
of multidrug resistance in cancer therapy (Higgins, 2001; Linton & Higgins, 1998). Each 
year, thousands of cancer deaths are attributed to the overexpression of ABC 
transporters which results in resistance to chemotherapeutic drugs (Higgins & Linton, 
2003). 
In bacteria, many ABC transporters are associated with being able to survive in different 
environments or are virulence determinants; with around 70 ABC transporters, 
approximately 5% of the E. coli genome is encoded by these transport molecules (Linton 
& Higgins, 1998). The number of ABC transporters encoded by different bacterial 
species varies widely and it is thought that this number is correlated with the diversity of 
environments that a particular species can adapt to live in i.e. bacteria that live in varied 
environments have more transporters than those which have a specific growth niche 
(Higgins & Linton, 2003).   
Typical structures of a bacterial importer and exporter are shown in figure 1.11. 
Bacterial ABC importers are formed from four polypeptide chains, that are often 
separately encoded (Saurin et al., 1999), and require an external binding protein which 
functions to deliver the substrate to the transporter (Dawson et al., 2007). In contrast, 
bacterial exporters are produced as one polypeptide where a single gene usually encodes 
both the transmembrane domain and a NBD domain (Saurin et al., 1999).  
1.4.1.1 ABC transporters in M. tuberculosis  
Approximately 2.5% of the M. tuberculosis genome comprises genes encoding putative 
ABC transporters; a total of 37 ABC transporters have been identified in M. 
tuberculosis, at least 26 of which appear to be complete i.e. contain at least one NBD  
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a. The pknF and Rv1747 genes and surrounding genomic region 
 
b. SMART domain structure of PknF 
 
c. SMART domain structure of Rv1747 
 
Figure 1.10 The pknF and Rv1747 genes plus the domain architecture of the two 
proteins. The pknF and Rv1747 genes are depicted in figure a. The marks on the 
chromosome are at 1000 bp intervals. Figures b and c depict the SMART domain 
structure of PknF and Rv1747 respectively. Regions shown in blue are the 
transmembrane domains. Figure b shows the kinase domain of PknF. Regions shown in 
pink denotes low complexity regions. Figure c shows the two FHA domains (yellow) 
and the ATPase domain of Rv1747 (Letunic et al., 2006).  
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Figure 1.11 Typical structures of bacterial ABC transporters. This figure shows the 
domain structure of an archetypal bacterial importer and exporter. TMD = 
transmembrane domain. NBD = nucleotide binding domain. Image adapted from 
Dawson et al. (2007).  
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and one TMD. Sixteen of these transporters have been categorised as importers and 21 
are presumed to be exporters (Braibant et al., 2000). 
The BacA (Rv1819c) ABC transporter is a recently characterised M. tuberculosis 
protein (Domenech et al., 2009). A ∆bacA mutant strain showed identical growth in the 
lungs and spleens of mice over 205 days in an aerosol model of infection. However, in a 
time-to-death experiment the mice infected with the mutant strain survived significantly 
longer indicating a role for this transporter in maintaining a persistent infection in the 
host; this phenotype has been observed in bacA mutants of other alphaproteobacteria 
although the precise substrate of the M. tuberculosis BacA transporter remained elusive 
(Domenech et al., 2009).  
Rv1280c-Rv1283c encodes an oligopeptide importer which includes a substrate binding 
protein OppA (Rv1280c) (Dasgupta et al., 2010). OppA was shown to bind the 
tripeptide glutathione and during a macrophage infection with an ∆Rv1281c mutant there 
was a decrease in apoptosis and cytokine release from the macrophages (Dasgupta et al., 
2010). In 2008, it was shown that the ProXVWZ (Rv3759c-Rv3756c) ABC importer 
allowed M. tuberculosis to obtain betaine from human macrophages to help initiate 
mycobacterial growth; a proXVWZ mutant was impaired for survival and growth in 
macrophages (Price et al., 2008). Together, these studies highlight the important role of 
ABC transporters in the virulence and persistence of M. tuberculosis infection. 
M. tuberculosis ABC transporters have also been implicated in drug discovery; Rv1218c 
is an efflux pump and an Rv1218c mutant was found to be more susceptible to a variety 
of classes of compounds compared with wild type H37Rv suggesting that this ABC 
transporter effluxes the compounds from the cell (Balganesh et al., 2010).  
1.4.1.1.1 The ABC transporter Rv1747 
The presence of fused nucleotide binding and transmembrane domains is a strong 
indicator of an ABC exporter (Davidson et al., 2008; Dawson et al., 2007). Based on its 
amino acid sequence Rv1747 belongs to the G subfamily of ABC transporters; this 
family consists of half-transporters which oligomerise to form the functional transporter 
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and have a unique domain arrangement where the nucleotide binding domain is located 
at the N-terminus of the protein with respect to the transmembrane spanning domains 
(Dassa, 2003). Furthermore an external binding protein required for the function of 
importers has not been identified for Rv1747 (Davidson & Maloney, 2007; Saurin et al., 
1999). Therefore, taken together, from its amino acid sequence and the fact that it is 
encoded by a single gene, Rv1747 is predicted to function as an ABC exporter. 
However, although it has been demonstrated that the function of Rv1747 is required for 
the growth of the bacterium in mice and macrophages (Curry et al., 2005), the identity 
of the substrate has not yet been revealed. Numerous hypotheses have been raised as to 
what the nature of the substrate may be by comparing the Rv1747 ABC transporter to 
analogous systems in other bacteria which are also required for growth and survival 
within the host. Bacterial ABC exporters transport many different substances which 
include cell surface components such as lipopolysaccharides, lipids, proteins involved in 
pathogenesis including haemolysin, and peptides, drugs and siderophores (Dassa & 
Bouige, 2001); Rv1747 could export any one of these molecules which would make the 
function of the transporter necessary for growth in vivo. A further discussion of possible 
substrates of Rv1747 is provided in the Introduction of Chapter 4. 
ABCdb is a bacterial and archaeal ABC transporter database (http://www-abcdb. 
biotoul.fr/).  According to this database Rv1747 was discovered to be similar to the gram 
positive soil bacterium Streptomyces coelicolor protein Q9AJX1 sharing 32.6 % identity 
with Rv1747. This protein contains two FHA domains, one nucleotide binding domain 
and five transmembrane domains. Furthermore the Streptomyces avermitilis protein 
Q829D9 also shares 31.5 % identity with Rv1747 and also contains the same domain 
structure suggesting that these two Streptomyces proteins are direct orthologs of 
Rv1747. Both these Streptomyces proteins are predicted to function as ABC transporters 
with currently no known function. Of the other M. tuberculosis ABC transporters 
Rv1747 is most closely related to Rv1687c, an uncharacterised ABC transport protein 
(Braibant et al., 2000).  
In humans, ABC transporters of the G family to which Rv1747 belongs, such as 
ABCG1, G4 and G5/8, are involved in ATP-dependent translocation of steroids and 
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possibly other lipids whilst ABCG2 (the breast cancer resistance protein) has been 
identified as a multidrug transporter (Velamakanni et al., 2007).  
It has been suggested (http://tuberculist.epfl.ch/) that the substrate of the Rv1747 ABC 
transporter may be a lipooligosaccharide. A review of all the M. tuberculosis ABC 
transporters published in 2000 revealed that Rv1747 falls into a sub-class of transporters 
which have an unknown function (Braibant et al., 2000). Rv1747 is similar to the White 
protein (ABCG family of transporters) from Drosophila melanogaster (17% homology) 
which is a permease necessary for the export of pigment precursors responsible for eye 
colour, and to NodI from Rhizobium strains (21% homology) which is a protein 
implicated in the nodulation process by export of a lipooligosaccharide (Braibant et al., 
2000). I have compared the homology with other known ABC transporters from other 
organisms, and in addition to the two proteins mentioned above, an NCBI Blast of the 
Rv1747 protein revealed similarities with a cobalt transport family protein found in 
bacteria, eukaryotes and archaea and with an ABC group A subfamily which functions 
to transport a variety of lipid compounds suggesting that the Rv1747 transporter could 
be involved in any one of these functions in M. tuberculosis. 
1.4.2 Previous studies on the PknF-Rv1747 system 
Previous studies have investigated the interaction between PknF and Rv1747 and the 
possible substrates of Rv1747. A deletion mutant of Rv1747 was shown to be attenuated 
in a mouse intravenous injection model of M. tuberculosis infection where the bacterial 
load of the mutant was 10-fold lower than that of the wild type in both lungs and spleen 
(Curry et al., 2005). Furthermore, the Rv1747 strain was attenuated for growth in both 
naïve macrophages and dendritic cells (Curry et al., 2005); in contrast the mutant grew 
as well as the wild type in vitro highlighting that this gene does not cause a general 
growth defect but is required for the full virulence of M. tuberculosis during infection 
thus warranting further studies to determine why this protein is important. A deletion 
mutant of pknF was also generated and a diagram showing the two gene deletions and 
the respective complementing strains is shown in figure 1.12. 
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Autophosphorylation of PknF occurs on threonine residues T173 and T175 of the 
activation loop (Duran et al., 2005) and both FHA domains of Rv1747 seem to be 
required for the interaction of PknF and Rv1747 (Curry et al., 2005; Molle et al., 2004). 
Yeast-2-hybrid analysis demonstrated interaction between PknF and Rv1747. This 
interaction was abolished in a kinase null mutant of PknF and by mutation of the 
presumed activation loop of PknF and in one of the FHA domains of Rv1747 (Curry et 
al., 2005). In vitro phosphorylation studies reported that the interaction was also stopped 
when one of the activation loop threonines known to be involved in PknF 
autophosphorylation was mutated (Molle et al., 2004). Additionally, in the Molle et al. 
study it was also shown that the nucleotide binding domain of Rv1747 possessed 
ATPase activity suggesting that it was able to hydrolyse ATP to provide energy to 
transport a substrate across the M. tuberculosis membrane. Furthermore mutation of the 
serine residue in each of the FHA domains, which are essential for binding to the 
phosphothreonine residue, resulted in a reduced level of phosphorylation of Rv1747, 
thus highlighting the importance of the serine residue in these domains to mediate 
phosphorylation by PknF (Molle et al., 2004).  
In vitro assays have shown that PknF also phosphorylates another FHA domain 
containing protein, Rv0020c (Grundner et al., 2005). Additionally, Molle et al. 
performed in vitro assays to demonstrate that PknF phosphorylates KasA, KasB (Molle 
et al., 2006a) and the GroEL1 chaperone (Canova et al., 2009). Furthermore, in 2009 the 
same group showed that PknF phosphorylates mtFabH to negatively regulate the FASII 
cycle involved in mycolic acid synthesis (Veyron-Churlet et al., 2009). In addition, 
PknF was shown to phosphorylate InhA in vitro, but not as effectively as PknA, PknB or 
PknH (Khan et al., 2010). Domains of Rv1747 have also been shown, at least in vitro, to 
be phosphorylated by PknB, PknD, PknE and PknF (Grundner et al., 2005). Clearly 
therefore, there is a complex web of phosphorylation-dependent interactions. 
A 2005 study reported that PknF negatively regulates glucose uptake; using antisense 
RNA to reduce the levels of PknF protein in M. tuberculosis, Deol et al. showed  
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Figure 1.12 Diagram of the genomic region of M. tuberculosis containing the pknF 
and Rv1747 genes. The figure shows the extent of the pknF and Rv1747 deletions and 
the complementing plasmids ppknF
+
 and pRv1747
+
. The pknF deletion was designed as 
an in frame deletion strain (R. Whalan, Personal Communication). The Rv1747 
complementing plasmid included a copy of pknF. The marks on the chromosome are at 
1,000 bp intervals. Figure adapted from Curry et al. (2005) and R. Whalan (Personal 
Communication). 
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increased glucose uptake 16-fold higher compared with wild type and the antisense 
strain also grew 1.5 fold faster (Deol et al., 2005). Additionally, the M. tuberculosis 
bacilli exhibited unusual cell morphology; the cells were shorter compared to wild type 
and the ends of the cells exhibited bulbous structures. This was interpreted as indicating 
that PknF may be regulating glucose uptake through phosphorylation of an ABC 
transporter (Deol et al., 2005) although not presumably Rv1747 given this has a 
sequence characteristic of an exporter (figure 1.11) (Saurin et al., 1999). The 
overexpression in M. smegmatis of the homologue of PknF resulted in irregular cell 
shape with bulbous like structures on the ends of the cells similar to the cell morphology 
observed after antisense expression (Deol et al., 2005; Gopalaswamy et al., 2007). 
Furthermore, M. smegmatis overexpressing the supposed PknF homologue 
(MSMEG3677) demonstrated reduced sliding motility and biofilm formation which was 
suggested could be due to alterations in glycopeptidolipid composition (Gopalaswamy et 
al., 2007); glycopeptidolipids are only present among some non-tuberculous 
mycobacteria and are not found in M. tuberculosis (Billman-Jacobe, 2004). PknF 
belongs to the Clade III group of kinases along with PknI and PknJ (Narayan et al., 
2007). Using a comparative genomic approach Narayan and colleagues showed that 
whilst PknF has orthologs in all sequenced M. tuberculosis strains (H37Rv, CDC1551, 
F11 and M.tb C), M. bovis, Mycobacterium avium ssp. paratuberculosis and 
Mycobacterium marinum, when looking at the co-localisation of genes, i.e. looking for 
an Rv1747 ortholog, they could not assign an ortholog in M. smegmatis or M. leprae 
since none of the Clade III members from these species showed conservation of synteny 
(Narayan et al., 2007).  
It is therefore of interest to investigate why Rv1747 is required for virulence, how PknF 
is controlling Rv1747, and to determine what molecules are transported by Rv1747 in 
order to understand how the pknF-Rv1747 signal transduction system functions in M. 
tuberculosis. 
1.5 Project Hypotheses and Aims 
This project focuses on investigating the function of PknF and Rv1747 in M. 
tuberculosis. The overarching hypothesis is that serine-threonine protein kinases and 
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their substrates are required for normal growth of M. tuberculosis in vivo and as such 
represent potential targets for drug intervention.  
1.5.1 Hypothesis 
Rv1747 is an ABC exporter, whose activity is controlled by phosphorylation 
mediated by PknF, that exports a cellular component essential for virulence and 
whose expression is controlled by stress to the bacterium. 
1.5.2 Aims 
• To characterise the pknF-Rv1747 operon: 
o To investigate the pknF stimulus,  
o To determine whether transcription of the pknF-Rv1747 genes is affected 
by external stresses to the bacterium. For example it is known that 
transcription of the pknE gene is affected by nitric oxide (Jayakumar et 
al., 2008). 
o To determine whether the pknF and Rv1747 mutant strains are more 
susceptible to any drug or stress reagent. 
• To investigate the nature of the Rv1747 substrate:  
o To determine if mutation of pknF or Rv1747 affects the transcription of 
other genes, which may give a clue to what is being transported by 
Rv1747.    
o To determine if there are changes in cellular composition of the pknF and 
Rv1747 mutants: lipid, protein, small molecule or metabolite. 
• To determine how PknF is controlling Rv1747 function: 
o To analyse the phosphorylation dependent interactions between the two 
proteins. 
• To determine the sites where PknF phosphorylates Rv1747 to give 
information about how the proteins function together. 
• To characterise the pknF-Rv1747 signalling system and analyse the importance 
of both genes for the virulence of M. tuberculosis: 
o To use M. tuberculosis infection models to assess the importance of 
different protein domains. 
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CHAPTER 2. MATERIALS AND METHODS 
Composition of all commonly used media, buffers and reagents are listed in 
Appendix I.  
2.1 Bacterial Strains and Plasmids  
Strains and plasmids used for cloning and expression of mycobacterial proteins are 
shown in tables 2.1 and 2.2. The mycobacterial strain used was Mycobacterium 
tuberculosis H37Rv (Steenken et al., 1934).  All Escherichia coli strains were grown 
on L. agar and in L. broth supplemented with appropriate antibiotics (table 2.3) 
overnight at 37 
o
C (with shaking for liquid cultures (250 rpm)). M. tuberculosis 
strains were grown on 7H11 agar plus 10 % OADC (Becton and Dickinson) 
containing appropriate supplements and antibiotics (table 2.3). Liquid cultures were 
grown in 50 ml Falcon tubes (Corning) or 1000 ml polycarbonate roller bottles 
(Nalgene) containing Dubos medium supplemented with 0.2 % v/v glycerol and 4 % 
v/v Dubos medium albumin (Becton and Dickinson) or Sauton’s medium plus or 
minus 0.05 % Polysorbate (Tween) 80 (Sigma) containing appropriate supplements 
(table 2.3) at 37 
o
C in a Bellco roll-in incubator (at 2 rpm). 
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Table 2.1. E. coli Strains used in this study 
Strain  Description Source 
Escherichia coli Strains 
E.coli One Shot 
TOP10 cells 
E. coli cloning strain: F
-
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆(ara-leu)7697 galU galK 
rpsL (Str
R
) endA1 nupG 
F
-
:  does not carry the F plasmid 
mcrA, mcrBC, mrr: mutations allowing methylated DNA not to be recognized as foreign. Important when cloning 
genomic/methlyated DNA.  
lacZ∆M15: partial deletion of lacZ that allows for blue/white screening of recombinant clones by alpha complementation 
recA1:  recombination deficient, increasing insert stability. 
araD139, galU, galK: blocks ability to catabolise arabinose, leucine, galactose.  
rpsL: streptomycin resistant 
endA1: endonuclease deficient. The mutation increases plasmid yield and quality 
nupG: Mutation for the transport of nucleosides  
Invitrogen 
E.coli DH5α 
Library Efficiency 
cells 
E. coli cloning strain: F
-
80lacZ∆M15 ∆(lacZYA-argF)U169 deoR recA1 endA1 hsdR17 (rk
-
, mk
-
) phoA supE44 thi-1 gyrA96 
relA1 λ
-
 
deoR: allows constitutive expression of nucleoside catabolism genes 
hsdR17: prevents methlyated DNA being recognized as foreign, allows for efficient transformation, 
supE44: tRNA glutamine suppressor 
gyrA96: DNA gyrase mutant.  
relA1: mutation to allow RNA synthesis to occur in the absence of protein synthesis. In wild type limiting amino acid 
concentrations results in the shutdown of RNA synthesis. 
Invitrogen 
E.coli BL21 Star 
(DE3) cells 
 
Protein expression strain.E. coli F
–
 ompT hsdSB(rB
–
, mB
–
)gal dcm rne131(DE3)  
ompT: outer membrane protease deficient designed to maximize the amount of recombinant protein 
λ(DE3): bacteriophage λ carries the gene for T7 RNA polymerase which is integrated into the host genome and controlled by the 
lavUV5 promoter. 
Contains lacI repressor: IPTG binds the lac repressor and de-represses the promoter; 
dcm: abolishes methylation at specific sequences to enable cleavage with certain restriction enzymes. 
rne131:  RnaseE mutant, protects against mRNA degradation. 
Invitrogen 
E. coli BL21 star 
(DE3)  pRep4-
groESL 
Protein expression strain.  E. coli BL21 star (DE3) plus pRep4-groESL  plasmid 
pRep4-groESL: Plasmid which expresses GroES and GroEL to increase protein solubility and yield. Kanamycin resistant.  
V.Molle  
SoloPack Gold 
Supercompetent 
cells 
E. coli cloning strain used for site directed mutagenesis: Tet
r
 ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 
recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZ∆M15 Tn10 (Tetr) Cam
r
]. 
lacIqZ∆M15 gene: allows blue-white screening for recombinant plasmids.  
Hte: High transformation efficiency.  
Tet
r
: Tetracycline resistant,  
Cam
r
: Chloramphenicol resistant 
Stratagene 
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Plasmid Description Source 
pCR4Blunt-
TOPO 
General cloning vector; Kan
r
, Amp
R
 Invitrogen 
pEJ414 pMV306 derivative containing a promoterless  
E. coli lacZ reporter gene, Kan
R
  
Papavinasasundaram et al., 
2001  
pGEX-6P-1 Replicating protein expression vector. N-
terminal GST-Tag, tac promoter, lacI repressor, 
Amp
R
 
GE Healthcare 
pBS-Int Suicide vector containing integrase, Amp
R
 Springer, 2001  
P2Nil Suicide gene delivery vector, oriE, Kan
R
 Hinds et al., 1999  
pRW69 p2Nil containing  Rv1747, Hyg
R
 Curry et al., 2005  
pKP186 Integrase negative derivative of the integrating 
vector pMV306, Kan
R
  
K.G. Papavinasasundaram 
pRW_76 Rv1747 complementing plasmid. pKP186 
derivative containing 609 bp Rv1745, pknF and 
Rv1747, Kan
R 
Hyg
R
 
R. Whalan 
pRW_95 PknF complementing plasmid. pKP186 
derivative containing 609 bp Rv1745, PknF and 
20 bp Rv1747, Kan
R
  
R. Whalan 
pRW_70 pRW_76 with S47A mutation in Rv1747 R. Whalan 
pRW_71 pRW_76 with S248A mutation in Rv1747 R. Whalan 
pVS_01 pEJ414 containing pknF promoter region, Kan
R
 This study 
pVS_02 pGEX-6P-1 containing pknF
1-292
,  Amp
R
 This study 
pVS_03 pGEX-6P-1 containing Rv1747
1-559
, Amp
R
 This study 
pVS_04 pGEX-6P-1 containing FHA1
1-120
, Amp
R
 This study 
pVS_05 pGEX-6P-1 containing FHA2
202-310
, Amp
R
 This study 
pVS_06 pGEX-6P-1 containing FHA1
1-120
 S47A, Amp
R
 This study 
pVS_07 pGEX-6P-1 containing Rv1747
1-559 
T150A, 
Amp
R
 
This study 
pVS_08 pGex6P-1 containing Rv1747
1-559 
T150D, Amp
R
 This study 
pVS_09 pGex6P-1 containing Rv1747
1-559 
T208A, Amp
R
 This study 
pVS_10 pGex6P-1 containing Rv1747
1-559
 T208D, Amp
R
 This study 
pVS_11 pGex6P-1 containing Rv1747
1-559 
T150A/ 
T208A, Amp
R
 
This study 
pVS_12 pGex6P1 containing Rv1747
1-559 
T150D/ T208D,  
Amp
R
 
This study 
pVS_13 pRW76 containing Rv1747
1-559 
 T150A mutation This study 
pVS_14 pRW76 containing Rv1747
1-559 
T150D mutation This study 
pVS_15 pRW76 containing Rv1747
1-559 
 T208A mutation This study 
pVS_16 pRW76 containing Rv1747
1-559 
T208D mutation This study 
pVS_17 pRW76 containing Rv1747
1-559 
T150A/T208A 
mutations 
This study 
pVS_18 pRW76 containing Rv1747
1-559 
T150D/T208D 
mutations 
This study 
pVS_19 pGEX-6P-1 containing pknF
1-292 
K41A, Amp
R 
 This study 
Table 2.2. Plasmids used and constructed in this study  
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Table 2.3 Antibiotics and supplements added to growth media.  
Antibiotic/Supplement Concentration used in E. coli 
(µg/ml) 
Concentration used in M. 
tuberculosis (µg/ml) 
Kanamycin 50 25 
Ampicillin 100 N/A 
Gentamycin 20 15 
Hygromycin 250 50 
Chloramphenicol 34 N/A 
X-gal 200 50 
Sucrose N/A 20 
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2.2 Recombinant DNA Techniques 
2.2.1 Design of oligonucleotides 
Primer sequences used in this study are listed in Appendix II. Oligonucleotides were 
designed according to the parameters set by the program PRIMER DESIGN FOR 
WINDOWS (Scientific and Educational Software). They were typically 16 to 25 base 
pairs in length and were checked for the presence of hairpins which could inhibit PCR. 
Primers were synthesised by Eurogentec or Sigma and were supplied desalted at 40 
nmol scale synthesis. Alternatively if they were to be used for site directed mutagenesis 
they were supplied RP-HPLC purified. 
2.2.2 Polymerase chain reaction (PCR) 
PCR facilitates amplification of template DNA using cycles of changing temperature.  
Template DNA is heated to force strand dissociation, followed by annealing of specific 
oligonucleotides to the DNA strand by lowering the temperature, and completed by an 
extension step which uses DNA polymerase to incorporate dNTPs and produce a 
complementary strand of DNA. For amplifications where it was necessary to use a proof 
reading enzyme eg. cloning, reactions were performed in 50 µl volumes in 0.2 ml 
thermo tubes containing 1 X Pfx Amplification buffer, 1 X Enhancer buffer (lowers the 
DNA melting temperature), 0.3 mM dNTPs, 0.3 µM of each oligonucleotide, 1 mM 
MgSO4, 80 ng M. tb DNA and 2.5 U Pfx enzyme (Invitrogen). DNA amplification was 
performed in an MWG Primus thermocycler using a touchdown cycle. Touchdown 
cycles help reduce non-specific background by starting with an annealing temperature a 
few degrees above the Tm of the primers and then lowering by one degree every two 
cycles. This increases the likelihood of primers binding their specific template DNA. A 
further 20 to 25 cycles are then employed to amplify the product. Cycles consisted of an 
initial 95 
o
C denaturation step for five minutes followed by the touchdown cycles with 
an annealing temperature from ~ 65 to 56 
o
C and extension period at 72 
o
C for one 
minute per kilobase of product. 20 to 25 cycles were then performed with an annealing 
temperature of 56 
o
C and completed with a final extension time of eight minutes. 
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For DNA amplifications where the proof reading capacity of DNA polymerase was not 
necessary PCR’s were performed using REDTaq Readymix (Sigma) in 25 µl volumes in 
0.2 ml thermo tubes containing 1 X REDTaq buffer, 0.2 mM dNTPs, 0.3 µM of each 
oligonucleotide, 1.5 mM MgCl2, 1.5 U Taq DNA polymerase, and one to five 
microlitres of Instagene DNA using the same touchdown cycle. HotStarTaq polymerase 
(Qiagen) was used for Reverse Transcription PCR following the same touchdown cycle 
and including a 15 minute initiation step at 95 
o
C. HotStarTaq is a modified Taq 
polymerase which is completely inactive at room temperature and requires a 15 minute 
step at 95 
o
C to activate the enzyme, thereby reducing non-specific amplification of 
products where primers have bound during PCR set up. 
2.2.3 Site directed mutagenesis (SDM) 
SDM oligonucleotides were designed with the desired mutation in the middle of each 
primer with approximately 20 nucleotides of correct sequence on each side and a 
melting temperature of approximately 78 
o
C. Primers were synthesised and RP-HPLC 
purified by Eurogentec or Sigma. 
PCR amplifications were performed in 50 µl volumes in 0.2 ml thermo tubes containing 
1 X Pfx Amplification buffer, 1 X Enhancer buffer, 0.3 mM dNTPs, 125 ng of each 
oligonucleotide, 1 mM MgSO4, 100-300 ng plasmid DNA and 2.5 U Pfx (Invitrogen). 
DNA amplification was performed in an MWG Primus thermocycler. An initial 
denaturation step at 95 
o
C for one minute was followed by 18 to 25 cycles of 95 
o
C for 
50 seconds, an annealing step of 60 
o
C for 50 seconds and a 68 
o
C extension temperature 
for two minutes per kb of plasmid and then completed by a final extension at 68 
o
C for 
seven minutes. Parental methylated DNA was then digested by addition of 1 µl DpnI 
(Fast Digest, Fermentas) and incubated at 37 
o
C for 15 minutes. DNA was then 
precipitated as outlined in section 2.2.6. One to three microlitres of resulting plasmid 
DNA was then used for transformation into E. coli Supercompetent cells (Strategene) 
using the heat-shock method as outlined in section 2.2.9. Plasmid DNA was extracted 
from the resulting colonies (2.2.4) and was sequenced as in section 2.2.12.  
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2.2.4 Agarose gel electrophoresis 
Agarose gel electrophoresis separates DNA fragments based on mass and charge. When 
a current is applied, the negatively charged DNA molecules migrate towards the positive 
pole. Smaller DNA fragments migrate through the gel faster than larger fragments. 
Ethidium bromide intercalates between DNA base pairs and is therefore used to 
visualise DNA. 
Depending on expected product/s size 0.8 to 2 % agarose gels were cast using 1 X TBE. 
The solution was boiled to dissolve the agarose, 0.5 µg/ml ethidium bromide (Bio-Rad) 
was added and gels were cast with a comb. Once set, gels were immersed in 1 X TBE. 1 
X loading buffer (30% glycerol, 0.25% bromophenol blue, 0.25% xylene cyanol) was 
added to each sample, 8 µl of a 1 kilobase DNA ladder (Hyperladder I, Bioline) was run 
alongside as a marker and voltage was applied at 100 V for 40 minutes or until DNA had 
sufficiently migrated. DNA fragments were visualised using a UV transilluminator 
(BioDoc-It Imaging System). 
2.2.5 Plasmid DNA preparation 
Plasmid DNA was purified from 5 ml of stationary phase E. coli cultures using the 
QIAprep Spin Miniprep Kit (Qiagen) following the manufacturer’s guidelines. Briefly, 
bacteria were lysed under alkaline conditions to denature proteins and DNA, and SDS 
solubilized phospholipids and proteins of the cell membrane. Lysates were neutralised 
and adjusted to high salt conditions which precipitates denatured proteins, detergent, 
debris and chromosomal DNA whilst plasmid DNA renatures and stays in solution. 
Plasmid DNA was purified by adsorption onto a silica membrane, contaminants were 
washed away with an ethanol based solution then DNA was eluted in 50 µl dH2O.  
2.2.6 DNA fragment extraction and purification from agarose gels 
DNA fragments were excised from the gel using a UV lightbox (at 302 nm) and scalpel. 
DNA was extracted and purified using the QIAquick Gel Extraction kit (Qiagen) 
following the manufacturer’s guidelines. Agarose gel slices were solubilised in a binding 
buffer with optimal pH and salt concentrations for DNA to be adsorbed to the silica 
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membrane. DNA was then adsorbed to the membrane, contaminants were washed away 
using an ethanol based wash solution and then DNA was eluted in 30 µl dH2O.  
2.2.7 Ethanol precipitation of nucleic acids 
DNA or RNA was precipitated from solution by addition of 0.1 volume 3M sodium 
acetate and 2.5 volumes cold 100 % ethanol, incubated at - 20 
o
C overnight and then 
centrifuged for 15 minutes in order to form a pellet. The pellet was washed with 70 % 
ethanol, left to dry at room temperature and then resuspended in dH2O. 
2.2.8 Restriction endonuclease digestion of DNA 
Restriction digestion of DNA was performed in 15 µl reactions, for one hour at 37 
o
C or 
five minutes at 37 
o
C if using FastDigest Enzymes (Fermentas), containing the DNA and 
restriction enzyme/s in appropriate buffers. Vector digests were subsequently treated 
with 5 U Antarctic Phosphatase (NEB) for 20 minutes at 37 
o
C followed by a five 
minute incubation at 65 
o
C to deactivate the enzyme. This step removes the 5´ phosphate 
group from linearised vectors to prevent vector re-ligation thereby increasing cloning 
efficiency by reducing vector background.  
2.2.9 Ligation of DNA 
Ligations were performed in 10 µl reactions using a 1:7, 1:5 or 1:3 ratio of vector:insert 
DNA using T4 DNA Ligase and 1X T4 DNA Ligase buffer (Promega). Ligations were 
performed at room temperature for four hours or at 4 
o
C for 16 hours.   
2.2.9.1 Ligation of DNA into pCR4Blunt-TOPO 
PCR products were initially cloned into pCR4Blunt-TOPO vector. The vector is 
supplied in a linearised form with topoisomerse I bound to the 3´ ends. Topoisomerase I 
ligates the PCR product into the vector and then dissociates from the DNA. 2 µl purified 
PCR product was combined with 0.5 µl pCR4Blunt-TOPO and 0.5 µl salt solution (1.2 
M NaCl), then incubated at room temperature for one hour. 
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2.2.10 Transformation of E. coli 
Transformations were performed with chemically competent E.coli One Shot TOP10, 
E.coli DH5α and E.coli BL21 Star using a heat shock transformation procedure or with 
electrocompetent E.coli BL21 Star pRep4 cells (table 2.1). Competent cells were 
defrosted on ice then 100 to 200 ng of plasmid DNA was carefully mixed with the cells 
and incubated on ice for 15 to 30 minutes. For heat shock transformation, cells were 
incubated at 42 
o
C for 30 to 45 seconds to facilitate uptake of plasmid into the cells. For 
electrocompetent strains, cells were electroporated with 2.5 kV, 1000 ohms and 25 µF in 
a Gene Pulser chamber (Biorad). Finally, LB or SOC medium was added to the cells and 
incubated at 37 
o
C with shaking for one hour to allow expression of selective markers 
before being plated on selective LB agar. 
2.2.11 Colony Screening and Glycerol Stocks 
Colonies potentially containing the desired plasmid insert were screened by PCR as 
described in section 2.1. Plasmid DNA was subsequently extracted from clones which 
appeared correct and then checked by sequencing. Glycerol stocks of correct clones 
were made by combining 850 µl of overnight culture with 150 µl sterile glycerol and 
stored at -80 
o
C. 
2.2.12 Determination of nucleic acid and protein concentration 
The concentration of nucleic acids was determined using a Nanodrop ND-100 
spectrophotometer, Version 3.1.2 (Labtech). 1.2 µl of sample was added to the 
spectrophotometer and the concentration readout was noted. To determine protein 
concentration the molecular weight and extinction coefficient of each protein was 
included in the calculation.   
2.2.13 DNA Sequencing  
Sequencing of PCR products and plasmids was performed by Geneservice Limited 
(Cambridge) containing 1 µg of plasmid DNA or 200 ng PCR product and 32 pmoles of 
each primer. 
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2.3 Transcriptional Analysis 
2.3.1 Reverse Transcription PCR 
Reverse transcription PCR was employed to assess the co-transcription of genes of 
interest using the Quantitect Reverse Transcription Kit (Qiagen) which uses a high 
efficiency reverse transcriptase enzyme capable of detecting low abundance transcripts. 
A reverse transcription reaction was set up containing 1 µg of DNA free RNA in 1 x 
Quantiscript RT buffer containing magnesium and dNTPs, RT primer mix and 1 µl 
Quantiscript reverse transcriptase. Reactions were incubated at 42 
o
C for 30 minutes to 
allow cDNA synthesis to occur. A negative control was also set up for each sample 
replacing the reverse transcriptase with 1 µl dH2O. Samples were then incubated at 95 
o
C for three minutes to inactivate the reverse transcriptase enzyme. PCR was then 
performed using the cDNA template with HotStarTaq as outlined in section 2.1. 
2.3.2  5´ Rapid Amplification of cDNA Ends (5´ RACE) 
5´ RACE was performed to determine the transcriptional start site of genes of interest 
using the 5` RACE Kit (Invitrogen) following the manufacturer’s guidelines. Three 
Gene Specific Primers (GSPs) were designed. GSP 1 is responsible for first strand 
cDNA synthesis and was designed to anneal at least 300 bp downstream from the 
mRNA 5´ end to allow for cDNA purification on a column. GSP 2 is responsible for the 
first PCR so was designed to anneal 3´ with respect to the cDNA. GSP 3 is used in a 
nested PCR to generate sufficient specific product for sequencing so was designed to 
anneal within the primary PCR sequence. 
cDNA synthesis was performed using 5 µg of M. tuberculosis RNA and 2.5 pmoles 
GSP1. The reaction was incubated at 70 
o
C for 10 minutes to denature the RNA then 
chilled for one minute on ice. First strand cDNA synthesis was then performed by 
addition of 1 x PCR buffer (20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl2 ), 10 
mM DTT, 0.4 mM dNTPs and 200 U SuperScript II Reverse Transcriptase (Invitrogen) 
to the RNA and incubated at 42 
o
C for 50 minutes. cDNA synthesis was then stopped by 
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incubation at 70 
o
C for 15 minutes. After cooling to 37 
o
C 1 µl of RNase mix was added 
and incubated for 30 minutes to remove the original mRNA template. 
cDNA was purified on a column to remove unincorporated primer and dNTPs.  Briefly, 
samples were bound to the column under high salt binding conditions, washed three 
times with cold 1 x wash buffer then twice with cold 70 % ethanol. cDNA was eluted in 
50 µl dH2O.  
A poly-C tail was then added to the 3´ ends of the cDNA using Terminal 
deoxynucleotidyl Transferase (TdT) and dCTP. TdT tailing creates a binding site for the 
Abridged Anchor Primer which was used with GSP2 to allow direct amplification by 
PCR using Taq DNA polymerase. Once complete, a second nested PCR amplification 
was then performed with the Abridged Universal Anchor Primer and GSP3 in order to 
generate sufficient specific product for sequencing. PCR products were separated on an 
agarose gel, extracted, purified and sequenced. 
2.3.3 Quantitative Real-Time PCR (qRT-PCR) 
qRT-PCR uses a fluorescence based PCR reaction to allow detection of accumulating 
nucleic acids in real time. SYBR green I (Applied Biosystems), a fluorophore which 
intercalates double-stranded DNA, was used for qRT-PCR. The dye fluoresces when 
bound to double-stranded DNA enabling detection of DNA products as they accumulate 
during cycles of PCR.  
cDNA was generated from 1 µg RNA (section 2.4.3) using the Quantitect reverse 
transcription kit (section 2.3.1). Due to assay sensitivity cDNA was diluted 
appropriately. DNA standards were generated using H37Rv genomic DNA. Primers 
were designed according to the parameters set in the Primer Express 3.0 program 
(Applied Biosystems). Reactions were performed in biological triplicate in 20 µl 
reactions with 2 x Fast SYBR green master mix (Applied Biosystems), 900 nM of each 
primer plus 5 µl DNA standard, cDNA or water (as a no template control) in MicroAmp 
fast optical 96-well reaction plates (0.1 ml) (Applied Biosystems). Absolute 
quantification qRT-PCR was performed as per manufacturer’s guidelines on a 7500 
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Real-Time PCR System (Applied Biosystems) using the following conditions: a 95 
o
C 
step for 20 seconds to activate enzymes in the master mix followed by 40 cycles with a 
95 
o
C denaturation step for three seconds and 60 
o
C annealing and extension steps for 30 
seconds. A dissociation step was performed at the end of qRT-PCR. This step gives the 
melting temperature (Tm) of each PCR product to indicate if more than one product was 
amplified (i.e. to check the PCR was specific). 
Data were analysed using the 7500 Fast System Software (Applied Biosystems). 
Quantities of cDNA within the samples were calculated from the cycle threshold (Ct) 
values, the cycle at which the fluorescence increased above the baseline level, using the 
appropriate standard curve. A reverse transcription negative control reaction was 
performed for each sample to control for any genomic DNA contamination. These 
values were subtracted from the reverse transcription positive values. All data was 
averaged and normalized to sigA expression to give the normalised transcription level of 
genes of interest.  
2.4 Mycobacteria Specific Techniques 
All Mycobacterium tuberculosis specific techniques were performed in Category Three 
Containment facilities using class I hoods.  
2.4.1 Preparation and transformation of electrocompetent M. tuberculosis 
Rolling cultures (100 ml) were grown to an OD600 of 1.0 before 0.1 volume of 2M 
glycine was added and incubated for a further 20 to 24 hours. Addition of glycine 
improves transformation efficiency of mycobacteria; glycine replaces alanine during 
peptidoglycan synthesis resulting in reduced cross-linking. Cells were harvested by 
centrifugation at 16, 000 rcf for 20 minutes. Cell pellets were resuspended in 100 ml 10 
% glycerol then re-harvested. A total of three washes were required. The cell pellet was 
finally resuspended in 10 ml 10 % glycerol. Electrocompetent cells were stored at 4 
o
C 
or - 80 
o
C until use. 
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2.4.1.1 Electroporation of mycobacteria 
400 µl of electrocompetent cells were added to an electroporation cuvette with the 
required amount of DNA (1 to 5 µl volume). Cuvettes were placed into the Gene Pulser 
chamber (Biorad) and electroporated with 2.5 kV, 1000 ohms and 25 µF. Cells were 
then added to 3.6 ml Dubos and recovered overnight at 37 
o
C. After recovery cells were 
diluted appropriately (usually 1/10 and 1/100 fold), plated on 7H11 agar plus appropriate 
supplements and selection agents and incubated at 37 
o
C for two to four weeks until 
colony growth was observed.  
2.4.2 DNA isolation from M. tuberculosis on 7H11 agar plates and in liquid culture 
Two methods were employed to extract DNA; when screening potential M. tb clones the 
Instagene Method (Biorad) was used whereas when high molecular weight good quality 
genomic DNA was needed either for PCR or whole genome sequencing a more stringent 
method was applied. Both methods are outlined below. 
1. Instagene Preparation of DNA 
A colony scraped from a plate or a pellet from 100 µl of mid-log culture was 
resuspended in 200 µl Instagene Matrix (Biorad) and incubated at 56 
o
C for 30 minutes. 
This step helps the matrix to bind to components in the preparation that may inhibit 
PCR. Samples were then boiled at 100
 o
C for eight minutes in a waterbath to both kill 
the M.tb and release genomic DNA. One to five microlitres of this preparation was then 
used in a colony screening PCR reaction as outlined in section 2.2.1.  
2. Genomic DNA isolation from M. tuberculosis for whole genome sequencing  
20 ml of an exponential phase culture was harvested by centrifugation at 1,700 rcf for 15 
minutes and the pellet was resuspended in 1 ml TE buffer. Bacteria were heat killed by 
incubation at 80 
o
C for one hour. Cells were pelleted by centrifugation at 13, 000 rcf and 
resuspended in 1 ml resuspension buffer. Bacteria were pelleted and washed in 450 µl of 
resuspension buffer. 100 µl of 10 mg/ml lysozyme (Sigma) was added and incubated at 
37 
o
C for two hours to facilitate cell lysis. 50 µl of 20 % SDS (Biorad) and 25 µl of 20 
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mg/ml Proteinase K (Sigma) was added to each sample and incubated at 55 
o
C for 40 
minutes to denature membrane lipids and digest proteins. 250 µl of 4M NaCl and 160 µl 
of centrimide saline solution was then added and incubated at 65 
o
C for 10 minutes to 
provide a buffer solution for extraction of DNA. One ml of chloroform:isoamyl alcohol 
(24:1) was added to each sample then the aqueous phase containing the nucleic acids 
was extracted by vigorous vortexing followed by centrifugation. The aqueous phase was 
transferred to a new tube and the previous step was repeated. 0.7 volumes of isopropanol 
was added and mixed to precipitate the DNA. The genomic DNA spool was extracted, 
washed in 70 % ethanol, dried for 15 minutes at room temperature and then resuspended 
in 50 µl TE buffer. DNA was confirmed to be all high molecular weight and not 
degraded by separating 3 µl on a 0.8 % agaroase gel. 5µg of this DNA was then sent to 
GATC Biotech for whole genome sequencing using Illumina’s Genome Analyser 
(Illumina).  
2.4.3 RNA isolation from M. tuberculosis liquid cultures 
Total RNA was isolated from 100 ml of mid-log phase rolling cultures using the Fast 
RNA Pro Blue kit (Qbiogene) as per the manufacturer’s guidelines. Cultures were 
harvested by centrifugation and then resuspended in 2 ml RNAPro solution which 
stabilizes RNA and inactivates RNases during cell lysis to prevent degradation. The 
resuspension was transferred into two matrix tubes and ribolysed (Hybaid) on setting six 
for 40 seconds to release the cellular RNA, DNA and proteins. The tubes were 
centrifuged at 13, 000 rcf for 5 minutes at 4 
o
C then the upper phase was transferred to a 
new tube. 300 µl of chloroform was added, tubes were vortexed and then incubated for 
five minutes at room temperature before being centrifuged as previously. The upper 
aqueous phase containing the RNA was transferred to a new tube, being careful not to 
touch the interphase or organic phase containing proteins and other contaminants.  
RNA was precipitated by addition of 500 µl of 100 % ethanol and incubated at - 20 
o
C 
overnight. The RNA was then pelleted by centrifugation and washed in 70 % ethanol 
(made with DEPC treated water). The pellet was allowed to air-dry and then 
resuspended in 100 µl DEPC H2O containing 40 U RNase inhibitor (Promega). 
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Contaminating DNA was removed by DNase digestion with 2 U RNase free DNase 
(Promega) in 5 mM magnesium sulphate and 100 mM sodium acetate with 80 U RNase 
inhibitor and incubated at 37 
o
C for one hour. A further 2 U of DNase was then added 
and incubated for a further hour as before. The presence of contaminating DNA was 
then checked using 35 cycles of touchdown PCR (section 2.2.1).  
Proteins and other contaminants were removed from RNA samples using the RNA 
cleanup kit (RNeasy kit, Qiagen) following the manufacturer’s guidelines. Briefly, RNA 
samples were suspended in a buffer containing guanidinium thiocynate (to denature the 
enzymatic activity of RNases) and ethanol which creates optimal conditions for RNA to 
bind to the spin column. Samples were then applied to the spin column. Contaminants 
were washed away with an ethanol based wash solution and RNA was eluted twice in 30 
µl of RNAse-free water. 200 ng of clean RNA was then run on a 2100 Bioanalyzer 
(Agilent Technologies) to assess integrity (R. Butler, NIMR). 
2.4.4 Generation of M. tuberculosis cell free extract  
Bacteria were isolated from exponential phase cultures (OD600 0.6-0.8) by centrifugation 
at 1,700 rcf for 20 minutes, washed in PBS, and then cells were broken in a ribolyser 
(Hybaid) on setting 6.5 for 30 seconds with 150-212 µm glass beads (Sigma). Culture 
supernatants were then filtered through low binding 0.22 µm Durapore membrane filters 
(Ultrafree-MC, Millipore) by centrifugation at 13,000 rcf for 5 minutes. Alternatively, 
cultures were isolated by centrifugation and supernatants filtered twice through 0.22 µM 
filters. 
2.4.4.1 Generation of M. tuberculosis protein extract for assessment of protein 
composition in culture supernatants 
Exponential phase cultures (OD600 0.6-0.8) were centrifuged as outlined in section 2.4.4 
and then supernatants were filtered twice through 0.22 µM filters. Trichloracetic acid 
(TCA) was then used to precipitate the proteins from the M. tuberculosis culture 
supernatants; TCA treatment ensured each protein sample was as concentrated as 
possible. 10% TCA was added to each sample of culture supernatant in a 1:1 v/v ratio. 
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Samples were incubated on ice for 30 minutes to allow precipitation to occur. They were 
then centrifuged at 13,000 rcf for 15 minutes at 4 
o
C to pellet the proteins. Pellets were 
washed in 300 µl of cold acetone, centrifuged as previously and then the pellet was 
allowed to dry before resusupension in dH2O. Half of each TCA precipitated sample was 
then digested with trypsin; this enzyme is a serine protease which cleaves proteins at the 
carboxyl side of arginine or lysine. 0.2 µg of trypsin (Sigma) was added to 100 µl of 
TCA precipitated protein sample and then incubated at 37 
o
C for 16 hours. TCA 
precipitated samples and trypsin digested samples were then analysed on a 12% SDS-
PAGE gel as described in section 2.5.1.  
2.4.5 M. tuberculosis RNA-DNA microarrays 
Whole genome microarrays of M. tuberculosis (version 2) were obtained from by Dr. J. 
Hinds and Dr. K. Gould (St. George’s, University of London). 7 µg of total RNA was 
labelled with 3 µg of random primers (Invitrogen) in the presence of 500 U SuperScript 
II Reverse transcriptase (Invitrogen), 1x first strand buffer, 10 mM DTT, 5 mM 
dA/G/TTP, 2 mM dCTP and 1.5 nmol Cy3 or Cy5 labelled dUTP. RNA and random 
primers were heated at 95 
o
C for five minutes in a final volume of 11 µl and snap cooled 
for two minutes. 500 U SuperScript II Reverse transcriptase (Invitrogen), 1x first strand 
buffer, 10 mM DTT, 5 mM dA/G/TTP, 2 mM dCTP and 1.5 nmol Cy3 or Cy5 labelled 
dUTP  was then added to the RNA and random primer mix and incubated at 25 
o
C for 10 
minutes, followed by 42 
o
C for 90 minutes to allow cDNA synthesis to occur. 
Microarray slides were prehybridised in 3.5 x SSC, 0.1 % SDS and 10 mg/ml BSA 
(Sigma) for 20 minutes at 60 
o
C and then washed for one minute in water and one 
minute in isopropanol. Slides were then placed inside 50 ml Falcon tubes and 
centrifuged at 300 rcf for five minutes to dry the slides. Labelled samples were 
competitively hybridised against a single microarray using two Lifterslips (Thermo 
Scientific) to cover the array, combining the samples and then pipetting the sample 
under the Lifterslips allowing the solution to cover the microarray by capillary action.  
Microarray slides were placed in hybridisation chambers, submerged in water and 
incubated in a 65 
o
C oven for 16 to 24 hours. Slides were then washed vigorously for 
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two minutes in 1 x SSC, 0.05 % SDS followed by two washes in 0.06 x SSC for two 
minutes each.  
Microarray slides were scanned with an Axon GenePix 4000A Microarray Scanner 
(Molecular Devices) using PMT voltages of 600-800 and then analyzed using GenePix 
Pro. Grids were fitted using Bluefuse software, and further analysis was performed using 
the GeneSpring 10 (Agilent) software program. Three biological replicates were 
performed for each condition and were carried out in duplicate (dye-swaps, to correct for 
dye-labelling bias). See appendix III for further details on microarray analysis. 
2.4.6 Lipid extraction and two dimensional thin layer chromatography of M. 
tuberculosis cell wall lipids 
Exponential phase cultures were labelled with 1 µCi/ml [
14
C] acetate (~300mCi/mmol) 
for 24 hours. Cultures were then washed thrice in PBS; resulting pellets were incubated 
at 80 
o
C for one hour whilst supernatants were filtered twice through low binding 0.22 
µm Durapore membrane filters (Ultrafree-MC, Millipore). Supernatants were then freeze 
dried using an E-C Modulyo (E-C. Apparatus Inc, USA) freeze-drier.  
I performed all thin layer chromatography experiments at the University of Birmingham 
in Professor Del Besra’s laboratory. To extract non-polar (apolar) lipids each sample 
was dissolved in 2 ml CH3OH : 0.3% NaCl (100:10, v/v) and 1 ml of petroleum ether 
(60-80 
o
C), transferred to a glass vial (Tube A) and mixed on a rotator for 15 minutes 
before centrifugation at 2,000 rcf for five minutes. The upper layer was transferred to a 
separate tube (Tube B). One ml of petroleum ether was added to the lower layer (A) then 
mixed and centrifuged as previously. The upper layer was transferred to tube (B). The 
upper layers (non-polar lipids) were then dried in a Techne Sample concentrator at 50 
o
C. 
To extract polar lipids 3 ml of CHCl3:CH3OH:NaCl (0.3 %) 90:100:30 was added to the 
bottom layer (Tube A), mixed as previously for 60 minutes on a rotator and centrifuged 
for five minutes at 2,000 rcf. Supernatants were transferred to separate tubes (Tube C). 
750 µl of CHCl3:CH3OH:0.3% NaCl 50:100:40 was added to the pellet, mixed for 30 
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minutes and centrifuged as previously. The supernatant was added to tube C. This step 
was repeated once more. The remaining pellet contained the non-extractable lipids. 1.3 
ml of CHCl3 and 1.3 ml of 0.3% NaCl was added to the pooled sample (Tube C), mixed 
on the rotator for five minutes and centrifuged for three minutes at 2,500 rcf. The lower 
layer contained the polar lipids. This was removed into a separate tube and dried as for 
non-polar lipids. Each dried sample was resuspended in 200 µl CHCl3: CH3OH 2:1 and 
centrifuged at 2,000 rcf for five minutes. 5 µl was spotted onto the bottom of a 
scintillation vial, allowed to dry, then 5 ml scintillation fluid was added, vortexed, and 
the radioactivity measured in a scintillation counter. Two dimensional thin layer 
chromatography was then performed to separate the lipids by spotting 20,000 cpm of 
each sample onto a silica plate (Merk). The lipids were separated in five systems in two 
directions using different combinations of solvents (table 2.4). Apolar lipids were 
separated in systems A to D and polar lipids were analysed in systems D and E. The 
silica plates were allowed to dry fully in between each run. The plates were then 
exposed overnight with X-ray film (Kodak) and then developed. 
 
 
Table 2.4.  Solvents used to separate the different lipid components of the M. 
tuberculosis cell wall.  
 
 
Direction I Components Ratio Number of 
runs 
System    
A Pet ether/ethyl acetate 98 :2 3 
B Pet ether/acetone 92:8 3 
C Chloroform/methanol 96:4 1 
D Chloroform/methanol/water 100:14:0.8 1 
E Chloroform/methanol/water 60:30:6 1 
Direction II    
System    
A Pet ether/acetone 98:2 1 
B Toluene/acetone 95:5 1 
C Toluene/acetone 80:20 1 
D Chloroform/acetone/methanol/water 50:60:2.3:3 1 
E Chloroform/aceticacid 
(glacial)/methanol/ water 
40:25:3:6 1 
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2.4.7 Transmission electron microscopy 
M. tuberculosis rolling cultures were grown in Dubos to an OD600 of 0.6. A 20 ml 
aliquot of each strain to be used for microscopy was transferred to a 50 ml Falcon tube. 
Cells were centrifuged at 1,200 rcf for 15 minutes and thoroughly resuspended in 2 % 
glutaraldehyde / 2 % paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 
18 hours. The cells were prepared for transmission electron microscopy by Liz Hirst 
(NIMR). Cells were post fixed in 1 % osmium tetroxide then washed and stained en bloc 
with 1 % aqueous uranyl acetate for 2 hours then dehydrated. They were embedded in 
medium hardness Agar resin for 24 hours before polymerization at 70 
o
C overnight. 50 
µm sections were mounted on pioloform coated slot grids and stained with saturated 
ethanolic uranyl acetate followed by Reynold's lead citrate. They were viewed in a Jeol 
1200 EX transmission electron microscope and images were taken using an Orius TEM 
Charge Coupled Device (CCD) camera at x 25,000 magnification (Gatan Inc.). 
2.4.8 ß-galactosidase transcription reporter assay 
The ß-galactosidase reporter assay was used to assess the promoter activity of pknF 
under different conditions. The pknF promoter region was fused upstream of lacZ in 
pEJ414 (the plasmid is integrated into the genome of M. tuberculosis using pBSInt so 
only one copy is present per cell). The lacZ gene product is ß-galactosidase. In the 
presence of ß-galactosidase the substrate ortho-nitrophenyl-β-galactoside (ONPG) is 
hydrolysed to galactose and ortho-nitrophenol; the latter is yellow in aqueous solution 
and can be measured at 405 nm.  
When required, a panel of drug and stress reagents were added to exponential phase 
cultures (OD600 of 0.6 to 0.8) for two hours at 37 
o
C with rolling (table 2.5). For acid 
stress, cultures at an OD600 of between 0.25 and 0.3 were harvested and then 
resuspended in either Dubos at pH 7.2 or Dubos adjusted to pH 5.5 and further incubated 
for 24 hours. All manipulations were then performed at 4 
o
C. 25 ml of exponential 
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(OD600 of 0.6 to 0.8) or stationary phase cultures (OD600 of 2) were harvested by 
centrifugation and resuspended in 10 ml cold Z buffer (no ß-mercaptoethanol). They 
were washed twice with 1 ml Z buffer (no ß-mercaptoethanol). Cells were then broken 
by ribolysis and filtered as described in section 2.4.4.  
Next, to normalise the assay the amount of protein present in each sample was 
determined using the copper based bicinchoninic acid (BCA) protein assay kit (Pierce). 
The assay works in two steps. In the first step peptides chelate with copper to form a 
blue coloured complex from the reduction of cupric ions (Cu
2+
) to cuprous ions (Cu
1+
) 
under alkaline conditions. In the second step BCA chelates with the cuprous ion (Cu
1+
) 
resulting in a purple colour which can be measured at 550 nm. 10 µl of each sample (in 
triplicate) was added to a 96 well microtitre plate. To the remainder of each sample 1.5 
µl ß-mercaptoethanol (Sigma) was added and stored at 4 
o
C until required. Addition of 
β-mercaptoethanol stabilizes the ß-galactosidase enzyme. Fifty parts of BCA reagent A 
containing Bicinchoninic acid and tartrate in an alkaline carbonate buffer and 1 part 
BCA reagent B containing 4% copper sulfate pentahydrate solution were mixed, 200 µl 
of this mixture was added to each well, plates were incubated at 37 
o
C for 30 minutes 
and then absorbance was measured at 550 nm. A standard curve was generated using 
titrations of bovine serum albumin (BSA) of known concentrations. 
The ß-galactosidase reporter assay was performed based on the method by Miller 
(1972). Assays were performed in biological triplicate. 100 µl of lysate was combined 
with 400 µl Z buffer plus 50 mM β-mercaptoethanol and equilibrated to 28 
o
C for five 
minutes. The reaction was started by addition of 100 µl of 15 mM ONPG. Colour 
formation was monitored, the reaction was stopped by addition of 250 µl 1M sodium 
carbonate when a yellow colour had developed and the time was noted. 300 µl of each 
sample (in duplicate) was added to a microtitre plate and absorbance was measured at 
405 nm in a Benchmark plus microplate spectrophotometer (Bio-rad). The enzymes 
specific activity (units of β-galactosidase per mg of protein per minute) were then 
calculated using the following formula originally described by Miller (1972) : (380 x 
OD (405 nm))/(time (minutes) x volume of lysate used in assay (ml) x protein 
concentration (mg/ml)).  
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Drug/stress reagent Final concentration 
Izoniazid 0.0125 µg/ml 
Ethambutol 0.375 µg/ml 
Streptomycin 0.0625 µg/ml 
Gentomycin 2 µg/ml 
Mitomycin C 0.02 µg/ml 
Ofloxacin 1 µg/ml 
Hydrogen peroxide 2 mM 
t-butyl hydrogen 
peroxide 
0.1 mM 
S-Nitrosoglutathione 5 mM 
Diamide 10 mM 
Plumbagin  0.5 mM 
Sodium nitroprusside 10 mM 
Table 2.5 The panel of drug and stress reagents used in this study to assess the 
promoter activity of pknF under different conditions.  
The final concentration of each reagent used is equal to 50 percent of the minimum 
inhibitory concentration (MIC). Each reagent was added to the cultures for two hours. 
2.4.9 M. tuberculosis growth inhibition (Alamar blue) assays  
Growth inhibition assays were performed to assess the susceptibility of M. tuberculosis 
strains to various drugs and stress reagents based on the method by Collins and 
Franzblau (1997). The assay utilises the CellTiter-Blue reagent (Promega) which 
contains the compound resazurin. In the presence of metabolically active cells resazurin 
is reduced to resorufin, a fluorescent pink compound which can be measured with an 
excitation wavelength of 579 nm and emission of 584 nm.  
Assays were carried out in 96 well plates (Greiner Bio-one). Two fold dilution series of 
the drug or stress reagent in 90 µl of Dubos were added to the plates. Positive (media 
plus bacteria) and negative (media only) control wells were included in all plates. 
Exponential phase M. tuberculosis cultures were diluted to give 1 x 10
4
 cells in 10 µl. 10 
µl of this dilution was added to the appropriate wells. Plates were incubated at 37 
o
C for 
five days to allow for M. tuberculosis growth. On day five 20 µl of CellTiter-Blue 
reagent was added to each well. Plates were incubated for 16 hours at 37 
o
C to allow 
cells to convert the resazurin to resorufin and then the fluorescent signal was measured 
in a Polarstar Galaxy plate reader (BMG) as per manufacturer’s guidelines. Data were 
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plotted as the percentage inhibition of growth compared to the positive control (media 
plus bacteria) versus the reagent concentration. 
2.4.10 Metabolic tests for M. tuberculosis: Phenotype Microarrays (BiOLOG)  
Phenotype MicroArrays
TM
 were used to assess cellular phenotypes (Biolog Inc., 
Hayward CA, USA). Each well of the 96 well plate arrays is designed to test a different 
phenotype. Phenotype microarray plates numbers one to ten containing metabolic tests 
for bacteria and fungi were used in this study. They included plates which tested the 
ability of M. tuberculosis to respire when exposed to a range of carbon, nitrogen, 
phosphorus and sulphur sources, various nutrient supplements, peptide nitrogen sources 
and osmolytes and also tested the ability of M. tuberculosis to respire in a range of pH 
conditions. Phenotype microarrays were initially set up at NIMR by Kathryn Lougheed. 
20 ml of mid-log M. tuberculosis (OD600 0.6-0.8) grown in Dubos was harvested by 
centrifugation. Cells were starved overnight by resuspension in 1 x PBS to ensure all 
traces of nutrients were metabolised to avoid false positive results in the assay. Cultures 
were harvested then resuspended in IF-0a base media (Biolog) recommended by the 
manufacturer and adjusted to an OD of 0.68. 0.88 ml was added to the Phenotype 
microarray stock solution which contained IF-0a base, phenotype microarray additive 
(which varied depending on which plate was used) and Dye Mix G containing a 
tetrazolium dye which is reduced in the presence of respiring cells forming a coloured 
compound. 100 µl of this mixture was added to each Biolog Plate well. Plates were 
incubated for seven days at 37 
o
C then absorbance was measured at 570 nm in a 
Polarstar Galaxy plate reader (BMG) as per the manufacturer’s guidelines.  
2.4.11 Analysis of small molecules and metabolites produced by M. tuberculosis  
Culture supernatants of M. tuberculosis strains grown in Dubos or Sauton’s medium 
were extracted at an OD600 of 0.3, 0.6, 1.0 and 2.0 by harvesting the cells and then 
filtering the supernatants twice through 0.22 µM filters as outlined in section 2.4.4. The 
metabolites present were then analysed by nuclear magnetic resonance (NMR) 
spectroscopy at Imperial College London by Volker Beherends (Dr Jake Bundy’s 
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Laboratory). Briefly, 500 µl of sample plus 20 % deuterium, 5 mM sodium azide, 40 
mM phosphate buffer and TSP was combined and added to a glass NMR vial then each 
sample was analysed in a Bruker DRX 600. 
2.4.12  Murine bone marrow-derived macrophage infections  
2.4.12.1 Differentiation of murine bone marrow derived macrophages (BMDMs) 
All buffers and reagents were endotoxin free. 
Bone marrow from six to eight week old female BALB/c immunocompetent mice was 
flushed into 10 ml of RPMI 1640 (Gibco, Invitrogen) supplemented with 10 % heat-
inactivated foetal calf serum (Gibco, Invitrogen), 2 mM L-glutamine, 1 mM sodium 
pyruvate, 10 mM HEPES and 50 µM ß-mercaptoethanol (called RPMI complete) in a 
Petri dish. Cell clumps were broken using a syringe and then transferred to a 50 ml 
Falcon tube. Cells were centrifuged at 250 rcf for five minutes to pellet the cells. RPMI 
was removed and a 10 ml aliquot of 0.83 % ammonium chloride was added for 5 
minutes at 37 
o
C to lyse the red blood cells. Cells were harvested again and the 
ammonium chloride was removed. Cells were washed in 10 ml 1 x PBS (Gibco, 
Invitrogen) then resuspended in 10 ml RPMI containing 20 % L cell conditioned 
medium (L-cell). L-cell is the supernatant produced from mouse fibroblast 929 cultures 
(prepared by the Large Scale Lab at NIMR) and contains colony stimulating factor 
which stimulates the differentiation of bone marrow derived monocytes into 
macrophages (Austin et al., 1971). The cell solution was filtered through a 70 µm filter 
(BD Biosciences) to remove bone and muscle tissue. A 50 µl aliquot of the cell 
suspension was mixed with 50 µl trypan blue stain (Fluka) and 10 µl of this mix was 
counted using a Bright-Line haemocytometer (Sigma) counting chamber and an 
Axiovert 25 microscope (Zeiss). Monocytes were plated out in Petri dishes at a 
concentration of 4 x 10
6 
cells per plate in RPMI plus 20 % L-cell supplement in a total 
volume of 10 ml. Cells were incubated at 37 
o
C with 5 % CO2. After 72 hours a further 
10 ml of RPMI plus 20 % L cell supplement was added to each Petri dish. After a further 
48 hours macrophages were ready to use. All media and non-adherent cells were 
removed from the Petri dishes. 5 ml of cold (4 
o
C) 4 mM EDTA in 1 x PBS was added 
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to each Petri dish and a 10 ml stripette was used to gently flush the cells from the plate. 
Addition of EDTA helps to detach adherent cells as it is a chelating agent that binds 
calcium. Cells were transferred to a 50 ml Falcon tube and centrifuged at 250 rcf for five 
minutes. The supernatant was discarded and the cell pellet resuspended in RPMI 
containing 5 % L-cell supplement. A 50 µl aliquot of the cell suspension was mixed with 
50 µl Trypan Blue and 10 µl of this mix was counted using a haemocytometer as before. 
2 x 10
5
 macrophages were seeded per well in a 1 ml volume in a 24 well cell culture 
plate (Tissue Culture Treated plates, Costar). When required, mouse interferon-γ (IFNγ) 
was added at 20 ng/ml (Roche) to activate the macrophages. Cells were plated out in 
triplicate for each M. tuberculosis strain and post-infection time point. Prior to infection 
cells were incubated for 18 hours at 37 
o
C with 5 % CO2 to allow adherence and 
activation. 
2.4.12.2 Preparation of bacterial strains and infection of BMDMs  
M. tuberculosis rolling cultures were grown in Dubos medium to an OD600 of 0.6. A 20 
ml aliquot of each strain to be used for infection was transferred to a 50 ml Falcon tube. 
Cells were centrifuged at 1,200 rcf for 15 minutes and thoroughly resuspended in PBS 
plus 0.05 % Tween 80. Cells were centrifuged at 50 rcf for five minutes to spin down 
any clumped cells and the supernatant was transferred to a new tube. The OD600 of each 
culture was determined and converted to CFU/ml (based on an OD600 of 1.000 being 
equivalent to 5 x 10
8
 CFU/ml). M. tuberculosis strains were added to the macrophages in 
a 50 µl volume at a multiplicity of infection of one bacterium to two macrophages. 
Plates were incubated for a further six hours to allow the macrophages to phagocytose 
the bacteria. Extracellular bacteria were then removed from all the wells using an 
aspirator and cells were washed three times with 500 µl HBSS salt solution (Gibco). 1 
ml RPMI complete containing 5 % L-cell was added to each well and cells were placed 
in a 37 
o
C incubator with 5 % CO2. Survival and multiplication of M. tuberculosis within 
the macrophages was assessed at six, 24, 72, 120 and 168 hours post infection. At each 
time point media was removed from each well and macrophages were lysed in 500 µl 
dH2O plus 0.05 % Tween 80 for 30 minutes. Appropriate dilutions of bacteria were then 
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plated onto 7H11 agar plates and incubated at 37 
o
C for two to four weeks. Colonies 
were then counted and CFU/ml was calculated.  
2.4.12.3 Greiss nitrite assay  
Macrophages are activated by IFN-γ secreted by T helper cells. Activated macrophages 
produce nitric oxide and oxygen radicals which both have antimicrobial activity. Nitrite 
(NO2
-
) is a stable breakdown product of nitric oxide and thus can be used as an indicator 
of macrophage activation using the Greiss assay which is based on a diazotization 
reaction. Under acidic conditions sulfanilamide and N-1-napthylethylenediamine 
dihydrochloride (NED) react with NO2
-
 to give a coloured azo derivative which can be 
measured at 540 nm. 
Culture supernatants from macrophage infections at various time points were filtered 
twice through 0.22 µM filters as in section 2.4.4. Assays were performed in 96 well flat 
bottomed plates (Greiner Bio-one). A standard curve was generated by diluting 0.1 M 
sodium nitrite (NaNO2) 1:1,000 in supplemented RPMI to give a 100 µM solution of 
NO2
-
. A two fold dilution series was performed to produce the standard curve. 50 µl of 
each experimental sample was added to the wells (in triplicate). 50 µl of Solution A (1 % 
sulfanilamide, 5 % phosphoric acid) was then added to both experimental samples and 
standards and plates were incubated at room temperature in the dark for 10 minutes. 50 
µl of Solution B (0.1 % NED) was then added to all wells and incubated as before. 
Absorbance was then measured at 540 nm in a Benchmark plus microplate 
spectrophotometer (Bio-rad). 
2.4.13 Preparation of bacterial strains for infection in a mouse aerosol model 
M. tuberculosis rolling cultures were grown in Dubos to an OD600 of 0.6. Cultures were 
pelleted and resuspended in DMEM (Sigma) plus 2 mM L-Glutamine and 50 % foetal 
calf serum to a concentration of 10
9 
bacteria per ml. Aerosol infections were performed 
at the National Institute for Biological Standards and Control by Dr. Barry Walker and 
Dr. Angela Rodgers.  
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2.4.14 Enzyme-linked immunosorbent assays (ELISAs) 
Two ELISA methods were employed; a cytokine ELISA and M. tuberculosis whole cell 
ELISA. Both methods are outlined below. They each used Maxisorp F96 Nunc-Immuno 
plates (Nunc) whose surface has high affinity for molecules with mixed hydrophilic and 
hydrophobic domains.  
1. Cytokine ELISAs 
Cytokine ELISAs were used for the measurement and quantification of cytokines 
secreted by macrophages post infection with M. tuberculosis. Murine bone marrow 
derived macrophages were differentiated and M. tuberculosis strains were prepared as in 
section 2.4.4.12. Post infection, macrophages were not washed and media was not 
replaced. Instead, at six, 24, 72 and 96 hours post infection the media was filtered twice 
through 0.22 µM membranes as in section 2.4.4 to remove extracellular M. tuberculosis 
and then ELISAs were performed. All incubation steps were performed at room 
temperature unless stated otherwise. Briefly, 50 µl of desired capture antibody in 
Coating Buffer (eBioscience) was immobilized onto Maxisorp plates overnight at 4 
o
C. 
Plates were washed three times in 1 x PBS plus 0.05 % Tween 20 (Sigma). Wells were 
then blocked by incubation for one hour with 200 µl/well of 1 x Assay Diluent 
(eBioscience). Wells were then washed as previously. Standards were diluted in 1 x 
Assay Diluent to make the standard curve and added to each plate. 50 µl of each filtered 
sample were then added to the plate (in triplicate) and incubated for two hours. Wells 
were washed as previously then 50 µl/well of biotin-conjugated detection antibody 
(eBioscience) diluted in 1 x Assay Diluent were added and incubated for one hour. 
Wells were washed and then 50 µl/well of Avidin-HRP diluted in 1 x Assay Diluent 
were added and incubated for 30 minutes. Wells were then washed seven times as 
previously and developed by addition of 50 µl 3,3´,5,5´-Tetramethylbenzidine (TMB) 
substrate for horseradish peroxidase (Sigma). To stop the reaction 50 µl 1M H2SO4 was 
added and plates were measured at 450 nm in a Benchmark plus microplate 
spectrophotometer (Bio-Rad). 
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2. M. tuberculosis whole cell ELISAs 
Mid-log rolling cultures of M. tuberculosis were harvested, resuspended in PBS and heat 
killed for one hour at 80 
o
C. 50 µl of the cell suspension was applied to each well and 
incubated at room temperature for two hours to allow adsorption to the bottom of each 
well. Wells were then blocked overnight at 4 
o
C with 200 µl of 1 % BSA in TBS (50 
mM Tris-HCl pH8, 150 mM NaCl) to reduce non-specific binding of primary 
antibodies. Primary antibodies against LAM and various capsular components of the M. 
tuberculosis cell wall were raised in mice (IgM purified) and were kindly provided by 
Drs Ben Appelmelk and Jeroen Geurtsen (VU University Medical Centre, Amsterdam). 
Mab F183-24 primarily recognises PIM6, but also ManLAM capped with 3 mannosyl 
residues; Mab F30-5 recognises the Ara6 structure present in LAM; Mab Baba 
recognises capsular glucan and 55.92.1a1 recognises ManLAMs capped with single 
mannosyl residues. Plates were washed three times in 1 x PBS plus 0.05 % Tween 20 
(Sigma). Appropriate dilutions of primary antibody in 50 µl volumes in TBS were added 
to each well and incubated at 37 
o
C for 90 minutes. Wells were washed as before then 50 
µl of a 1:10, 000 dilution of secondary antibody (Goat Anti-Mouse IgM (µ-chain 
specific) peroxidase conjugate (Sigma)) was added to each well and incubated as 
previously. Wells were washed and developed by addition of 50 µl 3,3´,5,5´-
Tetramethylbenzidine (TMB) substrate for horseradish peroxidase (Sigma). Colour 
formation was monitored (wells turn blue in the presence of secondary antibody) and the 
reaction was stopped by adding 50 µl 1M H2SO4 to each well producing a yellow 
coloured product. Plates were then measured at 450 nm in a Benchmark plus microplate 
spectrophotometer (Bio-Rad). 
2.5 Protein Expression and Analysis Techniques 
2.5.1 Sodium dodoecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
All SDS-PAGE experiments were performed with eight to 15 % Acrylamide/Bis-Tris 
gels cast in 1 mm Casettes (Invitrogen) according to Sambrook (Sambrook & Russell, 
2001). Protein samples were mixed with 4 x Laemmli Sample Loading Buffer (0.25 M 
Tris pH 6.8, 6 % SDS, 40 % glycerol, 0.04 % Bromophenol blue, 20 % ß-
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mercaptoethanol) and heated to 100 
o
C for five minutes prior to loading. Five to 20 µl of 
each sample was typically loaded alongside a Dual Color Precision Plus Protein Standard 
(Bio-Rad). Gels were run in 1 x SDS Running Buffer (14.4 g Glycine, 3 g Tris, 1 g SDS) 
at 170 to 200 V for 45 to 60 minutes in an XCell SureLock mini-cell (Invitrogen). Gels 
were developed by staining with InstantBlue Coomassie stain (Expedeon) according to the 
manufacturer’s instructions and imaged on a BioDoc-It Imaging System. 
2.5.2 Expression and purification of M. tuberculosis proteins in E. coli 
2.5.2.1 Protein expression 
The pGex-6P-1 vector (GE Healthcare) was chosen for all protein expression studies. 
pGex-6P-1 has an N-terminal Glutathione S-Transferase (GST) tag which binds to 
glutathione sepharose allowing for affinity purification of target proteins. A site 
cleavable with PreScission Protease (GE Healthcare) is situated 3´ to the GST tag to 
allow for removal of the GST. Protein expression is under control of the tac inducible 
promoter (situated upstream of the GST gene) which is a hybrid of two strong 
promoters, trp and lac. The tac promoter is induced with isopropyl beta-D-
thiogalactoside (IPTG). In addition, pGex-6P-1 also contains an internal lacI gene. LacI 
is a repressor protein which binds to the tac promoter in the absence of inducer thus 
allowing for tighter control of protein expression.  
All expression studies used E. coli BL21 (DE3) star competent cells (Invitrogen) or E. 
coli BL21 (DE3) pRep4 (V. Molle, Personal Communication) cells which contain an 
extra chaperone expressing plasmid to enhance protein stability. One colony from an 
overnight transformation plate was picked into L. broth containing appropriate selection 
antibiotics and grown with shaking (250 rpm) overnight at 37 
o
C. 0.01 volumes of 
overnight culture was inoculated into fresh L. broth (usually two to four litres) and 
grown as previously until the OD600 reached 0.6 (mid-log phase). Protein expression was 
then induced with 0.1 mM IPTG for 16 hours at 4 
o
C. All subsequent steps were 
performed at 4 
o
C unless stated.  
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Cells were harvested by centrifugation for 20 minutes at 13,500 rcf, washed in PBS then 
resuspended in 10 ml of lysis buffer (50 mM Tris-HCl pH 8, 300 mM NaCl, plus one 
Complete EDTA-Free Protease Inhibitor Cocktail Tablet (Roche) per 50 ml) per gram of 
cells. When required, 10 % glycerol was added to all protein buffers to increase protein 
stability. DNase, RNase (Promega) and lysozyme (Sigma) were added to the cells to aid 
lysis and reduce viscosity. Cells were lysed by sonication (Vibracell, Sonics) on ice with 
ten bursts of ~ 20 seconds at amplitude 10. Cell lysates were then centrifuged for one 
hour at 100,000 rcf to separate the soluble from the insoluble fraction.  
2.5.2.2 Protein Purification  
The soluble lysate was applied to an appropriate amount of prepared Glutathione 
Sepharose 4B resin (three to five ml) (GE Healthcare) equilibrated in lysis buffer. It was 
incubated overnight at 4 
o
C with gentle mixing. The resin was collected by 
centrifugation at 400 rcf for five minutes then washed with one litre of wash buffer (50 
mM Tris (pH 8), 500 mM NaCl). At this stage two different methods were employed. If 
an un-cleaved GST-fusion protein was required the target protein was eluted at this stage 
with wash buffer supplemented with 10 mM reduced glutathione (Sigma) by incubation 
overnight with mixing as previously. Alternatively, if a cleaved protein was required 
washed resin was equilibrated with PreScission protease cleavage buffer (50 mM Tris 
(pH 8), 200 mM NaCl, 1mM EDTA, 0.5 mM DTT). 50 µl of PreScission protease was 
then added to the resin and incubated overnight with mixing as previously. Elutions 
were concentrated in a 20 ml Vivaspin ultrafiltration concentrator (VivaScience) with an 
appropriate molecular weight cut off filter (three to 10 kDa). Samples were concentrated 
by centrifugation at 2,000 rcf. 
2.5.2.2.1 Size exclusion chromatography 
To remove any protein contaminants in the preparations each sample was purified by 
size exclusion chromatography with a pre-packed HiLoad 16/60 Superdex 200 prep 
grade column (GE Healthcare) using an AKTA Prime system. The column was 
equilibrated in gel filtration buffer (40 mM Tris (pH 8), 200 mM NaCl), the sample was 
loaded and then run at between 0.5 and 1 ml per minute collecting fractions. Appropriate 
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fractions containing the protein of interest were checked by SDS-PAGE, pooled, 
concentrated and snap-frozen at -80 
o
C in 20 to 100 µl aliquots.  
2.5.2.3 Mass spectrometry 
Proteins were identified by MALDI-TOF and electrospray mass spectrometry. For 
MALDI-TOF the protein band was gel excised, cut into 2 mm x 2 mm pieces, then 500 
µl 200 mM ammonium bicarbonate (ABC) and 50 % acetonitrile was added for 30 
minutes at 25 
o
C to extract SDS and Coomassie Blue. The protein was then reduced in 
200 µl 20 mM DTT, 200 mM ABC and 50 % acetonitrile for one hour at 25 
o
C. The gel 
pieces were then washed extensively in 500 µl 200 mM ABC and 50 % acetonitrile 
buffer. Cysteines were alkylated in 5 mM iodoacetamide, 200 mM ABC and 50 % 
acetonitrile for 1 hour at 25 
o
C in the dark and then washed extensively with 20 mM 
ABC in 50 % acetonitrile. 500 µl neat acetonitrile was then added for 10 minutes. All 
liquid was then removed and the gel pieces allowed to dry. They were then trypsin 
digested for 24 hours at 37 
o
C by dissolving trypsin (Promega) in 5 mM ABC to a final 
concentration of 2 µg/ml and adding 35 µl to the gel pieces. MALDI was then performed 
by Steven Howell (NIMR). For electrospray ionisation (ESI) mass spectrometry 100 
pmols of purified protein were analysed by Steven Howell (NIMR).   
2.5.3 Biochemical techniques 
2.5.3.1 In vitro phosphorylation assays 
In vitro phosphorylation was carried out in 20 µl reactions containing the recombinant 
kinase (1 µg), substrate (1 µg) (if necessary) and 200 µCi/ml [γ -32P] ATP (Perkin 
Elmer) in phosphorylation buffer (25 mM Tris-HCl pH 6.8, 1 mM DTT, 5 mM MgCl2, 1 
mM EDTA). The reaction was carried out for 30 minutes at 37 
o
C. The reaction was 
stopped by addition of Laemmli Sample Loading Buffer and incubated at 100 
o
C for five 
minutes before analysis by SDS-PAGE. After electrophoresis gels were washed in 10 % 
trichloracetic acid for 10 minutes at 90 
o
C then stained with InstantBlue Coomassie stain 
(Expedeon) or dried on a Gel Drier (Savant, Slab Drier) then exposed to a 
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phosphoimager screen (Molecular Dynamics) and developed on a Storm Scanner 
(Amersham).  
2.5.3.2 Liquid chromatography / mass spectrometry / mass spectrometry 
(LC/MS/MS)  
LC/MS/MS was performed in collaboration with V. Molle (IBCP, France) to identify 
residues in Rv1747 that were phosphorylated by PknF. Recombinant PknF
1-292
 and 
Rv1747
1-559
 was supplied to V. Molle for the phosphorylation site identification. LC-
MS/MS was performed as outlined in two papers (Canova et al., 2008; Molle et al., 
2006). Briefly this technique involved the in vitro phosphorylation of Rv1747 by PknF 
with ATP and then the phosphorylated Rv1747 protein was separated from the kinase by 
liquid chromatography. Phosphorylated Rv1747 peptides were identified by on-target 
dephosphorylation/MALDI-TOF which is where a phosphatase is used to remove 
phosphoryl groups from peptides leading to de-phosphorylated peptides appearing as 
new or more abundant peaks on the MS spectra (Molle et al., 2006). LC/MS/MS was 
then performed to reveal the location of the phosphorylation sites. This technique uses 
liquid chromatography (LC) to separate the pool of phosphopeptides which helps in the 
identification of phosphorylation sites by reducing the complexity of the mixture, 
coupled with MS for the identification of the phosphorylated residues (Molle et al., 
2006). Repeated rounds of mass spectrometry were required to identify multiple 
phosphorylation sites. 
2.5.3.3 Isothermal titration calorimetry (ITC) 
ITC was used to determine the binding kinetics between FHA domains and potential 
phosphopeptide substrates. Experiments were performed with the MicroCal iTC200 
system (GE Healthcare). The instrument can determine the binding affinity (KA), 
enthalpy change (∆H) and binding stochiometry (n) between two reactants in a single 
experiment. The aim of ITC is to calculate the dissociation constant (KD) which 
measures how tightly a ligand binds to a particular protein. Lasse Stach (NIMR) 
provided expert help with the use of the instrument and phosphopeptides were 
synthesised by Dr. W. Mawby (University of Bristol).  
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The instrument is composed of a reference cell and sample cell. In the reference cell is 
an aqueous solution. Both reference cell and sample cell were cooled to 10 
o
C while the 
surrounding buffer was cooled to 9 
o
C so that the instrument needed to use a specific 
amount of energy to keep the reference cell solution at 10 
o
C. 200 µl of FHA protein (at 
50 µM) in 20 mM Tris pH8 and 150 mM NaCl was loaded into the sample cell. 100 µl 
of phosphopeptide (at 500 µM) in the same buffer was loaded into the syringe. During 
the experiment 2 µl of ligand was titrated into the sample cell every 180 seconds with a 
total of 20 injections. Binding of the protein to the peptide can be an exothermic or 
endothermic reaction (due to the net outcome of hydrogen bond formation and 
electrostatic interactions). The raw data for an experiment consisted of a series of spikes 
which were plotted as the amount of power (in µcal/sec) needed to maintain the 
reference and sample cell at the same temperature. Each spike represented one injection 
of ligand. The total heat effect per injection was then calculated by integrating each 
spike with respect to time. From this, the dissociation constant was determined. The KD 
is defined as the concentration of ligand at which the binding site on a particular protein 
is half occupied, hence the smaller the dissociation constant, the more tightly bound the 
ligand.  
2.5.3.4 Size-Exclusion Chromatography Combined with Multiangle Laser Light 
Scattering (SEC-MALLS). 
SEC-MALLS is a technique which combines size exclusion chromatography and light 
scattering to measure the absolute molecular mass and concentration of proteins of 
interest. Briefly, protein samples are separated by size using a gel filtration column 
before passing through light scattering, absorbance and refractive index detectors. When 
a laser light hits a protein it causes light to scatter, the intensity of which is directly 
proportional to the molar mass and can be shown by the following equation: 
Intensity of scattered light = molecular weight x concentration of protein (mg/ml) 
Light scattering was measured at 90
o
. For proteins over 500 kDa or with unusual 
structures multi-angle laser light scattering is necessary to accurately calculate the mass 
as scattering varies greatly with each angle measurement but this was not necessary in 
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this study. The concentration of the protein sample can be measured using absorbance or 
differential refractive index detectors. For this study the differential refractive index was 
calculated as the protein construct does not absorb UV due to an absence of tyrosine, 
tryptophan and phenylalanine residues. The refractive index detector is formed of two 
cells of which one acts as a reference cell (Optilab rEx). Both cells are conditioned with 
buffer. When a protein sample passes through the sample cell the difference in the 
refractive index between the two cells is measured and this has been shown to be 
directly proportional to the concentration of protein. Therefore measuring the molecular 
mass of each protein peak is possible by combining measurements from light scattering 
and the differential refractive index.  
SEC-MALLS was used to investigate whether FHA2
202-310
 became dimeric when 
phosphorylated at the N-terminus of the construct (at residue T208) by PknF. FHA2
202-
310
,
 
PknF
1-292
 and GST-PknF
1-292
 were expressed and purified to homogeneity as 
described in section 2.5.2. Phosphorylation reactions (250 µl volume) were performed 
for four hours at 37 
o
C containing FHA2
202-310
 and GST-PknF
1-292
 (at a 10:1 ratio) with 
500 µM ATP in phosphorylation  buffer (25 mM Tris-HCl pH 6.8, 1 mM DTT, 5 mM 
MgCl2, 1mM EDTA). FHA2
202-310 
was typically used in the range of 1 to 5 mg/ml. 
Negative controls containing no ATP were also included. After the four hour incubation 
prepared Glutathione Sepharose 4B resin (100 µl) (GE Healthcare) equilibrated in 
phosphorylation buffer was added to each sample and mixed on a rotator for 1 hour at 4 
o
C to allow GST-PknF
1-292
 to bind to the resin. Samples were then filtered through low 
binding 0.22 µm Durapore membrane filters (Ultrafree-MC, Millipore) to remove resin 
containing the bound GST-PknF
1-292
. Next, 100 µl volumes of each sample were loaded 
onto a Superdex 200, 10/300 GL column (at 25 
o
C) conditioned with phosphorylation 
buffer plus NaCl (25 mM Tris-HCl pH 6.8, 150 mM NaCl, 1 mM DTT, 5 mM MgCl2, 
1mM EDTA, 3 mM sodium azide) at a speed of 0.5 ml/minute before passing through 
UV, refractive and light scattering detectors (Dawn Heleos and Optilab rEx, Wyatt). 
Data were analysed and graphs were drawn using JASCO ChromPass Chromatography 
data system and ASTRA [EASIGraph] plotting the retention time (in minutes) of each 
protein versus the molar mass (g/mol). Lasse Stach (NIMR) helped in the analysis of 
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data. Electrospray mass spectrometry was also carried out to confirm the 
phosphorylation of FHA2
202-310 
as described in section 2.5.2.3. 
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CHAPTER 3. CHARACTERISATION OF THE pknF-Rv1747 
OPERON, INVESTIGATION INTO THE pknF STIMULUS 
AND INITIAL ASSESSMENT OF THE pknF AND Rv1747 
MUTANT STRAINS 
3.1 Introduction 
This study initially set out to define the operon structure of the genomic region from 
pknF to Rv1749c and to map the transcriptional start site of pknF. pknF lies within a 
putative operon with Rv1747. Co-transcription of genes can suggest that proteins act 
together to serve a particular function. In the case of the FHA domain containing 
proteins of M. tuberculosis, four of the six FHA proteins, including Rv1747, lie in 
putative operons with serine-threonine protein kinases. They include embR (Rv1267c) 
which forms a putative operon with pknH. Studies have demonstrated that EmbR, a 
transcriptional regulator, is phosphorylated by PknH (Molle et al., 2003). Furthermore, 
phosphorylation by PknH increases the DNA binding capacity of EmbR to the promoter 
regions of the embCAB genes thus increasing their transcription (Sharma et al., 2006). 
The embCAB genes are arabinosyltransferases which are involved in the arabinosylation 
of lipomannan to make lipoarabinomannan and the arabinosylation of arabinogalactan, 
two key virulence associated components of the mycobacterial cell wall (Sharma et al., 
2006).  In addition, the FHA domain containing proteins fhaA (Rv0020c) and fhaB 
(Rv0019c) both lie in the same putative operon with pknA (Rv0015c) and pknB 
(Rv0014c). pknA and pknB are essential genes in M. tuberculosis and have been shown 
to play a role in cell wall synthesis and cell morphology (Kang et al., 2005). PknB is 
known to phosphorylate both Rv0019c and Rv0020c in vitro (Grundner et al., 2005; 
Gupta et al., 2009). Therefore it was of interest to assess whether pknF and Rv1747 were 
part of an operon. 
Transcriptional start site mapping can yield insights into how gene expression is 
regulated by indicating the position and number of promoters present for genes of 
interest. Mapping transcriptional start sites also aids in the design of promoter reporter 
plasmid constructs for experiments investigating the stimulus of a particular gene. 
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Therefore, when the transcriptional start site of pknF was mapped by 5´RACE, 
experiments investigating the possible stimulus of pknF at the transcriptional level were 
performed using a promoter-lacZ fusion construct containing the pknF promoter region. 
It was hypothesised that upon subjecting the M. tuberculosis cell to a particular stress the 
pknF promoter activity may increase, presumably through the binding of a transcription 
or sigma factor to the promoter, leading to a greater abundance of pknF and Rv1747 
transcript, which may in turn be translated into an increased amount of protein. 
Autophosphorylation of PknF might then occur after sensing the stress signal making the 
protein functionally active, and then sequentially PknF may phosphorylate Rv1747 in 
order to transduce the signal and regulate the activity of the transporter. In 2008 
Jayakumar and colleagues demonstrated that the pknE promoter showed increased 
activity when M. tuberculosis cells were exposed to nitric oxide stress (Jayakumar et al., 
2008). They went on to demonstrate that a pknE mutant conferred increased resistance to 
nitric oxide donors and related it to a mechanism where pknE senses nitric oxide stress 
and prevents apoptosis in the host cell by interfering with signalling mechanisms. 
Therefore it was of interest to investigate whether the pknF promoter showed any 
change in activity when M. tuberculosis cells were exposed to a variety of stresses.   
Initial characterisation of the pknF and Rv1747 null mutants showed their growth was 
the same as the wild type strain under in vitro growth conditions (R. Whalan, Personal 
communication and Curry et al., 2005). The next aim in this study was to further 
characterise both mutants by assessing their susceptibility to a range of drug and stress 
reagents compared with the parental wild type H37Rv strain. This was achieved by 
performing a series of 96 well plate growth inhibition assays. It was hypothesised that 
any differences in susceptibility between the strains may yield clues as to the function of 
the two proteins.  
3.1 Experiments to determine co-transcription of pknF and Rv1747 
The genomic localization of pknF and Rv1747 (figure 3.1a) suggested that the two genes 
could potentially form an operon; the intergenic region between pknF and Rv1747 is 
only 62 base pairs in size. RT-PCR experiments were performed as outlined in section 
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2.3.1 to answer this question. The results, shown in figure 3.1b, clearly show a transcript 
present running from pknF through the intergenic region into Rv1747 demonstrating that 
these two genes are indeed co-transcribed. Primers used in the RT-PCR study can be 
found in Appendix II. A transcript was also present for each investigated gene when 
using gene specific internal primers. No transcript was detected in the intergenic region 
between Rv1747 and Rv1748 when using a forward primer within Rv1747 with a reverse 
primer within Rv1748, indicating that these two genes are not co-transcribed. In addition 
a transcript was not present between Rv1748 and Rv1749c which agrees with theory as 
the two genes are convergent. The results conclusively showed that pknF and Rv1747 
form a single operon.  
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Figure 3.1 pknF and Rv1747 are co-transcribed. a. Schematic showing the positions of pknF, Rv1747 and the surrounding 
genomic region of M. tuberculosis (adapted from Tuberculist (http://tuberculist.epfl.ch)). The marks on the chromosome are 
at 2000 bp intervals b. RT-PCR results showing the products of cDNA amplification. 10 µl of a 50 µl RT reaction was 
analysed by agarose gel electrophoresis.  Labels above the gel show the primer pairs used in each PCR (Appendix II). Lane 
one of each primer pair is the positive control (H37Rv genomic DNA). Lane two is a negative control (no mRNA added to the 
RT reaction). Lane three is the RT positive lane. Lane four is RT negative (no reverse transcriptase present in RT reaction). 
The pknF-Rv1747 transcript is highlighted with a red box. M is the DNA ladder and the relevant sizes in base pairs are 
labelled.   
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3.2 Determination of the transcriptional start site of pknF 
5´RACE is a technique in which cDNA is generated from RNA and then PCR 
amplification is used to map the 5´ end of transcripts thus revealing the position of 
transcriptional start site/s (described in section 2.3.2).  
The transcriptional start site of pknF was mapped; figure 3.2a shows the products of the 
primary and secondary PCR reactions. The product from the secondary PCR reaction 
was gel purified, cloned into pCR4Blunt-TOPO and six resulting transformants were 
sequenced; figure 3.2b summarises the 5´RACE results highlighting the possible 
transcriptional start sites. As 5´RACE incorporates a poly-cytosine tail onto the 3´ end of 
cDNA this technique cannot precisely map sites where transcription may begin at a 
cytosine residue. Therefore from the sequencing results it was not possible to determine 
whether transcription starts from either of the cytosine residues highlighted in blue or 
whether transcription is in fact coupled to translation and hence the start site is the 
adenine shown in red (figure 3.2b). The sequencing results demonstrate that the 
transcriptional start site of pknF is most probably the same as the translational 
start site.  
For this study it was important to determine the transcriptional start site of pknF to aid in 
the design of the promoter-lacZ fusion construct which was to be used to investigate the 
possible stimulus to which the pknF promoter may respond. The pknF promoter would 
most likely be situated in close proximity upstream of the transcriptional start site. 
Therefore by using 5´RACE to narrow down the possible start site to a very small region 
it helped in designing the promoter-lacZ fusion construct.  
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Figure 3.2 The transcriptional start site of pknF. a. 5´ RACE results of pknF showing 
the products of the primary and secondary PCR reactions. 10 µl of each PCR product 
was analysed by agarose gel electrophoresis. M is the DNA ladder and the relevant sizes 
in base pairs are labelled. Lane 1 shows the products of the primary PCR amplification 
and lane 2 shows the products of the secondary nested PCR reaction which map the 
transcriptional start site. b. Summary of the 5´ RACE results mapping the possible 
transcriptional start site/s of pknF (highlighted in blue) and the translational start site 
according to the Institute Pasteur in Tuberculist (shown in red) 
(http://tuberculist.epfl.ch/).   
 
 
 
 
 
 
 
 
 
 
 
a 
b 
5´ cctgccctcctggcgggctacgatgccgccatgccgctcgcggaaggt 3´ 
M                               1               2  600 
400 
200 
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3.3 Investigation of the transcription of the pknF-Rv1747 operon after 
stress 
PknF is a transmembrane protein kinase that contains an intracellular kinase domain and 
an extracellular domain thought to be responsible for signal recognition. The external 
stimulus that PknF recognises is unknown; it is possible that this signal influences pknF 
transcription and as a consequence was investigated at the transcriptional level in 
promoter-lacZ reporter gene assays utilising ß-galactosidase activity as a measure of 
promoter activity (section 2.4.8). One hypothesis was that upon subjecting the M. 
tuberculosis cell to a particular stress the pknF promoter activity may increase, leading 
to a greater abundance of pknF and Rv1747 transcript, which may in turn be translated 
into a greater amount of functional protein. A promoter-lacZ fusion construct was 
generated by cloning 321 bp upstream of the pknF transcriptional start site in front of the 
lacZ gene in pEJ414 (there are 146 bp between pknF and its upstream divergent gene 
idi). This construct was sequenced and confirmed to be correct before electroporating 
into M. tuberculosis. Three separate M. tuberculosis colonies transformed with either 
pknF-pEJ414 or pEJ414 vector control were assessed for their promoter activity as 
described in section 2.4.8. Figure 3.3 shows that the pknF promoter in this assay had a 
specific activity of 320 units of ß-galactosidase whilst the pEJ414 vector control strain 
had a specific activity of 10 units. These results confirm the presence of the pknF 
promoter within the construct and demonstrate that the promoter is active during 
exponential growth in vitro. 
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Figure 3.3 ß-galactosidase assay on the pknF promoter-lacZ strain and pEJ414 
control strain in M. tuberculosis. The ß-galactosidase assay was performed on CFE of 
M. tuberculosis strains containing pEJ414 and pVS_01. The data presented are the 
means of three biological replicates each assayed in duplicate and the error bars 
represent standard deviations. An unpaired t-test (two-tailed) was used for a pairwise 
comparison between pEJ414 and pVS_01. The ß-galactosidase activity levels were 
determined to be significantly higher within strains containing pVS_01 compared with 
the control strain pEJ414. *** highlights the significant P value of <0.0001.  
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Next, to investigate whether transcription of the pknF-Rv1747 operon was affected by 
external conditions ß-galactosidase assays were performed to assess promoter activity 
after treating cells for two or 24 hours with a variety of drugs and stress reagents as 
described in section 2.4.8. 
The panel of stress reagents tested in this study included the first line anti-tuberculosis 
drugs isoniazid and ethambutol. The prodrug isoniazid is activated by the catalase 
peroxidise enzyme KatG and then binds to InhA resulting in inhibition of mycolic acid 
synthesis. Ethambutol acts on the biosynthesis of arabinogalactan, the major 
polysaccharide of the TB cell wall, by inhibiting the polymerization of arabinan. Both 
these drugs were chosen as it was hypothesised that Rv1747 could be involved in 
transporting a component of the cell wall and so the promoter of pknF may be induced if 
faced by cell wall stresses. 
Gentamycin and streptomycin fall into the aminoglycosides category of antibiotics. They 
bind to the 30S ribosomal subunit blocking further protein synthesis. Hydrogen 
peroxide, t-butyl hydrogen peroxide and diamide are oxidative stress-inducing agents 
and treatment of cells with plumbagin results in superoxide stress. GSNO and sodium 
nitroprusside are nitric oxide donors and were chosen for investigation along with 
hydrogen peroxide based on the earlier pknE promoter study (Jayakumar et al., 2008).    
Mitomycin C is a DNA damaging agent that crosslinks DNA thus blocking replication. 
Ofloxacin is a fluoroquinolone which can also be considered to cause DNA damage as it 
interferes with DNA replication by inhibiting DNA gyrase function necessary for cell 
division. All these compounds were tested for their ability to alter the ß-galactosidase 
activity of the pknF promoter region in order to indicate a possible role for this kinase in 
M. tuberculosis. Isoniazid, ethambutol, gentomycin, streptomycin, hydrogen peroxide, t-
butyl hydrogen peroxide, mitomycin C, ofloxacin, s-nitrosoglutathione and sodium 
nitroprusside were added to M. tuberculosis cells at an OD600 of 0.6 to 0.8 for two hours 
at concentrations equal to 50 percent of the published minimum inhibitory concentration 
(MIC) and CFEs were made as detailed in section 2.4.8. The ß-galactosidase activity of 
pknF after a 24 hour incubation in acidified medium to generate acid stress was also 
assessed as was the level of activity in stationary phase of growth (OD600 of 2.0).  
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The results from this study are shown in figure 3.4. The data labelled ‘control, no stress’ 
represent the results shown in figure 3.3 where CFE was generated from cultures in 
exponential phase of growth after having no form of treatment. All other data are 
labelled with the treatment that they were given. In all cases the ß-galactosidase activity 
levels were significantly higher within strains containing pVS_01 compared with the 
control strain pEJ414. The results show that there are no significant changes in the 
levels of ß-galactosidase activity upon treatment with any of the reagents tested. In 
addition, no significant changes were observed between the control strains after 
treatment. Data are displayed as the mean of three biological replicates. Data labelled 
‘pH7.2’ represents the control experiment for the acid stress treatment labelled ‘pH5.5’. 
As outlined in section 2.4.8 these cultures were harvested at an OD600 of 0.3 and then 
resuspended in either normal Dubos medium at a pH of 7.2 or Dubos medium adjusted 
to a pH of 5.5 to induce acid stress. Furthermore, the activity of the pknF promoter in 
stationary phase is comparable to that in exponential phase of growth. 
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Figure 3.4 ß-galactosidase assays on the pknF promoter-lacZ strain and pEJ414 
control strain in M. tuberculosis after a panel of treatments. The ß-galactosidase assay 
was performed on CFEs of M. tuberculosis strains containing pEJ414 and pVS_01 after a 
panel of treatments. All reagents were added to the M. tuberculosis cultures for two hours 
prior to harvesting for CFE with the exception of acid stress and stationary phase conditions. 
For acid stress, cultures at an OD600 of 0.3 were harvested and resuspended in Dubos 
adjusted to pH7.2 (control) or Dubos adjusted to pH 5.5 (acid stress) and incubated for a 
further 24 hours (section 2.4.8). For assessing activity in stationary phase cultures were 
harvested when at an OD600 2. The data presented are the averages of three biological 
replicates each assayed in duplicate and the error bars represent standard deviations. In all 
cases the ß-galactosidase activity levels were significantly higher within strains containing 
pVS_01 compared with the control strain pEJ414. No other significant differences were 
noted in the ß-galactosidase activity levels between any of the treatments. 
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3.4 Assessment of the susceptibility of the ∆pknF and ∆Rv1747 mutants 
to a panel of drug and stress reagents. 
Initial characterisation of the pknF and Rv1747 null mutants showed their growth was 
the same as the parental wild type strain under normal in vitro growth conditions (Curry 
et al., 2005; R. Whalan, personal communication). The next aim of this study was to 
further characterise both mutants by assessing their susceptibility to a range of drug and 
stress reagents compared with the wild type H37Rv strain. It was hypothesised that 
increased sensitivity may be observed when subjecting one or both of the mutant strains 
to a particular treatment generating clues as to the function of the two proteins in M. 
tuberculosis. To investigate this hypothesis growth inhibition assays were performed 
using the alamar blue method as outlined in section 2.4.9 and the minimum inhibitory 
concentrations (MICs) for all three strains subjected to each stress reagent were 
calculated from the data. 
The drugs and stress reagents tested were isoniazid, ethambutol, streptomycin, 
ciprofloxacin, ofloxacin, hydrogen peroxide, s-nitrosoglutathione, ethidium bromide, 
mitomycin C and sodium dodecyl sulphate. Ciprofloxacin is another member of the 
fluoroquinolone family which causes DNA damage by inhibiting DNA gyrase activity 
necessary for cell division. Sodium dodecyl sulphate (SDS) is an anionic surfactant 
detergent which can disrupt the cell wall of bacteria and lyse cells in high enough 
concentrations. It was hypothesised that if one or both of the mutants harboured a defect 
in their cell wall due to the lack of a particular component that may be transported by 
Rv1747, then there might be a difference in the MIC between the parental and mutant 
strains when subjected to SDS treatment. Mycobacteria contain active efflux pumps 
which are involved in natural drug resistance and ethidium bromide is a small molecule 
which is known to be pumped out of mycobacterial cells (Danilchanka et al., 2008). For 
example, Rv0194 is a novel multidrug efflux pump of M. tuberculosis; expression of 
Rv0194 significantly reduced accumulation of ethidium bromide in the cell and 
conferred multidrug resistance of Mycobacterium smegmatis (Danilchanka et al., 2008). 
Furthermore, Rv1747 belongs to the G subfamily of ABC transporters and ABCG2 has 
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been identified as a multidrug transporter in humans (Velamakanni et al., 2007). It was 
therefore hypothesized that the Rv1747 transporter, as a secondary function, might 
actively export molecules and if Rv1747 was indeed an efflux pump capable of 
transporting ethidium bromide or one of the fluroquinolones or other antibiotics then 
there may be an increased sensitivity to one or more of these molecules in the ∆Rv1747 
strain. In addition, changes in sensitivity may also be observed in the ∆pknF strain 
depending on the mechanism of regulation between the two proteins (i.e. whether the 
kinase activity of PknF positively or negatively regulates the transporter function of 
Rv1747). 
All the aforementioned hypotheses were tested in growth inhibition assays and the 
results of this investigation are shown in figure 3.5. Data were plotted as the 
concentration of stress reagent versus the percentage growth inhibition. The MICs for all 
three strains subjected to each stress reagent were calculated from the data and the 
results are summarized in table 3.1. The MIC was taken to be the lowest concentration 
of a drug or stress reagent capable of causing ≥90% inhibition compared to the untreated 
bacteria only controls. In all cases the ∆pknF and ∆Rv1747 mutants were not more 
susceptible or resistant to any of the drug and stress reagents tested compared with 
wild type H37Rv, and hence there were no differences in MICs observed between the 
strains. 
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Figure 3.5 Growth inhibition assays assessing the susceptibility of wild type H37Rv, 
∆pknF and ∆Rv1747 strains to a range of drug and stress reagents. Data are plotted as 
the concentration of each stress reagent versus percentage growth inhibition. Figure 3.5a 
shows the percentage growth inhibition after treating cells for five days with isoniazid, 3.5b 
shows the results for ethambutol, 3.5c streptomycin, 3.5d ciprofloxacin, 3.5e ofloxacin, 3.5f 
hydrogen peroxide, 3.5g GSNO, 3.5h EtBr, 3.5i mitomycin c and 3.5j shows the results 
after a five day treatment of cells with varying concentrations of SDS. The data presented 
are the averages of two biological replicates each assayed in duplicate and the error bars 
represent standard deviations. In all cases the ∆pknF and ∆Rv1747 mutants are not more 
susceptible or resistant to any of the drug and stress reagents tested compared with wild type 
H37Rv. 
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Table 3.1 Summary of the minimum inhibitory concentrations derived from 
growth inhibition assays of wild type H37Rv, ∆pknF and ∆Rv1747 strains after 
treatment with a panel of drug and stress reagents. 
 
 
 
 
 
 
 
 
Minimum inhibitory concentration Treatment 
Wild type ∆pknF ∆Rv1747 
Isoniazid 0.05 µg/ml 0.05 µg/ml 0.05 µg/ml 
Ethambutol 0.75 µg/ml 0.75 µg/ml 0.75 µg/ml 
Streptomycin 1 ng/ml 1 ng/ml 1 ng/ml 
Ciprofloxacin 0.063 µg/ml 0.063 µg/ml 0.063 µg/ml 
Ofloxacin 1 µg/ml 1 µg/ml 1 µg/ml 
Hydrogen peroxide 0.5 mM 0.5 mM 0.5 mM 
S-nitrosoglutathione 2.5 ng/µl 2.5 ng/µl 2.5 ng/µl 
Ethidium bromide 0.15 ng/ml 0.15 ng/ml 0.15 ng/ml 
Mitomycin C 10 ng/µl  10 ng/µl 10 ng/µl 
SDS 0.025 % 0.025 % 0.025 % 
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3.5 Discussion 
3.5.1 pknF and Rv1747 are co-transcribed  
RT-PCR demonstrated that there was a transcript present running from pknF through the 
intergenic region into Rv1747 showing that these two genes were indeed co-transcribed 
and formed a single operon. In addition, the presence of Rv1747 and pknF in the same 
operon gives further merit to the hypothesis that Rv1747 may not only function as an 
ABC transporter but may also play a role in a signal transduction system with PknF thus 
warranting further investigation in the following chapters of this study.  
However, there is also the possibility that there is a promoter present for Rv1747 within 
the coding sequence of pknF. For the primer pair that spanned from pknF through the 
intergenic region into Rv1747 approximately 300 bp of pknF transcript and 300 bp of 
Rv1747 transcript was amplified. It is possible that there is an Rv1747 promoter just 
upstream of the forward primer used in this amplification. Although unlikely, to further 
investigate this idea one would have to design a probe within Rv1747 and perform a 
Northern blot. In addition, one could perform a series of experiments in which constructs 
of varying lengths were designed upstream of the Rv1747 translational start site. Each 
region of DNA would have to be cloned into the lacZ fusion vector pEJ414, transformed 
into M. tuberculosis and assessed for levels of promoter activity. If promoter activity 
was discovered this may also answer the question as to whether there is an Rv1747 
promoter present within the coding region of pknF. Additionally 5´RACE or primer 
extension could be performed to see if a transcriptional start site for Rv1747 could be 
mapped. For this study as a whole however, these were not an important subset of 
experiments to perform and therefore the study progressed into determining the 
transcriptional start site of pknF. 
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3.5.2 The transcriptional start site of pknF  
Using 5´ RACE three possible transcriptional start sites were mapped for pknF. Due to 
the caveat that 5´ RACE incorporates a poly-cytosine tail onto the 3´ end of cDNA it 
was not possible to determine whether transcription started at either of the cytosine 
residues or the adenine nucleotide which also forms the translation initiation codon 
(figure 3.2b). It cannot be ruled out, however, that there was secondary structure in the 
RNA and therefore complete extension to the 5´ end of the message was not achieved. 
This could be proved using S1 nuclease mapping. Furthermore, by using tobacco 
pyrophosphatase (TAP) one could distinguish between a processed and unprocessed 
start site. However, a Solexa sequencing trace of the M. tuberculosis transcriptome 
showed that the mRNA transcript level of the region upstream of the annotated 
translational start site of pknF is negligible and mRNA levels rise sharply immediately 
after the translation initiation codon suggesting that transcription and translation initiate 
at the same site (Kristine Arnvig, personal communication). 
It was also a possibility that the annotated translational start site of pknF was incorrect 
and this could be tested using translational start site mapping (Smollett et al., 2009). In 
the M. tuberculosis genome, sequencing data suggests that AUG is the preferred start 
codon with the GUG initiation codon occurring at a lower frequency (Cole et al., 1998) 
and TTG being a very rare start codon (Salazar et al., 1996). In the case of pknF there 
are 12 amino acids between the annotated start codon according to Tuberculist 
(http://tuberculist.epfl.ch/) and the beginning of the kinase domain as determined by the 
SMART domain prediction software (Letunic et al., 2009; Schultz et al., 1998). Within 
this 12 amino acid sequence there is no alternative start codon present in the genome 
indicating that the annotated translational start site is correct. 
M. tuberculosis promoter consensus sequences are notoriously difficult to identify. A 
number of studies have been published defining the M. tuberculosis sigma factor 
consensus sequences; a study by Homerova et al., in 2008 describes the consensus 
sequences identified from numerous studies and also identifies a sigJ dependent 
promoter (Homerova et al., 2008). Furthermore, the spacing between the -10 and -35 
Chapter 3. Characterisation of the pknF-Rv1747 operon, investigation into the pknF 
stimulus and initial assessment of the pknF and Rv1747 mutant strains 
 108 
boxes can vary between 14 bp to 22 bp in length making the search for M. tuberculosis 
promoters all the more challenging. When examining the region upstream of the mapped 
pknF transcriptional and translational start site one finds that it contains a perfect match 
to the sigA dependent -10 consensus sequence of TAyGAT (where y is a C or T residue) 
6 nucleotides upstream of the transcriptional start point. In a study examining the 
distance between transcriptional start sites and the -10 box for M. tuberculosis promoters 
it was found that the distance was most frequently 6 or 7 base pairs (Timm et al., 1999). 
This provides further evidence supporting the fact that transcription and translation of 
pknF begin at the same nucleotide. Transcription has been shown to initiate at the 
translational start codon of a few previously studied genes in the mycobacteria. These 
include the M. tuberculosis gene purC which is part of the purine biosynthetic pathway 
(Jackson et al., 1996) and oxyR from M. leprae which is a DNA binding protein 
(Dhandayuthapani et al., 1997). Furthermore, in an actinomycete comparative study of 
transcriptional and translation start sites by Strohl in 1992 they found that there were 11 
genes (out of a total of 44 studied) where transcription and translation appeared to start 
at the same nucleotide suggesting that this is not an uncommon occurrence among the 
actinomycete family (Strohl, 1992).  
3.5.3 Investigation into the transcription of the pknF-Rv1747 operon after 
stress 
The ß-galactosidase assay results showed that the pknF promoter in this experiment had 
a specific activity of 320 units of ß-galactosidase but there were no significant changes 
in the levels of ß-galactosidase activity upon treatment with any of the reagents tested. 
Although there were no changes in the levels of ß-galactosidase activity upon treatment 
with any of the reagents tested in this study, it does not rule out the possibility that there 
is a stress condition which alters the level of activity of the pknF promoter as was found 
for pknE in the Jayakumar investigation (Jayakumar et al., 2008); it is just that to date 
the stimulus for pknF has not been discovered. In the Jayakumar study the pknE 
promoter was upregulated 1.5 fold after a two hour exposure to the nitric oxide donors 
sodium nitroprusside and s-nitrosoglutathione. Conversely after treatment with the 
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oxidative stress agent hydrogen peroxide the promoter activity was decreased after a two 
hour exposure, although not significantly so (Jayakumar et al., 2008).  
The levels of ß-galactosidase activity calculated when testing the effect of acid stress 
(harvesting cells and resuspending them in Dubos adjusting to pH5.5 for 24 hours) and 
its control (harvesting cells resuspending them in Dubos at pH7.2 for 24 hours) were 
lower than all other experiments with an average ß-galactosidase activity of 
approximately 265 units compared to the no drug or stress control of approximately 320 
specific units. The protein content of each CFE sample was determined as outlined in 
section 2.4.8 to normalise each data set and make the results comparable to one another 
between the treatments. A possible explanation for the lower ß-galactosidase activity 
readout for these two sets of data is because some cells may have died when they were 
washed and re-suspended in fresh medium. Therefore, when normalising to the amount 
of protein after 24 hours the dead cells would possibly still have contributed to the total 
amount of protein but obviously there would be no ß-galactosidase activity generated 
from the plasmid integrated into the dead cells. However, what is important is that the 
levels of ß-galactosidase activity in the acid stress control and acid stress experiment are 
the same and therefore tells us that the pknF promoter does not respond to low pH/acid 
stress.  
3.5.4 Assessment of the susceptibility of the ∆pknF and ∆Rv1747 mutants to a 
panel of drug and stress reagents. 
Growth inhibition assays showed that there were no differences in the susceptibility of 
the ∆pknF and ∆Rv1747 mutants to any of the drug and stress reagents tested compared 
with wild type H37Rv (figure 3.5), and hence the calculated MICs between the strains 
for each treatment were the same (see table 3.1). It was hypothesised that increased 
sensitivity may be observed when subjecting one or both of the mutant strains to a 
particular treatment generating clues as to the function of the two proteins. 
There are many characterised mutants in M. tuberculosis which have increased or 
decreased sensitivity to various reagents; furthermore, this has led to being able to derive 
functions for these particular proteins. For example as well as the pknE mutant 
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conferring increased resistance to nitric oxide donors (Jayakumar et al., 2008) in 2002 a 
study showed a knockout of the M. tuberculosis ahpC gene which encodes and 
alkylhydroperoxide reductase showed increased sensitivity to peroxynitrite as did the M. 
smegmatis ortholog knockout (Master et al., 2002). A role was then established for ahpC 
in antioxidant defence mechanisms. Furthermore, in a recent study carried out by Vandal 
and colleagues in 2009, they discovered four mutants (Rv2136c, Rv2224c, ponA2, and 
lysX) from a screen of over 10, 000 M. tuberculosis transposon mutants, that not only 
were susceptible to acid stress but which were also hypersensitive to SDS, antibiotics 
and reactive oxygen and nitrogen intermediates demonstrating an association between 
acid resistance and resistance to other forms of stress (Vandal et al., 2009).  
Unfortunately in this present study the pknF and Rv1747 mutants demonstrated no 
differences in susceptibility to any of the stresses investigated. Yet again this does not 
mean that there is not a drug or stress reagent which alters the susceptibility of the 
mutants, it is just that in this piece of research which assessed many of the commonly 
investigated stress reagents, no reagent was found in which the mutant strains behaved 
differently to wild type. Furthermore, this study assessed the susceptibility of the two 
mutants to drug and stress reagents in vitro.  It is known that growth of the Rv1747 
mutant is impaired in both macrophage and mouse intravenous models of infection 
(Curry et al., 2005). Therefore another possibility is that one would not see a 
susceptibility phenotype of these mutants in vitro because their function is only required 
in vivo.  
In conclusion, this chapter characterised the pknF-Rv1747 operon by identifying a 
transcriptional start site for pknF and confirmed co-transcription of the two genes. 
An initial assessment of both the mutant strains was then performed but no clues as to 
the function of the two proteins were gained from these investigations.  
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CHAPTER 4. INVESTIGATION INTO THE NATURE OF 
THE Rv1747 SUBSTRATE 
4.1 Introduction 
Approximately 2.5 percent of the M. tuberculosis genome comprises genes encoding 
putative ABC transporters; a total of 37 ABC transporters have been identified in M. 
tuberculosis, 16 have been categorised as importers and 21 as exporters (Braibant et al., 
2000). Rv1747 was classified as a member of a sub-class of transporters which have an 
unknown function (Braibant et al., 2000). ABC transporters are integral membrane 
proteins comprising two transmembrane domains and two cytoplasmic nucleotide 
binding domains. The transporters bind and hydrolyse ATP providing energy for uptake 
or export of substrates across cell membranes. Functions of ABC transporters include 
the uptake of nutrients into the cells and the export of virulence factors and toxins. 
Bacterial ABC importers are typically formed from four polypeptide chains that are 
often separately encoded (Saurin et al., 1999) and require an external binding protein 
which functions to deliver the substrate to the transporter (Dawson et al., 2007). In 
contrast, bacterial exporters are produced as one polypeptide where a single gene usually 
encodes both the transmembrane domain and an ATPase (nucleotide binding) domain 
(Saurin et al., 1999). The presence of fused nucleotide binding and transmembrane 
domains is a strong indicator of an ABC exporter (Davidson et al., 2008; Dawson et al., 
2007). Based on its amino acid sequence Rv1747 belongs to the G subfamily of ABC 
transporters; this family consists of half-transporters which oligomerise to form the 
functional transporter. Furthermore this protein encodes both the transmembrane and 
nucleotide binding domains in one polypeptide. Therefore, taken together, from its 
amino acid sequence and the fact that it is encoded by a single gene Rv1747 is predicted 
to function as an ABC exporter. 
It is known that the function of Rv1747 is required for the growth of M. tuberculosis in a 
mouse intravenous injection model and in bone-marrow derived macrophages and 
dendritic cells (Curry et al., 2005). Curry et al. showed that the Rv1747 deletion mutant 
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had a bacterial load which was 10-fold lower than that of the wild type strain in both 
lungs and spleens of mice and furthermore a similar pattern of growth impairment was 
observed with the mutant in both macrophages and dendritic cells. This mutant 
phenotype was lost when a complementing wild type allele of Rv1747 was introduced 
into the genome confirming that the growth attenuation observed was due to the deletion 
of Rv1747. What is more, when cultured in vitro, the Rv1747 deletion strain has a 
similar doubling time to that of the wild type strain illustrating that the function of the 
Rv1747 protein is only required for the growth of M. tuberculosis in cell lines and inside 
mice, therefore making the function of this protein all the more interesting and relevant 
to M. tuberculosis research. 
However, although it has been demonstrated that the function of Rv1747 is required for 
the growth of the bacterium in mice and macrophages, the identity of the substrate has 
not yet been revealed. Numerous hypotheses have been raised as to what the nature of 
the substrate may be by comparing the Rv1747 ABC transporter to analogous systems in 
other bacteria which are also required for growth and survival within the host. Bacterial 
ABC exporters transport many different substances which include cell surface 
components such as lipopolysaccharides, lipids, proteins involved in pathogenesis 
including haemolysin, and peptides, drugs and siderophores (Dassa & Bouige, 2001); 
Rv1747 could export any one of these molecules which would make the function of the 
transporter necessary for growth in vivo.  
One particular hypothesis raised is that Rv1747 could export a component of the cell 
wall required for the growth of the bacterium in macrophages and inside mice. In Gram-
negative bacteria a multi-protein pathway transports lipopolysaccharide (LPS) across the 
cell envelope (Ruiz et al., 2009). LPS (also known as endotoxin) is a glycolipid 
comprised of lipid A, a core oligosaccharide and a long polysaccharide which is present 
at the outer membrane of Gram-negative bacteria and is responsible for inducing the 
immune system and causing septic shock. LPS is located at the cell surface and is 
responsible for making the outer membrane an impermeable barrier which is crucial for 
the survival of many Gram-negative bacteria in many different environments (Ruiz et 
al., 2009). The proteins that are required to transport LPS from the inner membrane, 
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which is the site of synthesis, to the cell surface have been identified. The ABC exporter 
MsbA flips rough LPS (only containing lipid A and the core region) across the inner 
membrane. LPS is then extracted from the inner membrane by LptC and three proteins 
which comprise another ABC exporter (LptF, LptG and LptB). LPS is then transported 
to an assembly site at the outer membrane (Ruiz et al., 2009). Clearly, LPS transport and 
assembly is a very complex system which has taken many decades to fully elucidate and 
comprises of multiple steps and multiple ABC export proteins. Mycobacteria, being 
gram-positive, do not have LPS, but have other cell wall molecules that may undertake 
analogous functions with respect to virulence. In M. tuberculosis two ABC transporters 
have been identified which are required for the correct localisation of dimycocerosate 
(DIM) in the cell envelope (Camacho et al., 2001). These are the DrrABC and MmpL7 
transporters. Camacho et al. demonstrated that a DIM mutant had increased cell wall 
permeability and became more sensitive to SDS which is associated with an increase in 
the outer membrane permeability (Camacho et al., 2001) although the DIM mutant had 
similar growth rate to the wild type in naïve macrophages (Camacho et al., 1999). In 
analogy with LPS in gram-negative bacteria, it is hypothesised that Rv1747 may 
function to export a protein or lipid component of the M. tuberculosis outer membrane 
that is also necessary for growth and survival within the host. 
Another hypothesis to be considered in this study was that Rv1747 may be exporting a 
protein required for growth. For example Rv1747 could be involved in exporting a 
siderophore involved in iron uptake. Siderophores are small compounds secreted by 
bacteria which act to chelate iron; iron is essential for many fundamental cellular 
processes and is transported back inside the mycobacterial cell. In M. tuberculosis one 
iron siderophore exporter has already been characterised; the ABC transporter IrtA 
(Rv1348), which contains a substrate binding domain and ATPase domain, is a 
siderophore exporter whilst the IrtB-Rv2895c system functions to import ferrated 
siderophores (Farhana et al., 2008). IrtB is an ABC transporter and Rv2895c is a 
siderophore binding protein (Farhana et al., 2008). 
It has been suggested (http://tuberculist.epfl.ch/) that the substrate of the Rv1747 ABC 
transporter may be a lipooligosaccharide. A review of all the M. tuberculosis ABC 
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transporters published in 2000 revealed that Rv1747 falls into a sub-class of transporters 
which have an unknown function (Braibant et al., 2000). Rv1747 is highly similar to the 
White protein from Drosophila melanogaster which is a permease necessary for the 
transport of pigment precursors responsible for eye colour and NodI from Rhizobium 
strains which is a protein implicated in the nodulation process by export of a 
polysaccharide (Braibant et al., 2000). I have compared the homology with other known 
ABC transporters from other organisms, and in addition to the two proteins mentioned 
above, an NCBI Blast of the Rv1747 protein revealed similarities with a cobalt transport 
family protein found in bacteria, eukaryotes and archaea and with an ABC group A 
subfamily which functions to transport a variety of lipid compounds suggesting that the 
Rv1747 transporter could be involved in one of these functions in M. tuberculosis. 
Another hypothesis is that Rv1747 could be exporting a small molecule. As previously 
mentioned the Rv1747 transporter shares similarity with a cobalt transport family 
protein. Cobalt is a transition metal which is an essential component of many enzymes.  
It must also be taken into consideration that there is no conclusive evidence to prove that 
Rv1747 does not function as an ABC importer; however all the gathered evidence 
suggests that Rv1747 most likely functions as an exporter. Consequently, the 
experiments performed in this study to search for the Rv1747 substrate were designed in 
such a way so that they were not dependent on knowing the direction of substrate 
transport. All the aforementioned hypotheses will be explored and discussed in this 
chapter of the study with the aim to identify the Rv1747 substrate which is required for 
growth of the bacterium in vivo.  
4.2 Transcriptional microarray studies of the ∆pknF and ∆Rv1747 
mutant strains  
As the identity of the Rv1747 substrate is unknown the initial approach taken to generate 
a hypothesis as to the nature of the substrate was to use cDNA microarray technology to 
analyse the effects of M. tuberculosis global gene expression in the pknF and Rv1747 
deletion strains. Microarrays can be used as a screening tool to allow for comparative 
analysis of the entire transcriptome of all genes in an organism simultaneously. 
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Transcriptional microarrays were used in this study to compare gene expression between 
wild type H37Rv and both the pknF and Rv1747 deletion strains. Changes in gene 
expression can allow one to obtain insights into the possible function of proteins.  
Global gene expression differences were evaluated between wild type M. tuberculosis 
and both the pknF and Rv1747 deletion strains using RNA-DNA microarrays. RNA 
from wild type M. tuberculosis and RNA extracted from a null mutant were directly 
compared; labelled cDNAs were competitively hybridised against a single array. Three 
biological replicates were performed for each condition and they were carried out in 
technical duplicate (dye-swaps) as described in section 2.4.5 and Appendix III. A t-test 
against zero was performed for each data-set. Data were taken to be significant if the p-
value was less than 0.05 and a two-fold level of change cut-off was initially applied to 
all the data (Appendix III). In order to be certain that the transcriptional profiles 
observed were due to the Rv1747 and pknF deletions microarrays were also performed 
comparing gene expression levels in wild type H37Rv and both the complementing 
strains. The genes present in all the Results Tables only include those whose differential 
gene regulation was restored to wild type levels in the complementing strains. Seven 
genes in the Rv1747 deletion experiment and three genes in the pknF deletion 
experiment were not complemented and are listed in tables 4.1 and 4.2 respectively. As 
these genes were not complemented upon replacement of the Rv1747 or pknF genes then 
they were considered not important to this investigation as they would not help to 
generate clues as to the function of the two proteins. 
4.2.1 The expression of many M. tuberculosis genes were affected by Rv1747 
deletion 
When applying a two-fold level of change cut-off to the data comparing global gene 
expression in wild type H37Rv and ∆Rv1747 strains there were 40 genes whose relative 
transcription level differed significantly upon Rv1747 deletion and whose differential 
expression was restored in the complementing strain (see Appendix IV). Fourteen of 
these genes were up-regulated and 26 were down-regulated. The microarray data for the 
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ten most highly up-regulated and down-regulated genes within the Rv1747 deletion 
strain are shown in tables 4.3 and 4.4 respectively. When the fold change cut-off level  
 
 
Gene Number Gene Name Gene Product Fold change in 
mutant 
Fold change in 
complement 
Rv0281 Rv0281 Conserved 
hypothetical 
protein 
2.0 (up-reg) 2.9 (up-reg) 
Rv0282 eccA3 Esx conserved 
component 
2.1 (up-reg) 1.9 (up-reg) 
Rv0796 Rv0796 Putative 
transposase 
2.2 (down-reg) 1.5 (down-reg) 
Rv1764 Rv1764 Putative 
transposase 
2.2 (down-reg) 1.5 (down-reg) 
Rv2031c HspX Heat shock 
protein 
2.6 (up-reg) 2.5 (up-reg) 
Rv2106 Rv2106 Probable 
tranposase 
2.1 (down-reg) 1.4 (down-reg) 
Rv3131 Rv3131 Conserved 
hypothetical 
protein 
2.1  (up-reg) 6.32 (down-reg) 
 
Table 4.1 Microarray data for the genes whose differential expression levels were 
not restored upon complementation with the Rv1747 gene. Up-reg = fold up-
regulated. Down-reg = fold down-regulated. 
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Gene Number Gene Name Gene Product Fold change in 
mutant 
Fold change in 
complement 
Rv3614c espD Esx1 secretion 
associated 
protein 
2.5 (down-reg) 2.5 (down-reg) 
Rv3615c espC Esx1 secretion 
associated 
protein 
2.3 (down-reg)  2.4 (down-reg) 
Rv3616c espA Esx1 secretion 
associated 
protein 
2.1 (down-reg) 2.3 (down-reg) 
 
Table 4.2 Microarray data for the genes whose differential expression levels were 
not restored upon complementation with the pknF gene. Up-reg = up-regulated. 
Down-reg = down regulated. 
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was reduced to 1.5 there were 483 genes whose transcription was differentially regulated 
between the wild type and Rv1747 deletion strain which is approximately 5% of the M. 
tuberculosis genome. 
Expression of Rv1747 was 29 fold down-regulated in the ∆Rv1747 strain compared to 
wild type which was expected as Rv1747 is the gene which was deleted from the 
genome (table 4.4). In the Rv1747 complement strain expression of Rv1747 was 1.3 fold 
up-regulated compared to wild type confirming the restoration of gene expression. 
The gene most up-regulated in the ∆Rv1747 strain was the isoniazid-inducible gene iniB 
(table 4.1). This gene was 3.8 fold up-regulated in the null mutant compared to wild type 
with a p-value of 2.4 x10
-4
. Furthermore the second most upregulated gene was iniA (3.2 
fold, p-value of 8.14x10
-5
). iniB forms an operon with iniA and iniC. Interestingly iniC 
was also upregulated 1.6 fold (p-value of 6.48x10
-4
). The promoter of the iniBAC operon 
is specifically induced by a broad range of inhibitors to cell wall biosynthesis (Alland et 
al., 2000). The list of the top ten up-regulated genes also included the probable acyl-
CoA dehydrogenase fadE23 (2.1 fold change). A probable ferredoxin, fdxA, was also up-
regulated 2.1 fold. Genes with a 2.0 fold up-regulation in the null mutant also comprised 
gyrB (DNA gyrase subunit B), PE_PGRS41 (a PE_PGRS family protein), ethA (whose 
gene product activates the pro-drug ethionamide) and ino1 (involved in the 
phosphatidyl-myo-inositol (PI) biosynthetic pathway). The two conserved hypothetical 
proteins Rv0047c (2.2 fold) and Rv0822c (2.0 fold) were also included in the list. A 
search of the M. tuberculosis kinases revealed that pknF was up-regulated 1.9 fold (p-
value 0.001) in the ∆Rv1747 strain as was pknD (1.8 fold, p-value 0.001). Interestingly 
pknF expression was still 2.0 fold up-regulated with a p-value of 0.003 in the Rv1747 
complement strain.  
 
 
 
 
 
Chapter 4. Investigation into the nature of the Rv1747 substrate 
 119 
 
 
 
 
 
 
Gene Number Gene Name Gene Product Fold Up-regulated p-value 
Rv0341  iniB Isoniazid inducible 
gene protein IniB 
3.8 2.4E-04 
Rv0342  iniA Isoniazid inducible 
gene protein IniA 
3.2 8.1E-05 
Rv0047c  Rv0047c Conserved 
hypothetical protein 
2.2 4.1E-05 
Rv3140  fadE23 Probable acyl-CoA 
dehydrogenase 
FadE23 
2.1 0.001 
Rv2007c  fdxA Probable ferredoxin 
FdxA 
2.1 0.005 
Rv0822c Rv0822c Conserved 
hypothetical protein 
2.0 4.E-05 
Rv0005 gyrB DNA gyrase subunit B 2.0 0.001 
Rv2396  PE_PGRS41 PE-PGRS family 
protein 
2.0 7.E-04 
Rv3854c  ethA Monooxygenase EthA 2.0 0.003 
Rv0046c  ino1 Myo-inositol-1-
phosphate synthase 
Ino1 
2.0 3.E-04 
 
Table 4.3 Microarray data for the ten M. tuberculosis genes most highly up-
regulated upon Rv1747 deletion 
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Gene 
Number 
Gene Name Gene Product Fold Down-regulated p-value 
Rv1747  Rv1747  Probable conserved 
transmembrane ATP-
binding protein ABC 
transporter 
29.2 8.9E-06 
Rv2415c  Rv2415c Conserved hypothetical 
protein 
2.3 7.9E-04 
Rv1380  pyrB Probable aspartate 
carbamoyltransferase 
PyrB 
2.2 0.001 
Rv1999c  Rv1999c Probable conserved 
integral membrane 
protein 
2.2 0.004 
Rv2814c  Rv2814c Probable transposase 2.2 0.011 
Rv1382  Rv1382 Probable export or 
membrane protein 
2.2 6.2E-04 
Rv2528c  mrr Probable restriction 
system protein Mrr 
2.1 1.9E-04 
Rv1040c  PE8 PE family protein 2.1 0.013 
Rv2265  Rv2265 Possible conserved 
integral membrane 
protein 
2.1 0.005 
Rv2577  Rv2577 Conserved hypothetical 
protein 
2.1 0.015 
 
Table 4.4 Microarray data for the ten M. tuberculosis genes most highly down-
regulated upon Rv1747 deletion.  
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Apart from Rv1747, other down-regulated genes in the top ten list included the 
conserved hypothetical proteins Rv2415c (2.3 fold) and Rv2577 (2.1 fold) (table 4.4). 
Two possible conserved integral membrane proteins, namely Rv1999c and Rv2265, were 
also down-regulated in the null strain 2.2 and 2.1 fold respectively. mrr which is 
involved in the acceptance of foreign DNA was down-regulated 2.1 fold. The probable 
export/membrane protein Rv1382 was also downregulated 2.2 fold. Finally the probable 
aspartate carbamoyltransferase pyrB was down-regulated 2.2 fold as was Rv2814c, a 
probable transposase.  
4.2.2 The expression of only a few M. tuberculosis genes were affected by 
pknF deletion 
Upon examination of the transcriptional profiles of the arrays which hybridised the wild 
type and ∆pknF strains, when a two fold cut-off was applied to the data the relative 
transcription level of only 12 genes were differentially regulated greater or equal to two-
fold. In addition all 12 genes were found to be down-regulated. Due to the low number 
of differentially regulated genes passing a two fold cut-off the stringency was reduced to 
1.5 fold. With a 1.5 fold cut-off the number of genes found to be differentially regulated 
rose to 72 and they are listed in Appendix IV. Of the 72 differentially expressed genes 
only 12 were up-regulated. The microarray data for the ten most highly up-regulated and 
down-regulated genes within the pknF deletion strain are shown in tables 4.5 and 4.6 
respectively. The pknF gene itself did not appear in the microarray results list. This was 
because the gene did not pass the filtering stages within the microarray analysis.  
Interestingly, the gene most upregulated in the ∆pknF strain was iniB (1.8 fold, p-value 
0.001), the same gene that was most highly up-regulated in the ∆Rv1747 strain. iniA was 
also upregulated 1.5 fold in the pknF deletion strain with a p-value of 0.005. Other genes 
present in the ∆pknF list that were also up-regulated in the Rv1747 null strain were fdxA 
(1.8 fold) and ethA (1.7 fold up-regulated). glpQ1, a probable glycerophosphoryl diester 
phosphodiesterase, was up-regulated 1.8 fold in the pknF null mutant. The conserved 
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hypothetical proteins Rv3850 and Rv1738 were up-regulated 1.7 and 1.6 fold 
respectively in the ∆pknF strain. espE, an esx1 secretion-associated protein  
 
 
 
Gene 
Number 
Gene Name Gene Product Fold Up-
regulated 
p-value 
Rv3842c  glpQ1 Probable glycerophosphoryl diester 
phosphodiesterase GlpQ1 
1.8 0.006 
Rv2007c  fdxA Probable ferredoxin fdxA 1.8 0.023 
Rv0341  iniB Isoniazid inductible gene protein 
iniB 
1.8 0.001 
Rv3854c  ethA Monooxygenase EthA 1.7 0.006 
Rv3850  Rv3850 Conserved hypothetical protein 1.7 0.002 
Rv1738  Rv1738 Conserved hypothetical protein 1.6 0.005 
Rv3864  espE Esx-1 secretion-associated protein 
EspE 
1.6 0.003 
Rv3727  Rv3727 Possible oxidoreducatse 1.5 0.008 
Rv0175  Rv0175 Probable conserved mce associated 
membrane protein 
1.5 0.002 
Rv3728  Rv3728 Probable conserved two domain 
membrane protein 
1.5 0.006 
 
Table 4.5 Microarray data for the ten M. tuberculosis genes most highly up-
regulated upon pknF deletion 
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Gene 
Number 
Gene  
Name 
Gene Product Fold Down-
regulated 
p-value 
Rv2480c  Rv2480c Possible transposase for 
insertion sequence element 
IS6110 
2.4 0.003 
Rv1371  Rv1371 Probable conserved membrane 
protein 
2.4 0.042 
Rv2106  Rv2106 Probable transposase 2.0 0.029 
Rv1372  Rv1372 Conserved hypothetical protein 2.2 0.037 
Rv1370c  Rv1370c Putative transposase for 
insertion sequence element 
IS6110 
2.0 0.042 
Rv3640c  Rv3640c Probable transposase 2.0 0.036 
Rv2815c  Rv2815c Probable transposase 2.0 0.044 
Rv2515c Rv2515c Conserved hypothetical protein 2.0 0.034 
Rv2167c  Rv2167c Probable transposase 2.0 0.015 
Rv0796  Rv0796 Putative transposase for 
insertion sequence element 
IS6110 
2.0 0.035 
 
Table 4.6 Microarray data for the ten M. tuberculosis genes most highly down-
regulated upon pknF deletion  
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was also up-regulated 1.6 fold. Rv3727 (probably involved in cellular metabolism), 
Rv3728 (probably involved in an efflux system) and Rv0175 (a probable conserved mce 
associated membrane protein) were all up-regulated 1.5 fold. 
The top ten list of genes down-regulated in the ∆pknF strain comprised seven possible 
transposases; Rv2480c (2.4 fold), and Rv1380, Rv2106, Rv3640c, Rc2815c, Rv2167c, 
Rv0796 (all 2.0 fold down-regulated). The remaining three differentially regulated genes 
were Rv1371 (2.4 fold) and Rv1372 (2.2 fold) which are annotated as a probable 
conserved membrane protein and a conserved hypothetical protein and Rv2515c (2.0 
fold), also annotated as a conserved hypothetical protein. 
4.2.3 The effect of the pknF and Rv1747 deletions were confirmed for a 
selection of genes  
To confirm the effect of the pknF and Rv1747 deletions on gene expression, a selection 
of genes were tested for their altered relative abundance of transcripts in the null strains 
using quantitative real-time PCR (qRT-PCR). It was particularly important to determine 
the levels of expression of pknF in the pknF null and complement strain as this gene did 
not pass the filtering within the microarray analysis. qRT-PCR was performed as 
outlined in section 2.3.3 and a list of primers can be found in Appendix II. qRT-PCR 
was initially performed with genomic DNA to check that a good amplification plot was 
achieved for each primer pair and to confirm the absence of non-specific products (data 
not shown). qRT-PCR was then performed with cDNA made from RNA extracts from 
all five strains with sigA primers (the gene to which all results were to be normalised) to 
confirm that the expression of this gene did not alter between the five strains. Results are 
shown in Figures 4.1a (wild type, pknF null and pknF complement strains) and 4.1b 
(wild type, Rv1747 null and Rv1747 complement strains) and demonstrate that there 
were no differences in the expression of sigA between the strains.  
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Figure 4.2 shows the results of qRT-PCR for wild type, ∆Rv1747 and the respective 
complement strain. Data are the means of three biological replicates and the error bars 
show the standard deviations. The normalised transcription level for the following genes 
were plotted; Rv1747 (figure 4.2a), pknF (figure 4.2b), iniB (figure 4.2c), iniA (figure 
4.2d), iniC (figure 4.2e), ethA (figure 4.2f) and pknD (figure 4.2g). Figure 4.2a confirms 
that expression of Rv1747 in the null mutant is almost undetectable and transcription is 
restored to wild type levels in the complementing strain. Figure 4.2b shows that the 
levels of pknF transcript do not increase in the ∆Rv1747 strain but do increase in the 
complementing strain, presumably due to the presence of an extra copy of pknF in the 
Rv1747 complementing plasmid. Microarray results also showed that pknF was up-
regulated in the Rv1747 complementing strain but unlike the microarray data the level of 
pknF transcript does not increase in the ∆Rv1747 strain when determined by qRT-PCR. 
Figures 4.2 c-e show that the transcriptional profiles of these genes follows the same 
patterns as shown by the microarray results; transcript abundance levels all increase in 
the Rv1747 mutant strain and are complemented when the Rv1747 gene was replaced. 
This is particularly striking for iniB (figure 4.2c) and iniA (figure 4.2d) where there is 
approximately three times as much transcript present in the mutant strain compared with 
wild type. These results confirm the microarray results which showed that iniB and iniA 
were up-regulated by 3.8 and 3.2 fold respectively in the ∆Rv1747 strain.  
Figure 4.3 shows the results of qRT-PCR for wild type, ∆pknF and the respective 
complemented strain. Again, data are the means of three biological replicates and the 
error bars show the standard deviations. The normalised transcription level for the 
following genes were plotted; pknF (figure 4.3a), Rv1747 (figure 4.3b), iniB (figure 
4.3c), iniA (figure 4.3d) and iniC (figure 4.3e). Figure 4.3a confirms that expression of 
pknF in the null mutant is undetectable and transcription is restored to almost wild type 
levels in the complementing strain. Figure 4.3b shows that the levels of Rv1747 
transcript are the same in all three strains. Figures 4.3 c-e show that the transcriptional 
profiles of iniB (figure 4.3c), iniA (figure 4.3d) and iniC (figure 4.3e) follow the same 
pattern as shown by the microarray data (i.e. iniB and iniA have increased normalised 
transcript levels in the ∆pknF strain which is restored to wild type levels in the 
complement). The iniC gene did not appear in the gene lists generated by microarrays in 
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the pknF mutant or complement strain. Indeed, figure 4.3e clearly show that the levels of 
iniC transcript do not change in the pknF mutant strain but are in fact slightly decreased 
in the pknF complemented strain.  
 
 
 
 
 
 
 
 
Figure 4.1 qRT-PCR to confirm that transcription of sigA does not change between 
wild type, ∆pknF, pknF complement, ∆Rv1747 and Rv1747 complement strains.  
qRT-PCR was performed with cDNA which was made as described in 2.3.3. Figure a 
shows the expression of sigA in wild type, ∆pknF and pknF complement strains. Figure 
b shows the expression of sigA in wild type, ∆Rv1747 and Rv1747 complement strains. 
Data plotted are the mean of three biological replicates and the error bars show the 
standard deviations. Data show there were no significant differences in levels of sigA 
expression between the strains.  
a b 
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Figure 4.2 qRT-PCR to confirm the effect of 
Rv1747 deletion and complementation on the 
relative transcription levels of selected genes.  
qRT-PCR was performed with cDNA which was 
made as described in 2.3.3. Each figure shows the 
normalised transcription level of each gene 
investigated in wild type, ∆Rv1747 and 
complemented strains. The normalised transcription 
level for the following genes was plotted; Rv1747 
(figure 4.2a), pknF (4.2b), iniB (4.2c), iniA (4.2d), 
iniC (4.2e), ethA (4.2f) and pknD (4.2g). Data 
plotted are the mean of three biological replicates 
and the error bars show the standard deviations. 
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Figure 4.3 qRT-PCR to confirm the effect of 
pknF deletion and complementation on the 
relative transcription levels of selected genes.  
qRT-PCR was performed with cDNA which was 
made as described in 2.3.3. Each figure shows the 
normalised transcription level of each gene 
investigated in wild type, ∆pknF and complement 
strains. The normalised transcription level for the 
following genes were plotted; pknF (figure 4.3a), 
Rv1747 (4.2b), iniB (4.2c), iniA (4.2d) and iniC 
(4.2e). Data plotted are the mean of three biological 
replicates and the error bars show the standard 
deviations. 
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4.3 Assessment of the lipid composition of the M. tuberculosis cell wall  
Microarray and qRT-PCR analysis (section 4.2) showed there to be up-regulation of genes 
involved in cell wall stress and synthesis in both of the null mutants. Therefore it was 
hypothesised that Rv1747 may export a component of the cell envelope. To further 
investigate this hypothesis two dimensional thin-layer chromatography (2D TLC) was 
used to analyse the total lipid composition of H37Rv wild type, ∆Rv1747 and ∆pknF 
strains plus their respective complements. The pknF mutant was included in this study for 
two reasons; firstly, the differentially regulated gene lists generated in the microarray 
studies were similar for both the ∆pknF and ∆Rv1747 mutants and secondly, PknF is 
hypothesised to regulate the transporter activity of Rv1747. Therefore it made sense to 
include this strain plus its respective complement in the study because depending on 
whether phosphorylation of Rv1747 by PknF positively or negatively regulates the 
transporter activity of the protein then we may have observed similar differences, if there 
were any, in the lipid content of the cell in both the kinase and transporter mutants.  
Cultures of wild type H37Rv, ∆Rv1747, ∆pknF and their respective complements were 
grown in Dubos medium to exponential phase (OD600 0.6-0.8) and then labelled with 
14
C-
acetate for 24 hours as described in section 2.4.6. Acetate is a carbon source for lipid 
synthesis and therefore was incorporated into all newly synthesised lipids over the 24 hour 
period. M. tuberculosis has a doubling time of approximately 18 hours so by labelling for 
24 hours it ensured that a full round of replication had occurred. All lipids were then 
extracted both from the cell pellets and from the culture supernatants for analysis by 2D 
TLC.  
Figure 4.4 shows the initial panel of 2D TLC experiments that were performed examining 
the lipid profiles of the cell pellets in wild type and both mutant strains. Systems A to D 
show separation of the apolar lipids and systems D and E show separation of the polar 
lipids. See table 2.4 in the Material and Methods section for the list of the combinations of 
solvents used in each system. System A separated triacyl glycerol (TAG) and phthiocerol 
dimycocerosates (PDIM). System B separated diacyl glycerol (DAG), free fatty acids and 
free mycolic acids. System C separated DAG and free fatty acids. Apolar system D 
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separated diacyl trehalose (DAT), glucose monomycolate (GMM), sulpholipids 1, 2 and 3 
(SL-III), phospholipids (P) and trehalose dimycolates (TDM). Polar system D separated 
DAT and system E separated P, phosphatidyl-myo-inositol (PI) and acylated phosphatidyl-
myo-inositol dimannoside (AC2PIM2). Upon examination of the profiles of the polar lipids 
in system D it was found that there was an accumulating lipid in the pknF and Rv1747 
mutant strains. Blue arrows highlight this lipid in figure 4.4. The lipid is an unidentified 
lipid which had not been previously characterised.  
The lipid profiles of the complementing strains were then analysed. Results showing the 
polar lipids present in system D for all five strains are in figure 4.5. The chromatography 
shows that the accumulating lipid present in both the knockout strains, again highlighted 
with arrows, is also present in both of the complemented strains demonstrating that the 
lipid difference was not restored when either gene was replaced. Next, to determine 
whether the lipid accumulating within the cell of the mutants (and complementing strains) 
were a result of an inability to transport the lipid across the cell membrane, the profiles of 
the lipids present in the culture supernatants were analysed. Figure 4.6 shows the results of 
the chromatography examining the polar lipid profiles of the culture supernatants after 
separation in polar system D, the same system which showed the previous accumulation. 
Figure 4.6 shows that there is in fact a lipid present in the wild type strain of the culture 
supernatants (figure 4.6a) that is not present in either of the deletion or complementing 
strains (figures 4.6b to 4.6e). It is not possible to say whether this lipid present in the 
culture supernatants is the same one as observed in the cell pellets of the mutant and 
complementing strains. 
In summary, the results showed that in the cell pellets there was a lipid accumulating in 
the mutant strains in system D (figure 4.5) and in the culture supernatants there was a lipid 
present in the wild type strain, in the same system, that was absent in the deletion strains 
(figure 4.6). However, the reciprocal lipid accumulations were not restored in the 
complemented strains. 
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Figure 4.4 Two dimensional thin-layer chromatography of wild type H37Rv, ∆pknF and ∆Rv1747 strains showing the apolar and polar lipids present in 
the cell pellets after separation in five different systems. Lipids were extracted as outlined in section 2.4.6. 20, 000 cpm of each sample was spotted onto a 
silica plate and then the lipids were separated in two different directions before being exposed to x-ray film. The top panels label each known and characterized 
lipid. For information about the acronyms see text in Results section 4.3. The blue arrows highlight the accumulating polar lipid in the ∆pknF and ∆Rv1747 
strains in system D.
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Figure 4.5 Two dimensional thin-layer chromatography of wild type H37Rv, ∆pknF, 
∆Rv1747, pknF complement and Rv1747 complementing strains showing the polar 
lipids present in the cell pellets after separation in system D. Lipids were extracted from 
cell pellets as outlined in section 2.4.6. 20, 000 cpm of each sample was spotted onto a 
silica plate and then the lipids were separated in two different directions before being 
exposed to x-ray film. The black arrow highlights the accumulating lipid in the ∆pknF and 
∆Rv1747 strains (figures 4.2b and 4.2c). Figures 4.2d and 4.2e show that the lipid is still 
present in the pknF and Rv1747 complementing strains.
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Figure 4.6 Two dimensional thin-layer chromatography of wild type H37Rv, 
∆pknF, ∆Rv1747, pknF complement and Rv1747 complementing strains showing 
the polar lipids present in the culture supernatant of the M. tuberculosis strains 
after separation in system D. Lipids were extracted from M. tuberculosis supernatants 
as outlined in section 2.4.6. 20, 000 cpm of each sample was spotted onto a silica plate 
and then the lipids were separated in two different directions before being exposed to x-
ray film. The black arrow highlights the accumulating lipid in the wild type H37Rv 
strain (figure 4.3a). Figures 4.3b to 4.3e show that the accumulating lipid is not present 
in either of the knockout or complementing strains. 
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4.3.1 Whole genome sequencing of wild type, ∆Rv1747 and Rv1747 
complementing strains of M. tuberculosis  
Whole genome sequencing of M. tuberculosis strains was performed to assess whether 
there were any other mutations within the genome of the Rv1747 deletion strain and its 
respective complementing strain, apart from the Rv1747 gene deletion itself, which 
could account for the lipid phenotypes observed in the 2D TLC investigation. The wild 
type H37Rv parental strain was also sequenced so this could be compared with the 
deletion and complement strains. M. tuberculosis genomic DNA was prepared as 
outlined in section 2.4.2 and whole genome sequencing was performed by GATC 
Biotech. Single nucleotide polymorphisms (SNPs) were mapped for each of the three 
strains by comparing them to the original sequenced H37Rv strain (Cole et al., 1998) 
with the help of Iñaki Comas (NIMR).  
Figure 4.7 shows a Venn diagram summarising the distribution of SNPs found in and 
between the wild type, ∆Rv1747 and Rv1747 complementing strains. All three strains 
shared 51 SNPs which differed from the H37Rv sequence (Cole et al., 1998); it is 
known that the 1998 reference strain contains between 50 and 80 sequencing errors 
(Iñaki Comas, personal communication) and hence this is the reason the three strains 
share 51 SNPs. These SNPs were not important to this investigation as the focus of this 
analysis was on SNPs present only in individual strains and those shared between two 
strains. Table 4.7 shows each SNP identified after genome sequencing that was not 
shared between all three strains. Two types of SNP were identified in this study; a 
synonymous SNP, which does not change protein function as the nucleotide change does 
not result in an amino acid replacement, and a nonsynonymous SNP, which has the 
potential to alter protein function as the nucleotide change results in an amino acid 
substitution in the protein.  
One SNP was found which was present in the wild type strain only. The SNP was 
identified as synonymous and was found to reside in Rv1200 which is a probable 
conserved integral membrane transport protein. There were no SNPs found only in the 
∆Rv1747 strain but there were three SNPS present only in the Rv1747 complement 
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which were all nonsynonymous. A SNP was found in ctpA (Rv0092) which is a probable 
cation transporter P-type ATPase, Rv1640c which is a lysyl tRNA synthetase enzyme 
that catalyses the reaction which joins a specific amino acid with a tRNA, and the third 
SNP was found in Rv1747.  
Furthermore, two SNPs were found to be shared between the wild type and ∆Rv1747 
strain. A synonymous SNP was identified in drrA (Rv2936) which is a probable 
daunorubicin ABC transporter and a nonsynonymous SNP was identified in cpbK 
(Rv2070c), probably involved in cobalamin biosynthesis. As both of these SNPs were 
shared between the wild type and deletion strain they could not have contributed to the 
lipid phenotypes observed in the TLC experiments.  
Importantly, two SNPs were identified that were shared between the Rv1747 deletion 
and complement strains. Both these SNPS were of interest because an alteration in 
protein function here could account for why the lipid phenotypes were seen and 
furthermore could offer an explanation as to why they could not be complemented. The 
first polymorphism was found in the intergenic region between two convergent genes, 
Rv2813 and Rv2814c. Rv2813 is annotated as a conserved hypothetical protein and 
Rv2814c is a probable transposase. The second nonsynonymous SNP was found in 
Rv1748 at amino acid position 139 of the protein which resulted in a leucine residue 
being replaced with a serine. Rv1748 is a hypothetical protein which according to 
Tuberculist is possibly exported and has a single transmembrane helix between amino 
acid residues 23 to 45 (http://tuberculist.epfl.ch).  
In summary, the results showed that there were two nonsynonymous SNPs shared 
between the Rv1747 deletion and complement strains which may have offered an 
explanation as to why the lipid phenotypes were observed in the 2D TLC study and also 
provide an answer as to why they were not complemented. 
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Figure 4.7 Summary of whole genome sequencing results. Whole genome sequencing 
of H37Rv wild type, ∆Rv1747 and Rv1747 complement strains was performed by GATC 
Biotech as described in 2.4.2. The numbers in each section of the Venn diagram show 
how many single nucleotide polymorphisms were identified compared with the H37Rv 
reference strain sequenced in 1998 (Cole et al., 1998). The blue circle represents the 
H37Rv wild type strain, the red circle is the ∆Rv1747 strain and the green circle is the 
Rv1747 complement strain. The numbers in brackets after the name of each strain 
indicate the total number of SNPs found within that strain. 
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Strain Gene Gene 
function 
SNP Position on 
chromosome  
Synonymous or 
nonsynonymous 
SNPs in 
H37Rv wild 
type 
Rv1200 Integral 
membrane 
transport 
protein 
A-C 1344078 L379L: 
Synonymous 
SNPs in 
∆Rv1747  
- - - - - 
SNPs in 
Rv1747 
complement 
Rv0092/ctpA Cation 
transporter 
ATPase 
G-T 100706 V42F: 
Nonsynonymous 
 Rv1640c/lysX Lysyl-tRNA 
synthetase 
G-A 1849437 P867S: 
Nonsynonymous 
 Rv1747 ABC 
transporter 
T-C 1974267 M213T: 
Nonsynonymous 
SNPS 
shared by 
H37Rv wild 
type and 
∆Rv1747 
Rv2070c/cobK probably 
involved in 
cobalamin 
biosynthesis 
C-G 2327933 R98P: 
Nonsynonymous 
 Rv2936/drrA Probable 
daunorubicin 
ABC 
transporter 
drrA 
 
 
C-A 
3272465 I84I : 
Synonymous 
SNPs 
shared by 
∆Rv1747 
and Rv1747 
complement 
Rv1748 Conserved 
hypothetical 
protein 
T-C 1977015 L139S: 
Nonsynonymous 
 Intergenic 
region between 
Rv2813 and 
Rv2814c 
- G-C 3119451 - 
SNPs 
shared by 
H37Rv wild 
type and 
Rv1747 
complement 
- - - - - 
Table 4.7 Summary of SNPs identified from whole genome sequencing. Whole 
genome sequencing of H37Rv wild type, ∆Rv1747 and Rv1747 complement strains was 
performed by GATC biotech as described in 2.4.2. Each SNP identified after genome 
sequencing that was not shared between all three strains is shown in the table.  
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4.4 Assessment of the lipoarabinomannan content of the mycobacterial 
cell wall  
One hypothesis raised during this study was that perhaps the Rv1747 ABC transporter 
could transport lipoarabinomannan (LAM) to the outer membrane of the M. tuberculosis 
cell. LAM is an important immunomodulatory molecule of the cell surface of M. 
tuberculosis (like LPS is in Gram-negative bacteria) and it was proposed that to 
transport lipoglycans from the cytoplasm where they are synthesised to the outer layer of 
the cell envelope must require a yet unidentified ABC transporter (Pitarque et al., 2008). 
This hypothesis was investigated using four antibodies raised against LAM and various 
capsular components of the M. tuberculosis cell wall in whole cell ELISAs. M. 
tuberculosis cell suspensions from wild type, ∆Rv1747 and Rv1747 complement cultures 
were adsorbed to 96-well ELISA plates. After incubation with the primary antibodies an 
IgM secondary antibody peroxidise conjugate was added to each well. This antibody 
allowed for development with tetramethylbenzidine (TMB) substrate for horseradish 
peroxidise. Colour formation was monitored (wells turned blue in the presence of 
secondary antibody) and the reaction was stopped by adding H2SO4 to each well 
producing a yellow coloured product. Plates were then measured at 450 nm as described 
in section 2.4.14. 
Unfortunately two antibodies did not work in the assay. These were Mab Baba which 
recognises capsular glucan and 55.92 1a1 which recognises ManLAMs capped with 
single mannosyl residues. Figure 4.8 shows the results from the whole cell ELISAs 
using the Mab F183-24 and Mab F30-5 antibodies. Mab F183-24 recognises ManLAM 
capped with three mannosyl residues and Mab F30-5 recognises the Ara6 structure 
present in LAM. Figure 4.9 shows a schematic structure of ManLAM highlighting the 
different proteins that each antibody recognised. Figure 4.8a shows the results of the 
ELISAs performed with Mab F183-24 and figure 4.8b plots the results of the ELISAs 
performed with Mab F30-5. The data in figures 4.8a and 4.8b show that there are no 
differences in the levels of ManLAM between the wild type, ∆Rv1747 and Rv1747 
complementing strains. 
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Figure 4.8 M. tuberculosis whole cell ELISAs comparing the levels of ManLAM in 
H37Rv wild type, ∆Rv1747 and Rv1747 complement strains. M. tuberculosis whole 
cell ELISAs were performed as outlined in section 2.4.14. Data are plotted as the 
amount of primary antibody used in the ELISA in µg/ml versus the absorbance of the 
secondary peroxidise conjugated antibody at OD450nm after development with TMB 
substrate. Figure a shows the data from the Mab F183-24 experiment and figure b shows 
the data from the Mab F30-5 experiment. Data are plotted as the average of three 
technical replicates and the error bars show the standard deviations.  
 
 
 
a b 
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Figure 4.9 Schematic structure of mannose-capped LAM (ManLAM). The 
schematic shows a generalised figure of ManLAM showing the mannose cap, the 
mannose core and the phosphatidylinositol anchor. Highlighted by the three red boxes 
are the proteins which are recognized by the antibodies used in the LAM ELISAs. 55.92 
1a1 antibody recognises ManLAMs capped with single mannosyl residues, Mab F183-
24 recognises ManLAM capped with three mannosyl residues and Mab F30-5 
recognises the Ara6 structure present in LAM. Figure adapted from Torrelles et al 
(Torrelles et al., 2004) 
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4.5 Transmission electron microscopy of the M. tuberculosis cell wall  
Transmission electron microscopy was performed to examine if there were any 
differences in the cell wall structure and composition between wild type, ∆pknF, 
∆Rv1747 and the respective complementing strains. M. tuberculosis cultures were grown 
to exponential phase (OD600 0.6-0.8) in Dubos medium before being resuspended in 2% 
glutaraldehyde / 2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 
18 hours in order to fix the cells. Cells were then prepared for TEM and sectioned by E. 
M. Hirst (NIMR). Images were then taken with a CCD camera at x 25,000 
magnification. Ten images were taken per section and three sections were examined per 
strain. 
Figures 4.10 and 4.11 show images taken of each M. tuberculosis strain. Both figures 
show a representative cross section of cells including both longitudinal and transverse 
sections. Figures 4.10 a, b and c show sections of wild type H37Rv cells; figures 4.10d, 
e and f show sections of ∆pknF cells and figures 4.9g, h and i show sections of pknF 
complement cells. In addition, sections c, f and i contain a zoomed image to highlight 
the cell wall structure. No discernable differences in cell wall structure were evident 
between the strains. Figures 4.11 a, b and c show sections of wild type H37Rv cells;  d, e 
and f show sections of ∆Rv1747 cells; g, h and i show sections of Rv1747 complement 
cells.  Sections c, f and i contain a zoomed image to highlight the cell wall structure. 
Again, no discernable differences in cell wall structure were evident between the strains.  
4.6 Assessment of the protein composition of M. tuberculosis culture 
supernatants  
A hypothesis proposed during this study was that the Rv1747 transporter may export a 
protein required for the growth of the bacterium in vivo. Therefore, to assess this 
possibility the composition of culture supernatants were examined in the wild type, 
∆pknF, ∆Rv1747 and respective complementing strains. M. tuberculosis cultures were  
Chapter 4. Investigation into the nature of the Rv1747 substrate 
 142 
 
Figure 4.10 Transmission electron micrographs of M. tuberculosis comparing cell wall structure in wild type H37Rv, ∆pknF and pknF 
complement strains. Images were taken at x 25,000 magnification with a CCD camera. The scale bar on each image represents 100 nm. The figure 
shows a representative cross section of cells including both longitudinal and transverse sections. a, b and c show sections of wild type H37Rv cells;  d, 
e and f show sections of ∆pknF cells; g, h and i show sections of pknF complement cells.  Sections c, f and i contain a zoomed image to highlight the 
cell wall structure.  
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Figure 4.11 Transmission electron micrographs of M. tuberculosis comparing cell wall structure in wild type H37Rv, ∆Rv1747 and Rv1747 
complement strains. Images were taken at x 25,000 magnification with a CCD camera. The scale bar on each image represents 100 nm. The figure 
shows a representative cross section of cells including both longitudinal and transverse sections. Figures 4.10 a, b and c show sections of wild type 
H37Rv cells;  d, e and f show sections of ∆Rv1747 cells; g, h and i show sections of Rv1747 complement cells.  Sections c, f and i contain a zoomed 
image to highlight the cell wall structure.  
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grown in Dubos medium to exponential phase (OD600 0.6-0.8), cells were harvested and 
then the culture supernatants were prepared as described in section 2.4.4.1. 
Trichloracetic acid (TCA) was then used to precipitate the proteins from the M. 
tuberculosis culture supernatants; TCA treatment ensured each protein sample was as 
concentrated as possible to maximise the chances of observing any differences between 
the strains. Half of each TCA precipitated sample was then digested with trypsin; the 
enzyme is a serine protease which cleaves proteins at the carboxyl side of arginine or 
lysine. Samples were subjected to trypsin treatment to digest each protein into smaller 
fragments in case any differences in protein composition were hidden in the un-digested 
samples by a protein which made up a large proportion of the sample. Proteins were then 
separated by SDS-PAGE as described in 2.5.1.  
Figure 4.12 shows the proteins present in the M. tuberculosis culture supernatants of all 
five strains after separation by SDS-PAGE. No significant differences in protein content 
can be observed between the strains after either treatment. The large abundance of a ~ 67 
kDa protein observed in each lane is albumin, a component of the Dubos medium. 
Supernatants were also assessed for differences in protein content when M. tuberculosis 
cultures were at an OD600 of 0.3 and 1.0 (data not shown). There were no significant 
differences between the proteins present in the strains in either of these experiments.  
4.7 Analysis of small molecules produced by M. tuberculosis  
Nuclear magnetic resonance (NMR) spectroscopy experiments were performed to 
determine if mutation of Rv1747 affected the small molecules or metabolites produced 
by M. tuberculosis. It was hypothesised that if the R1747 transporter exported a small 
molecule from the cell then we may have observed an absence of the molecule when 
examining the ∆Rv1747 strain compared with wild type and the complementing strain. 
Culture supernatants were harvested throughout growth (at an OD600 of 0.3, 0.6 1.0 and 
2.0) and then analysed by NMR by Volker Beherends (Imperial College) as described in 
section 2.4.11. The small molecules and metabolites present in the supernatants of all 
three strains were the same throughout growth (data not shown). 
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Figure 4.12 SDS-PAGE of proteins present in the supernatant of wild type M. 
tuberculosis, ∆pknF, pknF complement, ∆Rv1747, and Rv1747 complement strains. 
Protein extracts were prepared as outlined in section 2.4.4.1. Lanes 1 to 5 are 
trichloracetic acid precipitated samples and lanes 6 to 10 are trypsin digested samples. 
20 µl of each sample was analysed by SDS-PAGE. Lanes 1 and 6 show supernatants 
from wild type H37Rv strains, lanes 2 and 7 show supernatants from the ∆pknF strain, 
lanes 3 and 8 show supernatants from the pknF complement strain, lanes 4 and 9 show 
supernatants from the ∆Rv1747 strain and lanes 5 and 10 show supernatants from the 
Rv1747 complement strain. M is a protein marker and the relevant protein sizes are 
shown on the left hand side of the figure. No differences in protein content can be 
observed between the strains after either treatment. 
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4.8 Metabolic tests for M. tuberculosis: Phenotype MicroArrays
TM
 
(BiOLOG) 
Phenotype MicroArrays
TM
 were used to assess numerous cellular phenotypes of wild 
type, ∆pknF, ∆Rv1747 and the two complementing strains. The Phenotype MicroArrays 
used in this study tested the ability of M. tuberculosis to respire when exposed to a range 
of substrates which included carbon, nitrogen, phosphorus and sulphur sources, various 
nutrient supplements, peptide nitrogen sources and osmolytes and also tested the ability 
of the cells to respire in a range of pH conditions. It was hypothesised that differences 
found in substrate usage may yield clues as to the function of the two proteins and may 
help to identify the substrate for the Rv1747 ABC transporter. 
M. tuberculosis strains were prepared according to section 2.4.10 and then added to each 
well of the arrays and incubated for seven days at 37 
o
C. In the presence of respiring 
cells a purple coloured compound formed from the reduction of a tetrazolium dye 
(Biolog’s patented redox chemistry) which was added to the inocula. On day seven the 
A570 of each well was measured.  
Pair-wise comparisons were made between the wild type strain and both the mutant 
strains and the wild type strain versus both the complement strains. The absorbance of 
each plate was normalised to the average absorbance across the entire plate to correct for 
any differences in growth between the plates. The background absorbance from the 
negative control well (cells but no substrate) was then subtracted. Finally, fold changes 
were calculated for substrates where at least one of the strains had an absorbance higher 
than the negative control well. Results showed that there were no reproducible 
differences in substrate usage found between the wild type and mutant strains (data not 
shown). 
4.9 Discussion 
The aim of this study was to identify the substrate transported by Rv1747. Previous 
work in the laboratory highlighted the important function of this protein in macrophage 
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and mouse models of infection thus warranting further analysis in this investigation 
(Curry et al., 2005).   
4.9.1 Transcriptional Microarrays and qRT-PCR 
Microarray data showed that there were significant changes in the transcriptional 
profiles between wild type strains and both the mutant strains. Interestingly, the gene 
most up-regulated in both of the mutant strains was iniB. Furthermore, the iniA gene was 
also up-regulated in both the mutants whilst the iniC gene was significantly up-regulated 
in the ∆Rv1747 strain only. The iniBAC genes were first identified as three isoniazid-
induced genes in a screen in 1998 which assessed gene expression changes in M. 
tuberculosis in response to isoniazid treatment (Alland et al., 1998). Furthermore, this 
study showed that the iniA gene was also induced by ethambutol which is another M. 
tuberculosis therapeutic that also targets the cell wall but has a different mechanism of 
action compared to isoniazid. In a later study using M. bovis BCG the promoter of the 
iniBAC operon was shown to be specifically induced by a broad range of inhibitors to 
cell wall biosynthesis including antibiotics that inhibited the synthesis of peptidoglycan, 
arabinogalactans, mycolic acids and fatty acids (Alland et al., 2000). Using a luciferase 
reporter assay they demonstrated that the iniBAC promoter was induced 10 to 30 fold 
following a 24 or 48 hour treatment with inhibitory concentrations of a range of cell wall 
targeted drugs, including isoniazid, ethambutol and 5-chloropyrazinamide. In addition, a 
3 to 5 fold induction was observed after treatment with ampicillin which targets 
peptidoglycan. They also showed that this induction was only possible when treating 
actively growing cells. The same study then showed the iniBAC promoter was not 
induced or repressed by other stress conditions including hydrogen peroxide, heat shock, 
acid stress, kanamycin, ciprofloxacin and rifampin, all of which do not directly target 
cell wall biosynthesis but are toxic to the cell via other mechanisms. Furthermore the 
luciferase reporter activity did not increase when cells were treated with lysozyme 
showing that cell lysis did not induce the promoter (Alland et al., 2000). This suggested 
that the increased iniBAC promoter activity was a specific response to cell wall 
biosynthesis stress or damage. In 2005, a study was published which showed that iniA 
was essential for the activity of an efflux pump which conferred resistance to isoniazid 
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and ethambutol (Colangeli et al., 2005). In this study M. tuberculosis iniA was over 
expressed in M. bovis BCG and this strain was shown to survive longer upon treatment 
with inhibitory concentrations of isoniazid and ethambutol compared with the control. 
Conversely, an M. tuberculosis iniA deletion strain had increased susceptibility to 
treatment with isoniazid. Using these two strains Colangeli and colleagues then showed 
the overexpression strain had a decreased accumulation of ethidium bromide compared 
with the control whereas the deletion strain accumulated ethidium bromide. What is 
more, these effects could be reversed using an efflux pump inhibitor. The pump inhibitor 
also reversed the resistance to isoniazid observed in the overexpression strain. They 
concluded that iniA is a pump component but does not directly transport isoniazid from 
the cell (Colangeli et al., 2005). All these findings would be compatible with the Rv1747 
transporter exporting a component of the cell wall necessary for full virulence of the 
bacillus.  
Many other significant changes in gene expression were found in the microarray study. 
For the ∆Rv1747 study these most notably included the expression of Rv1747 which was 
29 fold down-regulated in the ∆Rv1747 strain compared to wild type. In the Rv1747 
complement strain expression of Rv1747 was 1.3 fold up-regulated compared to wild 
type confirming the restoration of gene expression. This result was important as it 
confirmed (along with the qRT-PCR results) that there was no expression of Rv1747 in 
the null strain and demonstrated that the abundance of transcript returned to wild type 
levels in the complement. Therefore, using the Rv1747 null strain with no presence of 
transcript would allow for reliable experiments to be performed to try and identify the 
transported substrate. Furthermore, the fact that the levels of transcript in the 
complemented strain were very similar to wild type levels meant that the complement 
could be used in experiments to determine if any differences seen between the wild type 
and deletion strains were due to the deletion of Rv1747 or were the result of another 
genetic difference between the strains.  
Other significant changes in gene expression in the ∆Rv1747 microarray study included 
Rv0047c, fadE23, fdxA, Rv0822c, gyrB, PE_PGRS41, ethA and ino1, all of which were 
in the top ten list of up-regulated genes in the study. All these genes were found to be 
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up-regulated two fold or more. A two fold cut-off level was applied to the data because 
any changes smaller than two fold were deemed to be probably not significant in terms 
of gene function. EthA functions to activate the pro-drugs ethionamide, thiacetazone and 
isoxyl which all use different mechanisms to inhibit mycolic acid synthesis (Dover et al., 
2007). Mycolic acids are another important constituent of the M. tuberculosis cell wall. 
Ino1 is involved in the phosphatidyl-myo-inositol (PI) biosynthetic pathway and was up-
regulated 2.0 fold in the Rv1747 deletion strain. This phospholipid is also a component 
of the cell envelope and can be seen in the 2D TLC results (figure 4.4 system E). 
However, the profile of this lipid did not change between the wild type and mutant 
strains (figure 4.4). Consequently, the fact that ethA and ino1 were also both up-
regulated in the ∆Rv1747 strain, like the iniBAC operon, added further weight to the 
hypothesis that Rv1747 functioned to transport an important component of the M. 
tuberculosis cell wall; furthermore, up-regulation of all these genes may be acting as a 
compensatory mechanism for the loss of the function of Rv1747. The list of the top ten 
down-regulated genes included two genes annotated as being conserved integral 
membrane proteins, namely Rv1999c and Rv2265, and one gene, Rv1382, annotated as a 
probable export or membrane protein. This is perhaps interesting as Rv1747 is also a 
membrane protein with an export function; however, little is known about the function 
of these genes. Rv1382 was predicted to be an essential gene in the Sassetti transposon 
mutagenesis screen (Sassetti et al., 2003).  
Microarray data also showed that pknF was 2.0 fold up-regulated in the ∆Rv1747 strain 
and was still 2.0 fold upregulated in the Rv1747 complement. The level of up-regulation 
seen in the Rv1747 complement is most likely because the Rv1747 complementing 
plasmid included a copy of the pknF gene to ensure that all the upstream elements 
required for normal expression of Rv1747 were there, and to make certain the promoter 
was also present. Having an extra copy of pknF integrated into the M. tuberculosis 
genome in the Rv1747 complement strain would mean that it would be likely that there 
would be twice the amount of pknF transcript present, hence when performing the 
microarrays and qRT-PCR this fact would account for the elevated levels of pknF 
transcript. In the qPT-PCR analysis however, the levels of pknF transcript were not 
increased in the ∆Rv1747 strain, unlike the microarray data which showed the transcript 
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was 2.0 fold up-regulated. This highlights why microarrays should only be used as a 
screening tool to generate hypotheses and must always be backed up by another method 
to confirm gene expression changes.  
In the pknF microarray experiment there were fewer genes whose expression level 
altered significantly upon deletion of pknF. This was particularly striking when a two 
fold level of change cut-off was applied to the data and it was discovered that there were 
only 12 genes that were differentially regulated between the wild type and mutant strain 
compared with the 40 genes which passed the cut-off in the Rv1747 experiment. In 
addition all 12 genes were found to be down-regulated. Due to the low number of 
differentially regulated genes passing a two fold cut-off the stringency was reduced to 
1.5 fold. With a 1.5 fold cut-off the number of genes found to be differentially regulated 
rose to 72. Yet again 72 differentially regulated genes is a very small number passing a 
1.5 fold cut-off compared with the 483 genes which passed in the ∆Rv1747 microarray 
analysis. One possible explanation for this finding could be because of crosstalk between 
the STPKs. Thus, PknF is one of 11 serine-threonine protein kinases present in M. 
tuberculosis. It has been shown that multiple kinases can phosphorylate the same 
substrate in vitro and that one kinase can phosphorylate multiple substrates. For 
example, in a 2005 study PknB, PknD, PknE and PknF were all shown to be able to 
phosphorylate an Rv1747 expression construct (Grundner et al., 2005). Furthermore, 
PknF has been shown to phosphorylate another FHA domain containing protein, 
Rv0020c (Grundner et al., 2005). Additionally, Molle et al performed in vitro assays to 
demonstrate that PknF phosphorylates KasA, KasB (Molle et al., 2006a) and the 
GroEL1 chaperone (Canova et al., 2009). The GroEL1 chaperone was also found to be 
phosphorylated by PknA, B, D, E, H and L although to a lesser extent than PknF. 
Furthermore, in 2009 the same group showed PknF phosphorylates mtFabH to 
negatively regulate the FASII cycle involved in mycolic acid synthesis (Veyron-Churlet 
et al., 2009). Although these studies were performed in vitro, which is an extremely 
unnatural environment for the proteins to be in and does not reflect the intracellular 
conditions faced by the bacterium including spatial and temporal separation, these data 
suggest there may be some level of redundancy between the kinases. Therefore deleting 
one kinase from the genome may mean that others can compensate for the effects of the 
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deletion. This may explain why we see fewer genes differentially expressed in the pknF 
deletion compared with the Rv1747 deletion strain. However, what was interesting from 
this study was the observation that iniB and iniA were also up-regulated in the ∆pknF 
strain and well as the ∆Rv1747 strain.  
Although the levels of fold change were lower in the ∆pknF data set, genes present in 
the ∆pknF list that were also differentially regulated in the Rv1747 null strain included 
fdxA (1.8 fold up-regulated) and ethA (1.7 fold up-regulated). fdxA is a probable 
ferredoxin involved in electron transfer and is involved in the response to hypoxia in M. 
tuberculosis. The fdxA gene is induced 22 fold by hypoxia suggesting it is involved in 
survival in hypoxic conditions such as those faced by M. tuberculosis within the host in 
granulomas (Sherman et al., 2001). Furthermore, seven genes in the top ten list of genes 
most highly down-regulated upon pknF deletion were putative transposases. 
Transposases are enzymes which catalyse the movement of a transposon to another part 
of the genome and there are more than 30 transposable elements within the genome of 
M. tuberculosis (Guilhot et al., 1999).  
In the microarrays comparing expression levels between wild type and ∆pknF strains the 
pknF gene itself did not pass the filtering in the analysis steps. This could have been due 
to anomalous hybridisation of cDNA to the pknF spot on the microarray slides. This 
again highlights why using qRT-PCR to substantiate microarray results is important. 
qRT-PCR results confirmed that expression of pknF in the null mutant was undetectable 
and the normalised transcription level was restored to almost wild type levels in the 
complementing strain. Additionally, in all qRT-PCR data the normalised level of 
transcription of Rv1747 was higher than that for pknF. This is unusual because generally 
the transcript abundance decreases from the first gene to the last gene of an operon as is 
shown in the qRT-PCR results for the iniBAC operon. This highlights that the 
mechanism of regulation of Rv1747 might be more complex than first thought. 
However, previous work demonstrated that it was unlikely that there is a promoter 
present for Rv1747 (section 3.1 and 3.2) and in addition a Solexa sequencing trace of the 
M. tuberculosis transcriptome showed that the mRNA transcript abundance does not 
increase between pknF and Rv1747 (Kristine Arnvig, personal communication).  
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4.9.2 The search for the Rv1747 substrate  
Results from the microarray studies led to the hypothesis that the Rv1747 transporter 
could export a component of the M. tuberculosis cell wall necessary for growth of the 
bacterium in vivo. The M. tuberculosis cell wall is highly complex and is rich in lipids 
which make up to 60 percent of the dry weight of the bacteria (Kremer & Besra, 2005) 
and are critical for pathogenicity. The extreme hydrophobicity of the cell wall accounts 
for its low permeability and resistance to many drugs and chemotherapeutics. Therefore 
the first group of experiments in this study investigated whether Rv1747 exported a lipid 
from the cell, then explored whether there were any changes in lipoarabinomannan 
content between the strains and also examined the cells by transmission electron 
microscopy to determine whether there were any structural differences between the wild 
type and mutant strains.  
Two dimensional thin-layer chromatography showed that there was a lipid accumulating 
in the cell pellets of the mutant strains in system D. Also, in the culture supernatants 
there was a lipid present in the wild type strain, in the same system, that was absent in 
the mutant strains. However, these reciprocal differences could not be complemented. It 
is possible that the lipid accumulation observed in both the ∆pknF and ∆Rv1747 cell 
pellets was because of an inactive (in the case of the ∆pknF strain) or deleted ABC 
transporter (in the case of the ∆Rv1747 strain). This theory assumes that there is a 
positive mechanism of regulation between the kinase and the transporter, i.e. 
phosphorylation of Rv1747 by PknF activates the transporter activity of Rv1747. The 
fact that microarray data showed similar patterns of gene expression changes is 
compatible with this theory. It could then be hypothesised that although the levels of 
transcription were restored to wild type levels or above in both the Rv1747 and pknF 
complemented strains perhaps this did not translate into functional protein and therefore 
the lipid phenotype was not complemented. However, although an in vivo experiment, 
the Rv1747 deletion could be fully complemented in a mouse intravenous injection 
model of tuberculosis (Curry et al., 2005). An alternative explanation therefore was that 
the lipid differences observed were the result of another genetic difference between the 
wild type, mutant and complementing strains. To test this hypothesis the wild type, 
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∆Rv1747, and respective complement strain were sequenced by whole genome 
sequencing. 
Whole genome sequencing of M. tuberculosis strains was performed to assess whether 
there were any other mutations within the genome of the Rv1747 deletion strain and its 
respective complementing strain, apart from the Rv1747 gene deletion itself, which 
could account for the lipid phenotypes observed in the 2D TLC investigation. The wild 
type H37Rv parental strain was also sequenced so this could be compared with the 
deletion and complemented strains. Additionally, there was also the possibility that the 
lipid phenotypes seen in the TLC investigations could have been caused by a mutation in 
the wild type strain that occurred after the construction of the both the deletion strains. 
One SNP was found which was present in the wild type strain only. A polymorphism in 
the wild type strain could have explained why the lipid phenotypes seen in the other four 
strains were not seen in this strain. However, the SNP was identified as synonymous and 
was therefore not of interest to this study. There were no SNPs found only in the 
∆Rv1747 strain but there were three SNPS present only in the Rv1747 complement strain 
which were all nonsynonymous. A SNP was found in ctpA (Rv0092) which is a probable 
cation transporter P-type ATPase, Rv1640c which is a lysyl tRNA synthetase enzyme 
that catalyses the reaction which joins a specific amino acid with a tRNA to form an 
aminoacyl tRNA, and the third SNP was found in Rv1747. The first two SNPs described 
would not have affected the complementation or function of Rv1747 and furthermore, 
they would not have caused the lipid phenotype seen in both the mutant and complement 
strains as they were not present in the mutant strain. However, the Rv1747 SNP in the 
complementing strain could have potentially meant that the function of Rv1747 was not 
complemented if indeed the phenotype which was seen was due to the deletion of 
Rv1747. The SNP was at amino acid position 213 and replaced a methionine residue 
with a threonine. Position 213 is situated in the Rv1747 protein between the FHA-2 
domain and the nucleotide binding domain; this SNP is not in a functional domain of the 
protein. The mutation most probably occurred during the construction of the Rv1747 
complementing plasmid. It could be argued that this SNP was the reason that the lipid 
phenotype observed in the Rv1747 deletion strain was not complemented. However, as 
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the Rv1747 complement is able to rescue the phenotype seen in macrophage and murine 
infection experiments and coupled with the fact that the mutation is not in one of the 
annotated domains, it further substantiates the proposal that this SNP did not affect the 
function of the ABC transporter. Furthermore the SNP would also not explain why the 
same lipid phenotype was observed in the ∆pknF and pknF complement strains.  
Two SNPs were found to be shared between the wild type and ∆Rv1747 strain. A 
synonymous SNP was identified in drrA (Rv2936) which is a probable daunorubicin 
ABC transporter and a nonsynonymous SNP was identified in cpbK (Rv2070c), 
probably involved in cobalamin biosynthesis. As both of these SNPs were shared 
between the wild type and deletion strain they could not have contributed to the lipid 
phenotypes observed in the TLC experiments.  
Importantly, two SNPs were identified that were shared between the Rv1747 deletion 
and complemented strains. Both these SNPS were of interest because an alteration in 
protein function in these strains could account for why the lipid phenotypes were seen 
and furthermore could offer an explanation as to why they could not be complemented. 
The first polymorphism was found in the intergenic region between two convergent 
genes, Rv2813 and Rv2814c. Rv2813 is annotated as a conserved hypothetical protein 
and Rv2814c is a probable transposase. As the two genes are transcribed convergently it 
is not possible for a promoter or regulatory region for either gene to be present in the 
intergenic region; therefore the SNP could not influence the regulation of either of the 
genes in this way. However, although the SNP was found in an intergenic region it was 
possible that there may have been a small RNA present in this region, which was not 
annotated, which could have had regulatory effects on various genes if the SNP was 
nonsynonymous and affected its function. Upon further examination of a Solexa 
sequencing trace of the M. tuberculosis transcriptome in exponential phase, the mRNA 
transcript level of the intergenic region was found to be minimal providing further 
evidence that that there is no gene present in this region (Kristine Arnvig, personal 
communication). Therefore this SNP is not likely to have caused the phenotypes seen in 
the TLC study.  
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The second nonsynonymous SNP was found in Rv1748 at amino acid position 139 of 
the protein which resulted in a leucine residue being replaced with a serine. Rv1748 is a 
hypothetical protein, which is 243 amino acids in size, and according to Tuberculist is 
possibly exported and has a single transmembrane helix between amino acid residues 23 
and 45 (http://tuberculist.epfl.ch). This mutation was most likely introduced into the 
∆Rv1747 targeting construct and therefore when homologous recombination occurred to 
produce the Rv1747 deletion the Rv1748 SNP was introduced. Rv1748 is 732 bp in 
length and the intergenic region between Rv1747 and Rv1748 is 337 bp. The Rv1747 
targeting construct included ~ 1.5 kb of homologous DNA on either side of the deletion 
meaning that the whole Rv1748 gene was included in the ∆Rv1747 targeting construct. It 
can be hypothesised that if Rv1748 is involved in lipid metabolism then perhaps this 
could offer an explanation for the phenotypes observed. To test this hypothesis an 
Rv1747 complementing plasmid could be designed which included pknF, Rv1747 and 
Rv1748. This plasmid could be transformed into the ∆Rv1747 strain and 2D thin-layer 
chromatography could be repeated; one would expect that if Rv1748 was responsible for 
the phenotypes then they would be restored in this complementing strain. 
However, the whole genome sequencing results did not immediately offer an 
explanation as to why the lipid phenotypes were also observed in the ∆pknF and pknF 
complement strains (figures 4.4 to 4.6). It was therefore assessed whether the Rv1748 
SNP could account for all the lipid phenotypes observed. It was discovered in this study 
that pknF is only co-transcribed with Rv1747 and does not also form an operon with 
Rv1748 (figure 3.1). Therefore, a deletion of pknF would not affect the regulation of 
transcription of the Rv1748 gene. Furthermore, the pknF deletion was constructed as an 
in-frame deletion and therefore there should have been no downstream effects on 
Rv1747 transcription or effects on subsequent genes. Indeed, this was demonstrated by 
qRT-PCR which showed that the levels of transcription of Rv1747 in the ∆pknF strain 
were the same as in the wild type and pknF complement strain (figure 4.3b). In addition 
the pknF deletion targeting construct only included the first 1654 bp of Rv1747 and 
therefore there was no part of the Rv1748 gene within the deletion plasmid. 
Consequently it can be assumed that there was not an Rv1748 mutation introduced into 
the pknF deletion strain when the targeting vector was introduced into the genome. 
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However, it was not unreasonable at this stage to hypothesise that a nonsynonymous 
mutation in Rv1748 could have occurred within the pknF deletion strain and may be the 
explanation as to the observed lipid phenotypes. Furthermore, if correct, the phenotypes 
would not have been restored by replacement of the pknF gene. As previously discussed, 
because Rv1748 has no categorised function it could be that this protein was involved in 
the metabolism of a lipid that was seen accumulating in the two deletion and two 
complementing strains. A nonsynonymous mutation in Rv1748 could prevent correct 
metabolism and therefore it could have meant that the lipid was not processed correctly 
in order for it to be exported from the M. tuberculosis cell. A SMART domain search 
revealed that Rv1748 has a single transmembrane domain and no other domains of 
homology demonstrating that Rv1748 itself cannot transport substrates due to a lack of a 
nucleotide binding domain and several transmembrane domains. Furthermore, a BLAST 
search revealed that Rv1748 has no strong homology with any other bacterial proteins 
whose function has been characterised hence no clues could be found as to the function 
of this protein. Additionally Rv1748 is predicted to be non-essential in the Sassetti 
mutagenesis screen (Sassetti et al., 2003). Therefore the predicted function of the protein 
remains unknown. To investigate the hypothesis that a mutation in Rv1748 was the 
cause of the lipid phenotypes, the Rv1748 gene plus its promoter region was sequenced 
in the ∆pknF strain (data not shown). Upon examination of the sequencing results they 
revealed that there were no mutations within the Rv1748 gene or the 373 bp intergenic 
region between Rv1747 and Rv1748 thus suggesting that the lipid phenotype observed in 
the ∆pknF and ∆Rv1747 deletion strains were not due to rendering Rv1748 non-
functional.   
Assessment of the ∆pknF and pknF complemented strains in terms of PknF protein 
function is extremely difficult as no phenotype of this mutant has been discovered or 
characterised. Therefore, one cannot be certain whether the function of this kinase is 
restored in the pknF complementing strain as there is no measurable readout of 
phenotype in the mutant; however, at the transcriptional level the relative abundance of 
pknF transcript was returned to wild type levels in the pknF complemented strain (figure 
4.3a) and the most highly upregulated gene in the deletion strain, iniB, was restored to 
wild type levels in the complementing strain (figure 4.3c). Both of these results suggest 
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that the function of the kinase is restored in the pknF complementing strain. Obviously 
one has to bear in mind that levels of transcription do not always correlate to levels of 
protein expression and furthermore cannot indicate levels of protein function.  
Another hypothesis which could explain the phenotypes observed in the lipid study is 
that there could be a nonsynonymous mutation that is shared between all the deletion 
and complementing strains in one or more of the PE/PPE/PGRS genes. The PE and PPE 
gene families are highly repetitive proteins containing many glycine and alanine residues 
and constitute approximately ten percent of the genome in H37Rv (Marri et al., 2006). 
M. tuberculosis has approximately 60 genes belonging to the PPE family and another 
100 genes which are part of the PE or PE-PGRS family (Marri et al., 2006).  Members 
of the PE/PPE family are known to be cell wall associated proteins which can have 
effects on the immune response to infection (Voskuil et al., 2004). Due to their inherent 
repetitiveness throughout the genome these genes have to be removed from the re-
sequencing data set prior to analysis. Therefore it is also possible that there may be an 
unidentified mutation in one of these genes in both the deletion and complementing 
strains that resulted in the lipid phenotypes observed.  
However, it still remains an alternative hypothesis that the lipid phenotype was indeed a 
consequence of Rv1747 deletion (or Rv1747 inactivation in the case of the ∆pknF strain) 
if PknF positively regulates Rv1747, and the reason the lipid accumulation was still 
present in the Rv1747 complementing strain could be due to incomplete 
complementation. Moreover, the Rv1747 complementing plasmid included an extra copy 
of pknF (see figure 1.12) which may have affected complementation, and secondly, it 
has recently been discovered that Rv1747 has a ~150 bp 3’ untranslated region which 
may play a role in transcript stability and this was not included in the Rv1747 
complementing plasmid (K. Arnvig, Personal Communication) (figure 1.12).  
In summary, it cannot be completely eliminated that the lipid phenotypes observed 
in the 2D-TLC investigation were the result of incomplete complementation of the 
Rv1747 and pknF deletion strains, thus implicating this system in lipid synthesis or 
transport. A viable alternative explanation however, is that there is a mutation in 
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one or more of the PE/PPE gene family in both the ∆pknF and ∆Rv1747 mutant 
strains. 
Lipoarabinomannan (LAM) is an important immunomodulatory molecule of the cell 
surface of M. tuberculosis. A study by Pitarque et al in 2008 labelled M. bovis BCG cell 
surface lipoglycans with biotin and found that a group of them, including 
lipoarabinomannan, were exposed at the cell surface and thus were presumably inserted 
into the outer most membrane of the bacterium (Pitarque et al., 2008). They then 
proposed that to transport the lipoglycans from the cytoplasm where they are synthesised 
to the outer layer of the cell envelope must require a yet unidentified ABC transporter. 
In the 2008 study Pitarque and colleagues tested one possible candidate, a putative 
polysaccharide ABC transporter encoded by Rv3781 and Rv3783. The Rv3783 ortholog 
in M. smegmatis was deleted by homologous recombination; however, this strain 
secreted similar amounts of LAM, glucan, arabinomannan and mannan. Furthermore, in 
the mutant, lipoglycans were as effectively tagged by biotin as the wild type parental 
strain leaving the identity of the transporter unknown (Pitarque et al., 2008). It was 
therefore hypothesised that Rv1747 could function to transport LAM to the outer layer 
of the M. tuberculosis cell envelope. In this present study ELISAs were performed to 
investigate this hypothesis. However, results showed that there were no differences in 
the levels of LAM and its components between the wild type, ∆Rv1747 and Rv1747 
complementing strains conclusively showing that Rv1747 does not export LAM to the 
mycobacterial outer cell surface. Unfortunately, two of the antibodies did not work, 
presumably because the antibody protein became denatured in transit and thus I was 
unable to detect the components of the M. tuberculosis cell wall by ELISA.   
Next, transmission electron microscopy was performed to examine if there were any 
differences in the cell wall structure and composition between wild type, ∆pknF, 
∆Rv1747 and the respective complementing strains. In all cases there were no 
discernable differences in cell wall structure between the strains. This result showed 
that Rv1747 does not appear to export any component of the cell wall that is 
involved in formation of an observable structure otherwise a difference would have 
been noted between the strains in the microscopy.  
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Protein composition of the supernatants of wild type, ∆pknF, ∆Rv1747, and the 
respective complementing strains were examined throughout growth by SDS-PAGE. No 
differences in protein composition were observed between the strains. One could 
hypothesise that there might have been a protein absent in the ∆Rv1747 strain if the 
ABC transporter did in fact export a protein. However, this result suggested that Rv1747 
does not export a protein. Nevertheless, perhaps this technique is not sensitive enough to 
spot any protein differences between the strains. One alternative technique that could be 
attempted is two dimensional (2D) gel electrophoresis. This technique separates all 
proteins in a sample based on two properties, for example protein mass and isoelectric 
point. Protein molecules are more effectively separated in this system compared with the 
SDS-PAGE performed in this study as proteins are much less likely to share two 
different properties.  
Nuclear magnetic resonance spectroscopy was performed to investigate whether there 
were any differences in the small molecules present in the culture supernatants of the 
wild type, ∆Rv1747 and Rv1747 complementing strains. The hypothesis was that 
Rv1747 could export a small molecule or metabolite which is essential for the virulence 
of M. tuberculosis. Any product or intermediate from metabolism is defined as a 
metabolite. For example this could include amino acids, chemical messengers such as 
cyclic AMP and other signalling molecules. Results showed that yet again there were no 
differences in the small molecules present between the strains meaning that the Rv1747 
transporter probably does not export anything detectable by NMR. However, if the 
substrate of Rv747 is incorporated into part of the M. tuberculosis cell then NMR would 
not have detected it as this technique only examined molecules present in the culture 
supernatants.  
Finally, Phenotype MicroArrays
TM
 were used to assess if either of the mutants had a 
phenotype when subjected to various substrates. Prior to inoculation the M. tuberculosis 
cultures were washed and then starved in PBS for 18 hours to ensure that the cells had 
metabolised any nutrients, carbon sources and other growth factors remaining from the 
Dubos medium. This was important as otherwise false positive results may have been 
observed. It was hypothesised that any phenotypic differences observed between the 
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strains may help in identifying a function for PknF and Rv1747. However, results 
showed that there were no reproducible differences in substrate usage found 
between the wild type and mutant strains. Although disappointing in this study, 
Phenotype MicroArray
TM
 technology has been successful in previous investigations to 
help identify substrates for proteins and to help elucidate their function. For example, a 
study in 2006 showed that Phenotype MicroArray
TM
 technology was an effective 
screening method to assess cellular phenotypes in Staphylococcus aureus (von Eiff et 
al., 2006). von Eiff and colleagues were able to characterise the phenotype of two 
mutants using this technique, namely menD and hemB, both of which form small 
colonies. They discovered that both mutants had defects in carbon utilisation and carbon 
metabolism and these were confirmed in further growth studies. In addition they were 
able to record digital images of the microarrays while they were in the incubator which 
stored colour change data thus generating real-time kinetics results. This latter technique 
is not currently available in our laboratory but highlights the potential of the method to 
screening M. tuberculosis mutants with no known phenotype. 
In conclusion, the results presented in this chapter have highlighted the inherent 
difficulties of trying to identify the substrate for Rv1747. Although many hypotheses 
were tested, the experiments performed did not yield conclusive evidence as to the 
nature of the substrate. Furthermore, although lipid profile analysis highlighted a 
difference in lipid composition between wild type and mutant strains this difference 
could not be complemented. Consequently, the identity of the Rv1747 substrate has 
remained elusive. In the future if a potential substrate is identified this can be tested 
using inverted membrane vesicles in a transport assay. Briefly, inverted membrane 
vesicles are enriched with Rv1747, then in the presence of ATP the substrate in 
transported inside the inverted vesicles and can then be quantified. 
In further chapters of this study the biochemical aspects of protein-protein interactions 
will be explored and the mechanism of regulation will be investigated in order to further 
understand how PknF regulates the function of Rv1747. 
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CHAPTER 5. HOW IS PknF CONTROLLING Rv1747 
FUNCTION? PART 1 
ANALYSIS OF THE PHOSPHORYLATION DEPENDENT 
INTERACTIONS BETWEEN RECOMBINANT PknF AND 
Rv1747 IN VITRO 
5.1 Introduction 
Serine-threonine protein kinases (STPKs) are key proteins in signalling systems which 
act by regulating the function of their protein substrates. Eleven STPKs have been 
identified in the M. tuberculosis genome, from PknA to PknL (there is no PknC), nine of 
which are predicted to be transmembrane bound kinases (Av-Gay & Everett, 2000; Cole 
et al., 1998). This study focussed on the transmembrane bound kinase PknF with the aim 
of exploring how this kinase was controlling the function of Rv1747, an FHA domain 
containing ABC transporter required for the full virulence of M. tuberculosis (Curry et 
al., 2005). The hypothesis was that PknF regulates the function of Rv1747 in a 
phosphorylation dependent manner. As it was unknown how PknF was controlling 
Rv1747 function, this study initially characterised the phosphorylation dependent 
interactions between the two recombinant proteins.  
Numerous studies have been conducted which have characterised the interactions 
between other M. tuberculosis STPKs and their putative FHA domain containing 
substrates (Molle et al., 2003; Nott et al., 2009; O'Hare et al., 2008; Villarino et al., 
2005). However, in the case of PknF and Rv1747 only two studies have been published 
which presented a preliminary analysis of the interaction between these two proteins 
(Curry et al., 2005; Molle et al., 2004). In 2005 Curry et al. used yeast two-hybrid 
analysis to demonstrate that the Rv1747 protein interacted with PknF (Curry et al., 
2005). Furthermore, they went on to demonstrate that the interaction appeared to be 
phosphorylation dependent as the interaction was abrogated in a kinase null mutant, 
when the presumed activation loop of PknF was mutated and when the FHA-1 domain 
of Rv1747 was mutated (Curry et al., 2005). In 2004 Molle et al. used in vitro 
phosphorylation assays to show that the PknF kinase domain phosphorylated the Rv1747 
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nucleotide binding domain in vitro. However, in their purification of Rv1747 they kept 
the large GST-fusion tag as part of the recombinant protein. Therefore it could be argued 
firstly that GST-Rv1747 was not folded correctly, due to the large tag, and therefore 
serine or threonine residues not normally accessible to PknF were now rendered 
accessible to phosphorylation and vice versa, and secondly, the kinase may have 
phosphorylated a residue within the GST protein itself. Therefore in this current 
investigation all recombinant proteins were produced without any tags unless necessary 
for a specific technique.  
Both these studies highlighted that there was probably a phosphorylation dependent 
interaction between PknF and Rv1747; however, the identity of the phosphorylation 
sites and the importance of these sites on the ability of PknF to phosphorylate Rv1747 
and regulate its activity had not been explored. This therefore warranted further 
investigation to help gain a more in depth understanding of how these two proteins 
interacted and how PknF controlled Rv1747 function in the context of M. tuberculosis 
infection and virulence. The consequences of phosphorylation of Rv1747 by PknF will 
be investigated in this chapter and the following chapter of this study. 
The main objective of this study was to begin to understand the mechanism by which 
PknF controls the function of Rv1747. It was hypothesised that PknF controlled the 
function of Rv1747 by phosphorylation on specific threonine residues. The first aim of 
this study was to express and purify PknF and Rv1747 from E. coli. The second aim was 
to ascertain whether recombinant PknF was an active kinase and to identify whether this 
kinase could phosphorylate Rv1747 in vitro; the next objective was to identify the 
specific sites on Rv1747 which were phosphorylated by PknF. Finally, the significance 
of these sites were characterised in in vitro phosphorylation assays.  
5.2 Expression and purification of PknF and Rv1747 from E. coli 
As a necessary preliminary to exploring the phosphorylation dependent interactions 
between PknF and Rv1747 both the recombinant proteins were expressed and purified 
from E. coli. 
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The kinase domain of PknF and the nucleotide binding domain of Rv1747 were cloned 
into the N-terminal GST-fusion vector pGEX-6P-1 and then expressed and purified from 
BL21 star E.coli cells. Figure 5.1 highlights the domain architecture of PknF and 
Rv1747 according to the SMART database (Schultz et al., 1998). Figure 5.1a shows the 
domain architecture of PknF which comprises of a kinase domain (shown in red) and a 
transmembrane domain (shown in blue). It was important not to include any of the 
transmembrane domains in the protein expression constructs as it is inherently difficult 
to produce soluble proteins which contain these domains due to their hydrophobicity.  
Furthermore, the aim of the investigation was to study the function of the kinase domain 
so the transmembrane domain was not required. According to the SMART database the 
PknF kinase domain ends at amino acid 274 and the transmembrane domain begins at 
residue 307. Therefore amino acid residues 1 to 292 were chosen to be cloned into 
pGex-6P-1 to ensure the complete kinase domain was present but to make sure the 
transmembrane domain was not included (Figure 5.1a). In figure 5.1a this region is 
highlighted with a black box. The protein domains of Rv1747 are depicted in Figure 
5.1b. According to the SMART database the nucleotide binding domain ends at amino 
acid 528 and the transmembrane domain begins at position 613. Therefore amino acids 1 
to 559 were cloned into pGex-6P-1 for the Rv1747 expression work to ensure that the 
complete ATPase domain was included in the construct and to make sure the first 
transmembrane domain was excluded. In figure 5.1b this region is highlighted with a 
black box.  
PknF
1-292
 and Rv1747
1-559
 were PCR amplified from M. tuberculosis genomic DNA, 
ligated into pGex-6-P1 and confirmed by sequencing as described in sections 2.2.2, 2.2.9 
and 2.2.13 respectively. These DNA fragments were then transformed into either E. coli 
BL21 star (DE3) cells in the case of PknF
1-292
 or E. coli BL21 star (DE3) pRep4-groESL 
cells in the case of Rv1747
1-559
. Initial solubility and purification trials found that it was 
very difficult to identify an expression condition which yielded a high abundance of 
soluble Rv1747
1-559 
protein in BL21 star cells which could then be purified from its 
contaminants (data not shown). An alternative expression cell type for Rv1747
1-559 
purification was then sought. The pRep4-groESL plasmid encodes GroEL and GroES, 
two bacterial molecular chaperones (Amrein et al., 1995). The yield of soluble  
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Figure 5.1 Protein domains cloned for expression and purification from E. coli. 
Figure 5.1a shows the domain architecture of PknF and figure 5.1b shows the domain 
architecture of Rv1747. Images were produced using the SMART database (Letunic et 
al., 2009). Figure 5.1a highlights the kinase domain of PknF (in red) plus the 
transmembrane (blue) and regions of low complexity (pink). Figure 5.1 b shows both the 
FHA domains of Rv1747 (yellow), the ATPase domain (grey), the transmembrane 
domains (blue) and the regions of low complexity (pink). Numbers represent amino acid 
positions. Cloned residues are highlighted with a black box. 
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Rv1747
1-
 
559 
protein in the BL21 star (DE3) pRep4-groESL expression strain was much 
higher and it was possible to purify the soluble protein from its contaminants using size 
exclusion chromatography. This E. coli expression strain was therefore used for all 
Rv1747
1-559 
purifications. 
PknF
1-292
 and Rv1747
1-559 
were expressed and purified as described in section 2.5.2. The 
N-terminal GST-tag was removed from both the kinase and transporter during the 
purification using PreScission protease. It was felt that it was important to remove the 
tag from both the proteins for two reasons; firstly, the tag is comparatively large (~26 
kDa) and so it was thought that this may interfere with the correct folding of the two 
recombinant proteins; if the proteins did not fold correctly then it would be likely that 
they would be rendered non-functional. Secondly, as Rv1747 was to be used in 
phosphorylation assays to determine if and where PknF phosphorylated the ABC 
transporter, it was decided that the only domains present in the Rv1747 purified protein 
would be those from Rv1747 itself. Cleavage of the tag from the proteins left five amino 
acids at the N-terminus of each protein: GPLGS.  
Figure 5.2 shows the results of the purifications of both the kinase and the ABC 
transporter. All protein purifications required a size exclusion chromatography step to 
remove contaminating proteins that eluted after PreScission protease cleavage. Figure 
5.2a is a UV trace generated from size exclusion chromatography of a PknF
1-292 
purification. Size exclusion chromatography was performed as outlined in section 
2.5.2.2.1. Figure 5.2a highlights the UV absorbance peak corresponding to PknF
1-292
. All 
other UV absorbance peaks are from contaminating proteins which separated into other 
fractions. When both the proteins had been separated from their contaminants by size 
exclusion chromatography the fractions containing the desired protein were pooled and 
concentrated. 10 µl of this sample was then analysed by SDS-PAGE; figure 5.2b shows 
the result of a PknF
1-292
 purification and figure 5.2c shows the result of a Rv1747
1-559 
purification. Figure 5.2b shows that PknF
1-292
 was purified to homogeneity. Interestingly 
this protein also runs as a doublet. The identity of each purified protein was confirmed 
by mass spectrometry and was performed as described in 2.5.2.3. Figure 5.2c shows that 
Rv1747
1-559 
was purified to near homogeneity; the contaminating protein at 
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approximately 70 kDa was identified by mass spectrometry as E. coli heat shock protein 
70. This chaperone protein was always present in Rv1747
1-559 
purifications. 
5.3 Recombinant PknF
1-292
 is an active kinase capable of 
autophosphorylation 
In order to determine whether recombinant PknF
1-292 
was a functional kinase, an in vitro 
phosphorylation assay was performed where PknF
1-292 
was labelled with [γ-
32
P] ATP for 
30 minutes before being separated by gel electrophoresis (figure 5.3a) and checked for 
incorporation of radioactivity by autoradiography (figure 5.3b). Figure 5.3b lane 2 
clearly shows that PknF
1-292 
incorporated radio-labelled ATP demonstrating that it was 
indeed an active kinase capable of autophosphorylation. Furthermore, electrospray mass 
spectroscopy confirmed the presence of additional phosphate groups on the recombinant 
kinase after purification from E. coli indicating that in vitro PknF
1-292 
is capable of 
autophosphorylating itself numerous times (figure 5.3c).  
5.4 Autophosphorylation activity of PknF
1-292
 is dependent on one 
specific lysine residue 
Archetypal serine-threonine protein kinases contain a lysine residue within their active 
site that is critical for autophosphorylation due to its role in ATP binding (see figure 1.4) 
(Kornev et al., 2006; Young et al., 2003). To further explore whether this was the case 
for PknF
1-292
 site directed mutagenesis was employed to make a K41A mutation within 
the expression construct. The result of the PknF
1-292 
K41A purification is shown in figure 
5.4a. PknF
1-292 
K41A was then assessed for its autophosphorylation capabilities using an 
in vitro kinase assay. Figure 5.4c lane 2 shows that the K41A mutation abolished the 
autophosphorylation activity of PknF
1-292 
which was observed in the wild type control in 
lane thus confirming the essentiality of the lysine residue for kinase function. More 
importantly, this result demonstrated that the autophosphorylation activity of PknF
1-292
 
observed in the in vitro phosphorylation experiment was the result of autocatalytic 
activity and not due to phosphorylation by an E. coli protein during the purification 
process. 
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Figure 5.2 Expression and purification of recombinant PknF
1-292
 and Rv1747
1-559 
from 
E.coli. PknF
1-292
 and Rv1747
1-559
 were expressed and purified as described in section 2.5.2. All 
protein purifications required a size exclusion chromatography step to remove contaminating 
proteins. Size exclusion chromatography was performed with a gel filtration column (HiLoad 
16/60 Superdex 200 prep grade column) and an AKTA Prime system as described in section 
2.5.2.2.1. Figure 5.2a shows a UV trace from a PknF
1-292
 purification. All other UV absorbance 
peaks are from contaminating proteins which separated into other fractions. After purification 10 
µl of each pooled and concentrated protein sample was analysed by SDS-PAGE as described in 
section 2.5.1. Figure 5.2b shows the result of a PknF
1-292
 purification and figure 5.2c shows the 
results of an Rv1747
1-559
 purification. PknF
1-292
 was purified to homogeneity. Rv1747
1-559
 was 
purified to near homogeneity; the contaminating protein at ~ 70kDa was identified as E. coli heat 
shock protein 70. This contaminating protein was always present in all Rv1747
1-559
 purifications. 
PknF
1-292
 = 32 kDa, Rv1747
1-559
 = 58 kDa. 
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Figure 5.3. Recombinant PknF
1-292
 is an active kinase capable of 
autophosphorylation.  In vitro phosphorylation assays were performed with expressed 
and purified PknF
1-292
 as described in section 2.5.3.1. PknF
1-292 
was incubated for 30 
minutes at 37 
o
C, in the case of lane 2, in the presence of 200 µCi/ml [γ-
32
P] ATP, and 
subjected to gel electrophoresis (Figure 5.2a). Radioactive bands were revealed by 
autoradiography (Figure 5.2b). Approximately 1 µg of protein was loaded into each 
lane. Figure 5.3b lane 2 shows a radioactive signal corresponding to the size of PknF
1-292
 
(32.4 kDa) demonstrating that the kinase is capable of autophosphorylation. Figure 5.3c 
shows an electrospray mass spectrometry analysis of PknF
1-292
 showing the 
autophosphorylation activity of the PknF
1-292
 kinase domain. Each peak labeled ‘+’ 
followed by a number represents the number of additional phosphate groups on PknF
1-
292
; i.e. ‘+2’ means PknF 
1-292
 plus 2 phosphate groups. The net gain of a phosphate 
group results in an increase in mass of 80 Da. 
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Figure 5.4 A mutation of the critical lysine residue abolishes the 
autophosphorylation activity of PknF
1-292
. Site directed mutagenesis was used 
generate a K41A mutation within the PknF
1-292
 construct as described in section 2.2.3. 
Figure 5.4a shows that PknF
1-292
 K41A was expressed and purified to homogeneity. In 
vitro phosphorylation assays were performed with wild type PknF
1-292 
and PknF
1-292
 
K41A. The proteins were incubated with 200 µCi/ml [γ-
32
P] ATP for 30 minutes, 
subjected to gel electrophoresis (Figure 5.3b) and radioactive bands were revealed by 
autoradiography (Figure 5.4c). Approximately 0.5 µg of protein was loaded into each 
lane. Figure 5.4c lane 1 shows that wild type PknF
1-292 
is capable of 
autophosphorylation. Figure 5.4c lane 2 clearly demonstrates that the 
autophosphorylation activity of the kinase was abolished in the PknF
1-292
 K41A mutant. 
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5.5 PknF
1-292
 phosphorylates Rv1747
1-559
 in vitro 
Prior to any experiments being carried out to determine the sites of Rv1747 
phosphorylation it first had to be determined whether PknF could phosphorylate Rv1747 
in vitro. Both the recombinant proteins were combined in an in vitro phosphorylation 
assay. Figure 5.5b lane 2 shows that PknF
1-292
 does indeed phosphorylate Rv1747
1-559
 in 
vitro as demonstrated by the presence of a radio-labelled band corresponding to the size 
of Rv1747
1-559
 (58 kDa). Furthermore, as expected, Rv1747 does not have any 
autophosphorylation activity (figure 5.5d lane 1).  
5.6 PknF phosphorylates Rv1747 in vitro on specific threonine residues 
The next aim of this study was to identify the sites on Rv1747 which were 
phosphorylated by PknF. Phosphorylation site mapping was achieved using LC-MS/MS 
as described in section 2.5.3.2. Purified PknF
1-292
 and Rv1747
1-559
 were supplied to V. 
Molle (Lyon, France) for site identification. Two phosphorylated threonine residues 
were identified on Rv1747
1-559
 and these are shown in figure 5.6. The two 
phosphorylated threonine residues identified were T150 and T208. T150 is situated 
between the FHA-1 domain and the FHA-2 domain and T208 is just upstream of the 
FHA-2 domain core region (figure 5.6).  
5.7 Construction of Rv1747 phosphorylation-null expression strains in 
E. coli  
It was hypothesised that PknF controlled the function of Rv1747 through 
phosphorylation on specific threonine residues. To further investigate the importance of 
the identified pT150 and pT208 sites on the ability of PknF to phosphorylate Rv1747 in 
vitro a panel of threonine to alanine mutations were created in the Rv1747
1-559
 protein 
expression construct. Three mutations were generated; T150A, T208A and a double 
T150A/T208A mutant. Replacement of a threonine residue with an alanine residue 
renders the site incapable of acting as a phosphoacceptor (phosphorylation-null). Site 
directed mutagenesis was performed as described in section 2.2.3 and a list of primers 
can be found in appendix II. Two rounds of site directed mutagenesis were required to  
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Figure 5.5 In vitro phosphorylation of Rv1747 by PknF. In vitro phosphorylation 
assays were performed with PknF
1-292 
and Rv1747
1-559
 as outlined in section 2.5.3.1. The 
proteins were incubated with 200 µCi/ml [γ-
32
P] ATP for 30 minutes, subjected to gel 
electrophoresis (Figure 5.5a and c) and radioactive bands were revealed by 
autoradiography (Figure 5.5b and d). Approximately 1 µg of protein was loaded into 
each lane. Figure 5.5b shows that PknF
1-292
 is an active kinase capable of 
autophosphorylation (lane 1) and that it is able to phosphorylate Rv1747
1-559
 in vitro 
(lane 2). Figure 5.5d shows that Rv1747 does not have any autophosphorylation activity 
(lane 1) and the relevant controls are shown in lanes 2 and 3. PknF
1-292
 = 32 kDa, 
Rv1747
1-559
 = 58 kDa.  
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KEY : 
FHA-1 core domain 
FHA-2 core domain 
 
FHA domain regions used for ITC 
 
Phosphorylated threonine residue T150 
Phosphorylated threonine residue T208 
 
The conserved serine residue in each FHA domain (S47 & S248) is underlined  
 
Phosphorylated residues identified in the Prisic et al., 2010 study 
 
Figure 5.6 Identification of phosphorylated threonine residues on Rv1747
1-559
. 
Recombinant PknF
1-292
 and Rv1747
1-559 
were expressed and purified as outlined in 
section 2.5.2. LC/MS/MS was performed in collaboration with V. Molle as described in 
section 2.5.3.2 to identify phosphorylated threonine residues. Two residues were 
discovered which were phosphorylated in vitro by PknF
1-292
. The two residues are 
highlighted in figure 5.6 which shows Rv1747 amino acid residues 1 to 559. The two 
phosphorylated threonine residues identified were T150 and T208 which are highlighted 
in green and purple respectively. The two FHA domains are also highlighted in figure 
5.6; the FHA-1 core domain is highlighted red and the FHA-2 core domain is 
highlighted in blue. The amino acids highlighted in grey show the residues cloned to 
make the FHA-1 (pVS_04) and FHA-2 (pVS_05) protein expression constructs.  
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generate the double threonine to alanine mutant. It was expected that a reduction in 
phosphorylation would be observed in the double threonine to alanine mutant if indeed 
the two identified sites were important for Rv1747 phosphorylation by PknF.  
The effects of the threonine to alanine mutations on the ability of PknF
1-292
 to 
phosphorylate Rv1747
1-559
 in vitro were then assessed. 
5.8 Expression and purification of Rv1747
1-559
 threonine to alanine 
mutants in E. coli 
Figure 5.7 shows the results of the expression and purification of the threonine to alanine 
mutant proteins from E. coli. 10 µl of each concentrated protein sample was analysed by 
SDS-PAGE. It can be seen that all proteins were purified to near homogeneity with the 
exception of the contaminating E. coli hsp70 protein which was present in all Rv1747
1-
559
 purifications. 
5.8.1 Assessment of the phosphorylation state of the Rv1747
1-559 
mutants  
Next, in vitro phosphorylation assays were performed to examine the effects of the 
threonine to alanine mutations on the ability of PknF to phosphorylate Rv1747. Results 
of the assays are shown in figure 5.8. After incubation with [γ-
32
P] ATP proteins were 
subjected to gel electrophoresis (figure 5.8a) and radioactive bands were revealed by 
autoradiography (figure 5.8b). Phosphorylation of Rv1747
1-559
 by PknF
1-292
 is reduced in 
all the threonine to alanine mutants (figure 5.8b) and was most significantly reduced in 
the double threonine to alanine mutant (figure 5.8b, lane 5). This result demonstrated 
that phosphorylation of Rv1747 by PknF is highly impaired in a double threonine to 
alanine mutant in sites T150 and T208 of Rv1747 in vitro. If the two phospho-threonine 
sites identified were the only sites on Rv1747 phosphorylated by PknF then it was 
expected that in the double mutant no radioactive band corresponding to the 
phosphorylation of Rv1747 would be observed. Interestingly, although very little radio 
labelled ATP was incorporated into the Rv1747 protein in the double threonine to 
alanine mutant, there also was no radioactive band present corresponding to the size of 
the kinase. This was a very surprising result as one would expect the kinase to remain  
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Figure 5.7 Expression and purification of wild type Rv1747
1-559
, Rv1747
1-559
 T150A, 
Rv1747
1-559
 T208A and Rv1747
1-559
 T150A/T208A. Proteins were expressed and 
purified as described in section 2.5.2. After purification 10 µl of each pooled and 
concentrated protein sample was analysed by SDS-PAGE as described in section 2.5.1. 
Figure 5.7 demonstrates that all proteins were purified to near homogeneity; the 
contaminating protein at ~ 70kDa was identified as E. coli heat shock protein 70. The 
contaminating protein was always present in all Rv1747
1-559
 purifications. Rv1747
1-559
 = 
58 kDa.  
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Figure 5.8 In vitro phosphorylation of Rv1747
1-559
 by PknF
1-292
 is reduced in the 
threonine to alanine mutants. In vitro phosphorylation assays were performed with 
PknF
1-292 
and wild type Rv1747
1-559
, Rv1747
1-559
 T150A, Rv1747
1-559
 T208A or 
Rv1747
1-559
 T150A/T208A as outlined in section 2.5.3.1. The various proteins were 
incubated together with 200 µCi/ml [γ-
32
P] ATP for 30 minutes, subjected to gel 
electrophoresis (Figure 5.8a) and radioactive bands were revealed by autoradiography 
(Figure 5.8b). Approximately 1 µg of protein was loaded into each lane.  
 
 
 
 
 
 
 
PknF 
PknF 
Rv1747 
Rv1747 
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autophosphorylated in this situation when it could no longer phosphorylate Rv1747 
sufficiently. 
5.9 Assessment of the phosphorylation of Rv1747
1-559
 by other M. 
tuberculosis serine-threonine protein kinases 
It has long been hypothesised that more then one M. tuberculosis serine-threonine 
protein kinase could phosphorylate the same substrate in vivo leading to a level of 
redundancy between the kinases and suggesting that substrates may be regulated by 
multiple signals (Grundner et al., 2005). This hypothesis is further supported by the fact 
that only two out of the 11 STPKs have to date been shown to be essential for M. 
tuberculosis viability (Sassetti et al., 2003). To test this hypothesis with Rv1747 in our 
in vitro model, phosphorylation assays were performed as previously with Rv1747, 
PknF, PknG and PknB. Figure 5.9 shows the results from the assays. The radioactive 
bands present in lanes 1 and 3 in figure 5.9b demonstrate that both the kinases were 
active and capable of autophosphorylation. Lane 2 shows the Rv1747
1-559 
control 
demonstrating that Rv1747 was phosphorylated by PknF
1-292
. Figure 5.9b lane 4 shows 
that PknG
 
does not phosphorylate Rv1747 in vitro demonstrated by the absence of a 
radio-labelled band corresponding to the size of Rv1747. Figure 5.9c lane 1 clearly 
demonstrates that PknB was a functionally active kinase but Rv1747 was not a good 
substrate for this kinase. This result clearly illustrated that PknG could not phosphorylate 
Rv1747
1-559 
and that PknB could only marginally phosphorylate Rv1747
1-559
 in vitro. 
Again, it was interesting that the autophosphorylation activity of PknG and PknB was 
dramatically reduced when the Rv1747 protein was included in the phosphorylation 
assay compared with the levels of ATP incorporated into the kinases when they were 
incubated in the absence of Rv1747.  
As a control experiment to check that PknG
1-759 
and PknB
1-279
 were indeed functional 
kinases it was investigated whether they could phosphorylate Rv1827. Rv1827 is 
another FHA domain containing protein in M. tuberculosis which is phosphorylated by 
PknB and PknG on two specific threonine residues (Nott et al., 2009; O'Hare et al., 
2008; Villarino et al., 2005). The results from the in vitro phosphorylation assays are  
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Figure 5.9 Assessment of the phosphorylation of Rv1747
1-559
 by other M. 
tuberculosis serine-threonine protein kinases. In vitro phosphorylation assays were 
performed with wild type Rv1747
1-559
 and PknF
1-292
, PknG
1-759
 or PknB
1-279
 as outlined 
in section 2.5.3.1. Purified PknG
1-759
 and PknB
1-279 
were a gift from the Division of 
Protein Structure (NIMR). The different proteins were incubated together with 200 
µCi/ml [γ-
32
P] ATP for 30 minutes, subjected to gel electrophoresis (Figure 5.9a) and 
radioactive bands were revealed by autoradiography (Figure 5.9b and c). Approximately 
1 µg of protein was loaded into each lane. Figure a is a Coomassie blue stained gel and 
figure b is the result of autoradiography of the gel in figure a.
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Figure 5.10 Phosphorylation of Rv1827 by multiple kinases. In vitro phosphorylation 
assays were performed with Rv1827
1-162
 and PknF
1-292
, PknG
1-759
 or PknB
1-279
 as 
outlined in section 2.5.3.1. The proteins were incubated together with 200 µCi/ml [γ-
32
P] 
ATP for 30 minutes, subjected to gel electrophoresis (Figure 5.10a) and radioactive 
bands were revealed by autoradiography (Figures 5.10b and c). Approximately 1 µg of 
protein was loaded into each lane. Figure a is a Coomassie blue stained gel and figure b 
is the result of autoradiography of the gel in figure a. Rv1827
1-162
 = 17 kDa, PknF
1-292
 = 
32 kDa, PknG
1-759
 = 81 kDa, PknB
1-279
 = 30 kDa.
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shown in figure 5.10 and demonstrate that Rv1827
1-162 
can indeed be phosphorylated in 
vitro by PknG (figure 5.10a and b lane 4) and PknB (figure 5.10c lane 2) demonstrating 
that the reason both these kinases did not phosphorylate Rv1747 was not because the 
kinases were non-functional.  
Interestingly results in figure 5.10a and b lane 2 demonstrate that PknF can also 
phosphorylate Rv1827 showing that FHA domain-containing proteins can be 
phosphorylated by more than one serine-threonine protein kinase in vitro. 
5.10 Discussion 
The aim of this study was to explore the phosphorylation dependent interaction between 
PknF and Rv1747, to identify the sites on which PknF phosphorylated Rv1747 and to 
characterise the significance of these sites in terms of the phosphorylation status of 
Rv1747.  
5.10.1 Protein purification 
PknF
1-292
 and Rv1747
1-559
 were successfully expressed and purified from E. coli under 
non-denaturing conditions. Each protein’s native conformation was retained throughout 
the complete purification; this means that the recombinant proteins were more likely to 
be folded into their correct conformation than if the proteins were purified under 
denaturing conditions and then refolded. However, it must be taken into consideration 
that the recombinant proteins consisted of only certain domains of the full proteins; the 
kinase domain of PknF was purified (residues 1 to 292 out of a total of 476) and the 
nucleotide binding and FHA domains of Rv1747 were purified (residues 1 to 559 out of 
865). In the M. tuberculosis cell both these proteins are anchored in the cell membrane 
as indicated by the presence of transmembrane domains in both of the proteins. 
Therefore as the transmembrane domains were not included in the recombinant proteins 
it could be argued that it may have affected the folding of the proteins resulting in 
different conformations compared to when fixed in the cell membrane.  
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An interesting feature of recombinant PknF was that it separated on an SDS-PAGE gel 
as a doublet (figure 5.2). This is a feature quite common to recombinant protein kinases. 
For example, recombinant PknB also runs as a doublet (as shown in this study and 
Villarino et al., 2005) as does PknG (figures 5.9 and 5.10). A reason why this may occur 
is because PknF appears to contain multiple autophosphorylation sites. This is further 
supported by the electrospray mass spectrometry data in figure 5.3 which highlighted the 
fact that PknF
1-292
 can become autophosphorylated at multiple sites. It can be 
hypothesised that one of the autophosphorylation sites may result in a conformational 
change in the protein structure resulting in the kinase separating into two distinct protein 
bands. 
Although it was possible to purify PknF
1-292 
to homogeneity the purification of Rv1747
1-
559 
proved much more problematic. Initial solubility and purification trials proved 
unsuccessful; when very small amounts of soluble protein were obtained it seemed to 
bind irreversibly to the glutathione-S-transferase resin. This problem was overcome by 
expressing Rv1747
1-559 
in BL21 star pRep4-groESL expression cells and through the 
addition of ten percent glycerol to all the protein purification buffers. Glycerol is a 
viscous liquid that is known to assist to keep proteins stable and furthermore it makes 
proteins less sensitive to freezing and thawing by helping to prevent protein damage 
caused by ice crystal formation. pRep4-groESL encodes GroEL and GroES, two 
bacterial molecular chaperones (Amrein et al., 1995). Chaperones function to fold 
proteins correctly into their native conformation and thus improve the solubility of 
recombinant proteins by producing correctly folded and active proteins. GroEL is an 
Hsp60 family member and together with GroES they form a complex which hydrolyses 
ATP to provide energy for protein folding. The chaperone complex functions by 
repeatedly binding unfolded proteins, re-folding and then releasing proteins until they 
are folded into their native conformation (Horwich et al., 2006). GroEL is approximately 
60 kDa in size and GroES is 10 kDa in size. Purification of Rv1747
1-559
 was achieved in 
the BL21 pRep4-groESL cells; Rv1747
1-559 
was purified to near homogeneity but there 
was a low abundance of E. coli heat shock protein 70 (Hsp70) in all purifications. This 
protein was identified by MALDI-TOF mass spectrometry. The fact that the Hsp70 
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chaperone co-purified with Rv1747 suggests that this heat shock protein was required to 
maintain the solubility of the ABC transporter.  
When aiming to conduct studies on the relationship between two proteins it is always 
optimal to purify both proteins to homogeneity. This is because the aim of the 
investigation is to observe the effects of the interaction between two proteins and not to 
obtain results as a consequence of contaminating proteins which inevitably leads to 
spurious results. However, for Rv1747
1-559
 the best purification that could be achieved 
included a low abundance of Hsp70. 
5.10.2 Autophosphorylation activity of recombinant PknF 
Using an in vitro kinase assay recombinant PknF
1-292
 was shown to be able to 
incorporate radio-labelled ATP and was therefore demonstrated to be an active 
kinase capable of autophosphorylation. Electrospray mass spectrometry analysis 
confirmed the presence of additional phosphate groups on the recombinant kinase after 
purification from E. coli ranging from plus two phosphate groups to plus seven 
indicating that in vitro PknF
1-292 
is capable of autophosphorylation at numerous sites 
(figure 5.3).  
Autophosphorylation by STPKs occurs in the activation loop of the kinase domain on 
specific threonine residues and autophosphorylation can occur more than once. The 
activation loop is situated in the catalytic domain of the kinase (see figure 1.4 for a 
schematic of a typical protein kinase showing the activation loop) (Villarino et al., 
2005). Autophosphorylation of PknF could occur in cis or trans, i.e. the phosphate group 
from one molecule could be transferred to its own activation loop or to an adjacent 
molecule’s activation loop, both resulting in activation of the kinase (Lochhead, 2009). 
The solved structures of PknB, PknD and PknE kinase domains have shown them to be 
dimeric, which in the cell would presumably occur upon extracellular ligand binding to 
the sensor domain, and this dimerisation seemingly results in trans or cis 
autophosphorylation of the activation loop causing a conformational change leading to 
activation of the kinase (Gay et al., 2006; Greenstein et al., 2007; Mieczkowski et al., 
2008; Ortiz-Lombardia et al., 2003; Scherr et al., 2007; Young et al., 2003). This 
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mechanism of activation is suggested to be conserved among other mycobacterial 
STPKs (Young et al., 2003). For PknF, it is unknown whether a similar dimerisation 
event occurs; the predicted extracellular domain contains regions of low complexity and 
lacks a ligand binding domain with a recognisable function (Greenstein et al., 2007).  
Autophosphorylation can also occur in the juxtamembrane region between the kinase 
and transmembrane domains and also at the N-terminus of the protein. This was 
demonstrated for PknB, PknD, PknE and PknF in a study by Duran et al (Duran et al., 
2005). They showed using MALDI-TOF mass spectrometry combined with reverse-
phase HPLC that PknF contained nine phosphorylated residues compared with PknB 
which contained five and PknD and PknE which both contained 11 (Duran et al., 2005). 
Their PknF data supports the electrospray mass spectrometry data obtained in this study 
which showed that PknF contained up to seven additional phosphate groups but did not 
detect the remaining two additional phosphate groups found in the Duran et al. study.  
In the 2005 study two phosphorylated activation loop threonine residues were identified 
for PknF, namely T173 and T175 (Duran et al., 2005). For PknB, the same threonine 
residues were shown to be phosphorylated both in the Duran study and in previous 
investigations (Boitel et al., 2003; Duran et al., 2005; Young et al., 2003). This reflects a 
degree of conservation between the activation mechanisms of the enzymes. Furthermore 
Duran and colleagues mutated the essential catalytic lysine residue to alanine in the 
PknB active site and showed that this mutant was not phosphorylated demonstrating that 
the phosphorylation observed in the experiments was the result of autocatalytic activity 
and not due to phosphorylation by an E. coli protein during the purification process 
(Duran et al., 2005). Next, they focussed further on PknB and investigated whether 
phosphorylation of the activation loop affected kinase activity. They mutated the two 
phosphorylated active site threonine residues (T173 and T175) to alanines. Upon 
mutation of both these residues the kinase had 300 fold less activity compared to the 
wild type protein when assessed for its ability to phosphorylate myelin basic protein 
(Duran et al., 2005). This result demonstrated that phosphorylation of the activation loop 
plays a significant role in the enzyme activity which has also been shown for another 
bacterial STPK in Bacillus subtilis (Madec et al., 2003). Apart from the activation loop 
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threonines a further two phosphorylated residues were identified for PknF in the 
juxtamembrane region, namely threonine residue 287 and serine 290 but mutation of 
these residues did not affect kinase activity (Duran et al., 2005) suggesting that they 
perform a different function in the signalling cascade.  
5.10.2.1 The essential role of lysine 41 in PknF 
As mentioned above, serine-threonine protein kinases have an essential catalytic lysine 
residue in their active site which is critical for enzyme activation due to its role in 
binding the α and ß phosphates of ATP (Kornev et al., 2006; Young et al., 2003). In this 
study it was examined whether the homologous lysine residue in PknF was also critical 
for phosphorylation. This was investigated to check that the autophosphorylation activity 
of PknF
1-292
 observed in the in vitro phosphorylation experiment was the result of 
autocatalytic activity and not due to phosphorylation by an E. coli protein during the 
purification process. The lysine residue at position 41 of PknF was mutated to alanine 
and it was shown that this rendered the kinase inactive which was demonstrated by the 
fact that this strain did not incorporate radio-labelled ATP (figure 5.4). This result 
showed the autophosphorylation activity of PknF
1-292
 observed in the in vitro 
phosphorylation experiment was indeed the result of autocatalytic activity. It has 
been previously shown that PknF K41M cannot phosphorylate myelin basic protein 
(MBP) (Koul et al., 2001).  
Interestingly, E. coli harbouring the PknF
1-292
 K41A plasmid had the expected doubling 
time of 20 minutes up until induction of gene expression at an OD600 of 0.6; however the 
PknF
1-292 
wild type strain had a much slower doubling time of approximately 35 to 40 
minutes. Furthermore, when harvesting the cells after 18 hours of induction the E. coli 
cell pellets were also smaller in the wild type strain compared to the mutant strain 
suggesting that the doubling time of the E. coli strain expressing the wild type protein 
continued to be slower throughout the course of protein expression (data not shown). 
Control of recombinant protein expression in E. coli is rarely perfect i.e. in the absence 
of inducer, which in this system was IPTG, some protein expression often still occurs. If 
this was the case for the PknF expression constructs then it could explain why the 
doubling time of E. coli harbouring the PknF
1-292 
wild type plasmid was considerably 
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slower: the active kinase was probably using ATP generated by E. coli to 
autophosphorylate. This in turn would result in there being less energy available for the 
E. coli cells to replicate resulting in the doubling time of this strain being considerably 
longer. In the PknF
1-292 
K41A strain this was not the case as the mutation rendered the 
kinase incapable of binding ATP.  
5.10.3 Rv1747 and PknF and other kinase/substrate interactions 
In vitro phosphorylation assays confirmed that Rv1747 was a substrate for PknF (figure 
5.5). This result verified the findings that Molle et al. published in 2004 but the present 
study further confirmed that the sites of phosphorylation must be within the Rv1747 
protein itself as the GST-tag was cleaved off the recombinant protein leaving only five 
uncleaved amino acids at the N-terminus (GPLGS) (Molle et al., 2004). However, it has 
to be noted that of the five amino acids one was a serine residue and thus had the 
potential of becoming phosphorylated by PknF. 
Apart from the 2004 study investigating the interaction between PknF and Rv1747 
(Molle et al., 2004), numerous studies have been conducted which have characterised 
the interactions between other M. tuberculosis STPKs and their putative FHA domain 
containing substrates. A 2005 study by Villarino et al. used M. tuberculosis whole cell 
protein extracts, representing all the soluble proteins in M. tuberculosis, and investigated 
the ability of PknB to phosphorylate proteins in the extract. They demonstrated by two 
dimensional PAGE that PknB phosphorylated Rv1827, an FHA domain containing 
protein involved in the TCA cycle, and identified threonine residue 22 as the sole 
phosphate acceptor (Villarino et al., 2005). Furthermore, in 2008 O’Hare and colleagues 
showed that PknG also phosphorylated Rv1827. They incubated Rv1827 with PknG and 
ATP and using mass spectrometry analysis showed that PknG phosphorylated Rv1827 at 
threonine residue 21 (O'Hare et al., 2008) whereas PknB phosphorylated Rv1827 at 
threonine residue 22 (Villarino et al., 2005). Furthermore, the phosphorylation of 
Rv1827 by PknB or PknG abrogated binding of Rv1827 to three proteins which are all 
involved in α-ketoglutarate metabolism (England et al., 2009; Nott et al., 2009). In 2003 
it was demonstrated that EmbR was a substrate for PknH (Molle et al., 2003). EmbR is 
involved in the biosynthesis of arabinogalactan, an important component of the 
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mycobacterial cell wall. Although only a few M. tuberculosis STPKs and their substrates 
have been characterised to date, it is clear that the interaction between kinases and their 
FHA domain containing substrates is involved in the regulation of key cellular processes 
in M. tuberculosis, previously predicted from bioinformatical analysis (Pallen et al., 
2002). 
5.10.3.1 Identification and characterisation of Rv1747 phospho-threonine residues 
The next aim of this study was to identify the threonine residues on Rv1747 that were 
phosphorylated by PknF which would then allow for an investigation into how 
phosphorylation of Rv1747 by this kinase was controlling the function of the ABC 
transporter. The catalytic subunit of STPKs function to transfer a γ-phosphate from ATP 
to the side chain hydroxyl group of a serine or threonine residue in the substrate protein. 
Substrate phosphorylation can result in a conformational change in the protein structure 
or can lead to the recruitment of a phospho-serine/phospho-threonine binding domain in 
order to transduce the signal resulting in activation or repression of protein function. 
Two phosphorylated threonine residues were identified for Rv1747, namely T150 and 
T208. As depicted in figure 5.6 residue T150 is situated approximately half way between 
the FHA-1 domain and the FHA-2 domain. Residue T208, although not in the FHA-2 
core region is situated just upstream of the domain. FHA domains function to bind 
phospho-threonine (pT) epitopes.  
A study published in 2010 used a mass spectrometry based approach to identify 
phosphorylated proteins in M. tuberculosis (Prisic et al., 2010). Of the 301 
phosphoproteins they identified, 60 % had threonine residues as the phosphoacceptor 
and 40 % had serine residues as the phosphoacceptor. Furthermore they also found that 
PknA, PknB, PknD and PknG were themselves phosphorylated in vivo suggesting that 
these four kinases are all active in the growth conditions tested. They then combined 
bioinformatic analysis of the identified in vivo phosphorylation sites with data from in 
vitro kinase assays to identify phosphorylation site motifs for PknA, PknB, PknD, PknE, 
PknF and PknH (Prisic et al., 2010). The motif identified for PknF is shown in figure 
5.11. The motif of the six investigated kinases all included a threonine residue as the 
phosphoacceptor and hydrophobic residues at the pT+3 and pT+5 positions. 
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Furthermore, they found that the phosphoacceptor threonine could not be substituted for 
a serine for any kinase. For PknF, the overrepresented amino acids at the pT+3 position 
included phenylalanine, threonine, isoleucine and methionine and at the pT+5 position 
isoleucine was found to be the predominant residue (figure 5.11).  
The phosphorylated threonine residues on Rv1747 identified in this study both share 
some of the features of the PknF preferred phosphorylation motif lending further support 
to the hypothesis that the identified phosphoacceptor threonine residues are real and are 
likely to be significant in terms of Rv1747 protein function. Site T208 has a methionine 
residue at pT+3 and an isoleucine residue at pT+5 (figure 5.6), both of which appear in 
the PknF preferred phosphorylation site motif. Furthermore, the identified T150 
phosphorylation site contains an isoleucine residue at the pT+3 position which also 
appears in the predicted consensus motif; however, it does not contain an isoleucine or 
other hydrophobic residue at position pT+5 although it does have an alanine residue at 
position pT+6 which appears as one of the residues in the PknF motif.   
By generating a model PknB structure in complex with a substrate peptide Prisic and 
colleagues then went on to map those residues on the peptide that were likely to come 
into contact with the active site residues of the kinase and potentially form hydrogen 
bonds (Prisic et al., 2010). They showed that the central part of the PknB activation loop 
was in close contact with the substrate residues around the pT site, from residues pT-1 to 
pT+3. It was suggested that any of these sites could form hydrogen bonds with the 
kinase active site. As the pT+3 and pT+5 residues are conserved in the kinase motifs it 
suggested they are important for phosphorylation to occur. Furthermore the pT+3 
position has been demonstrated to be important in FHA domain recognition (Liang & 
Van Doren, 2008) suggesting that STPKs and FHA domains have co-evolved to 
recognise overlapping consensus motifs. 
Interestingly, the Prisic study also identified two phosphopeptides on Rv1747 in the M. 
tuberculosis protein lysates, both of which were not identified in our investigation: these 
were S161 and S178. Phosphorylated S161 was identified under all conditions tested: 
exponential and stationary phase, NO stress, peroxide stress, hypoxia and when grown 
with acetate as a carbon source. The S178 containing phosphoprotein was only identified 
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when M. tuberculosis had been growth with acetate as a carbon source (Prisic et al., 
2010). However, as the phosphorylation site motif analysis for PknF showed that the 
phosphoacceptor is a threonine residue and furthermore because FHA domains are 
phospho-threonine binding molecules, then one may argue that Rv1747 phosphorylation 
on a serine residue suggests that the phosphoacceptor site is not important for interaction 
with FHA domains or for the transduction of the signal leading to activation or 
repression of the function of the ABC transporter. 
5.10.3.1.1 Regulation of Rv1747 by phosphorylation 
One hypothesis into a possible mechanism of action of the Rv1747 protein is as follows. 
Upon PknF autophosphorylation the enzyme is rendered active, the peptide binding 
pocket of an Rv1747 FHA domain may then bind to one of the activation loop 
threonines. Binding of the FHA domain would also deliver the substrate protein into the 
active site of the kinase enabling substrate phosphorylation. This possible mechanism is 
shown in figure 5.12 (Villarino et al., 2005). After substrate release, the FHA domain 
may then recognise and bind the pT epitope on Rv1747 causing a conformational change 
within the protein structure which would either confer it into an active or inactive 
conformation for the transport of the substrate across the M. tuberculosis cell membrane. 
As the T208 site is very close to the FHA-2 domain it would be impossible for the FHA-
2 domain to rotate in such a way that it could bind the pT at position T208. Therefore 
one hypothesis raised during this study was that perhaps T208 phosphorylation causes 
FHA-2 dimerisation. The Rv1747 transporter is translated as a half-transporter which is 
predicted to dimerise to form the functional transporter and is anchored in the cell 
membrane. The hypothesis is that the FHA-2 domain from one half of the protein could 
bind to the pT208 of the other half of the protein and vice versa. The conformational 
change induced by this dimerisation could affect the function of the transporter. This 
hypothesised mechanism of regulation will be further explored in the subsequent chapter 
of this study. Furthermore, this mechanism of regulation has been previously observed 
in the human Chk2 serine-threonine protein kinase which is involved in the DNA 
damage response (Li et al., 2008). Chk2 contains an N-terminal FHA domain and a C-
terminal kinase domain. Li and colleagues showed that when Chk2 is phosphorylated at  
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Figure 5.11 Phosphorylation site motif analysis for PknF. Figure adapted from Prisic 
et al 2010. At the 0 position is the pT phosphoacceptor site, residues above the midline 
were found to be overrepresented and those under the line were found to be 
underrepresented in their study.  The red line indicates the 0.01 significance level. The 
figure shows that T is the preferred phosphoacceptor residue and hydrophobic residues 
were selected for at the pT+3 and pT+5 positions. 
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Figure 5.12 Proposed mechanism for the interactions between PknF and Rv1747. 
Figure adapted from Villarino et al. 2005. In the absence of autophosphorylation the 
kinase domain is in an inactive state (figure 5.12a). Upon autophosphorylation of the 
activation loop the kinase becomes enzymatically active (figure 5.12b). The Rv1747 
FHA domains are then recruited to the kinase (figure 5.12c) where they bind an 
activation loop pT residue in their peptide binding pocket and then Rv1747 can be 
brought to the active site for phosphorylation on residues T150 and T208 (figure 5.12c). 
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position T68 the FHA domain of another molecule of Chk2 binds to the residue forming 
a tight dimer (Li et al., 2008). 
5.10.3.1.2 Mutation of Rv1747 residues T150 and T208  
Mutation of both the Rv1747 T150 and T208 residues to alanines, rendering them 
incapable of receiving a donor phosphate group, dramatically reduced the level of 
Rv1747 phosphorylation observed in the in vitro phosphorylation assays (figure 5.8). 
This result demonstrated that the two residues identified are both important for 
PknF phosphorylation of Rv1747. Due to the fact that there was still a faint radio-
labelled band in the double threonine to alanine mutant it cannot be ruled out that there 
is another threonine residue in Rv1747 that can also be phosphorylated (figure 5.8b lane 
5). To investigate this LC-MS/MS could be repeated. In addition, when looking at the 
amount of radio-labelled ATP incorporated into both the Rv1747 single threonine 
mutant proteins it is clear that the T150A mutant incorporated less ATP compared with 
the T208A mutant, perhaps suggesting that the T150 site is more important in terms of 
protein phosphorylation and therefore protein function. Consequently, the results 
suggested that the T150 site is phosphorylated to a greater proportion compared to the 
T208 site although in the T208A mutant a reduction in incorporation of ATP can also be 
observed, but not to as great an extent as in the T150A mutant. 
Interestingly, throughout all the in vitro phosphorylation assays with Rv1747 addition of 
various versions of Rv1747 to PknF resulted in a reduction or loss of the radio labelled 
PknF band (figures 5.5, 5.8 and 5.9). A similar occurrence was also noted in the Rv1827 
experiments (figure 5.10). This loss of kinase activity is presumably through binding of 
an FHA domain to a pT residue in the kinase activation loop. At this stage one has to 
remember that after purification from E. coli PknF is already phosphorylated multiple 
times (figure 5.3c). Addition of radio labelled ATP only results in incorporation of radio 
labelled phosphate groups onto the residual threonine sites not already phosphorylated. 
In the case of PknF autophosphorylation, the incorporation of a radio labelled phosphate 
group could be in the activation loop or indeed on any other threonine residue on the 
protein which is accessible. Therefore the radio labelled kinase band may not be a result 
of incorporation of radio labelled phosphate groups into the activation loop. Furthermore 
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this means that FHA domain binding to an activation loop pT residue could occur in the 
absence of any incorporation of radio labelled phosphate groups. It is clear from these 
investigations that somehow binding of an FHA domain onto the PknF activation loop 
blocks further autophosphorylation activity of the kinase.  
When the reactants are combined: PknF + Rv1747 + [γ-
32
P]ATP an FHA domain would 
be able to bind to the activation loop of PknF immediately if a threonine in this loop was 
already phosphorylated (during purification PknF can use ATP generated by E. coli to 
autophosphorylate itself). A phosphate group from the addition of radio labelled ATP 
could then be used to phosphorylate the substrate protein. This could explain why we see 
a reduction or loss of kinase activity upon addition of substrate proteins. 
Alternatively, perhaps when one of the FHA domains docks to a pT residue in the 
activation loop of PknF it does not dissociate until the substrate is phosphorylated in the 
active site. If the active site of the enzyme does not or can not phosphorylate a threonine 
residue at positions T150 or T208 of Rv1747, then in a sense the mutated Rv1747 
protein may act as an inhibitor of kinase activity as the FHA domain would remain 
bound to the pT residue in the activation loop and therefore the radio-labelled kinase 
band on the autoradiogram could become diminished. 
The hypothesised explanations discussed above may also offer an explanation for the 
results obtained when it was investigated whether two other STPKs could phosphorylate 
Rv1747. Results showed that when PknG and Rv1747 (figure 5.9b lane 4) or PknB and 
Rv1747
 
(figure 5.9c lane 2) were incubated together an inhibition of kinase activity was 
observed. Rv1747 was shown not to be a substrate for PknG and to be a very poor 
substrate for PknB. In this instance the threonine sites were not mutated but Rv1747 was 
not a substrate for these two kinases. Therefore one could hypothesise that an FHA 
domain could dock to a pT residue in the kinases activation loop and although the 
enzymes could not then phosphorylate Rv1747, the action of the FHA domain binding to 
the activation loop could have resulted in a reduction or loss of kinase activity.  
Interestingly, a study by Prisic et al. found that PknG and PknK had a distinctly different 
phosphorylation consensus motif compared with PknF, PknA, PknB, PknD, PknE and 
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PknH perhaps offering an explanation as to why PknG could not phosphorylate Rv1747 
at all in vitro (Prisic et al., 2010). Furthermore the soluble proteins PknG and PknK 
contain different kinase domains compared with the other STPKs (Narayan et al., 2007) 
suggesting why they would probably have different preferred phosphorylation motifs 
compared with the transmembrane bound kinases.  
This study only assessed the ability of PknF, PknB and PknG to phosphorylate Rv1747; 
there are eight other STPKs in the M. tuberculosis genome that could also phosphorylate 
Rv1747 not only in vitro but also in vivo. For example, pknE is situated in relatively 
close proximity upstream of Rv1747 in the genome so perhaps this kinase could play a 
role in controlling Rv1747 function; furthermore, the PknE preferred phosphorylation 
consensus motif is highly similar to that of PknF (Prisic et al., 2010). In addition, a 
publication in 2005 demonstrated that PknE, PknD, PknB and PknF could all 
phosphorylate one or both Rv1747 FHA domain-containing constructs (Grundner et al., 
2005). PknE was shown to only phosphorylate the FHA-1 domain-containing construct 
and coupled with its close genomic localisation to Rv1747 it therefore warrants future 
work investigating the possible role this kinase plays in controlling Rv1747 function. 
PknE may phosphorylate Rv1747 on different threonine residues compared with PknF as 
was demonstrated for Rv1827 with PknB and PknG (O'Hare et al., 2008).  
5.10.4 Rv1827 in vitro phosphorylation assays 
To confirm that recombinant PknG and PknB were functional kinases it was assessed 
whether they could phosphorylate Rv1827. The results showed that Rv1827
1-162 
can 
indeed be phosphorylated in vitro by PknG, PknB and PknF demonstrating that the 
reason PknB and PknG did not phosphorylate Rv1747 was not because the kinases were 
non-functional but was because Rv1747 was not a substrate for these kinases. 
Furthermore, the results demonstrated that FHA domain-containing proteins can be 
phosphorylated by more than one serine-threonine protein kinase in vitro. These data 
corroborate previous data showing that Rv1827 can be used as an in vitro substrate by 
PknF, PknD and PknE (Villarino et al., 2005).  
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Moreover, it is clear from the results of this study that PknB is the preferred kinase for 
Rv1827 as the incorporated radio labelled signal is much greater when Rv1827 is 
phosphorylated with PknB compared to PknG. PknB and PknG phosphorylate Rv1827 
on two distinct threonine residues. The importance of PknB phosphorylation on Rv1827 
function was described in a publication by Nott et al. where they demonstrated that 
phosphorylation of a threonine residue by PknB at the N terminus of Rv1827 caused an 
intramolecular association with the Rv1827 FHA domain, blocking the association of 
this domain with its three binding partners which are all key metabolic enzymes 
involved in the α-ketoglutarate metabolism in the TCA cycle (Nott et al., 2009). 
However, a proteomics based study only conclusively identified T21 (the residue 
phosphorylated by PknG) as a phosphoacceptor site in Rv1827 (Prisic et al., 2010).  
5.10.5 In vitro phosphorylation assays 
The use of in vitro phosphorylation assays to study protein-protein interactions is a 
widely accepted method which has helped many scientists derive the function of specific 
proteins. However, it must be taken into consideration that all the assays in this study 
were performed in vitro and an in vitro substrate does not confirm an in vivo 
physiological substrate. In more general terms, inside the M. tuberculosis cell there are 
both temporal and spatial separations of protein expression; proteins can be expressed at 
different times throughout replication or throughout the course of infection and they can 
also be expressed at different places in the cell, both cases meaning that two proteins 
might never actually come into contact with one another. This is exemplified by the 
result from this study which showed that PknF could phosphorylate Rv1827 in vitro 
(figure 5.10). In the M. tuberculosis cell Rv1827 is involved in α-ketoglutarate 
metabolism in the TCA cycle; it therefore seems extremely unlikely that PknF would 
also have an involvement in the regulation of this protein therefore suggesting that 
Rv1827 is not a physiological in vivo substrate for PknF. This is the reason why one 
must be very careful when performing in vitro assays and it must be ensured that 
findings are always followed up with in vivo experiments. 
In this present study the Rv1747 threonine mutants have been analysed in both in vitro 
and in vivo experiments. Thus in the next chapter murine bone marrow derived 
Chapter 5. How is PknF controlling Rv1747 function? Part 1 
 194 
macrophage infection and murine aerosol infection experiments have been performed to 
deduce the effect of Rv1747 phosphorylation within the M. tuberculosis cell by using 
phenotype as readout of protein function due to the fact that the Rv1747 deletion strain is 
attenuated for growth in these models. 
5.10.6 Summary 
In this chapter it has been shown that PknF does indeed play a role in a signal 
transduction system with Rv1747 and using mass spectrometry two phosphorylated 
threonine residues on the ABC transporter have been identified which were shown 
to be critical for the phosphorylation of Rv1747 by PknF. Furthermore, this data also 
gives credence to the hypothesis that PknF controls Rv1747 function by phosphorylation 
thus warranting further investigation in the final chapter of the study where the 
significance of the phosphorylated threonine sites will be determined by both in vitro 
and in vivo experiments. In addition, the importance of the FHA domains will be 
characterised and the question as to whether phosphorylation by PknF positively or 
negatively regulates the activity of the Rv1747 ABC transporter will be explored.  
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CHAPTER 6. HOW IS PknF CONTROLLING Rv1747 
FUNCTION? PART 2 
FURTHER CHARACTERISATION OF THE pknF-Rv1747 
SIGNALLING SYSTEM AND ANALYSIS OF THE 
IMPORTANCE OF BOTH GENES FOR THE VIRULENCE 
OF M. tuberculosis  
6.1 Introduction 
Upon inhalation of M. tuberculosis bacilli, the bacteria enter the respiratory tract of the 
host and are phagocytosed by alveolar macrophages lining the lungs. M. tuberculosis has 
the ability to evade the host’s defence mechanisms by inhibiting phagosome-lysosome 
fusion allowing survival and replication within the macrophages until the infection 
usually becomes contained within a granulomatous lesion. Macrophages derived from 
the bone marrow of mice (BMDMs) are used in many areas of M. tuberculosis research 
which include investigating the effects of M. tuberculosis gene disruption. M. 
tuberculosis typically grows and replicates inside BMDMs, just like in human alveolar 
macrophages, and they are therefore used as a model for experiments assessing the 
growth and survival of different M. tuberculosis strains. In this study the growth and 
survival of the ∆Rv1747, ∆pknF and various versions of the Rv1747 complemented 
strains containing point mutations in key domains or in phosphorylation sites were 
assessed.  
Previous investigations in this study (Chapter 5) had determined that PknF does indeed 
play a role in a signal transduction system with Rv1747 and using mass spectrometry 
two phosphorylated threonine residues on the ABC transporter were identified which 
were shown to be critical for the phosphorylation of Rv1747 by PknF. These findings 
gave further credence to the hypothesis that PknF controls Rv1747 function by 
phosphorylation. The aim of this final chapter was to determine the significance of the 
phosphorylated threonine sites, to characterise the importance of the FHA domains in 
terms of protein regulation, to investigate whether phosphorylation by PknF positively 
or negatively regulates the activity of the Rv1747 ABC transporter and to propose a 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 196 
model of how PknF controls Rv1747 based on the data generated in this study as a 
whole. 
6.2 Assessment of the Rv1747 null mutant in a murine macrophage infection 
model  
The first aim of this study was to determine whether the Rv1747 gene plays a role in the 
virulence of M. tuberculosis. The hypothesis was that the Rv1747 deletion strain would 
be attenuated for growth in both naïve and IFNγ activated macrophages; a previous 
investigation in 2005 had discovered that the ∆Rv1747 strain was attenuated for growth 
in naïve macrophages, dendritic cells and in the lungs and spleens of mice (Curry et al., 
2005). To further explore this hypothesis, the growth of wild type H37Rv, ∆Rv1747 and 
Rv1747 complement strains were assessed in naïve and IFNγ activated murine bone 
marrow derived macrophages (BMDMs) over an infection time course of 168 hours. 
Macrophages were derived from six to eight week old female BALB/c mice as described 
in section 2.4.12.1, activated as required with 10 ng/ml IFNγ and infection with M. 
tuberculosis strains was performed as outlined in section 2.4.12.2. At 6, 24, 72, 120 and 
168 hours post infection macrophages were lysed and M. tuberculosis surviving within 
the macrophages were enumerated. Growth of M. tuberculosis colonies on 7H11 agar 
plates was monitored for at least four weeks to ensure that all colonies were counted and 
to correct for any differences in the time colonies took to grow between the strains.  
To confirm that treatment with IFNγ activated the BMDMs a Greiss nitrite assay was 
performed. Nitrite (NO2
-
) is a stable breakdown product of nitric oxide and thus can be 
used as an indicator of macrophage activation using the Greiss assay. Naïve and 
activated BMDMs were infected with wild type H37Rv, ∆Rv1747 and Rv1747 
complementing strains and the concentration of NO/nitrite present in the supernatants of 
the infected BMDMs was assessed over 120 hours of infection as described in section 
2.4.12.3. Naïve BMDMs produced virtually no measurable concentration of NO/nitrite 
over the course of the experiment when infected with either of the three M. tuberculosis 
strains (figure 6.1). However, BMDMs pre-stimulated with IFNγ prior to infection and 
then replaced with media containing IFNγ after removal of the extracellular M. 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 197 
tuberculosis following six hours of infection did indeed produce NO/nitrite showing that 
the activation procedure had been successful (figure 6.1). Results also demonstrated that 
there were no differences observed in the levels of NO/nitrite produced when infected 
with the three different M. tuberculosis strains. Sodium nitrite concentrations ranged 
from an average of 1.9 µM at 6 hours to 29.5 µM at 120 hours post infection in IFNγ 
stimulated cells. The results presented verified that BMDMs are indeed activated when 
pre-incubated with IFNγ for 18 hours prior to infection with M. tuberculosis and 
maintain an increasing concentration of NO/nitrite throughout the course of infection.   
Results from a BMDM infection experiment in both naïve (figure 6.2a) and IFNγ 
activated cells (figure 6.2b) showed that in naïve cells the bacterial load of the wild type 
and Rv1747 complement strains of M. tuberculosis continued to increase throughout the 
experiment. However, in the Rv1747 deletion strain, although a similar number of bacilli 
were phagocytosed by the macrophages as indicated by the data at the 6 hour uptake 
time point, this strain replicated significantly slower and by 168 hours post infection the 
bacterial load of this strain was approximately 10 fold lower compared to that of the 
wild type and complementing strains. This growth attenuation was shown to be 
statistically significant at 168 hours post infection (p<0.01). 
The higher NO/nitrite concentration within the activated BMDMs were seen to limit the 
M. tuberculosis replication at later time points (figure 6.2b). However, the wild type and 
Rv1747 complementing strains again demonstrated a similar pattern of growth to one 
another whilst the ∆Rv1747 strain appeared to grow very little and the bacterial load of 
this strain actually decreased between 120 and 168 hours post infection. This growth 
attenuation was shown to be statistically significant at 120 (p<0.01) and 168 (p<0.001) 
hours post infection. 
Taken together, the results obtained confirm that an Rv1747 deletion strain is attenuated 
for growth and supports the hypothesis that Rv1747 is important for the growth and 
replication of M. tuberculosis in BMDMs. These results corroborate an earlier study 
where the Rv1747 deletion strain was shown to be attenuated for growth in both 
BMDMs and mice (Curry et al., 2005). 
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Figure 6.1 Greiss nitrite assay after infection of BMDMs with wild type H37Rv, 
∆Rv1747 and Rv1747 complement M. tuberculosis strains. The concentration of 
NO/nitrite present in the supernatants of infected BMDMs was assayed over 120 hours 
as described in section 2.4.12.3. The concentration of NO/nitrite was calculated from 
naïve and IFNγ activated BMDMs infected with wild type H37Rv, ∆Rv1747 and Rv1747 
complement M. tuberculosis strains. Data plotted are the mean + S.D of three technical 
replicates assayed in duplicate. There is a significant difference between the 
concentration of sodium nitrite in naïve and IFNγ activated cells from 24 hours onwards.  
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Figure 6.2 Bone marrow derived macrophage infection with wild type H37Rv, 
∆Rv1747 and Rv1747 complement M. tuberculosis strains. Infection of BMDMs with 
M. tuberculosis strains was performed with an MOI of 0.5:1 (M.tb:macrophage) as 
outlined in section 2.4.12.2. Results show the growth of wild type (blue), ∆Rv1747 (red) 
and Rv1747 complement (green) strains over 168 hours. Figure a shows the growth of 
M. tuberculosis strains in naïve macrophages and figure b shows the growth of M. 
tuberculosis strains in IFNγ activated cells. Error bars indicate the mean +S.D of three 
technical replicates. Data show that the ∆Rv1747 strain is attenuated for growth in both 
naïve and IFNγ activated macrophages. p-values are derived from an unpaired Students 
t-test between the wild type and ∆Rv1747 strains. 
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6.3 Assessment of the growth of the Rv1747 phosphorylation-mimic and 
phosphorylation-null mutants in macrophage and murine infection models 
Previous investigations in this study had identified two threonine residues on Rv1747 
that were phosphorylated by PknF (figure 5.6); furthermore both these pT sites were 
demonstrated to be important for the in vitro phosphorylation of Rv1747 by PknF (figure 
5.8). The working hypothesis was that PknF controls the function of the ABC transporter 
in a phosphorylation dependent manner. It was therefore hypothesised that both the 
identified phospho-threonine sites on Rv1747 may be important for Rv1747 transporter 
function. In view of the fact that the M. tuberculosis ∆Rv1747 strain was shown to be 
attenuated for growth in both naïve and IFNγ activated BMDMs (figure 6.2) this same 
macrophage infection model was employed to assess whether the two identified pT sites 
were important for Rv1747 function using phenotype as a readout of protein function. 
The aim was to mutate the T150 and T208 residues within the Rv1747 complementing 
plasmid and then transform these plasmids into the ∆Rv1747 strain and assess each 
strain for its ability to complement the growth phenotype observed in the ∆Rv1747 
mutant strain in BMDMs. 
6.3.1 Construction of the panel of threonine mutations 
As it was not known whether phosphorylation of Rv1747 by PknF positively or 
negatively regulated the activity of the ABC transporter two types of threonine 
mutations were created in the Rv1747 complementing plasmid. The first mutation 
altered the threonine residues to alanine residues rendering each site incapable of 
phosphorylation (phospho-null); the second mutation changed the threonine residues to 
aspartic acid. Aspartic acid is an amino acid whose structure mimics the structure of a 
phosphorylated threonine (pT) residue and therefore these mutants should act as 
constitutive phosphorylation mimics (phospho-mimic). Site directed mutagenesis was 
performed as described in section 2.2.3 and a list of primers can be found in appendix II. 
Six mutations were made in all, namely T150A, T208A, T150A/T208A, T150D, T208D 
and T150D/T208D. The panel of Rv1747 complementing plasmids were each 
transformed into the ∆Rv1747 strain and the BMDM infection experiments were then 
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performed to assess each strains’ ability to complement the growth phenotype observed 
in the mutant strain. It was hypothesised that if phosphorylation by PknF inhibited the 
transporter activity of Rv1747 then we may see an attenuation of growth in the Rv1747 
T150D/T208D complemented strain whereas if phosphorylation activated the transporter 
activity of Rv1747 then it was hypothesised that a growth phenotype might be observed 
in the Rv1747 T150A/T208A complementing strain.  
6.3.2 Assessment of the growth of the Rv1747 phosphorylation-mimic and 
phosphorylation-null double mutants in a macrophage infection model 
The growth of the Rv1747 complement T150A/T208A and Rv1747 complement 
T150D/T208D strains were assessed in a BMDM infection experiment. It was 
hypothesised that if one of the mutations rendered Rv1747 non-functional then the 
∆Rv1747 growth phenotype would be also observed with this strain. Figure 6.3 shows 
the results from a BMDM infection experiment in both naïve (figure 6.3a) and IFNγ 
activated cells (figure 6.3b). Figure 6.3 shows under both conditions the ∆Rv1747 strain 
is attenuated for growth compared with the wild type and Rv1747 complement strains. In 
the naïve BMDM infection the growth of the Rv1747 complement T150A/T208A and 
the Rv1747 complement T150D/T208D strains were significantly different from the wild 
type strain at 120 and 168 hours post infection (p<0.05). In the IFNγ activated 
macrophages both the Rv1747 complement T150A/T208A and the Rv1747 complement 
T150D/T208D strains had an intermediate growth phenotype between that of the wild 
type and the ∆Rv1747 strains, the growth difference were shown to be statistically 
significant from the wild type strain at 168 hours post infection (p<0.05).  
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Figure 6.3 Bone marrow derived macrophage infection with wild type H37Rv, 
∆Rv1747, Rv1747 complement, Rv1747 complement T150A/T208A and Rv1747 
complement T150D/T208D M. tuberculosis strains. Results show the growth of the 
five strains over 168 hours. Figure a shows the growth of M. tuberculosis strains in naïve 
macrophages and figure b shows the growth of M. tuberculosis strains in IFNγ activated 
cells. Data show a representative experiment from two biological replicates performed 
technical triplicate. Error bars indicate the mean +S.D of three technical replicates. Data 
show that the ∆Rv1747 strain is attenuated for growth in both naïve and activated 
macrophages. p-values are derived from unpaired Students t-tests between the wild type 
and ∆Rv1747, Rv1747 complement T150A/T208A, or Rv1747 complement 
T150D/T208D strains. 
 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 203 
6.3.3 Assessment of the growth of the Rv1747 phospho-mimic and phospho-null 
double mutants in a murine aerosol infection model 
The next aim of this study was to determine whether the Rv1747 complement 
T150A/T208A and Rv1747 complement T150D/T208D strains had a growth phenotype 
in a murine aerosol model of infection. M. tuberculosis strains were prepared for 
infection into female BALB/c mice as described in section 2.4.13. M. tuberculosis 
aerosol infections were performed by Angela Rodgers and Barry Walker at the National 
Institute for Biological Standards and Control. Results are shown in figure 6.4. Each 
time point consisted of five mice and the viable M. tuberculosis colonies were 
enumerated from both the lungs and spleens. Data from the lungs shows that the 
∆Rv1747 strain is attenuated for growth compared with the wild type strain (figure 6.4a). 
The Rv1747 full complement strain grew similarly to the wild type up until day 90 when 
the growth of this strain and the two mutated complement strains decreased in CFU 
(figure 6.4a). 
Interestingly, at day 30, mice infected with the ∆Rv1747 and Rv1747 complement 
T150A/T208A strains had no M. tuberculosis bacilli present in the spleens (figure 6.4b). 
Furthermore, at day 60 only three of the five animals infected with the ∆Rv1747 strain 
had bacilli in the spleens suggesting that both this mutant and the Rv1747 complement 
T150A/T208A strain are defective for growth in the spleens. Furthermore, the Rv1747 
complement T150D/T208D strain also did not grow as well as the Rv1747 complement 
in the spleens. Overall, in the spleens the Rv1747 complementing strain had an 
intermediate growth phenotype between that of the ∆Rv1747 and wild type strains. 
6.3.4 Assessment of the growth of the Rv1747 phospho-mimic and phospho-null 
single mutants in a murine macrophage infection model 
It was assessed whether any of the single threonine to alanine or threonine to aspartic 
acid mutant constructs had a growth phenotype in BMDM infection experiments. 
Experiments were performed to determine whether either one of the identified pT 
residues were particularly important for the regulation of the function of the ABC 
transporter. Indeed, from the in vitro phosphorylation assays it was concluded that the 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 204 
T150 site was probably more important than the T208 site due to the level of 
phosphorylation loss observed when the T150A mutation was introduced into the 
Rv1747 protein expression construct (figure 5.8). It was hypothesised that if one residue 
was particularly important then a growth phenotype may be observed in that mutant in 
BMDMs if it affected Rv1747 protein function.  
The growth of the wild type, ∆Rv1747, Rv1747 complement, Rv1747 complement 
T150A, Rv1747 complement T150D, Rv1747 complement T208A and Rv1747 
complement T208D M. tuberculosis strains in naïve BMDMs was assessed (figure 6.5). 
As previously observed, results showed that the ∆Rv1747 strain is attenuated for growth 
compared with the wild type and Rv1747 complement strains at 120 and 168 hours post 
infection. The Rv1747 complement T150A and Rv1747 complement T208A strains 
followed a very similar growth pattern to that of the wild type and Rv1747 complement 
strains throughout the time course of infection. There were no significant differences 
between the bacterial loads of the single mutant strains and the wild type strain apart 
from in Rv1747 complement T150D strain at 120 hours post infection. At 168 hours post 
infection there was no longer a statistically significant difference between the growth of 
this strain and the wild type strain. At 120 hours post infection the Rv1747 complement 
T208D strain had a calculated bacterial load which was in between that of the wild type 
and Rv1747 deletion strain although this was not deemed to be a significant difference. 
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Figure 6.4 Murine aerosol infection experiment with wild type H37Rv, ∆Rv1747, Rv1747 
complement, Rv1747 complement T150A/T208A and Rv1747 complement T150D/T208D 
M. tuberculosis strains. M. tuberculosis strains were prepared for infection into female 
BALB/c mice as described in section 2.4.13. The results for each time point are the means of the 
CFU determinations performed on organs from five mice and the error bars show the standard 
error of the means. The growth of the ∆Rv1747 strain is significantly different compared with 
the wild type in the lungs and spleens at 30, 60 and 90 days post infection (p<0.05). The growth 
of the Rv1747 complement T150A/T208A and Rv1747 complement T150D/T208D strains are 
significantly different compared with the wild type in the spleens at 30, 60 and 90 days post 
infection and in the lungs at  30 and 90 days post infection (p<0.05).  
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Figure 6.5 Bone marrow derived macrophage infection with wild type H37Rv, 
∆Rv1747, Rv1747 complement, Rv1747 complement T150A, Rv1747 complement 
T150D, Rv1747 complement T208A and Rv1747 complement T208D M. tuberculosis 
strains. Results show the growth of wild type, ∆Rv1747, Rv1747 complement and the 
four single mutant strains in naïve BMDMs over 168 hours. Data show a representative 
experiment from two biological replicates performed technical triplicate. Error bars 
indicate the mean +S.D of three technical replicates. Data show that the ∆Rv1747 strain 
is attenuated for growth in naïve macrophages. p-values are derived from unpaired 
Students t-tests between the wild type and ∆Rv1747 or Rv1747 complement T150D 
strains. 
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6.4 Analysis of cytokine profiles  
One hypothesis raised in this study was that perhaps the reason why the ∆Rv1747 strain 
demonstrated a growth attenuation phenotype in BMDMs was because infection with 
this strain induces a different cytokine response from the BMDMs which leads to 
inhibition of growth or increased killing of the ∆Rv1747 strain. A study examining the 
effects of the deletion of the pknE gene found that infection of THP-1 macrophages with 
this mutant caused the THP-1 cells to secrete significantly lower levels of the pro-
inflammatory cytokines TNFα and IL6 in the culture supernatants compared to the wild 
type and complementing strains (Jayakumar et al., 2008). It was therefore of interest to 
examine the cytokines secreted by BMDMs after infection with wild type H37Rv, 
∆Rv1747 and Rv1747 complementing strains. The secretion of three cytokines were 
examined throughout the course of infection; IL12-p40, TNFα and IL6. Each figure 
represents the results of one biological replicate performed in technical triplicate. 
Figure 6.6 shows the results of IL12-p40 secretion after infection with all three strains at 
a multiplicity of infection (MOI) of 0.5:1 (M.tb:macrophage) (figure 6.6a) and 5:1 
(figure 6.6b). An MOI of 0.5:1 was used for all BMDM infection experiments where the 
growth of M. tuberculosis was enumerated. As expected, infection with a higher MOI 
and a greater number of macrophages seeded per well resulted in a greater secretion of 
IL12-p40 and furthermore in both figures at each individual time point the amount of 
secreted cytokine produced by naïve cells was always significantly lower that that of the 
IFNγ activated cells. Figures 6.6a and 6.6b show that at both MOIs there were no 
differences observed in the levels of secreted cytokine produced by infection with the 
three M. tuberculosis strains.  
Figure 6.7 shows the results of TNFα secretion; again, as predicted, infection with a 
higher MOI resulted in a higher concentration of TNFα to be secreted by the 
macrophages and furthermore in figure 6.7b at each individual time point the amount of 
secreted cytokine produced by naïve cells was always lower that that produced by the 
IFNγ activated cells. Figure 6.7b shows there were no significant differences in the 
concentrations of secreted TNFα produced between the wild type, ∆Rv1747 and Rv1747  
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Figure 6.6 IL12-p40 production by BMDMs infected with wild type, ∆Rv1747 and 
Rv1747 complement M. tuberculosis strains. Naïve and IFNγ activated BMDMs were 
infected with wild type H37Rv, ∆Rv1747 and Rv1747 complement strains. At 6, 24, 72 
(and 120 hours in figure 6.6a) hours post infection culture supernatants were prepared 
for ELISAs as described in section 2.4.14. Figure 6.6a shows the data generated from an 
M. tuberculosis infection with an MOI of 0.5:1 (M. tb:macrophage) with 2x10
5
 
macrophages seeded per well. Figure 6.6b shows the data generated from an M. 
tuberculosis infection with an MOI of 5:1 (M. tb:macrophage) with 5x10
5
 macrophages 
seeded per well. Data plotted are the mean + S.D of three technical replicates. Data show 
there is significantly more IL12-p40 produced by the IFNγ activated BMDMs compared 
with the naïve cells.  
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Figure 6.7 TNFα production by BMDMs infected with wild type, ∆Rv1747 and 
Rv1747 complement M. tuberculosis strains. Naïve and IFNγ activated BMDMs were 
infected with wild type H37Rv, ∆Rv1747 and Rv1747 complement strains. Figure 6.7a 
shows the data generated from an M. tuberculosis infection with an MOI of 0.5:1 (M. 
tb:macrophage) with 2x10
5
 macrophages seeded per well. Figure 6.6b shows the data 
generated from an M. tuberculosis infection with an MOI of 5:1 (M. tb:macrophage) 
with 5x10
5
 macrophages seeded per well. Data plotted are the mean + S.D of three 
technical replicates. In all results there is significantly more TNFα produced by the IFNγ 
activated BMDMs compared with the naïve cells. 
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Figure 6.8 IL6 production by BMDMs infected with wild type, ∆Rv1747 and 
Rv1747 complement M. tuberculosis strains. Naïve and IFNγ activated BMDMs were 
infected with wild type H37Rv, ∆Rv1747 and Rv1747 complement strains. At 6, 24 and 
72 hours post infection culture supernatants were prepared for ELISAs as described in 
section 2.4.14. Figure 6.8 shows the data generated from an M. tuberculosis infection 
with an MOI of 0.5:1 (M. tb:macrophage) with 2x10
5
 macrophages seeded per well. 
Data plotted are the mean + S.D of three technical replicates. 
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complement strains. However, interestingly when the MOI was 0.5:1 at the 6 hour time 
point in IFNγ activated macrophages infected with the wild type strain the cells secreted 
19 pg/ml of TNFα whereas macrophages infected with the mutant and complement 
strains produced levels below that of the negative control well (figure 6.7a). 
Furthermore, at 96 hours post infection the IFNγ activated cells secreted more TNFα 
when infected with the wild type and ∆Rv1747 strains (101 pg/ml and 107 pg/ml 
respectively) compared to the Rv1747 complementing strain which secreted an average 
of 37 pg/ml (figure 6.7a).  
Figure 6.8 shows the results of IL6 secretion into the culture supernatants. Results show 
that at all time points in both naïve and IFNγ activated macrophages there were no 
significant differences in the levels of IL6 secreted between the wild type and ∆Rv1747 
strains. However, at 6 and 72 hours post infection in the IFNγ activated cells lower 
levels of IL6 production were calculated from the macrophages infected with the 
Rv1747 complement strain compared to the wild type and deletion strains. 
6.5 Assessment of the growth of the ∆pknF and pknF complement strains in 
a macrophage model of infection model 
It was not known whether the pknF gene played a role in the growth of M. tuberculosis 
in vivo. This study to date had not discovered any observable phenotype in the ∆pknF 
null strain. Therefore the growth of the wild type, ∆pknF and pknF complement strains 
were assessed in the macrophage model of infection. Furthermore it was hypothesised 
that by examining the growth of this mutant in BMDMs it may also provide a further 
indication as to whether PknF positively or negatively regulates the activity of the 
Rv1747 ABC transporter. 
The results from a BMDM infection experiment in both naïve (figure 6.9a) and IFNγ 
activated cells (figure 6.9b) showed that in naïve BMDMS there was no growth 
phenotype of the ∆pknF null or complement strains up until 168 hours post infection 
when a significant difference was observed in the bacterial load of the mutant and 
complement strains compared with the wild type strain; the ∆pknF and complement 
strains had a significantly lower bacterial load at this time point compared with the wild 
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type strain. Similarly, in IFNγ activated BMDMs the growth of all three strains was 
comparable up until 168 hours post infection where the ∆pknF strain had a significantly 
lower bacterial load compared with the wild type (the pknF complementing strain also 
had a lower bacterial load compared with the wild type but this was not found to be 
significant) (figure 6.9b). 
Due to the differences in uptake of M. tuberculosis at six hours post infection the results 
were then normalised to the initial six hour uptake values of each strain (figure 6.10). 
Normalised values showed that the pknF complement had a similar growth pattern to the 
wild type strain; furthermore, the ∆pknF strain also followed a similar growth pattern to 
120 hours post infection and then became attenuated for growth between 120 and 168 
hours in naïve cells only (p<0.05). 
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Figure 6.9 Bone marrow derived macrophage infection with wild type H37Rv, 
∆pknF and pknF complement M. tuberculosis strains. Results show the growth of 
wild type (blue), ∆pknF (yellow) and pknF complement (pink) strains over 168 hours. 
Figure a shows the growth of M. tuberculosis strains in naïve macrophages and figure b 
shows the growth of M. tuberculosis strains in IFNγ activated cells. Data shown is a 
representative experiment from two biological replicates performed in triplicate. Error 
bars indicate the mean +S.D of three technical replicates.  
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Figure 6.10 Bone marrow derived macrophage infection with wild type H37Rv, 
∆pknF and pknF complement M. tuberculosis strains normalised to the six hour 
uptake data. Results show the normalised growth of wild type (blue), ∆pknF (yellow) 
and pknF complement (pink) strains over 168 hours. Figure a shows the growth of M. 
tuberculosis strains in naïve macrophages and figure b shows the growth of M. 
tuberculosis strains in IFNγ activated cells. 
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6.6 Characterisation of the function of the Rv1747 FHA domains  
6.6.1 Assessment of the growth of the Rv1747 complement S47A (∆FHA-1) and 
Rv1747 complement S248A (∆FHA-2) strains in a murine macrophage infection 
model 
The effect of rendering each FHA domain non-functional on bacterial growth was 
assessed using the macrophage infection model. It was hypothesised that if the function 
of either of the phospho-threonine binding domains were critical for Rv1747 function 
then a growth phenotype may be observed in this strain in a macrophage infection 
model; this may then have provided a clue as to the importance of each domain and may 
have helped to create a model of how the pknF-Rv1747 signal transduction system is 
controlled. Site directed mutagenesis was used to create a serine to alanine mutation at 
position 47 of the FHA-1 domain and position 248 of the FHA-2 domain in the Rv1747 
complementing plasmid (R. Whalan, NIMR). The serine residue is essential for FHA 
domain binding to the pT epitopes so if either of the domains played an essential role in 
transduction of the signal to regulate the activity of the transporter then it was 
hypothesised that a phenotype may be observed in this mutant strain.  
The results from a BMDM infection experiment in both naïve (figure 6.11a) and IFNγ 
activated cells (figure 6.11b) showed that the Rv1747 complement S47A (FHA-1) strain 
was attenuated for growth compared with the wild type strain at 120 (IFNγ activated 
cells only) and 168 (naïve and IFNγ activated cells) hours post infection. However, the 
Rv1747 complement S248A (FHA-2) strain showed a similar growth pattern to the wild 
type strain in both naïve and IFNγ activated macrophages. These results suggested that 
the FHA-1 domain is important for Rv1747 in vivo function.  
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Figure 6.11 Bone marrow derived macrophage infection with wild type H37Rv, ∆Rv1747, 
Rv1747 complement S47A (∆FHA-1) and Rv1747 complement S248A (∆FHA-2) M. 
tuberculosis strains. Infection of BMDMs with M. tuberculosis strains was performed with an 
MOI of 0.5:1 (M.tb:macrophage) as outlined in section 2.4.12.2. Results show the growth of 
wild type (blue), Rv1747 complement S47A (∆FHA-1) (orange) and Rv1747 complement 
S248A (∆FHA-2) (purple) strains over 168 hours. Figure a shows the growth of M. tuberculosis 
strains in naïve macrophages and figure b shows the growth of M. tuberculosis strains in IFNγ 
activated cells. Data show a representative experiment from two biological replicates performed 
in triplicate. Error bars indicate the mean +S.D of three technical replicates. Data show that the 
Rv1747 complement S47A (∆FHA-1) strain is attenuated for growth in both naïve and activated 
macrophages. 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 217 
6.6.2 Expression and purification of FHA-1, FHA-2 and FHA-1 S47A domains of 
Rv1747 from E. coli 
The next aim of this study was to further elucidate the mechanism of how the FHA 
domains interacted with the pT peptides to regulate the activity of the Rv1747 ABC 
transporter. It was hypothesised that one of the FHA domains may be responsible for 
binding to one of the phospho-threonine epitopes and vice versa to regulate the control 
of the ABC transporter. If this hypothesis was correct then we may observe differences 
in the binding affinities between each FHA domain and the pT epitopes. The overall aim 
of this set of experiments was to further understand the function of the FHA domains by 
studying their interactions with the identified pT epitopes on Rv1747. 
As a necessary preliminary in order to determine the binding kinetics between the FHA 
domains and the Rv1747 phosphopeptides each FHA domain first had to be expressed 
and purified from E. coli as described in section 2.5.2. Three protein constructs were 
purified; FHA-1 domain residues 1-120, FHA-2 domain residues 202-310 and FHA-1 
S47A domain residues 1-120 (see figure 5.6 for a diagram highlighting the cloned 
residues). Site directed mutagenesis was performed to generate the S47A mutation 
within the FHA-1 domain construct. As previously mentioned FHA domains contain a 
conserved serine residue that is critical for binding to phosphopeptides hence this strain 
was generated to act as a control in the binding studies; an S47A mutation should render 
the FHA-1 domain incapable of binding the phosphopeptides. An SDS-PAGE gel shows 
each purified protein (figure 6.12).  
The two identified phosphorylation sites on Rv1747 were synthesised as 
phosphopeptides by W. Mawby (Bristol University) for use in the binding studies with 
the FHA domains. Each peptide contained an identical N-terminal sequence which 
contained a tyrosine residue to allow for an accurate concentration to be determined by 
spectrometry. The sequence of the pT150 peptide was K-K-Y-A-G-Q-Q-L-P-P-A-pT-T-
R-I-P-A-A and the sequence of the pT208 peptide was K-K-Y-A-G-T-E-A-G-N-L-A-
pT-S-M-M-K where pT is the phosphothreonine residue.  
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Figure 6.12 Expression and purification of FHA-1, FHA-2 and FHA-1 S47A 
domains of Rv1747 from E. coli. The three proteins were expressed and purified as 
described in section 2.5.2. After purification 10 µl of each pooled and concentrated 
protein sample were analysed by SDS-PAGE. Figure 6.12 shows the results of FHA-1 
(lane 1), FHA-2 (lane 2) and FHA-1 S47A purification (lane 3) All proteins were 
purified to homogeneity. FHA-1
1-120 
= 14 kDa, FHA-2
202-310 
 =  12 kDa.  
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6.6.3 Determination of the binding kinetics between the FHA-1 and FHA-2 domains 
with the Rv1747 pT150 and pT208 peptides 
To determine the binding kinetics between both the FHA domains and the pT150 and 
pT208 phosphopeptides, isothermal titration calorimetry (ITC) was performed as 
described in section 2.5.3.3. The aim of ITC was to calculate the dissociation constant 
(Kd) which measures how tightly a ligand binds to a particular protein. The Kd is defined 
as the concentration of ligand at which the binding site on a particular protein is half 
occupied, hence the smaller the dissociation constant, the more tightly bound the ligand. 
In the following experiments the aim was to calculate the Kd between each FHA domain 
and the pT peptides. 
An ITC trace consists of two panels; the upper panel plots the raw data for an 
experiment which consisted of a series of heat spikes plotted as the amount of power (in 
µcal/sec) needed to maintain the reference and sample cell at the same temperature with 
each spike representing one injection of ligand. The lower panel showed the total heat 
effect per injection by integrating the area of the peaks and plotting then against the 
molar ratio of protein and ligand. A curve was then fitted to the data and this generated 
the binding data. From the shape of the curve it was possible to determine the 
stochiometry and enthalpy of the reaction as well as the binding affinity, the inverse of 
which is the dissociation constant.  
The results of the analysis of binding of the FHA-1 domain to the Rv1747 pT150 (figure 
6.13a) and pT208 phosphopeptides (figure 6.13b) demonstrated that the Kd was 20 µM 
between FHA-1 and pT150 and 16 µM between FHA-1 and pT208. The results of the 
analysis of binding of the FHA-2 domain to the Rv1747 pT150 (figure 6.14a) and pT208 
phosphopeptides (figure 6.14b) calculated that the Kd was 16 µM between FHA-2 and 
pT150 and 18 µM between FHA-2 and pT208. 
The results of the analysis of binding of the FHA-1 S47A domain to the Rv1747 pT150 
(figure 6.15a) and pT208 phosphopeptides (figure 6.15b) confirmed that mutation of the 
critical serine residue within the FHA-1 domain responsible for binding to the pT 
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residue completely abolished binding to both the pT peptides. This result showed that 
the wild type FHA domains were indeed specifically binding to the pT peptides. 
6.6.4 Determination of the binding kinetics between the FHA-1 and FHA-2 domains 
with the Rv1827 pT22 peptides 
Both the Rv1747 FHA domains were assessed for their ability to bind an Rv1827 pT22 
phosphopeptide. This investigation was performed to establish whether there were any 
notable differences in the ability of the Rv1747 FHA domains to bind a non-Rv1747 
phosphopeptide compared with the Rv1747 peptides. The sequence of the synthesised 
Rv1827 pT22 peptide was E-V-T-V-E-T-pT-S-V-F-R-A-D-Y-K-K where pT is the 
phosphothreonine residue. The results of the analysis of binding of the FHA-1 (figure 
6.16a) and FHA-2 (figure 6.16b) domains to the Rv1827 pT22 phosphopeptide 
calculated that the Kd was 22 µM between FHA-1 and pT22 and 21 µM between FHA-2 
and pT22. The calculated dissociation constants were quite similar to those found in the 
experiments which determined the binding kinetics between the FHA domains and the 
Rv1747 phosphopeptides.  
6.6.5 Determination of the binding kinetics between the FHA-2 domain and the 
Rv0020c pT377 peptide 
It was then assessed whether the FHA-2 domain could bind a phosphothreonine epitope 
from Rv0020c which along with Rv1827 is also phosphorylated by PknB (O'Hare et al., 
2008; Villarino et al., 2005). The sequence of the synthesised Rv0020c pT377 peptide 
was A-D-T-pT-R-Y-T-E-S. The results of the binding of the FHA-2 domain to the 
Rv0020c pT277 peptide (figure 6.17) showed that the Kd was 9 µM between FHA-2 and 
Rv0020c pT377. Again, the calculated dissociation constant was quite similar to those 
calculated in the experiments which determined the binding kinetics between the FHA 
domains and the Rv1747 phosphopeptides.  
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 221 
 
Figure 6.13 Analysis of binding of Rv1747 FHA-1 domain to the Rv1747 pT150 and 
pT208 phosphopeptides. ITC was used to determine the binding kinetics between FHA 
domains and potential phosphopeptide substrates and was performed as described in 
section 2.5.3.3. Figure 6.13a shows the binding of the FHA-1 domain to the pT150 
phosphopeptide and figure b shows the binding of the FHA-1 domain to the pT208 
phosphopeptide. The Kd was calculated as 20 µM between FHA-1 and pT150 and 16 
µM between FHA-1 and pT208. 
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Figure 6.14 Analysis of binding of Rv1747 FHA-2 domain to the Rv1747 pT150 and 
pT208 phosphopeptides. Figure 6.14a shows the binding of the FHA-2 domain to the 
pT150 phosphopeptide and figure b shows the binding of the FHA-2 domain to the 
pT208 phosphopeptide. The Kd was calculated as 16 µM between FHA-2 and pT150 and 
18 µM between FHA-2 and pT208. 
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Figure 6.15 Analysis of the binding of the Rv1747 FHA-1 S47A domain to the 
Rv1747 pT150 and pT208 phosphopeptides. Figure 6.15a shows the binding of the 
FHA-1 S47A domain to the pT150 phosphopeptide and figure b shows the binding of 
the FHA-1 S47A domain to the pT208 phosphopeptide. Results show that FHA-1 S47A 
cannot bind the pT150 or pT208 peptides. Note the very small scale in the top panels of 
figures a and b; the heat spikes generated were due to the heat of dilution that occurs 
when two protein species are mixed, this occurrence is not associated with protein 
binding. 
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Figure 6.16 Analysis of binding of the Rv1747 FHA-1 and FHA-2 domains to the 
Rv1827 pT22 phosphopeptide. Figure 6.16a shows the binding of the FHA-1 domain 
to the Rv1827 pT22 phosphopeptide and figure b shows the binding of the FHA-2 
domain to the Rv1827 pT22 phosphopeptide. The Kd was calculated as 22 µM between 
FHA-1 and Rv1827 pT22 and 21 µM between FHA-2 and Rv1827 pT22. 
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Figure 6.17 Analysis of binding of the Rv1747 FHA-2 domain to the Rv0020c 
pT377 phosphopeptide. The figure shows the binding of the FHA-2 domain to 
Rv0020c pT377 phosphopeptide. The Kd was calculated as 9 µM between FHA-2 and 
Rv0020c pT377.  
 
 
 
 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 226 
6.7 Does the FHA-2 domain dimerise upon phosphorylation at T208? 
Due to the close proximity of the pT208 residue to the FHA-2 domain (figure 5.6) it 
would not be possible for the FHA-2 domain to rotate in such a way that the 
phosphothreonine binding domain could bind the pT208 residue in its peptide binding 
pocket. Therefore, a hypothesis was proposed that upon T208 phosphorylation the FHA-
2 domain on one half of the transporter may bind the T208 residue on the other half and 
vice versa in order to transduce the signal and regulate the activity of the Rv1747 
transporter as depicted in figure 6.18; this hypothesis is similar to what was shown for 
the Chk2 protein (Li et al., 2008). 
The next set of experiments performed in this study set out to determine whether FHA-
2
202-310
 became dimeric after phosphorylation at position T208 by PknF
1-292
. 
6.7.1 Determination of the phosphorylation of FHA-2 domain by PknF  
Prior to studies being carried out to determine whether FHA-2
202-310
 becomes dimeric 
upon PknF
1-292
 phosphorylation it first had to be assessed whether PknF
1-292 
could 
phosphorylate FHA-2
202-310
 in vitro. 
6.7.1.1 In vitro phosphorylation of Rv1747, FHA-1 and FHA-2 domain by PknF 
An in vitro phosphorylation assay showed that PknF
1-292 
was capable of phosphorylating 
the FHA-1
1-120
 domain (figure 6.19b, lane 3) and most importantly there was a large 
radioactive band corresponding to the phosphorylation of FHA-2
202-310 
domain by PknF 
(figure 6.19b, lane 4). These results showed that PknF could indeed phosphorylate the 
FHA-2 domain in vitro. PknF could also phosphorylate the FHA-1 domain construct but 
to a much lesser extent (figure 6.19b, lane 3). This is because within the FHA-2 
construct the pT208 site is present whereas within the FHA-1 construct no identified pT 
site was present (see figure 5.6 for diagram of cloned residues). However, the presence 
of a radioactive band corresponding to phosphorylated FHA-1 indicated that this protein 
domain could still be phosphorylated to some extent and there are several threonine 
residues within this construct on which phosphorylation could occur. 
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Figure 6.18 Schematic representation of how FHA-2
202-310
 could potentially engage 
in an intermolecular interaction after phosphorylation at residue T208. The 
schematic shows how upon Rv1747 phosphorylation by PknF at residue T208 FHA-2 
could potentially engage in an intermolecular interaction and become dimeric. N-
terminal phosphothreonine residues are represented by a yellow circle containing pT208. 
N and C represent the N- and C- termini of the protein.  
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 228 
 
Figure 6.19 In vitro phosphorylation of Rv1747, FHA-1 and FHA-2 by PknF. In vitro 
phosphorylation assays were performed with the proteins as outlined in section 2.5.3.1. The 
proteins were incubated with 200 µCi/ml [γ-32P] ATP then subjected to gel electrophoresis 
(Figure 6.19a) and radioactive bands were revealed by autoradiography (Figure 6.19b). 
Approximately 1 µg of protein was loaded into each lane. Figure 6.19b shows that PknF1-292 
is an active kinase capable of autophosphorylation (lane 1) which phosphorylates Rv17471-
559 (lane 2), FHA-11-120 (lane 3) and in particular FHA-2202-310 (lane 4). PknF1-292 = 32 kDa, 
Rv17471-559 = 58 kDa, FHA-11-120 = 14 kDa, FHA-2202-310= 12 kDa.  
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6.7.1.2 Use of electrospray mass spectrometry to determine the phosphorylation 
status of FHA2
202-310
 
A condition then had to be determined where the FHA-2 domain was phosphorylated by 
PknF in preparation for SEC-MALLS. The addition of one additional phosphate group 
was assessed using electrospray mass spectroscopy. PknF, FHA-2 and ATP were 
incubated together as described in section 2.5.3.4 before being assessed for the 
incorporation of one additional phosphate group on the FHA-2
202-310
 domain. The results 
of electrospray mass spectroscopy after four hours of incubation showed that almost all 
the FHA-2 domain construct contained one additional phosphate group (figure 6.20). No 
protein remained which was not phosphorylated and there was a very small amount of 
the overall protein which had gained two additional phosphate groups. It had to be 
assumed that the additional phosphate group was added on to residue T208 of the FHA-
2
202-310
 domain construct.  
Taken together, these results showed that PknF
1-292
 was indeed capable of 
phosphorylating FHA-2
202-310
 domain in vitro and by mass spectrometry it was 
demonstrated that a four hour incubation with ATP was sufficient to add one additional 
phosphate group to the protein construct. This protein, along with a non-phosphorylated 
FHA-2
202-310
 control was then assessed by SEC-MALLS to investigate whether 
phosphorylated FHA-2 was indeed dimeric. 
6.7.2 Use of SEC-MALLS to determine if the FHA-2 domain dimerises upon 
phosphorylation 
SEC-MALLS is a technique which combines size exclusion chromatography and light 
scattering to measure the absolute molecular mass and concentration of proteins of 
interest. This technique was employed to determine the conformation of the FHA-2
202-310
 
domain after phosphorylation by PknF
1-292
 and was performed as described in section 
2.5.3.4. 
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Figure 6.20 Electrospray mass spectrometry of FHA-2
202-310
 phosphorylated for 
four hours with PknF
1-292
.  Each peak labelled ‘+’ followed by a number represents the 
number of additional phosphate groups present on the FHA-2 construct. The net gain of 
a phosphate group results in an increase in mass of 80 Da. Data show that after four 
hours of phosphorylation with PknF non-phosphorylated FHA-2 could not be detected 
and all the FHA-2 protein contained one additional phosphate group. In addition, a very 
small proportion of the protein contained two additional phosphate groups. 
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Figure 6.21 shows the results of a SEC-MALLS experiment. The traces showing 
phosphorylated FHA-2
202-310
 (red traces in figure 6.21) were compared with those 
showing the non-phosphorylated FHA-2
202-310 
domain (blue traces in figure 6.21). The 
results show that PknF eluted between 28 and 31 minutes (figure 6.21b) with a 
confirmed molecular weight of approximately 32 kDa (the correct size for recombinant 
PknF
1-292
). The results also show that phosphorylated FHA-2 eluted from the column 
prior to non-phosphorylated FHA-2; there was a difference in elution times of 
approximately 1.75 minutes. The fact that the phosphorylated FHA-2 protein eluted 
before the non-phosphorylated version suggested that the phosphorylated version might 
be larger. 
However, it can be observed that PknF was still eluting from the column when the FHA-
2 proteins (especially the phosphorylated version) began to elute (figure 6.21b). 
Consequently it was not possible to determine a precise molecular weight of the 
phosphorylated version of FHA-2.  
Therefore an alternative strategy was sought; it was decided to express and purify GST-
PknF
1-292
 and phosphorylate the FHA-2 construct with this protein; the GST tag is 26 
kDa in size meaning that the kinase and the FHA-2 domain should then elute separately. 
What is more, GST is dimeric meaning that the GST-PknF construct would actually run 
as a ~116 kDa protein.  
On figure 6.21a the peak eluting between 10 and 20 minutes is when the void volume 
had run through the column and the first protein species eluted. This fraction may have 
included protein contaminants and any large complexes in the reactions; large 
complexes eluting after the void volume can also be seen in figures 6.23a and 6.24a. 
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Figure 6.21 SEC-MALLS of FHA-2 domain with and without phosphorylation by 
PknF. SEC-MALLS was performed as described in section 2.5.3.4. Figure 6.21a shows 
the entire size exclusion experiment and figure 6.21b focuses on the proteins which 
eluted between 27 and 37 minutes. The protein which eluted between 28 and 31 minutes 
in both the phosphorylated and non-phosphorylated experiment was PknF with a 
confirmed molecular weight of approximately 32 kDa. Figure 6.21b shows that 
phosphorylated FHA-2 eluted from the column before non-phosphorylated FHA-2.  
PknF FHA-2 
Calculated 
Mw 
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6.7.3 Expression and purification of GST-PknF
1-292
 from E. coli 
GST-PknF
1-292
 was expressed and purified; the results of the protein purification 
demonstrated that the protein was purified to near homogeneity (figure 6.22). The GST-
tagged kinase was then used to phosphorylate FHA-2
202-310
 to determine whether this 
phospho-threonine binding domain became dimeric upon T208 phosphorylation.  
6.7.4 SEC-MALLS of FHA-2 phosphorylated by GST-PknF
1-292 
Figure 6.23 shows the results of SEC-MALLS of the FHA-2 domain without 
phosphorylation. The figure shows that FHA-2 at a concentration of 1 mg/ml and FHA-2 
at a concentration of 4 mg/ml have identical elution profiles and the calculated 
molecular mass of the proteins are the same. The traces of the phosphorylated FHA-2 
domains were then compared. Three different concentrations of phosphorylated FHA-2 
were compared; 1 mg/ml, 2 mg/ml and 4 mg/ml (figure 6.24). The results showed that 
the calculated molecular weights of all three concentrations of protein were comparable 
confirming that increasing protein concentration does not alter the elution profile.  
Figure 6.25 shows an overlay of the elution profiles of both the non-phosphorylated 
FHA-2 domain and the phosphorylated FHA-2 domain. The results show that the 
phosphorylated FHA-2 domain began to elute approximately 2 minutes prior to the non-
phosphorylated FHA-2 domain. The molecular weight of the phosphorylated FHA-2 
domain was shown to be 14.940 kDa at 31.8 minutes and the non-phosphorylated FHA-
2 domain had a calculated mass of 10.940 kDa at 33.5 minutes.  
The results showed that the phosphorylated FHA-2 domain elutes prior to the non-
phosphorylated FHA-2 domain suggesting that the phosphorylated domain is larger; 
however, the calculated molecular weights of the two proteins does not provide an 
insight into whether the FHA-2
202-310
 domain alters its conformation upon 
phosphorylation. 
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Figure 6.22 Expression and purification of GST-PknF
1-292
 from E. coli. GST-PknF
1-
292
 was expressed and purified as described in section 2.5.2. After purification 10 µl of 
the pooled and concentrated protein sample was analysed by SDS-PAGE; figure 6.22 
shows the result of a GST-PknF
1-292
 purification. GST-PknF
1-292
 = 58 kDa. 
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Figure 6.23 SEC-MALLS of the FHA-2 domain without phosphorylation by GST-
PknF. Figure 6.23a shows the entire size exclusion experiment and figure 6.23b focuses on the 
proteins which eluted between 30 and 37 minutes. The figure shows that FHA-2 at a 
concentration of 1 mg/ml and FHA-2 at a concentration of 4 mg/ml have identical elution 
profiles and the calculated molecular mass of the proteins are the same. 
FHA-2 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 236 
 
Figure 6.24 SEC-MALLS of the FHA-2 domain after phosphorylation by GST-
PknF. Three concentrations of the FHA-2 construct were phosphorylated by GST-
PknF
1-292 
and then SEC-MALLS was performed. Figure 6.24a shows the entire size 
exclusion experiment and figure 6.24b focuses on the proteins which eluted between 27 
and 37 minutes. FHA-2 at a concentration of 1 mg/ml, 2 mg/ml and 4 mg/ml are shown 
by the blue, pink and red traces respectively. The figure shows that the molecular mass 
of the three different concentrations of protein are approximately the same.  
FHA-2 
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Figure 6.25 SEC-MALLS of the FHA-2 domain with and without phosphorylation 
by GST-PknF. The FHA-2 construct was phosphorylated by GST-PknF
1-292 
when 
required
 
and then SEC-MALLS was performed. Figure 6.25 shows an overlay of figures 
6.23b and 6.24b with 4 mg/ml of FHA-2 domain protein. The results show that the 
phosphorylated FHA-2 domain begins to elute approximately 2 minutes prior to the non-
phosphorylated FHA-2 domain. The molecular weight of the phosphorylated FHA-2 
domain was shown to be 14.940 kDa at 31.8 minutes and the non-phosphorylated FHA-
2 domain had a calculated mass of 10.940 kDa at 33.5 minutes.  
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6.8 A hypothetical model of how PknF could be controlling Rv1747 function 
in M. tuberculosis 
Through combining all the data generated in this study a schematic representation of a 
potential mechanism by which PknF controls Rv1747 function was proposed and is 
diagrammatically shown in figure 6.26. Upon sensing an unknown signal PknF becomes 
autophosphorylated within the activation loop on residues T173 and T175 rendering the 
kinase functionally active. The peptide binding pocket of either of the Rv1747 FHA 
domains may then bind to one of the activation loop threonine residues. The function of 
the FHA-1 domain has been shown to be essential for Rv1747 function. Binding of the 
FHA domain also delivers the substrate protein into the active site of the kinase enabling 
substrate phosphorylation on residues T150 and T208. Upon substrate release, either of 
the FHA domains can then recognise and bind to either of the phosphothreonine epitopes 
on Rv1747, causing a conformational change within the protein structure to render it 
into an active conformation for the transport of the substrate across the M. tuberculosis 
cell membrane which is necessary for a virulent infection. 
6.9 Discussion 
6.9.1 ∆Rv1747 is attenuated for growth in BMDMs 
The bacterial load of the ∆Rv1747 mutant in BMDM infections was significantly 
impaired in both naïve and IFNγ activated cells compared to its parental wild type strain 
(figure 6.2). Furthermore, the mutant phenotype was lost when the Rv1747 gene was 
replaced in the chromosome confirming that the growth attenuation observed was due to 
the deletion of Rv1747. The results obtained demonstrated that the Rv1747 deletion 
strain is still attenuated for growth in murine BMDM infections and supports the 
hypothesis that Rv1747 is indeed required for a virulent infection. Furthermore, these 
results corroborate an earlier study where the Rv1747 deletion strain was also shown to 
be attenuated for growth (Curry et al., 2005), and demonstrates that this mutant 
phenotype has been stably inherited over many generations of growth. 
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Figure 6.26. Schematic representation of a potential mechanism by which PknF 
controls Rv1747 function in M. tuberculosis. In the absence of Rv1747 
phosphorylation the ABC transporter is inactive (figure 6.26a). Upon sensing a stress 
signal PknF autophosphorylates on residues T173 and T175 of the activation loop 
(figure 6.26b). The peptide binding pocket of the FHA-1 or FHA-2 domain is then able 
to bind one of the PknF activation loop threonine residues and deliver the substrate into 
the active site for phosphorylation on residues T150 and T208 (figure 6.26c - adapted 
from Villarino et al., 2005). Through presumed intra- and inter-molecular interactions 
between the FHA domains and the pT residues of both halves of the transporter the 
function of Rv1747 is activated and the substrate can be exported (figure 6.26d). Energy 
for transport is driven by the hydrolysis of ATP by the nucleotide binding domains 
(figure 6.26d). Protein domains are not drawn to scale. The Rv1747 transmembrane 
domains have been simplified and the two black lines in figures 6.26a, b and d represent 
an oversimplification of the M. tuberculosis cell wall. Note in figure 6.26d that the 
substrate could be transported to another part of the cell wall and not necessarily 
exported from the cell.
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IFNγ activation of the BMDMs resulted in reduced growth of all the M. tuberculosis 
strains compared to the growth seen in the naïve cells. In the IFNγ activated cells it 
can be noted that fewer cells of the ∆Rv1747 strain were phagocytosed inside the 
macrophages at 6 hours post infection compared with the wild type and 
complementing strains (figure 6.2b). The same inocula were used to infect both the 
naïve and IFNγ activated cells. In naïve cells the number of M. tuberculosis cells 
counted at 6 hours post infection was very similar for all three strains (figure 6.2a). 
Nonetheless, if the IFNγ data in figure 6.2b are plotted normalised to the initial 6 
hour uptake the ∆Rv1747 strain is still significantly attenuated for growth (data not 
shown). However, in figure 6.3b it can be clearly seen that the uptake of the strains 
into both naïve and IFNγ activated macrophages in this infection was very similar 
and thus the most likely explanation for the lower uptake observed in figure 6.2b was 
due to the variability in the data obtained in macrophage infections in general. 
Although patterns of data are consistent in BMDM infections i.e. a mutant with 
growth attenuation can always be observed, the individual time points can vary quite 
considerably from experiment to experiment. This is probably due to a number of 
reasons; mouse age (typically varies from 6 to 8 weeks), variability in uptake of the 
M. tuberculosis cells between the wells of the three technical replicates and 
variability in the serial dilutions of the lysed macrophages containing the M. 
tuberculosis.  
The Griess nitrite assay showed that cells treated with IFNγ were indeed activated as 
demonstrated by the presence of NO/nitrite in the supernatants of infected BMDMs 
(figure 6.1). The results also showed that there were no differences in the levels of 
nitrite produced when IFNγ stimulated cells were infected with wild type, ∆Rv1747 
and Rv1747 complement strains, suggesting that the reason the ∆Rv1747 deletion 
strain had a lower bacterial burden was not due to an increase in the nitrite 
concentration in the supernatant of cells infected only with this mutant strain which 
in turn may have lead to slower growth or an increased killing of this strain. 
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6.9.1.1 Assessment of the growth of the threonine mutant strains in BMDMs and 
mice and implications for the regulation of the PknF-Rv1747 system 
6.9.1.1.1 BMDM infection 
The two phospho-threonine sites identified in this study (figure 5.6), which were 
demonstrated to be important for the in vitro phosphorylation of Rv1747 by PknF 
(figure 5.8), were mutated to either warrant them incapable of receiving a phosphate 
group (T150A/T208A) or to mimic constitutively phosphorylated residues 
(T150D/T208D) within the Rv1747 complementing strain and tested for their ability 
to rescue the growth attenuation phenotype of the ∆Rv1747 strain in BMDM 
infection experiments. It was demonstrated that the bacterial load of both the 
T150A/T208A and T150D/T208D strains were attenuated for growth at 120 and 168 
hours post infection in naïve cells and also at 168 hours post infection in IFNγ 
activated cells (figure 6.3). However, the growth attenuation of both these strains was 
intermediate between the ∆Rv1747 deletion and wild type strain in IFNγ activated 
cells whereas in naïve cells both the point mutation strains appeared to grow similar 
to the ∆Rv1747 deletion strain.  
Aspartic acid is a negatively charged amino acid whose structure is very similar to 
that of a serine or threonine residue which has been phosphorylated. Therefore, this 
amino acid, along with glutamic acid which has similar properties to aspartic acid, 
are both used in phosphorylation studies to act as phosphorylation mimics (Veyron-
Churlet et al., 2009). However, one problem with the construction and use of these 
mimics is that they do not necessarily always act as phosphorylation mimics inside 
the cell. In this study the T150D/T208D phosphorylation mimic strain did not rescue 
the growth phenotype of the ∆Rv1747 strain; furthermore, the T150A/T208A 
phosphorylation null strain also did not rescue the growth attenuation phenotype of 
the Rv1747 deletion. Therefore it can be hypothesised that perhaps the 
phosphorylation mimic strain did not mimic phosphorylation successfully in terms of 
protein function; perhaps the FHA domains cannot bind aspartic acid residues and 
this is why the growth attenuation phenotype was not restored in this strain. 
Furthermore because the T150A/T208A strain also did not rescue the growth 
attenuation phenotype then this suggests that phosphorylation by PknF positively 
regulates the activity of the Rv1747 ABC transporter i.e. phosphorylation of the 
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T150 and T208 residues of Rv1747 by PknF serves to transduce the signal which 
activates the function of the transporter. This hypothesis corroborates the microarray 
data which showed that the same differential changes in gene expression were noted 
in both of the mutant strains, for example, the iniBAC operon was upregulated in 
both of the deletion strains (chapter 4).  
6.9.1.1.2 Murine infection 
The mouse aerosol infection experiment demonstrated that the ∆Rv1747 strain was 
attenuated for growth both in the lungs, and more significantly so in the spleens 
(figure 6.4); earlier findings from an intravenous infection model found that the 
Rv1747 deletion strain was attenuated for growth by a maximum of ten fold (1 log) 
in the lungs and spleens compared with wild type throughout the time course of 
infection (Curry et al., 2005). Results from this current study showed the growth 
phenotype of the ∆Rv1747 mutant to be more pronounced; in the lungs the mutant 
was attenuated by a maximum of 2.5 logs at 30 days post infection and in the spleens 
the mutant was attenuated for growth by 2.8, 3, and 3.8 logs at 30, 60 and 90 days 
respectively. Compared with the intravenous route of infection, an aerosol infection 
model is a better way to study M. tuberculosis virulence and pathogenesis because 
mice are infected through inhalation of bacilli, mimicking the mode of infection in 
humans, whereas in an intravenous infection the mice have TB bacilli injected into 
their tail vein; in this type of experiment approximately 10% of the inoculated 
bacteria travel straight to the spleens of the animals and only 1% goes to the lungs (J. 
Dillury, Personal Communication). This route is in effect the opposite way round to 
the mode of infection in humans. Therefore it was important in this study to assess 
the growth of the ∆Rv1747 deletion, complement, and both the mutated complement 
strains in the aerosol infection model. In a virulent M. tuberculosis infection, from 
the lungs the bacteria first spread to the lymph nodes and then to other organs 
including the spleen and liver via the circulatory system.  
Interestingly, at day 30, mice infected with the ∆Rv1747 and Rv1747 complement 
T150A/T208A strains had no M. tuberculosis bacilli present in their spleens (figure 
6.4b). Furthermore, at day 60 only three of the five animals infected with the 
∆Rv1747 strain had bacilli in the spleens suggesting that both this mutant and the 
Rv1747 complement T150A/T208A strain are highly attenuated for growth in the 
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spleens, highlighting the critically important role that the Rv1747 ABC transporter 
plays in M. tuberculosis pathogenesis. These results therefore corroborate the 
macrophage data again suggesting that PknF positively regulates the activity of the 
Rv1747 ABC transporter. Furthermore, the Rv1747 complement T150D/T208D 
strain also did not fully complement the Rv1747 deletion growth phenotype in the 
lungs or spleens and the most logical explanation is that this strain is not successfully 
acting as a phosphorylation mimic. Importantly, FHA domains cannot recognise 
aspartate residues (S. Smerdon, Personal Communication); therefore in a 
T150D/T208D mutant there can be no intra- or inter- molecular interactions between 
the FHA domains and these residues explaining why this mutant had a similar 
phenotype to the alanine mutant. Clearly, one also has to bear in mind that there may 
be another phosphorylation site present in Rv1747 that was not identified in the 
LC/MS/MS screen; indeed, in the in vitro phosphorylation assays there was a very 
faint band present corresponding to the size of Rv1747 in the T150A/T208A mutant 
(figure 5.8). If this were the case it may offer an explanation as to why neither of the 
double mutated complements displayed a growth phenotype as severe as the 
∆Rv1747 strain. Furthermore, the Rv1747 complement strain did not fully 
complement the ∆Rv1747 growth phenotype in the lungs or especially in the spleens 
(figure 6.4). The complement contains an extra copy of pknF (figure 1.12) which 
may have regulatory effects on the function of Rv1747 offering an explanation why 
the growth attenuation was not fully complemented. 
One hypothesis to discuss is whether the ∆Rv1747 and Rv1747 T150A/T208A 
complement strains (and to some extent the T150D/T208D strain) are defective in 
dissemination from the lungs to the spleens or whether these strains just harbour a 
growth defect in vivo. A 2001 paper described a heparin-binding haemagglutinin 
protein of M. tuberculosis (hbhA, Rv0475) which was shown to be required for extra-
pulmonary dissemination. A deletion mutant of this protein grew as well as wild type 
in the lungs and spleens of mice infected intravenously (Pethe et al., 2001). 
However, in an aerosol model of infection the growth of this mutant was 
indistinguishable from that of the wild type in the lungs but was severely attenuated 
for growth in the spleens (Pethe et al., 2001). These data conclusively showed that 
the mutant harboured a defect in dissemination because the strain grew at the same 
rate as the wild type in the spleens of mice infected via the intravenous route. In this 
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current investigation ∆Rv1747 was not only attenuated for growth in the lungs and 
spleens of mice infected via the aerosol route, but was also attenuated in both organs 
in an intravenous infection (Curry et al., 2005). Taken together, this suggests that the 
∆Rv1747 mutant strain is defective in growth in general in vivo and therefore is not 
required for extra-pulmonary dissemination. 
However, another study published in 2004 stated that an lspA mutant was also 
defective in extra-pulmonary dissemination (Sander et al., 2004). Their study showed 
that deletion of a lipoprotein signal peptidase (lspA, Rv1539) in M. tuberculosis did 
not affect in vitro growth but did result in significant growth attenuation in mouse 
macrophages and in the lungs of BALB/c mice following an aerosol route of 
infection; critically, like ∆Rv1747, this mutant failed to colonise the spleens of the 
infected animals over the time course of the experiment (42 days) (Sander et al., 
2004). Full complementation of growth was observed when the lspA gene was 
replaced into the chromosome and the mycolic acid pattern was similar for all three 
strains (Sander et al., 2004). The authors stated that these results showed that the 
lspA gene was required for dissemination of infection from the lungs to the spleens, 
even though the mutant strain was also attenuated for growth in the lungs.  
One could hypothesise at this stage that perhaps Rv1747 functions to export one of 
the 99 M. tuberculosis lipoproteins to the cell surface which is critical for 
pathogenesis because the in vivo phenotypes observed with the Rv1747 and lspA 
deletion strains were similar (Kovacs-Simon et al., 2010). To investigate this one 
could prepare cell extracts from wild type, ∆Rv1747 and the R1747 complementing 
strain and probe for lipoproteins using specific antibodies. 
6.9.1.1.3 BMDM infections with the single threonine mutants 
Assessment of the panel of single threonine mutants in the BMDM infection model 
showed that all four single mutant strains had a bacterial load similar to that of the 
wild type and the Rv1747 complementing strain throughout the time course of 
infection, with the exception of the T150D strain which displayed a growth 
attenuation phenotype 120 hours post infection (figure 6.5). However, by 168 hours 
post infection there was no longer a significant difference between the growth of this 
strain and the wild type strain. The data suggests that the reason why a phenotype 
Chapter 6. How is PknF controlling Rv1747 function? Part 2 
 245 
was observed at 120 hours was due to the inherent variability seen in macrophage 
infection experiments.  
6.9.1.1.4 Infection summary 
In summary, it was shown that the T150A/T208A and T150D/T208D strains 
displayed a growth attenuation phenotype in BMDMs and mice similar to that of the 
∆Rv1747 strain; the most logical explanation of the results was that the 
T150A/T208A mutation did not rescue the phenotype of the mutant strain because 
phosphorylation of Rv1747 by PknF positively regulates the activity of the 
transporter, and secondly, the phosphorylation mimic strain failed to render the 
Rv1747 transporter constitutively active because the FHA domains are unable to 
interact with aspartate residues. Furthermore, the fact that none of the single mutants 
displayed a marked growth phenotype suggested that the ABC transporter is still able 
to function to a degree even if one of the threonine residues is mutated and therefore 
mutation of both the T150 and T208 residues are necessary to prevent Rv1747 
transporter function. Perhaps the ABC transporter can function to a degree to rescue 
the growth attenuation phenotype if either one of the threonine residues is mutated 
but not if both residues are rendered unable to be a phospho-acceptor. These data 
also suggest a degree of redundancy between the two residues. 
6.9.1.2 Cytokine assays 
Cytokine ELISAs demonstrated there were no differences in the production of IL12-
p40 throughout the course of infection at two different MOIs (figure 6.6). When 
examining TNFα production there were no significant differences in the 
concentrations of secreted cytokine produced when the MOI was 5:1 (figure 6.7). 
However, when the MOI was 0.5:1 at the 6 hour time point in IFNγ activated 
macrophages infected with the wild type strain the cells secreted 19 pg/ml of TNFα 
whereas macrophages infected with the mutant and complement strains produced 
levels below that of the negative control well. Furthermore, at 120 hours post 
infection the IFNγ activated cells secreted more TNFα when infected with the wild 
type and ∆Rv1747 strains compared to the Rv1747 complementing strain. The reason 
for this is unclear as at an MOI of 5:1 no differences were noted. The sensitivity of 
the assay may offer an explanation of the result at 6 hours post infection as a 
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concentration of 19 pg/ml is very low so for the other two strains the levels of TNFα 
could easily have been undetectable. The results of IL6 secretion into the culture 
supernatants after infection with all three M. tuberculosis strains at an MOI of 0.5:1 
showed that at all time points in both naïve and IFNγ activated macrophages there 
were no significant differences in the levels of IL6 secreted between the wild type 
and ∆Rv1747 strains (figure 6.8). However, at 6 and 72 hours post infection in the 
IFNγ activated cells, lower levels of IL6 production were observed from the 
macrophages infected with the Rv1747 complement strain compared to the wild type 
and deletion strains. The reason for this is unclear but what is important is that the 
Rv1747 complementing strain was able to fully rescue the phenotype of the ∆Rv1747 
deletion strain. The results are from three technical replicates of one biological 
replicate so the assay should be performed again before final conclusions are drawn. 
The important conclusion from these assays was that there were no significant 
differences between the wild type and mutant strains which could have 
accounted for the growth attenuation phenotype due to a difference in cytokine 
response.   
One major limitation of this experiment is that the cytokine response which can be 
examined in infected macrophages over seven days does not mimic the response seen 
in infected animals over many months; perhaps a better experiment to perform would 
be to look at the cytokine response in infected mice. 
It was hypothesised in this study that the ∆Rv1747 mutant may have induced a 
different cytokine response due to the transporter not performing its function and this 
could be a reason why this strain fails to replicate/survive as well in macrophages; 
however, this was not the case. Although no major differences were noted in this 
investigation, previous studies have characterised mutants that induce different 
cytokine responses and have been able to relate those differences to the function of 
the protein. A study examining the effects of the deletion of the pknE gene found that 
infection of THP-1 macrophages with this mutant caused the THP-1 cells to secrete 
significantly lower levels of the pro-inflammatory cytokines TNFα and IL6 in the 
culture supernatants compared to the wild type and complementing strains 
(Jayakumar et al., 2008). Their study also showed that the pknE promoter sensed 
nitric oxide stress and furthermore they demonstrated that addition of nitric oxide 
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donors to macrophages induced increased apoptosis in those cells infected with the 
∆pknE strain which suggested that PknE played a role in the prevention of apoptosis. 
They then related these findings to propose a mechanism whereby PknE senses nitric 
oxide stress and then enhances macrophage viability by preventing apoptosis by 
interfering with the host signalling pathways (demonstrated by the reduced cytokine 
levels in the ∆pknE mutant compared with the wild type and complementing strains) 
(Jayakumar et al., 2008). Other studies on M. tuberculosis mutants have also found 
differences in the cytokine response including a study on the mce1 operon in which 
the mutant strain produced less TNFα and IL6 compared to the parental strain in a 
murine macrophage infection experiment (Shimono et al., 2003). This strain was also 
found to be hypervirulent in mice as it was unable to enter a stable persistent phase in 
the lungs of mice and all mice were dead by week 41 of the experiment compared 
with the wild type control where all the mice were still alive (Shimono et al., 2003). 
A 2007 study found that the Rv3083-Rv3089 operon of M. tuberculosis was induced 
17-33 fold when exposed in vitro to acidic conditions (Cheruvu et al., 2007). 
Furthermore the mutant displayed a growth attenuation phenotype in cell lines and 
THP-1 cells infected with this strain produced less IL1ß, IL6 and IL8 compared with 
the wild type strain in the first 48 hours of infection (Cheruvu et al., 2007). Taken 
together, these studies highlight the importance of investigating the cytokine 
responses to M. tuberculosis infection. 
Interestingly, no differences in cytokines were observed between the wild type and 
∆Rv1747 strains even though the numbers of intracellular bacteria were significantly 
different by 120 and 168 hours post infection (figure 6.2). Assessment of IL12-p40 
and TNFα levels were stopped at 120 hours post infection and assessment of IL6 
levels were only performed for the first 72 hours of infection; perhaps these studies 
should be extended to analyse the later time points.  
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6.9.2 PknF 
It was unknown whether the pknF gene played a role in the pathogenesis of M. 
tuberculosis. It was hypothesised that by examining the growth of this mutant and its 
respective complementing strain in BMDMs it may also provide further evidence as 
to whether this kinase positively or negatively regulates the activity of the Rv1747 
ABC transporter.  
6.9.2.1 BMDM infections 
Results showed that in naïve BMDMs there was no growth phenotype of the ∆pknF 
null or complement strains up until 168 hours post infection when a significant 
difference was observed in the bacterial load of the mutant and complement strains 
compared with the wild type strain (figure 6.9). In IFNγ activated BMDMs the 
growth of all three strains were comparable up until 168 hours post infection where 
the ∆pknF strain had a significantly lower bacterial load compared with the wild type 
and pknF complementing strains. The results therefore again suggested that PknF 
phosphorylation of Rv1747 positively regulates the activity of the transporter 
because when pknF was deleted from the chromosome this resulted in a growth 
attenuation phenotype. 
However, it was surprising that the pknF complementing strain had a significantly 
different bacterial load to that of the wild type strain in naïve cells at 168 hours post 
infection. In some previous M. tuberculosis studies it has not been possible to rescue 
the effects of a gene deletion by simple replacement of that gene back into the 
chromosome. However, in the case of this study the pknF complement did rescue the 
differential gene changes observed in the microarray and qRT-PCR studies 
suggesting that the function of the kinase is restored in this strain (see chapter 4). 
Results also showed that there was a difference in the 6 hour bacterial load uptake 
values between the three strains; in both naïve and IFNγ stimulated cells the wild 
type strain had a greater bacterial load compared to the mutant and complementing 
strains (figure 6.9). The reason for this result could be due to an error in the dilution 
of the inocula or due to a phenotype of the ∆pknF deletion and complementing 
strains themselves. The results were then normalised to the initial six hour uptake 
values of each strain; normalised values showed that the pknF complement has a 
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similar pattern to the wild type strain; furthermore, the ∆pknF strain followed a 
similar pattern to 120 hours post infection and then became attenuated for growth 
between 120 and 168 hours post infection (figure 6.10). However, this type of 
analysis should never be taken at face value because a real phenotype of the pknF 
deletion strain may be that it is not phagocytosed as efficiently as the wild type 
strain. In addition, if the experiment had been terminated at 120 hours post infection 
then no growth attenuation phenotype of the ∆pknF strain would have been observed 
regardless of how the data was analysed. 
Furthermore, the results showed very large error bars for the pknF complement strain 
in IFNγ activated cells. This was because between the three technical replicates the 
number of colonies obtained varied quite substantially. This was also observed in the 
second biological replicate of this experiment. Perhaps there is an additional 
mutation within this strain that is accounting for this phenotype; to investigate this 
the pknF complementing strain could be sequenced. 
One possible reason why a strong growth attenuation phenotype was not observed 
with the ∆pknF strain in BMDM infections is that there are 10 other kinases in the M. 
tuberculosis genome which may be able to phosphorylate Rv1747 to activate the 
function of the transporter. Indeed, by in vitro phosphorylation assays domains of 
Rv1747 have been shown to be phosphorylated by PknE, PknD, PknB and PknF 
(Grundner et al., 2005).  
To test the ∆pknF strain more thoroughly and to determine whether this kinase is 
required for the growth of M. tuberculosis in vivo the pknF deletion strain should 
now be tested in a murine infection model to determine if this strain is attenuated for 
growth in both the lungs and spleens of mice. This would perhaps give a clearer 
indication of the requirement for this kinase for the in vivo growth of M. 
tuberculosis.  
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6.9.3 Characterisation of the function of the Rv1747 FHA domains  
6.9.3.1 BMDM infections 
6.9.3.1.1 FHA domain function requires specific conserved residues 
Highly conserved residues within FHA domains directly contact the phosphopeptide, 
either by contacting the peptide backbone or by forming a network of hydrogen 
bonds with the pT residue on the epitope (Durocher & Jackson, 2002). In the well 
studied Rad53 FHA domain-containing protein, there are six highly conserved 
residues in the FHA-1 domain, five of which are located around the peptide binding 
site. Residues arginine-70 and serine-85 bind directly to the pT residue itself 
(Durocher et al., 2000). Consequently, mutation of the conserved serine 85 residue 
within one of the peptide binding loops abolishes the binding activity of the FHA 
domain to the pT residue. The orthologous serine residue in Rv1747 FHA-1 is serine 
47 and in the FHA-2 module is serine 248. Data in this study has shown that 
mutation of the serine 47 residue in the FHA-1 module resulted in severe attenuation 
of growth in BMDM infection experiments in both naïve and IFNγ activated cells 
whereas the FHA-2 domain S248A mutant demonstrated no growth phenotype 
compared with the wild type strain (figure 6.11). 
6.9.3.1.2 Conclusions drawn from Rv1747 FHA domain BMDM infections  
A number of conclusions can be drawn from the data. As the FHA-1 S47A mutation 
resulted in a growth attenuation phenotype it again suggests that regulation of 
Rv1747 by PknF is positive because when the FHA-1 domain can no longer bind 
a pT epitope either in the PknF activation loop or residues T150 or T208 of 
Rv1747 it resulted in a growth phenotype similar to that observed in the Rv1747 
deletion mutant (figure 6.2) suggesting that the FHA-1 mutation renders Rv1747 
unable to function. These results again support the earlier microarray and qRT-PCR 
data where the same pattern of differential gene regulation was observed in both the 
kinase and transporter mutant strains suggesting that there was a positive mechanism 
of regulation between PknF and Rv1747 (chapter 4). 
Furthermore, the growth attenuation data gathered for the FHA-1 S47A mutant 
suggests that the function of the FHA-2 domain alone within this mutant strain is not 
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sufficient for activation of the transporter activity of Rv1747. This makes sense 
because out of the six FHA domain containing proteins in M. tuberculosis, Rv1747 is 
the one to contain two FHA modules and there must, therefore be a functional reason 
for this. Perhaps the FHA-2 domain functions in intramolecular associations with the 
T150 and/or T208 residues on Rv1747 and it is the FHA-1 domain which binds to 
the PknF activation loop to allow substrate phosphorylation. If indeed the case, this 
hypothesis may offer an explanation as to why the FHA-1 domain is critical for 
Rv1747 protein function whereas from the data generated in this study the FHA-2 
domain does not appear to be as important.  
Mutation of the S248 residue in FHA-2 will also abolish the capability of this FHA 
domain to bind to pT residues; however, from the data generated it appears that the 
presence of a functional FHA-1 domain in this strain was able to rescue the growth 
attenuation phenotype, i.e. the ABC transporter is able to function enough so that the 
growth phenotype seen in the BMDM infections is rescued. As we have no other 
readout of phenotype for the ∆Rv1747 strain apart from growth attenuation in 
BMDM and mouse infection experiments we are unable to speculate any further at 
this stage about the ability of the transporter to function in the FHA-2 S248A domain 
mutant. 
Alternatively it could also be argued that it is the FHA-2 domain which functions to 
bind the activation loop of PknF and then the FHA-1 domain functions in 
intramolecular associations with T150 and T208 residues causing a conformational 
change to activate the activity of the transporter. However, this seems unlikely due to 
the fact that in the FHA-2 S248A mutant no growth phenotype is observed 
suggesting that in this mutant Rv1747 is phosphorylated by PknF and is functional to 
some extent. A third mechanism of regulation could involve both the FHA domains 
binding the activation loop of PknF; perhaps the binding of one FHA domain results 
in the phosphorylation of the T150 residue and binding of the other FHA module 
results in the phosphorylation of the T208 residue and then intramolecular 
associations happen if and when required to regulate the transporter activity of 
Rv1747. Unfortunately from the data generated in this study we are unable to 
speculate further at this time as to the precise mechanism of regulation. 
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Interestingly in the earlier 2005 study examining the interaction between PknF and 
Rv1747 in a yeast 2-hybrid system, it was found that the interaction was completely 
abrogated in an S47A mutant and was reduced by approximately three fold in a 
S248A mutant corroborating the evidence founding this study that the FHA-1 
domain is critically important for Rv1747 function (Curry et al., 2005). 
Taken together, these results suggest that the FHA-1 domain is critically important 
for the function of the Rv1747 transporter. To further investigate the importance 
of the Rv1747 FHA domains for M. tuberculosis pathogenesis animal infection 
studies with these mutant strains should be performed. Furthermore, a strain should 
be created in which both the Rv1747 FHA domains are mutated at their critical 
serine residues in the peptide binding loop; it can be hypothesised that this should 
result in the same growth attenuation phenotype as observed in the ∆Rv1747 and 
FHA-1 S47A mutants. 
6.9.3.2 Determination of the binding kinetics between FHA domains and pT 
peptides 
FHA modules are phosphothreonine epitope binding domains and the recruitment of 
the binding domain to the epitope results in transmission of the signal; in this case 
the binding of the Rv1747 FHA domains to the pT epitopes are presumed to control 
the activity of the ABC transporter.  
6.9.3.2.1 Use of ITC to determine binding kinetics 
ITC demonstrated that both FHA domains bound to both the Rv1747 
phosphopeptides with similar binding affinities and furthermore showed that the data 
generated was indeed due to the direct binding of the FHA domains to the 
phosphopeptides because in an FHA-1 S47A mutant all binding was abolished. As 
already discussed, in the Rad53 FHA-1 domain residues arginine-70 and serine-85 
bind directly to the pT residue itself (Durocher et al., 2000). Consequently, mutation 
of the conserved serine 85 residue within one of the peptide binding loops abolishes 
the binding activity of the FHA domain to the pT residue. The homologous serine 
residue in Rv1747 FHA-1 is serine 47 and this study has already demonstrated that 
this serine residue is critical for the function of the Rv1747 transporter (figure 6.11).  
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Since the data showed that both FHA domains bound both the phospho-threonine 
peptides with similar affinities it suggested that there was not a preferred peptide for 
each of the FHA domains. However, one has to bear in mind that in vivo both of the 
pT residues may not be available to both of the FHA domains for binding since 
physical constraints may prevent this from happening; for example the T208 site is 
very close to the FHA-2 domain so it would be not possible for this domain to rotate 
in such a way to bind the epitope unless the domain from one of the ‘half-
transporters’ bound the epitope on the other polypeptide. This hypothesis is 
discussed in the subsequent section. 
Furthermore, the fact that both the Rv1747 FHA domains bound both the Rv1747 pT 
peptides is not surprising; it is probably the result of epitope co-evolution between 
the FHA domains and the serine/threonine protein kinases. As previously discussed 
serine/threonine protein kinases and FHA domains have probably co-evolved to 
recognise overlapping consensus motifs.  
The binding kinetics between the Rv1747 FHA domains and non-Rv1747 peptides 
were also determined. Data demonstrated that FHA-1 and FHA-2 domains could also 
bind the pT22 peptide from Rv1827 with dissociation constants in the µM range (22 
µM and 21 µM respectively) and furthermore FHA-2 could also bind a phospho-
peptide from Rv0020c with a Kd of 9 µM. The ability of the FHA-1 domain to bind 
this peptide was not assessed. Titrations of the Rv1827 FHA domain with the pT22 
peptide resulted in a Kd of 12.8 µM, similar to what was determined for the Rv1747 
FHA domains (T. Nott, personal communication).  
6.9.3.2.2 FHA domain pT-containing epitope specificity 
For FHA domains to bind pT-containing epitopes the residue at position pT+3 has 
been shown to be critically important for this interaction (Durocher et al., 1999). The 
Rad53 FHA-1 phosphopeptide interaction was able to tolerate amino acid 
substitutions at pT-3 to pT-1and pT+1 to T+2 but the interaction was abolished when 
the pT+3 residue was mutated highlighting the importance of this residue for the 
interaction and suggesting that this residue is involved in the selectivity of binding 
(Durocher et al., 1999). Studies in 2000 confirmed this binding selectivity theory 
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using anchored peptide libraries to identify FHA domain consensus binding motifs 
(Durocher et al., 2000; Liao et al., 2000).  
The Rv1747 pT150 and pT208 phosphorylation sites contain hydrophobic residues in 
the pT+3 position, namely isoleucine for pT150 and methionine for pT208 as does 
the pT22 peptide from R1827 which has a phenylalanine residue at pT+3. The 
presence of a hydrophobic residue could explain why the Rv1747 FHA domains 
could bind all three peptides although FHA-2 was also shown to bind the pT377 
peptide from Rv0020c which contains a non-hydrophobic threonine residue at the 
pT+3 position. However, amino acids I, M, F, and T were all present at the pT+3 
position in the phosphorylation site motif analysis for PknF suggesting that through 
co-evolution the Rv1747 FHA domains could also potentially recognise pT 
containing epitopes with any of these residues at the pT+3 position (Prisic et al., 
2010). For PknB, which controls Rv1827 and Rv0020c by phosphorylation, residues 
overrepresented at the pT+3 position included I, F and M highlighting the 
overlapping consensus motifs of the two kinases (Prisic et al., 2010). 
Inside the M. tuberculosis cell there are spatial and temporal separations of protein 
expression and the bacterium will have evolved to minimise the necessary 
complexity. Therefore again it was not unexpected that the Rv1747 FHA domains 
could also bind to the Rv1827 and Rv0020c phosphopeptides as in vivo an FHA 
domain on Rv1747 is not likely to come into contact with a phosphopeptide on 
Rv1827 or Rv0020c.  
6.9.3.2.3 Principles of ITC and further explanation of results  
In ITC the signal that is generated is the heat of binding. Binding of the protein to a 
peptide can be an exothermic or endothermic reaction (due to the net outcome of 
hydrogen bond formation and electrostatic interactions); furthermore, as the FHA 
domain binds the peptide some buffer has to move out of the binding pocket and all 
these occurrences cause temperature fluctuations. In this study binding of the FHA-1 
and FHA-2 domains to phosphopeptides were always exothermic reactions. This is 
demonstrated by the series of heat spikes in the top half of each figure which plotted 
the amount of power (in µcal/sec) needed to maintain the reference and sample cell at 
the same temperature; as each reaction was exothermic it means the instrument 
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needed to use less energy to heat the cell which resulted in the generation of negative 
heat spikes. As each experiment progressed the binding sites on the peptide were 
gradually saturated and therefore the heat effect was reduced. This can be observed 
in the top panel of figures 6.13, 6.14, 6.16 and 6.17. Intriguingly, binding of the 
FHA-2 domain to phosphopeptides consistently gave a stronger heat signal upon 
each injection of protein into the cell compared to the FHA-1 domain. The heat 
spikes generated in the FHA-1 S47A studies were due to the heat of dilution that 
occurs when two protein species are mixed, this occurrence is not associated with 
protein binding. 
The lower panel in each figure showed the total heat effect per injection by 
integrating the area of the peaks and plotting them against the molar ratio of protein 
and ligand. A curve was then fitted and this generated the binding data. Several 
iterations of the fit of the curve were performed in order to get the best fit and the 
Chi-squared value gave information about the fit of the curve to the data. From the 
shape of the curve it was possible to determine the stochiometry and enthalpy of the 
reaction as well as the binding affinity (K), the inverse of which is the dissociation 
constant; Kd = 1/K. The binding stoichiometry (N) of the interactions investigated in 
this study should have been 1:1 as one FHA molecule can bind only one peptide 
molecule. Results showed that for FHA-1 interactions with Rv1747 peptides N was 
always approximately 1 or just above (figure 6.13). This shows that the calculated 
protein concentration of the FHA domain was approximately correct. For the FHA-2 
titrations with Rv1747 peptides N was 0.74 and 0.79 respectively (figure 6.14a and 
b). When N was less than 1 it suggested that the protein concentration was less than 
what was determined; the FHA-2 construct does not contain tryptophan, tyrosine or 
phenylalanine residues which contain conjugated aromatic rings enabling them to 
absorb light in the ultraviolet range. Consequently protein concentration could not be 
calculated by spectroscopy and had to be determined using the refractive index of the 
protein by SEC-MALLS; the ITC results demonstrated that the refractive index was 
probably not very accurate hence why the N ended up being less than 1. N was also 
slightly less than 1 in the titrations between both Rv1747 FHA domains and the non-
Rv1747 peptides with values of 0.84, 0.82 and 0.84 respectively reflecting the high 
degree of precision of the instrument (figures 6.16 and 6.17). 
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The enthalpy change (∆H) in all titrations was negative due to the gaining of new 
bonds when binding occurred resulting in a release of heat (exothermic reaction) 
(figures 6.13, 6.14, 6.16 and 6.17). In this study an increase in disorder (entropy 
(∆S)) occurred when titrating FHA-1 against both the Rv1747 phosphopeptides 
(figure 6.13), when titrating FHA-1 against pT22 from Rv1827 (figure 6.16a) and 
when titrating FHA-2 against the pT377 peptide from Rv0020c (figure 6.17). 
However, when titrating FHA-2 against the Rv1747 peptides (figure 6.14) or the 
Rv1827 peptide (figure 6.16b) the ∆S was negative. This was an intriguing result as 
it suggested that the system was becoming more ordered as protein binding occurred. 
When the ∆S was negative it can be noted that there was also a stronger negative ∆H 
of binding compared with when the ∆S was positive, presumably to compensate for 
the negative ∆S to allow binding to occur (see figures 6.13 and 6.14). Based on the 
theory of energy changes given by the equation ∆G = ∆H-T∆S where G is free 
energy content, H is enthalpy, T is temperature in Kelvin and S is entropy, for 
reactions to be favourable the sum of the free energy changes must be negative. If ∆S 
is negative then there must be a large negative ∆H of binding to make a negative ∆G 
to allow binding to occur. 
In summary, ITC demonstrated that both the FHA domains could recognise and 
bind to both the identified pT residues on Rv1747 lending further support to the 
hypothesis that the identified residues do indeed play an important role in the 
pknF-Rv1747 signalling system. 
6.9.3.3 Does the FHA-2 domain dimerise upon phosphorylation at T208? 
It was hypothesised that when residue T208 on Rv1747 was phosphorylated by PknF 
then the FHA-2 domain on one half of the transporter may bind the T208 residue on 
the other half and vice versa in order to transduce the signal and regulate the activity 
of the Rv1747 transporter. It was demonstrated that PknF could phosphorylate FHA-
2
202-310
 in vitro. The amount of radioactivity incorporated into the FHA-2 construct 
after phosphorylation by PknF was much greater that the amount incorporated by the 
FHA-1
1-120
 domain construct (figure 6.19). This is probably because T208 is present 
within the FHA-2 construct whereas for the FHA-1 construct no pT residue was 
identified between residues 1 and 120 although the data does suggest that FHA-1
1-120
 
is also phosphorylated to some extent due to the incorporation of radioactivity. 
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Using electrospray mass spectroscopy it was shown that after four hours of 
incubation of PknF
1-292
 with FHA-2
202-310
 and ATP almost all the FHA-2 protein was 
phosphorylated on one residue and a small proportion of the protein construct 
contained two phosphorylated residues demonstrated by the increase in mass of 160 
Da. Importantly, none of the protein was in its non-phosphorylated state. 
Electrospray mass spectrometry gives the precise molecular weight/s of the species 
in the protein sample but cannot inform on which residue the addition of a phosphate 
group occurred. For this investigation it had to be assumed that the phosphorylated 
residue was at position T208 because this was one of only two phosphorylated 
threonine residues identified that were phosphorylated by PknF; however, there is no 
conclusive evidence to prove this. Furthermore, there was a small abundance of the 
protein that contained two phosphorylated residues and it had to be hoped that this 
would not interfere with the experiments to determine if FHA-2
202-310
 became 
dimeric after phosphorylation. For future investigations LC-MS/MS could be 
employed to determine the residue of phosphorylation to be certain that it was 
residue T208.  
Using SEC-MALLS measuring the molecular mass of each protein peak is possible 
by combining measurements from light scattering and the differential refractive 
index. Experiments were performed to examine the FHA-2
202-310
 domain in both its 
phosphorylated and non-phosphorylated states. Initially experiments were performed 
with PknF
1-292
 although this proved problematic due to the fact that the kinase was 
still eluting from the column when the FHA-2 domain began to elute. Consequently 
GST-PknF
1-292
 was expressed and purified from E. coli and because this protein was 
much larger it did not elute from the column at the same time as the FHA-2 domain. 
Furthermore, after phosphorylation glutathione-s-transferase resin was added to the 
phosphorylation reaction and incubated with rotation for one hour at 4 
o
C in order for 
the GST-PknF to bind back to the resin. However, if some kinase remained in the 
reaction then it would probably elute in the void due to the large globular size of the 
protein. It is suggestive that there was some GST-PknF in the void because the void 
is much larger in the phosphorylated reaction (figure 6.24a) compared with the non-
phosphorylated reaction (figure 6.23a). Furthermore in figure 6.24a a negative 
refractive index is observed in all protein samples at approximately 40 minutes. The 
negative refractive index was most probably due to buffer exchange; there was less 
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salt present in the phosphorylation reactions than in the buffer which conditioned the 
column.  
The results showed that the phosphorylated FHA-2 domain began to elute 
approximately 2 minutes prior to the non-phosphorylated FHA-2 domain (figure 
6.25). The total area under the phosphorylated FHA-2 and non-phosphorylated FHA-
2 peaks are approximately the same, thus the concentrations of both proteins are 
approximately 4 mg/ml; the reason for the smaller peak with the phosphorylated 
protein is that it eluted over a longer time period and therefore the peak height is 
smaller. The molecular weight of the phosphorylated FHA-2 domain was shown to 
be 14.940 kDa at 31.8 minutes and the non-phosphorylated FHA-2 domain had a 
calculated mass of 10.940 kDa at 33.5 minutes. The molecular mass calculated from 
the electrospray mass spectroscopy of non-phosphorylated FHA-2 was 11976.5 Da 
and phosphorylated FHA-2 was 12055.9 Da. The SEC-MALLS results showed that 
the non-phosphorylated FHA-2 protein was approximately 1 kDa less than the 
calculated size by mass spectrometry and the phosphorylated FHA-2 was 2.88 kDa 
larger than the predicted molecular mass of phosphorylated FHA-2. Unfortunately 
the molecular weights generated are inconclusive and do not offer an explanation as 
to why the phosphorylated FHA-2 protein eluted before the non-phosphorylated 
protein (apart from that it is ~ 3 kDa larger). In terms of protein conformation 
nothing can be drawn from the data. Perhaps only a proportion of the FHA-2 domain 
was dimeric due to a weak dimerisation and maybe this could account for why the 
average mass only increased by 2.88 kDa; this is corroborated by the shape of the 
eluted phosphorylated peak which was not perfectly bell shaped as observed for the 
non-phosphorylated protein, the phosphorylated peak eluted over a larger area and 
had a longer tail (figure 6.25).  
Unfortunately, the data generated was inconclusive and did not provide an insight 
into whether the FHA-2
202-310
 domain alters its conformation upon phosphorylation; 
consequently no conclusions can safely be drawn regarding the effect that 
phosphorylation has on the structure of the FHA-2 domain and no hypotheses 
can be put forward about how this FHA domain may interact with the Rv1747 
pT residues to regulate protein function. 
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6.9.4 Summary  
This chapter has further uncovered the significant roles that the pknF and Rv1747 
genes play in M. tuberculosis pathogenesis and has demonstrated the critical 
importance of the FHA-1 domain for Rv1747 protein function. Both the FHA 
domains were shown to be functionally active in binding both the identified Rv1747 
pT epitopes. Furthermore, Rv1747 has been shown to not only be required for 
growth in the lungs but is also necessary for growth in the spleens. In addition, 
combining all the data generated in this study suggests that PknF positively regulates 
the function of the ABC transporter. A mechanism of regulation has been proposed 
(figure 6.26) although there is still a way to go to fully elucidate the molecular details 
of how the pknF-Rv1747 signal transduction system functions in M. tuberculosis. 
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CHAPTER 7. DISCUSSION AND FUTURE WORK 
7.1 Discussion 
When this study began little was known about the function of the PknF-Rv1747 
signalling system; it was recognised that Rv1747 was required for a virulent infection, 
furthermore both FHA domains and phosphorylation of the PknF activation loop seemed 
to be required for the PknF-Rv1747 interaction (Curry et al., 2005; Molle et al., 2004). 
However, the substrate of Rv1747 and the details of how the signalling system 
functioned in terms of protein phosphorylation and the importance of particular domains 
were unknown. This study set out to further define the roles of PknF and Rv1747 in 
relation to the virulence of M. tuberculosis with the view to explore whether either of 
these proteins or particular domains of the proteins might be suitable drug targets for 
new interventions, or whether either of the mutants might be useful as part of a novel 
live attenuated vaccine strain. 
This study has increased our knowledge of how the PknF-Rv1747 signalling system 
functions in M. tuberculosis. We now know that PknF does indeed play a role in a signal 
transduction system with Rv1747 and have further uncovered the significant roles that 
the pknF and Rv1747 genes play in M. tuberculosis pathogenesis. Rv1747 codes for an 
ABC transporter required for growth in mice that is presumed to export a cellular 
component. This study has determined that this function is positively controlled by 
PknF. This kinase interacts with the two FHA domains of Rv1747 in a phosphorylation 
dependent manner and FHA-1 mutation results in attenuation in macrophages 
demonstrating the critical importance of this domain for Rv1747 protein function. PknF 
mediated phosphorylation of two threonine residues on Rv1747 was shown to be 
important for the ABC transporter function in both macrophage and mouse infection 
models. Furthermore, both FHA domains bound each Rv1747 phosphopeptide with 
similar affinities providing a description of the nature of the inter- and intra-molecular 
protein interactions which control the function of the ABC transporter (figure 6.26).  
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7.2 Future work and implications for novel M. tuberculosis treatment 
interventions 
This study is the first to identify two threonine residues on Rv1747 that are 
phosphorylated, at least in vitro, by PknF. Many factors require investigation to further 
define the roles of PknF and Rv1747. Firstly, identification of the Rv1747 
phosphothreonine residues in vivo is of upmost importance to confirm that the residues 
identified in this study are indeed the ones phosphorylated inside the M. tuberculosis 
cell, although data generated in this investigation has already demonstrated the 
important role that these residues play in controlling the function of the ABC 
transporter. As the function of Rv1747 is only required for the in vivo growth and 
survival of M. tuberculosis this offered a potential explanation to why no substrate for 
Rv1747 was elucidated in in vitro experiments and also why both the mutants 
demonstrated no differences in susceptibility to any of the drug and stresses investigated. 
For PknF, it is unknown whether a dimerisation event occurs to activate the kinase as 
observed for the solved kinase domain structures of PknB, PknD and PknE (Gay et al., 
2006; Greenstein et al., 2007; Mieczkowski et al., 2008; Ortiz-Lombardia et al., 2003; 
Scherr et al., 2007; Young et al., 2003). The predicted PknF extracellular domain 
contains regions of low complexity and lacks a ligand binding domain with a 
recognisable function (Greenstein et al., 2007). It would therefore be of great interest to 
determine the structure of the PknF kinase domain to enable a further understanding of 
how this kinase functions in M. tuberculosis. It also has to be considered that in vivo 
PknF may be activated by trans-phosphorylation by another STPK and not necessarily 
activated by sensing a direct signal. However, the presence of an extracellular domain 
suggests that this protein does perform a sensory role although this study failed to 
elucidate the nature of the ligand. Also of considerable importance to further understand 
this signalling system would be to generate a pknF-Rv1747 double deletion mutant; 
characterising the phenotypes of this double mutant may aid in understanding how the 
system functions.  
The experiments performed within this study demonstrated the critical importance of the 
Rv1747 FHA-1 domain for ABC transporter function. Therefore it is also important to 
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put the FHA domain mutant strains through a mouse aerosol infection model and 
investigate whether the FHA-1 S47A strain has a growth attenuation phenotype as 
observed in macrophages. In addition, the ∆pknF mutant should also be characterised in 
the same infection model to determine whether this gene is required for the growth of M. 
tuberculosis in vivo. The prediction is that the pknF mutant would have at least some 
growth attenuation phenotype in vivo as this kinase positively regulates the activity of 
Rv1747. 
Results from this study do not corroborate findings by Deol et al. who reported that 
PknF negatively regulates glucose uptake; using antisense RNA to reduce the levels of 
PknF protein in M. tuberculosis they showed increased glucose uptake 16-fold higher 
compared with wild type and the antisense strain also grew 1.5 fold faster (Deol et al., 
2005). This study has shown that that the ∆pknF deletion strain grows at the same rate as 
wild type in vitro; also the phenotype microarrays showed the ∆pknF and ∆Rv1747 
deletion strains utilised glucose as well as the wild type strain. One might have expected 
that if PknF functioned to negatively regulate glucose uptake then glucose would have 
been used significantly more in the ∆pknF deletion strain compared to wild type; this 
was not the case. Furthermore, using the ∆pknF mutant in radioactive nutrient uptake 
assays it was not possible to repeat the results of the Deol study (R. Whalan, Personal 
Communication).  
Overall, the results of this study conclude that the PknF-Rv1747 signalling system is 
essential for the full virulence of M. tuberculosis in mice and macrophages. Further 
understanding of this relationship may allow the identification of potential new 
antimycobacterial drugs. In terms of novel therapies, the inhibition of essential 
signalling pathways in M. tuberculosis is an attractive prospect to yield novel classes of 
drug targets, however to date no kinase inhibitor has been discovered which has a high 
potency against M. tuberculosis despite appearing effective in in vitro assays (K. 
Lougheed, unpublished data; Magnet et al., 2010; Wehenkel et al., 2006).  
Perhaps a better potential new drug target for M. tuberculosis treatment intervention 
would be to identify small molecule inhibitors against FHA domain-containing proteins. 
Experiments in this study demonstrated that the FHA-1 domain is critical for Rv1747 
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function; therefore small molecule inhibitors could be identified against the domain to 
inhibit it binding a phosphothreonine epitope. As with protein kinase inhibitors, any 
such compound would have to be target-specific and not inhibit human FHA domain-
containing proteins. Although no such studies into the development of FHA domain 
inhibitors have been published to date, there have been a couple of studies reporting the 
discovery of specific inhibitors to a Polo-box domain (PBD) protein, which like FHA 
domains functions to bind phosphothreonine (and phosphoserine) containing epitopes 
(Reindl et al., 2008; Reindl et al., 2009). The PBD in question forms part of a 
serine/threonine kinase called Polo-like kinase 1 (Plk1) which is overexpressed in many 
types of cancerous human tumours and so inhibitors of this protein would be promising 
in the treatment of cancer patients (Reindl et al., 2008).  
Finally, due to the ∆Rv1747 deletion strain being attenuated for growth in the lungs and 
spleens of a murine model of infection, a mutation of this gene may be a good candidate 
for a component of a novel live attenuated M. tuberculosis vaccine strain.   
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APPENDIX I. MEDIA AND BUFFER COMPOSITION  
 
L-Broth/Agar 
10 g  Tryptone 
5 g  Yeast Extract 
10 g  NaCl 
15 g  Agar (if required; Difco, Becton Dickinson) 
dH2O to 1 litre 
Autoclave at 121 ºC for 15 mins 
 
Modified Dubos Medium 
1 g  KH2PO4 
6.25 g  Na2HPO4.12H2O 
1.25 g  Na3 Citrate 
0.6 g  MgSO4.7H2O 
2 g  Asparagine 
2 g  Casamino Acids 
5 ml   10% Tween 80 
2 ml   Glycerol  
dH2O to 960 ml 
Adjust to pH 7.2 
Autoclave at 121 ºC for 15 minutes 
40 ml  Dubos medium Albumin (Difco, Becton Dickinson) 
 
Mycobacteria 7H11 Agar 
21 g  Mycobacteria 7H11 Agar Powder (Difco, Becton Dickinson) 
5 ml  Glycerol  
dH2O to 960 ml 
Autoclave at 121 ºC for 15 minutes 
Add 40 ml or 100 ml Dubos Medium Albumin (Difco, Becton Dickinson) 
 
PBS  
10 g  NaCl 
0.25 g  KCl 
1.437 g Na2HPO4 
0.25 g   KH2PO4 
dH2O to 1 litre  
Autoclave at 121 ºC for 15 minutes 
 
Resuspension Buffer 
25 mM Tris-HCl pH7.9 
10 mM EDTA 
50 mM Glucose 
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Sauton’s Medium 
0.5 g   KH2PO4 
0.5 g   MgSO4 
4.0 g   L-asparagine 
60 ml   glycerol 
0.05 g   Ferric ammonium sulfate 
2.0 g   Citric acid 
0.1 ml 1 %  ZnSO4.7H2O 
dH2O to 1 litre  
Adjust to pH 7.0 
Filter sterilize (0.22 µM) 
 
SSC Buffer (20x) 
175.2 g  NaCl 
88.2 g  Tris-Sodium Citrate 
dH2O to 1 litre 
Adjust to pH 7.0-7.2 
Autoclave at 121 ºC for 15 minutes 
 
TBE Buffer (10X) 
121.1 g Tris Base 
61.83 g Boric acid 
18.6 g  EDTA 
dH2O to 1 litre 
Adjust to pH 8.0 
 
TE Buffer  
1.211 g Tris Base 
0.372 g  EDTA 
dH2O to 1 litre 
Adjust to pH 8.3 
Autoclave at 121 ºC for 15 minutes 
 
Z-Buffer (Miller, 1972)  
60 mM Na2HPO4 
40 mM NaH2PO4 
10 mM  KCl 
1 mM  MgSO4 
Adjust to pH 7.0  
Autoclave at 121 ºC for 15 minutes 
When required add β-mercaptoethanol to a final concentration of 50 mM 
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APPENDIX II. OLIGONUCLEOTIDES USED IN THIS 
STUDY 
 
RT-PCR Primer Pairs 
 
Primer Name Description Sequence (5'-3') 
pknF F gene specific internal primer AACATCCTGATCGCCAATCC 
pknF R gene specific internal primer TTGCAGCGTCGAGCAGTAGG 
pknF-Rv1747 F co-transcription primer AAGGCACCAACACCACCATCT 
pknF-Rv1747 R co-transcription primer GGACAGGTTGGGCAGGCGTAT 
Rv1747 F gene specific internal primer CGTTCACGCCGAATATGCCT 
Rv1747 R gene specific internal primer CCATGAAGACCGCACCGACA 
Rv1747-Rv1748 F co-transcription primer AGGATTCGCATTGGCATCAC 
Rv1747-Rv1748 R co-transcription primer GGCTTGTAGCTTGGCCTTGT 
Rv1748  F gene specific internal primer GGCGATCTTGCGTCGGATAG 
Rv1748 R gene specific internal primer GTACGGTCCGGCAACACGAT 
 
qRT-PCR Primer Pairs 
 
Primer 
Name Sequence (5'-3') 
pknF F CACGAACGTCGGCTGTTG 
pknF R GACGATCAGGTGAATCAGGATTG 
Rv1747 F TACGGTCGACCTGATCAAATTG 
Rv1747 R GCGCTGGCGGTGTGA 
iniA F TCATCGCAGTCTCATCACTGTTG 
iniA R TTGGACTCTTCGTTGAGCTCTTT 
iniB F TTATCGATTACATCCTGAGCCTGTT 
iniB R CGGAGCGGCAACGAA 
iniC F ACTCCGAATGCTAAGCCTTTTG 
iniC R CAGCGACGCGATTTCGT 
ethA F GCAAGCCCATCCTCGAGTAC 
ethA R CGGATATGCCTGTCGATTCC 
pknD F CAACGGACAGTTCTTTGTCGAA 
pknD R TGTTTCAATAGGGCGCGTAAA 
sigA F TCGGTTCGCGCCTACCT 
sigA R GGCTAGCTCGACCTCTTCCT 
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Primers for pknF 5'RACE 
 
Primer Name Sequence (5'-3') 
5' RACE GSP1 ACCGCAGTGATGATCTC 
5' RACE GSP2 GGACGGCGACGATGTGTGGATGC 
5' RACE GSP3 CCTGGCGGGGCAGTCTGGGAT 
 
Primer pair for cloning pknF promoter region 
 
 
Protein expression primers for cloning into pGEX-6P-1 
 
Primer Name Restriction site Sequence (5'-3') 
PknF 
1-292
 F BamHI GGATCCATGCCGCTCGCGGAAGGTTCG 
PknF 
1-292
 R XhoI plus STOP CTCGAGTCACGGTTGCGACACCCGCGT 
Rv1747 
1-559
 F BamHI GGATCCGTGCCGATGAGCCAACCAGCC 
Rv1747 
1-559
 R EcoRI plus STOP GAATTCTCAGTCGTCGGCGACGGTGCTGAA 
FHA 1 
1-120
 F BamHI plus ATG CCGGATCCGTGCCGATGAGCCAACCA  
FHA 1 
1-120
 R EcoRI plus STOP CCGGATTCTCAGCGTATCGACGTCGTCTG  
FHA 2 
202-310
 F BamHI plus ATG  CCGGATCCATGACTGAGGCGGGAAACCTC 
FHA 2 
202-310
 R EcoRI plus STOP CCGGATTCTCAGTTCTCTTCACGGCGCGC 
 
Site directed mutagenesis of pVS_03 and pRW76 
 
Primer Name Sequence (5'-3') (highlighted bases indicate mutation) 
Rv1747 T150A F TACAACAGCTTCCACCGGCCGCCACCCGGATACCCGCCGCTCC 
Rv1747 T150A R GGAGCGGCGGGTATCCGGGTGGCGGCCGGTGGAAGCTGTTGTA 
Rv1747 T150D F TACAACAGCTTCCACCGGCCGACACCCGGATACCCGCCGCTCC 
Rv1747 T150D R  GGAGCGGCGGGTATCCGGGTGTCGGCCGGTGGAAGCTGTTGTA 
Rv1747 T208A F CTGAGGCGGGAAACCTCGCGGCATCGATGATGAAGATCCTGCG 
Rv1747 T208A R CGCAGGATCTTCATCATCGATGCCGCGAGGTTTCCCGCCTCAG 
Rv1747 T208D F CTGAGGCGGGAAACCTCGCGGACTCGATGATGAAGATCCTGCG 
Rv1747T208D R CGCAGGATCTTCATCATCGAGTCCGCGAGGTTTCCCGCCTCAG 
 
 
 
 
Primer Name Restriction site Sequence (5'-3') 
pknF promoter  F XbaI CCTCTAGACTGATCGTGCAGATCGAACA 
pknF promoter  R HindIII CCAAGCTTGGCGGCATCGTAGCCCGCCA 
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Primers used for sequencing 
 
Sequencing primers for E. coli expression clones 
Primer Name Description Sequence (5'-3') 
M13 F 
To sequence DNA inserts in 
pCR4Blunt-TOPO TGTAAAACGACGGCCAGT 
M13 R 
To sequence DNA inserts in 
pCR4Blunt-TOPO CAGGAAACAGCTATGACC 
PGEX 3' 
To sequence DNA inserts in 
pGex6P1 CCGGGAGCTGCATGTGTCAGAGG 
PGEX 5' 
To sequence DNA inserts in 
pGex6P1 GGGCTGGCAAGCCACGTTTGGTG 
pEJ414 pmint2 
To sequence DNA inserts in 
pEJ414 ACGAGGGGCATTCACACCAGATTG 
pEJ414 lacR 
To sequence DNA inserts in 
pEJ414 TTCCCAGTCACGACGTTGTAAAA 
pMv306-4  CCAGCAACGCGGCCTTTTTACG 
pKP186 F 
To sequence DNA inserts in 
pKP186  
pKP186 R  
To sequence DNA inserts in 
pKP186  
Sequencing primers for site directed  mutagenesis conformation 
Rv1747 T150 F 
Forward primer to screen for 
T150 mutation AACCTGTCCGCGGGAGCGTGGCCC 
Rv1747 T150 R 
Reverse primer to screen for T150 
mutation GTGGCCACAACTGTTGCCCACC 
Rv1747 T208 F 
Forward primer to screen for 
T208 mutation CCCGCGGCGGAACTGAGGCG 
Rv1747 T208 R 
Reverse primer to screen for T208 
mutation ACTCCCCCGTCAACCTGCCTG 
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APPENDIX III. MICROARRAY DATA ANALYSIS 
To allow for statistical analysis three biological replicates were performed for each 
condition. Each biological replicate was performed in technical duplicate with dye-
swaps to correct for dye-labelling bias.  
Microarray data analysis was performed using the GeneSpring GX 10 software 
(Agilent Technologies) as follows: 
• An advanced workflow analysis was chosen using the generic two colour 
system  
• Data was then loaded into the experiment and the following operations were 
performed: 
a. The technology (M. tuberculosis genome annotation) was chosen: 
TB_v_2_2_flags_GX10 
b. Excel spreadsheets from Bluefuse output files were loaded  
c. Dye swaps were highlighted. Experiments were ticked in which the 
samples were labelled in the opposite direction. GeneSpring then 
reverses these colours and this is how dye bias is corrected for. 
d. Due to dye swaps the LOWESS normalization step was not required. 
LOWESS normalization is a mathematical correction for dye 
labelling bias but as this was corrected for using dye-swaps then this 
correction step was not necessary.  
• Parameters were set so that each microarray slide could be identified by 
biological replicate, technical replicate and strain/genotype.  
• Quality control on samples was then performed using principal components 
analysis. Microarray slides were removed from the analysis at this stage if 
they were outliers.  
• Quality control on genes was then performed. Data sets were filtered on 
Flags and Expression. Gene spots were removed from the analysis when: 
o The signal was not good enough. This step removed genes where 
expression was in the noise level i.e. there was no expression of the 
genes. 
o The signal was present or marginal for less than 3 microarray slides 
i.e values had to appear in at least half of the total number of 
microarray slides.  
o If necessary, data were then filtered on expression to remove 
unchanged genes. Upper cut off =100, lower = 20. This removes the 
0-20
th
 percentile of data.  
• Statistics were then performed.  
o A paired t-test on the strain/genotype parameter was performed on the 
data to give a list of significant differentially expressed genes and 
their p-values. The null hypothesis assumed that the difference 
between the two observations was zero. This test was chosen as we 
wanted to compare differences in gene expression between a wild 
type (wt) strain and a deletion (ko) strain. If the ratio between the wt 
gene and ko gene was 1 then there was no change; log2 (1) = 0.  
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APPENDIX IV. MICROARRAY RESULTS 
 
Genes up-regulated upon Rv1747 deletion (> 2 Fold, p-value less than 0.05) 
 
Gene 
Number 
Gene Name Gene Product Fold Up-
regulated 
p-value 
Rv0005  gyrB DNA gyrase (Subunit B) gyrB 2.0 0.001 
Rv0046c  
ino1 Myo-insositol-1-phosphate synthase 
ino1 2.0 3.3E-04 
Rv0047c  Rv0047c Conserved hypothetical protein 2.2 4.1E-05 
Rv0341  iniB Isoniazid inductible gene protein iniB 3.8 2.4E-04 
Rv0342  iniA Isoniazid inductible gene protein iniA 3.2 8.E-05 
Rv0511  
hemD Probable uroporphyrin-III C-
methyltransferase hemD 2.0 6.4E-04 
Rv0676c  
mmpL5 Probable conserved transmembrane 
protein mmpL5 2.0 0.009 
Rv0822c  Rv0822c Conserved hypothetical protein  2.0 4.0E-05 
Rv0823c  
Rv0823c Possible transcriptional regulatory 
protein 2.0 1.0E-04 
Rv2007c  fdxA Probbale ferredoxin fdxA 2.1 0.005 
Rv2396  PE_PGRS41 PE-PGRS family protein 2.0 7.0E-04 
Rv2590  fadD9 Probable fatty acid coA ligase fadD9 2.0 2.0E-04 
Rv3140  
fadE23 Probable acyl-coA dehydrogenase 
fadE23 2.1 0.001 
Rv3854c  ethA Monooxygenase ethA 2.0 0.003 
 
 
Genes down-regulated upon Rv1747 deletion (> 2 Fold, p-value less than 0.05) 
 
Gene 
Number 
Gene Name Gene Product Fold 
down-
regulated 
p-value 
CDC1551: 
MT0036 
CDC1551: 
MT0036 
Hypothetical protein 
2.0 7.3E-04 
CDC1551: 
MT2291  
CDC1551: 
MT2291 
Hypothetical protein 
2.1 7.1E-04 
Rv0091  
mtn Probable bifunctional 
mta/sah nucleosidase mtn 2.0 0.004 
Rv0320  
Rv0320 Possible conserved exported 
protein 2.0 0.011 
Rv0620  galK Probable galactokinase galK 2.0 4.1E-04 
Rv1040c  PE8 PE family protein 2.1 0.013 
Rv1380  
pyrB Probable aspartate 
carbamoyltransferase pyrB 2.2 0.001 
Rv1382  Rv1382 Probable export or 2.2 6.2E-04 
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membrane protein 
Rv1383  
carA Probable carbamoyl-
phosphate synthase small 
chain carA 2.0 3.7E-05 
Rv1515c  
Rv1515c Conserved hypothetical 
protein 2.0 5.1E-04 
Rv1747  
Rv1747 Probably conserved 
transmembrane ATP-
binding protein ABC 
transporter 29.2 8.9E-06 
Rv1756c  Rv1756c Putative transposase 2.2 0.006 
Rv1999c  
Rv1999c Probable conserved integral 
membrane protein 2.2 0.005 
Rv2106  Rv2106 Probable transposase 2.1 0.016 
Rv2265  
Rv2265 Possible conserved integral 
membrane protein 2.1 0.006 
Rv2268c 
cyp128 Probable cytochrome P450 
128 cyp128 2.1 0.005 
Rv2415c  
Rv2415c Conserved hypothetical 
protein 2.3 7.9E-04 
Rv2528c  
mrr Probable restriction system 
protein mrr 2.1 1.9E-04 
Rv2577  
Rv2577 Conserved hypothetical 
protein 2.1 0.016 
Rv2812  Rv2812 Probable transposase 2.0 0.006 
Rv2814c  Rv2814c Probable transposase 2.2 0.012 
Rv2874  
dipZ Possible integral membrane 
C-type cytochrome 
biogenesis protein dipZ 2.0 0.015 
Rv3326 Rv3326 Probable transposase 2.0 0.016 
Rv3380c  Rv3380c Probable transposase 2.0 0.016 
Rv3475  Rv3475 Probable transposase 2.1 0.014 
 
 
Genes up-regulated upon pknF deletion (> 1.5 Fold, p-value less than 0.05) 
 
Gene 
Number 
Gene 
Name 
Gene Product Fold Up-
regulated 
p-
value 
CDC1551: 
MT3972.1 
CDC1551: 
MT3972.1 
Hypothetical protein 
1.8 0.004 
Rv0175  
Rv0175 Probable conserved mce 
associated membrane protein 1.5 0.003 
Rv0341  
iniB Isoniazid inductible gene 
protein iniB 1.8 0.001 
Rv0831c  Rv0831c Conserved hypothetical protein 1.5 0.003 
Rv1738  Rv1738 Conserved hypothetical protein 1.6 0.005 
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Rv2007c  fdxA Probable ferredoxin fdxA 1.8 0.023 
Rv3727  Rv3727 Possible oxidoreductase 1.5 0.008 
Rv3728  
Rv3728 Probable conserved two-domain 
membrane protein 1.5 0.007 
Rv3842c  
glpQ1 Probable glycerophosphoryl 
diester phosphodiesterase glpQ1 1.9 0.006 
Rv3850  Rv3850 Conserved hypothetical protein 1.7 0.002 
Rv3854c  ethA Monooxygenase ethA 1.7 0.006 
Rv3864  
espE Esx-1 secretion associated 
protein espE 1.6 0.003 
 
 
Genes down-regulated upon pknF deletion (> 2.0 Fold, p-value less than 0.05) 
 
Gene Number Gene 
Name 
Gene Product Fold Down-
regulated 
p-
value 
MbAF212297-
1404  
Mb1404 Probable conserved 
membrane protein 2.4 0.006 
Rv0796  
Rv0796 Putative transposase for 
insertion sequence element 
IS6110 2.0 0.036 
Rv1370c  
Rv1370c Putative transposase for 
insertion sequence element 
IS6110 2.0 0.042 
Rv1371  
Rv1371 Probable conserved 
membrane protein 2.4 0.042 
Rv1372  
Rv1372 Conserved hypothetical 
protein 2.2 0.037 
Rv2106  Rv2106 Probable transposase 2.0 0.029 
Rv2167c  Rv2167c Probable transposase 2.0 0.016 
Rv2279  Rv2279 Probable transposase 2.0 0.030 
Rv2480c  
Rv2480c Possible transposase for 
insertion sequence element 
IS6110 2.4 0.003 
Rv2515c  
Rv2515c Conserved hypothetical 
protein 2.0 0.034 
Rv2815c  Rv2815c Probable transposase 2.0 0.043 
Rv3640c  Rv3640c Probable transposase 2.0 0.036 
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Genes down-regulated upon pknF deletion (> 1.5 Fold, p-value less than 0.05) 
 
Gene 
Number 
Gene 
Name 
Gene Product Fold 
Down-
regulated 
p-value 
CDC1551: 
Mt1849.1  
CDC1551: 
Mt1849.1 
Hypothetical protein 
1.7 0.012 
CDC1551: 
Mt1945  
CDC1551: 
Mt1945 
Hypothetical protein 
1.7 0.043 
CDC155: 
Mt3269  
CDC155: 
Mt3269 
Hypothetical protein 
1.7 0.029 
CDC1551: 
Mt3718.1  
CDC1551: 
Mt3718.1 
Hypothetical protein 
1.8 0.008 
CDC155: 
Mt3767.1  
CDC155: 
Mt3767.1 
Hypothetical protein 
1.7 0.013 
Rv0071  Rv0071 Possible maturase 1.6 0.021 
Rv0322  
udgA Probable udp-glucose 6-
dehydrogenase udgA 1.7 0.024 
Rv0520  Rv0520 Possible methyltransferase 1.5 0.012 
Rv0584  
Rv0584 Possible conserved exported 
protein 1.6 0.040 
Rv0797  
Rv0797 Putative transposase for insertion 
sequence element IS1547 1.6 0.047 
Rv1181  
pks4 Probable polyketide beta-
ketoacyl synthase pks4 1.7 0.040 
Rv1369c  Rv1369c Probable transposase 1.9 0.027 
Rv1552  
frdA Probable fumarate reductase 
frdA 1.6 0.019 
Rv1735c  Rv1735c Hypothetical membrane protein 1.7 0.023 
Rv1756c  Rv1756c Putative transposase 1.9 0.033 
Rv1758  cut1 Probable cutinase cut1 1.7 0.007 
Rv1762c  Rv1762c Hypothetical protein 1.5 0.028 
Rv1764 Rv1764 Putative transposase 1.9 0.034 
Rv2168c  
Rv2168c Putative transposase for insertion 
sequence element IS6110 1.9 0.023 
Rv2278  
Rv2278 Putative transposase for insertion 
sequence element IS6110 1.9 0.038 
Rv2317  
uspB Probable sugar-transport integral 
membrane protein ABC 
transporter uspB 1.9 0.040 
Rv2319c  Rv2319c Hypothetical protein 1.7 0.020 
Rv2320c  
rocE Probable cationic amino acid 
transport integral membrane 
protein rocE 1.6 0.029 
Rv2354  
Rv2354 Probable transposase for 
insertion sequence element 1.6 0.049 
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IS6110 
Rv2355  Rv2355 Probable transposase 1.9 0.027 
Rv2577  Rv2577 Conserved hypothetical protein 1.7 0.034 
Rv2648  
Rv2648 Probable transposase for 
insertion sequence element 
IS6110 1.8 0.042 
Rv2649  
Rv2649 Probable transposase for 
insertion sequence element 
IS6110 1.9 0.031 
Rv2813  Rv2813 Conserved hypothetical protein 1.5 0.015 
Rv2814c  Rv2814c  Probable transposase 1.9 0.032 
Rv3162c  
Rv3162c Possible integral membrane 
protein 1.5 0.005 
Rv3163c  
Rv3163c Possible conserved secreted 
protein 1.5 0.045 
Rv3185  Rv3185 Probable transposase 1.9 0.027 
Rv3187  Rv3187 Probable transposase 1.8 0.044 
Rv3189  Rv3189 Conserved hypothetical protein 1.7 0.030 
Rv3195 Rv3195 Conserved hypothetical protein 1.6 0.025 
Rv3324c  
moaC3 Probable molybdenum cofactor 
biosynthesis protein C moaC3 1.5 0.047 
Rv3325  
Rv3325 Probable transposase for 
insertion sequence element 
IS6110 1.9 0.019 
Rv3326  Rv3326 Probable transposase 1.9 0.028 
Rv3380c  Rv3380 Probable transposase 1.9 0.027 
Rv3473c  bpoA Possible peroxidise bpoA 1.7 0.041 
Rv3474  
Rv3474 Possible transposase for insertion 
sequence element IS6110 1.9 0.038 
Rv3475  
Rv3475 Possible transposase for insertion 
sequence element IS6110 1.9 0.035 
Rv3613c  Rv3613c Hypothetical protein 1.8 7.0E-04 
Rv3636  Rv3636 Possible transposase 1.6 0.027 
Rv3637  Rv3637 Possible transposase 1.8 0.033 
Rv3665c  
Rv3665c Porbable dipeptide-transport 
integral membrane protein ABC 
transporter dppB 1.6 0.027 
Rv3752c  
Rv3752c Possible 
cytidine/deoxycytidylate 
deaminase 1.6 0.006 
 
